{"25f7da464d6c2741505a8d8e92550a16f9b1960d": [["IntroductionGerminal centers (GCs) [1] [2] [3] are specialized microanatomical structures that emerge within the secondary lymphoid organs upon infection or immunization.", [["microanatomical structures", "ANATOMY", 63, 89], ["lymphoid organs", "ANATOMY", 123, 138], ["infection", "DISEASE", 144, 153], ["microanatomical structures", "MULTI-TISSUE_STRUCTURE", 63, 89], ["lymphoid organs", "MULTI-TISSUE_STRUCTURE", 123, 138], ["IntroductionGerminal centers (GCs)", "TEST", 0, 34], ["specialized microanatomical structures", "PROBLEM", 51, 89], ["infection", "PROBLEM", 144, 153], ["immunization", "TREATMENT", 157, 169], ["secondary lymphoid organs", "OBSERVATION", 113, 138], ["infection", "OBSERVATION", 144, 153]]], ["A GC typically contains up to a few thousand B cells that rapidly proliferate and mutate the immunoglobulin genes of their B cell receptors (BCRs).", [["B cells", "ANATOMY", 45, 52], ["B cell", "ANATOMY", 123, 129], ["B cells", "CELL", 45, 52], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 93, 107], ["B cell receptors", "GENE_OR_GENE_PRODUCT", 123, 139], ["BCRs", "GENE_OR_GENE_PRODUCT", 141, 145], ["B cells", "CELL_TYPE", 45, 52], ["immunoglobulin genes", "DNA", 93, 113], ["B cell receptors", "PROTEIN", 123, 139], ["BCRs", "PROTEIN", 141, 145], ["A GC", "TEST", 0, 4]]], ["GCs play a central role in mounting an effective immune response against infectious pathogens, and failures within their tightly regulated environment can lead to the development of autoimmune diseases [4] and cancer [5] .", [["GCs", "ANATOMY", 0, 3], ["cancer", "ANATOMY", 210, 216], ["autoimmune diseases", "DISEASE", 182, 201], ["cancer", "DISEASE", 210, 216], ["GCs", "CELL", 0, 3], ["cancer", "CANCER", 210, 216], ["infectious pathogens", "PROBLEM", 73, 93], ["autoimmune diseases", "PROBLEM", 182, 201], ["cancer", "PROBLEM", 210, 216], ["autoimmune", "OBSERVATION", 182, 192]]], ["Hence, a detailed investigation of the processes that regulate the dynamics of the GC reaction is of crucial importance to understand both healthy and pathological immune responses.IntroductionGCs are histologically divided into two different compartments, the dark zone (DZ) and light zone (LZ), which play distinct and important roles in the maturation and selection of B cells [6] .", [["compartments", "ANATOMY", 243, 255], ["DZ", "ANATOMY", 272, 274], ["B cells", "ANATOMY", 372, 379], ["B cells", "CELL", 372, 379], ["B cells", "CELL_TYPE", 372, 379], ["the GC reaction", "PROBLEM", 79, 94], ["IntroductionGCs", "TREATMENT", 181, 196], ["the dark zone (DZ) and light zone (LZ)", "PROBLEM", 257, 295], ["dark", "OBSERVATION_MODIFIER", 261, 265], ["zone", "OBSERVATION_MODIFIER", 266, 270], ["DZ", "OBSERVATION", 272, 274], ["LZ", "ANATOMY", 292, 294]]], ["The DZ consists primarily of a tight cluster of highly proliferative B cells, known as centroblasts (CBs), while the LZ is less compact and more diverse, including GC B cells, known as centrocytes (CCs), antigen-presenting follicular dendritic cells (FDCs) and a smaller population of T follicular helper cells (T FH ).", [["B cells", "ANATOMY", 69, 76], ["centroblasts", "ANATOMY", 87, 99], ["CBs", "ANATOMY", 101, 104], ["GC B cells", "ANATOMY", 164, 174], ["centrocytes", "ANATOMY", 185, 196], ["CCs", "ANATOMY", 198, 201], ["follicular dendritic cells", "ANATOMY", 223, 249], ["FDCs", "ANATOMY", 251, 255], ["T follicular helper cells", "ANATOMY", 285, 310], ["DZ", "CHEMICAL", 4, 6], ["B cells", "CELL", 69, 76], ["centroblasts", "GENE_OR_GENE_PRODUCT", 87, 99], ["CBs", "CELLULAR_COMPONENT", 101, 104], ["LZ", "GENE_OR_GENE_PRODUCT", 117, 119], ["GC B cells", "CELL", 164, 174], ["centrocytes", "GENE_OR_GENE_PRODUCT", 185, 196], ["CCs", "CELL", 198, 201], ["antigen", "GENE_OR_GENE_PRODUCT", 204, 211], ["follicular dendritic cells", "CELL", 223, 249], ["FDCs", "CELL", 251, 255], ["T follicular helper cells", "CELL", 285, 310], ["T FH", "CANCER", 312, 316], ["highly proliferative B cells", "CELL_TYPE", 48, 76], ["centroblasts", "CELL_TYPE", 87, 99], ["CBs", "CELL_TYPE", 101, 104], ["LZ", "PROTEIN", 117, 119], ["GC B cells", "CELL_TYPE", 164, 174], ["centrocytes", "CELL_TYPE", 185, 196], ["CCs", "CELL_TYPE", 198, 201], ["antigen-presenting follicular dendritic cells", "CELL_TYPE", 204, 249], ["FDCs", "CELL_TYPE", 251, 255], ["T follicular helper cells", "CELL_TYPE", 285, 310], ["T FH", "CELL_TYPE", 312, 316], ["highly proliferative B cells", "PROBLEM", 48, 76], ["CBs", "TEST", 101, 104], ["GC B cells", "PROBLEM", 164, 174], ["antigen", "TEST", 204, 211], ["follicular dendritic cells", "PROBLEM", 223, 249], ["DZ", "OBSERVATION", 4, 6], ["tight", "OBSERVATION_MODIFIER", 31, 36], ["cluster", "OBSERVATION_MODIFIER", 37, 44], ["highly", "OBSERVATION_MODIFIER", 48, 54], ["proliferative B cells", "OBSERVATION", 55, 76], ["LZ", "ANATOMY", 117, 119], ["less compact", "OBSERVATION_MODIFIER", 123, 135], ["more diverse", "OBSERVATION_MODIFIER", 140, 152], ["follicular dendritic cells", "OBSERVATION", 223, 249], ["smaller", "OBSERVATION_MODIFIER", 263, 270], ["population", "OBSERVATION_MODIFIER", 271, 281], ["follicular helper cells", "OBSERVATION", 287, 310]]], ["A GC reaction is initiated when naive B cells are activated by T FHs .", [["B cells", "ANATOMY", 38, 45], ["T FHs", "ANATOMY", 63, 68], ["B cells", "CELL", 38, 45], ["T FHs", "CELL", 63, 68], ["naive B cells", "CELL_TYPE", 32, 45], ["T FHs", "CELL_TYPE", 63, 68], ["A GC reaction", "PROBLEM", 0, 13], ["naive B cells", "TREATMENT", 32, 45]]], ["Upon activation, naive B cells initiate a phase of monoclonal expansion characterized by very rapid proliferation rates and somatic hypermutation (SHM) of their immunoglobulin genes [7, 8] .", [["B cells", "ANATOMY", 23, 30], ["B cells", "CELL", 23, 30], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 161, 175], ["naive B cells", "CELL_TYPE", 17, 30], ["immunoglobulin genes", "DNA", 161, 181], ["monoclonal expansion", "PROBLEM", 51, 71], ["very rapid proliferation rates", "PROBLEM", 89, 119], ["somatic hypermutation", "PROBLEM", 124, 145], ["very", "OBSERVATION_MODIFIER", 89, 93], ["rapid", "OBSERVATION_MODIFIER", 94, 99], ["proliferation", "OBSERVATION", 100, 113], ["somatic hypermutation", "OBSERVATION", 124, 145]]], ["After a few days, GCs become polarized into the DZ and LZ, and CBs migrate to the LZ, where they undergo a phase of selection.", [["GCs", "ANATOMY", 18, 21], ["DZ", "ANATOMY", 48, 50], ["CBs", "ANATOMY", 63, 66], ["LZ", "ANATOMY", 82, 84], ["DZ", "CHEMICAL", 48, 50], ["GCs", "CELL", 18, 21], ["DZ", "MULTI-TISSUE_STRUCTURE", 48, 50], ["LZ", "GENE_OR_GENE_PRODUCT", 55, 57], ["CBs", "CELLULAR_COMPONENT", 63, 66], ["CBs", "CELL_TYPE", 63, 66], ["DZ", "OBSERVATION", 48, 50], ["LZ", "ANATOMY", 55, 57], ["LZ", "ANATOMY", 82, 84]]], ["CCs in the light zone are committed to apoptosis and compete for survival signals delivered by T FHs .", [["CCs", "ANATOMY", 0, 3], ["T FHs", "ANATOMY", 95, 100], ["T FHs", "GENE_OR_GENE_PRODUCT", 95, 100], ["CCs", "CELL_TYPE", 0, 3], ["T FHs", "CELL_TYPE", 95, 100], ["survival signals", "PROBLEM", 65, 81]]], ["To receive such signals, CCs must first acquire antigen from FDCs.", [["CCs", "ANATOMY", 25, 28], ["FDCs", "ANATOMY", 61, 65], ["CCs", "CELL", 25, 28], ["FDCs", "CELL", 61, 65], ["FDCs", "CELL_TYPE", 61, 65]]], ["Higher affinity CCs can capture larger amounts of antigen, which is then engulfed, digested into peptides and returned to the B-cell surface bound to the major histocompatibility MHC class II.", [["B-cell surface", "ANATOMY", 126, 140], ["major histocompatibility MHC class II", "PROTEIN", 154, 191], ["Higher affinity CCs", "PROBLEM", 0, 19], ["larger amounts of antigen", "PROBLEM", 32, 57], ["larger", "OBSERVATION_MODIFIER", 32, 38], ["amounts", "OBSERVATION_MODIFIER", 39, 46]]], ["T FHs that bind with enough strength to the peptide-MHC complex (pMHC) deliver signals that stop apoptosis, upon which a CC can leave the GC and terminally differentiate into a plasma cell (PC), responsible for secreting antibodies, or into a long-lived memory B cell (MBC) that keeps memory of past infections and can rapidly respond to repeated antigen exposure.", [["CC", "ANATOMY", 121, 123], ["GC", "ANATOMY", 138, 140], ["plasma cell", "ANATOMY", 177, 188], ["PC", "ANATOMY", 190, 192], ["memory B cell", "ANATOMY", 254, 267], ["MBC", "ANATOMY", 269, 272], ["CC", "CHEMICAL", 121, 123], ["infections", "DISEASE", 300, 310], ["T FHs", "GENE_OR_GENE_PRODUCT", 0, 5], ["pMHC", "GENE_OR_GENE_PRODUCT", 65, 69], ["GC", "CELL", 138, 140], ["plasma cell", "CELL", 177, 188], ["PC", "CANCER", 190, 192], ["memory B cell", "CELL", 254, 267], ["MBC", "CANCER", 269, 272], ["T FHs", "PROTEIN", 0, 5], ["MHC complex", "PROTEIN", 52, 63], ["pMHC", "PROTEIN", 65, 69], ["plasma cell", "CELL_TYPE", 177, 188], ["antibodies", "PROTEIN", 221, 231], ["memory B cell", "CELL_TYPE", 254, 267], ["apoptosis", "PROBLEM", 97, 106], ["a plasma cell (PC", "TEST", 175, 192], ["secreting antibodies", "PROBLEM", 211, 231], ["past infections", "PROBLEM", 295, 310], ["repeated antigen exposure", "TREATMENT", 338, 363]]], ["Low affinity cells that do not receive enough T FH signaling are eliminated by apoptosis in a process that replicates Darwinian evolution at the cellular level.IntroductionIn addition, a fraction of CCs return to the DZ for additional rounds of cell division and BCR maturation [9] .", [["cells", "ANATOMY", 13, 18], ["cellular", "ANATOMY", 145, 153], ["CCs", "ANATOMY", 199, 202], ["cell", "ANATOMY", 245, 249], ["DZ", "CHEMICAL", 217, 219], ["cells", "CELL", 13, 18], ["T FH", "GENE_OR_GENE_PRODUCT", 46, 50], ["cellular", "CELL", 145, 153], ["CCs", "CELL", 199, 202], ["DZ", "SIMPLE_CHEMICAL", 217, 219], ["cell", "CELL", 245, 249], ["BCR", "GENE_OR_GENE_PRODUCT", 263, 266], ["BCR", "PROTEIN", 263, 266], ["Low affinity cells", "PROBLEM", 0, 18], ["apoptosis", "PROBLEM", 79, 88], ["cell division", "TREATMENT", 245, 258], ["BCR maturation", "TEST", 263, 277], ["affinity cells", "OBSERVATION", 4, 18]]], ["The speed of the cell cycle in the DZ is regulated by the amount of signalling received from the T FHs [10] , likely by upregulating cell-cycle regulators such as MYC [11] [12] [13] .", [["cell", "ANATOMY", 17, 21], ["cell", "ANATOMY", 133, 137], ["DZ", "CHEMICAL", 35, 37], ["cell", "CELL", 17, 21], ["DZ", "SIMPLE_CHEMICAL", 35, 37], ["cell", "CELL", 133, 137], ["MYC", "GENE_OR_GENE_PRODUCT", 163, 166], ["cell-cycle regulators", "PROTEIN", 133, 154], ["MYC", "PROTEIN", 163, 166]]], ["As a result, high-affinity cells that receive strong T FHs signals undergo accelerated cell cycles and can replicate up to 6 times, while lower affinity cells that capture less antigen divide fewer times [14] .", [["cells", "ANATOMY", 27, 32], ["cell", "ANATOMY", 87, 91], ["cells", "ANATOMY", 153, 158], ["cells", "CELL", 27, 32], ["T FHs", "GENE_OR_GENE_PRODUCT", 53, 58], ["cell", "CELL", 87, 91], ["cells", "CELL", 153, 158], ["high-affinity cells", "CELL_LINE", 13, 32], ["high-affinity cells", "PROBLEM", 13, 32], ["accelerated cell cycles", "TREATMENT", 75, 98], ["lower affinity cells", "PROBLEM", 138, 158], ["accelerated cell cycles", "OBSERVATION", 75, 98]]], ["The regulation of the cell cycle critically contributes to the selection and clonal expansion of high-affinity cells as well as to the observed progressive decline of clonal diversity in at least a subset of GCs [15] , although detailed quantitative models are still needed to understand mechanisms behind clonal evolution, competition and clonal burst induction.IntroductionQuantitative modelling of GCs: At the molecular level, the intracellular mechanisms associated with regulation of the B cells, T FHs and FDCs interactions implicates more than 100 transcription factors [16] , most of which interact in highly regulated non-linear networks [17] , making the precise quantitative modeling of GC reaction tremendously complex.", [["cell", "ANATOMY", 22, 26], ["high-affinity cells", "ANATOMY", 97, 116], ["GCs", "ANATOMY", 208, 211], ["intracellular", "ANATOMY", 434, 447], ["B cells", "ANATOMY", 493, 500], ["T FHs", "ANATOMY", 502, 507], ["FDCs", "ANATOMY", 512, 516], ["cell", "CELL", 22, 26], ["cells", "CELL", 111, 116], ["clonal", "CELL", 306, 312], ["GCs", "CELL", 401, 404], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 434, 447], ["B cells", "CELL", 493, 500], ["T FHs", "GENE_OR_GENE_PRODUCT", 502, 507], ["FDCs", "CELL", 512, 516], ["high-affinity cells", "CELL_TYPE", 97, 116], ["B cells", "CELL_TYPE", 493, 500], ["T FHs", "CELL_TYPE", 502, 507], ["FDCs", "CELL_TYPE", 512, 516], ["transcription factors", "PROTEIN", 555, 576], ["clonal expansion of high-affinity cells", "TREATMENT", 77, 116], ["clonal diversity", "PROBLEM", 167, 183], ["clonal burst induction", "TREATMENT", 340, 362], ["GCs", "TEST", 401, 404], ["the intracellular mechanisms", "PROBLEM", 430, 458], ["GC reaction", "PROBLEM", 698, 709], ["cell cycle", "OBSERVATION", 22, 32], ["clonal", "OBSERVATION_MODIFIER", 77, 83], ["expansion", "OBSERVATION_MODIFIER", 84, 93], ["affinity cells", "OBSERVATION", 102, 116], ["progressive", "OBSERVATION_MODIFIER", 144, 155], ["decline", "OBSERVATION_MODIFIER", 156, 163], ["clonal diversity", "OBSERVATION", 167, 183]]], ["As GCs are stochastic systems that display a high level of variability even within the same lymph node of the same individual [18] , mathematical models have been widely used to deepen our understanding of the cellular and molecular processes characterising these complex dynamic systems [19] .", [["lymph node", "ANATOMY", 92, 102], ["cellular", "ANATOMY", 210, 218], ["GCs", "CELL", 3, 6], ["lymph node", "MULTI-TISSUE_STRUCTURE", 92, 102], ["cellular", "CELL", 210, 218], ["a high level of variability", "PROBLEM", 43, 70], ["high level", "OBSERVATION_MODIFIER", 45, 55], ["variability", "OBSERVATION_MODIFIER", 59, 70], ["lymph node", "OBSERVATION", 92, 102]]], ["In particular, multi-scale stochastic [20] and spatial agent-based models have been proposed [21] [22] [23] .", [["[21] [22] [23]", "SIMPLE_CHEMICAL", 93, 107], ["spatial agent", "TREATMENT", 47, 60]]], ["The advantage of such models is their faithful replication of the probabilistic interactions between the different cellular populations in the GC.", [["cellular", "ANATOMY", 115, 123], ["GC", "ANATOMY", 143, 145], ["cellular populations", "CELL", 115, 135], ["GC", "CELL", 143, 145], ["cellular populations", "OBSERVATION", 115, 135]]], ["Spatial models can capture the spatial dynamics and cellular flow between the two GC compartments, although they are encumbered with several methodological challenges and computational complexity.", [["cellular", "ANATOMY", 52, 60], ["GC compartments", "ANATOMY", 82, 97], ["cellular", "CELL", 52, 60], ["Spatial models", "PROBLEM", 0, 14], ["cellular flow", "TEST", 52, 65], ["spatial dynamics", "OBSERVATION", 31, 47], ["cellular flow", "OBSERVATION", 52, 65], ["two", "OBSERVATION_MODIFIER", 78, 81], ["GC compartments", "OBSERVATION", 82, 97]]], ["In comparison to spatial models, stochastic models offer fast and efficient computation of the main statistical properties of the GC with the theoretical guaranties of convergence to the exact probabilistic cellular distributions.", [["cellular", "ANATOMY", 207, 215], ["cellular", "CELL", 207, 215], ["main", "OBSERVATION_MODIFIER", 95, 99], ["cellular distributions", "OBSERVATION", 207, 229]]], ["Alternatively, computational models based on ordinary differential equations (ODEs) tracking the evolution of individual cells have also been proposed, and concluded that there is limited correlation between subclone abundance and affinity [24] .", [["cells", "ANATOMY", 121, 126], ["cells", "CELL", 121, 126], ["individual cells", "PROBLEM", 110, 126], ["individual cells", "OBSERVATION", 110, 126]]], ["Other ODE models [25] were used to look at clonal diversity with a simple birth, death and mutation model.", [["death", "DISEASE", 81, 86], ["clonal", "CELL", 43, 49], ["mutation model", "TEST", 91, 105]]], ["While these models have successfully reproduced the GC dynamics and B cell maturation process, the accurate investigation of clonal diversity and burst emergence requires detailed modelling of the affinity maturation process based on more realistic representations of the BCRs, where the impact of newly acquired somatic mutations on the antigen binding capacity can be assessed.", [["B cell", "ANATOMY", 68, 74], ["B cell", "CELL", 68, 74], ["clonal", "CELL", 125, 131], ["BCRs", "GENE_OR_GENE_PRODUCT", 272, 276], ["antigen", "GENE_OR_GENE_PRODUCT", 338, 345], ["the GC dynamics", "PROBLEM", 48, 63], ["B cell maturation process", "PROBLEM", 68, 93], ["clonal diversity", "PROBLEM", 125, 141], ["burst emergence", "PROBLEM", 146, 161], ["the affinity maturation process", "TREATMENT", 193, 224], ["the BCRs", "TEST", 268, 276], ["newly acquired somatic mutations", "PROBLEM", 298, 330], ["the antigen binding capacity", "TEST", 334, 362], ["cell maturation", "OBSERVATION", 70, 85], ["clonal diversity", "OBSERVATION", 125, 141], ["burst", "OBSERVATION_MODIFIER", 146, 151]]], ["Advances in next-generation sequencing of immunoglobulin genes (Ig-seq) have revealed the dynamics of BCR sequence diversification across different B cell types in healthy and antigen-stimulated B cell donors [26] ; however, structural information about the BCR, which is crucial to accurately model antibody binding capability [27] , is not available in a sequencing experiment.", [["B cell", "ANATOMY", 148, 154], ["B cell", "ANATOMY", 195, 201], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 42, 56], ["Ig", "GENE_OR_GENE_PRODUCT", 64, 66], ["BCR", "GENE_OR_GENE_PRODUCT", 102, 105], ["B cell", "CELL", 148, 154], ["antigen", "GENE_OR_GENE_PRODUCT", 176, 183], ["B cell", "CELL", 195, 201], ["BCR", "GENE_OR_GENE_PRODUCT", 258, 261], ["immunoglobulin genes", "DNA", 42, 62], ["Ig", "PROTEIN", 64, 66], ["seq", "DNA", 67, 70], ["BCR sequence", "DNA", 102, 114], ["B cell types", "CELL_TYPE", 148, 160], ["BCR", "PROTEIN", 258, 261], ["immunoglobulin genes", "TEST", 42, 62], ["Ig", "TEST", 64, 66], ["BCR sequence diversification", "PROBLEM", 102, 130], ["the BCR", "TEST", 254, 261], ["cell types", "OBSERVATION", 150, 160]]], ["Preliminary work on BCR structural representations that model the BCR as a short amino acid chain of (\u223c10 AAs) on a rectangular lattice has recently been developed [28] .", [["amino acid", "CHEMICAL", 81, 91], ["amino acid", "CHEMICAL", 81, 91], ["BCR", "GENE_OR_GENE_PRODUCT", 20, 23], ["BCR", "GENE_OR_GENE_PRODUCT", 66, 69], ["amino acid", "AMINO_ACID", 81, 91], ["BCR", "PROTEIN", 20, 23], ["BCR", "PROTEIN", 66, 69], ["BCR structural representations", "PROBLEM", 20, 50], ["a short amino acid chain", "TEST", 73, 97], ["a rectangular lattice", "TREATMENT", 114, 135]]], ["Such detailed modelling comes however at a high computational cost-a single GC simulation takes a few hours, which currently limits its application to GC simulations.IntroductionIn this paper we build on a previous multi-scale GC model, where the cellular interactions of B cells, T FH and FDCs were modelled stochastically using the Gillespie algorithm [20] .", [["cellular", "ANATOMY", 247, 255], ["B cells", "ANATOMY", 272, 279], ["T FH", "ANATOMY", 281, 285], ["FDCs", "ANATOMY", 290, 294], ["cellular", "CELL", 247, 255], ["B cells", "CELL", 272, 279], ["T FH", "CELL", 281, 285], ["FDCs", "CELL", 290, 294], ["B cells", "CELL_TYPE", 272, 279], ["T FH", "CELL_TYPE", 281, 285], ["FDCs", "CELL_TYPE", 290, 294], ["a single GC simulation", "TREATMENT", 67, 89], ["GC simulations", "TEST", 151, 165], ["a previous multi-scale GC model", "TREATMENT", 204, 235]]], ["We improve the model by adding an abstract molecular representation of the BCR based on its nucleotide sequence that allows us to track the effect of SHM on the BCR affinity through time.", [["nucleotide", "CHEMICAL", 92, 102], ["BCR", "GENE_OR_GENE_PRODUCT", 75, 78], ["BCR", "GENE_OR_GENE_PRODUCT", 161, 164], ["BCR", "PROTEIN", 75, 78], ["BCR", "PROTEIN", 161, 164], ["the BCR", "PROBLEM", 71, 78], ["its nucleotide sequence", "TEST", 88, 111]]], ["Our quantitative GC model is driven by 10 stochastic cellular interactions, which are parameterized using recent experimental characterizations of the GC dynamics.", [["cellular", "ANATOMY", 53, 61], ["cellular", "CELL", 53, 61], ["Our quantitative GC model", "TEST", 0, 25], ["cellular interactions", "OBSERVATION", 53, 74]]], ["We expand the previous model by adding new regulatory mechanisms, such as centroblast division regulation by MYC, or centroblast apoptosis due to nonproductive BCRs, and use the extended model to explore different differentiation scenarios of B cells.", [["centroblast", "ANATOMY", 74, 85], ["centroblast", "ANATOMY", 117, 128], ["B cells", "ANATOMY", 243, 250], ["centroblast", "GENE_OR_GENE_PRODUCT", 74, 85], ["MYC", "GENE_OR_GENE_PRODUCT", 109, 112], ["BCRs", "GENE_OR_GENE_PRODUCT", 160, 164], ["B cells", "CELL", 243, 250], ["MYC", "PROTEIN", 109, 112], ["nonproductive BCRs", "PROTEIN", 146, 164], ["B cells", "CELL_TYPE", 243, 250], ["centroblast apoptosis", "PROBLEM", 117, 138], ["nonproductive BCRs", "PROBLEM", 146, 164], ["the extended model", "TREATMENT", 174, 192], ["B cells", "OBSERVATION", 243, 250]]], ["Our sequence-based BCR representation enables a detailed investigation of clonal evolution using phylogenetic trees [29] , and an analysis of the factors that determine the emergence of clonal dominance.", [["BCR", "GENE_OR_GENE_PRODUCT", 19, 22], ["clonal", "CELL", 74, 80], ["BCR", "PROTEIN", 19, 22], ["Our sequence", "TEST", 0, 12], ["an analysis", "TEST", 127, 138], ["clonal dominance", "OBSERVATION", 186, 202]]], ["Our paper summarizes the current quantitative knowledge about the GC responses, and gives additional information about clonal diversity and B-cell affinity maturation, which is particularly challenging to obtain from experimental data.Stochastic Model of the GCOur GC model includes reactions that occur in the low frequency regime where stochastic effects cannot be neglected, and hence cannot be simulated using ordinary differential equations.", [["B-cell", "ANATOMY", 140, 146], ["clonal", "CELL", 119, 125], ["B-cell", "CELL", 140, 146], ["clonal diversity", "PROBLEM", 119, 135], ["B-cell affinity maturation", "TREATMENT", 140, 166], ["the GCOur GC model", "TREATMENT", 255, 273], ["the low frequency regime", "TREATMENT", 307, 331], ["low frequency regime", "OBSERVATION_MODIFIER", 311, 331]]], ["Instead, we use the formalism of chemical kinetics, where each reaction represents a stochastic process between the following reactants: naive B cells (NB), centroblasts (CB), centrocytes (CC), selected centrocytes (CC sel ), memory B cells (MBC), plasma cells (PC), T follicular helper cells (T FH ), and follicular dendritic cells (FDC).", [["B cells", "ANATOMY", 143, 150], ["NB", "ANATOMY", 152, 154], ["centroblasts", "ANATOMY", 157, 169], ["CB", "ANATOMY", 171, 173], ["centrocytes", "ANATOMY", 176, 187], ["CC", "ANATOMY", 189, 191], ["centrocytes", "ANATOMY", 203, 214], ["CC sel", "ANATOMY", 216, 222], ["memory B cells", "ANATOMY", 226, 240], ["MBC", "ANATOMY", 242, 245], ["plasma cells", "ANATOMY", 248, 260], ["PC", "ANATOMY", 262, 264], ["T follicular helper cells", "ANATOMY", 267, 292], ["T FH", "ANATOMY", 294, 298], ["follicular dendritic cells", "ANATOMY", 306, 332], ["FDC", "ANATOMY", 334, 337], ["B cells", "CELL", 143, 150], ["NB", "CELL", 152, 154], ["centroblasts", "CELL", 157, 169], ["CB", "CELL", 171, 173], ["centrocytes", "CELL", 176, 187], ["CC", "CELL", 189, 191], ["centrocytes", "CELL", 203, 214], ["CC sel", "CELL", 216, 222], ["memory B cells", "CELL", 226, 240], ["MBC", "CELL", 242, 245], ["plasma cells", "CELL", 248, 260], ["PC", "CELL", 262, 264], ["T follicular helper cells", "CELL", 267, 292], ["T FH", "CELL", 294, 298], ["follicular dendritic cells", "CELL", 306, 332], ["FDC", "CELL", 334, 337], ["naive B cells", "CELL_TYPE", 137, 150], ["NB", "CELL_TYPE", 152, 154], ["centroblasts", "CELL_TYPE", 157, 169], ["CB", "CELL_TYPE", 171, 173], ["centrocytes", "CELL_TYPE", 176, 187], ["CC", "CELL_TYPE", 189, 191], ["centrocytes", "CELL_TYPE", 203, 214], ["CC sel", "CELL_TYPE", 216, 222], ["memory B cells", "CELL_TYPE", 226, 240], ["MBC", "CELL_TYPE", 242, 245], ["plasma cells", "CELL_TYPE", 248, 260], ["PC", "CELL_TYPE", 262, 264], ["T follicular helper cells", "CELL_TYPE", 267, 292], ["T FH", "CELL_TYPE", 294, 298], ["follicular dendritic cells", "CELL_TYPE", 306, 332], ["FDC", "CELL_TYPE", 334, 337], ["chemical kinetics", "TREATMENT", 33, 50], ["each reaction", "PROBLEM", 58, 71], ["a stochastic process", "PROBLEM", 83, 103], ["naive B cells", "TEST", 137, 150], ["centroblasts", "TEST", 157, 169], ["centrocytes", "TEST", 176, 187], ["selected centrocytes (CC sel", "TEST", 194, 222], ["memory B cells", "TEST", 226, 240], ["MBC", "TEST", 242, 245], ["plasma cells", "TEST", 248, 260], ["PC", "TEST", 262, 264], ["T follicular helper cells", "TEST", 267, 292], ["follicular dendritic cells", "PROBLEM", 306, 332], ["stochastic process", "OBSERVATION", 85, 103], ["plasma cells", "ANATOMY", 248, 260], ["follicular", "ANATOMY", 306, 316], ["dendritic cells", "OBSERVATION", 317, 332]]], ["If mutation renders a BCR nonproductive, the CB commits apoptosis (\u2205).", [["CB", "ANATOMY", 45, 47], ["BCR", "GENE_OR_GENE_PRODUCT", 22, 25], ["BCR", "PROTEIN", 22, 25], ["CB", "PROTEIN", 45, 47], ["mutation", "PROBLEM", 3, 11], ["a BCR nonproductive", "PROBLEM", 20, 39], ["nonproductive", "OBSERVATION_MODIFIER", 26, 39]]], ["After a few hours, CBs migrate to the light zone and become centrocytes (CCs).", [["CBs", "ANATOMY", 19, 22], ["centrocytes", "ANATOMY", 60, 71], ["CCs", "ANATOMY", 73, 76], ["CBs", "CELLULAR_COMPONENT", 19, 22], ["centrocytes", "CANCER", 60, 71], ["CCs", "CANCER", 73, 76], ["CBs", "CELL_TYPE", 19, 22], ["centrocytes", "CELL_TYPE", 60, 71], ["CBs", "TEST", 19, 22]]], ["High-affinity CCs can acquire large amounts of antigen from follicular dendritic cells (FDCs), which makes them more likely to receive survival signals from helper T cells (T FH ).", [["CCs", "ANATOMY", 14, 17], ["follicular dendritic cells", "ANATOMY", 60, 86], ["FDCs", "ANATOMY", 88, 92], ["helper T cells", "ANATOMY", 157, 171], ["follicular dendritic cells", "CELL", 60, 86], ["FDCs", "CELL", 88, 92], ["helper T cells", "CELL", 157, 171], ["T FH", "GENE_OR_GENE_PRODUCT", 173, 177], ["follicular dendritic cells", "CELL_TYPE", 60, 86], ["FDCs", "CELL_TYPE", 88, 92], ["helper T cells", "CELL_TYPE", 157, 171], ["T FH", "CELL_TYPE", 173, 177], ["High-affinity CCs", "PROBLEM", 0, 17], ["large amounts of antigen", "PROBLEM", 30, 54], ["follicular dendritic cells", "PROBLEM", 60, 86], ["survival signals", "PROBLEM", 135, 151], ["large", "OBSERVATION_MODIFIER", 30, 35], ["amounts", "OBSERVATION_MODIFIER", 36, 43], ["follicular dendritic cells", "OBSERVATION", 60, 86]]], ["Low affinity CCs, which acquire little or no antigen, cannot compete for T cell help and die through apoptosis (\u2205).", [["CCs", "ANATOMY", 13, 16], ["T cell", "ANATOMY", 73, 79], ["T cell", "CELL", 73, 79], ["Low affinity CCs", "PROBLEM", 0, 16]]], ["CCs that have received sufficient T FH signals may either recirculate into the dark zone for another round of division and hypermutation, or leave the GC as a memory B cell (MBC) or a plasma cell (PC).", [["CCs", "ANATOMY", 0, 3], ["GC", "ANATOMY", 151, 153], ["memory B cell", "ANATOMY", 159, 172], ["MBC", "ANATOMY", 174, 177], ["plasma cell", "ANATOMY", 184, 195], ["PC", "ANATOMY", 197, 199], ["CCs", "CELL", 0, 3], ["T FH", "GENE_OR_GENE_PRODUCT", 34, 38], ["memory B cell", "CELL", 159, 172], ["MBC", "CANCER", 174, 177], ["plasma cell", "CELL", 184, 195], ["PC", "CANCER", 197, 199], ["CCs", "CELL_TYPE", 0, 3], ["memory B cell", "CELL_TYPE", 159, 172], ["plasma cell", "CELL_TYPE", 184, 195], ["hypermutation", "PROBLEM", 123, 136], ["a plasma cell", "TEST", 182, 195]]], ["To model the set of equations, we use the Gillespie algorithm [30] , an algorithm that generates statistically correct trajectories of a stochastic system of equations according to simple mass-action kinetics.", [["an algorithm", "TEST", 69, 81], ["simple mass", "PROBLEM", 181, 192], ["mass", "OBSERVATION", 188, 192]]], ["Briefly, at each time step, a propensity p i , or instantaneous probability that a reaction takes place, is computed as p i = \u220f s j=1 N i j * r i , where N i j are the number of reactants involved in reaction i and r i is the reaction rate of the channel.", [["a reaction", "PROBLEM", 81, 91]]], ["The algorithm iteratively draws two random numbers: The first one is used to define a time interval according to an exponential distribution, and the second one is used to choose the reaction that takes place in that time interval.", [["the reaction", "PROBLEM", 179, 191], ["exponential", "OBSERVATION_MODIFIER", 116, 127], ["distribution", "OBSERVATION_MODIFIER", 128, 140]]], ["It can be proven that the Gillespie algorithm converges to the exact probabilistic cellular distribution of all reactants.", [["cellular", "ANATOMY", 83, 91], ["cellular", "CELL", 83, 91], ["the Gillespie algorithm", "PROBLEM", 22, 45], ["all reactants", "PROBLEM", 108, 121], ["all reactants", "OBSERVATION", 108, 121]]], ["Furthermore, it is computationally cheap compared to alternative simulation methods, and has been extensively applied to model biomolecular interactions [31] [32] [33] .Stochastic Model of the GCThe standard Gillespie algorithm assumes that all particles are identical, and hence, it cannot be applied to model cellular systems where individual cellular properties need to be distinguished, such as the amount of antigen acquired by a CC, or its BCR sequence which determines its affinity and probability of capturing antigen.", [["cellular", "ANATOMY", 311, 319], ["cellular", "ANATOMY", 345, 353], ["CC", "CHEMICAL", 435, 437], ["[31] [32] [33]", "SIMPLE_CHEMICAL", 153, 167], ["cellular", "CELL", 311, 319], ["cellular", "CELL", 345, 353], ["BCR", "GENE_OR_GENE_PRODUCT", 446, 449], ["BCR sequence", "DNA", 446, 458], ["alternative simulation methods", "TREATMENT", 53, 83], ["the GCThe standard Gillespie algorithm", "TREATMENT", 189, 227], ["its BCR sequence", "TEST", 442, 458], ["capturing antigen", "PROBLEM", 508, 525]]], ["To overcome this limitation, a modified Gillespie [20] algorithm was developed that enables the efficient simulation of particles with individual properties by exploiting Poisson thinning, a process whereby propensities that include undesired reactions are computed and subsequently rejected.", [["a modified Gillespie [20] algorithm", "TREATMENT", 29, 64], ["exploiting Poisson thinning", "PROBLEM", 160, 187], ["undesired reactions", "PROBLEM", 233, 252]]], ["The modified algorithm was applied to simulate the GC reaction where it demonstrated speed and accuracy.", [["The modified algorithm", "TREATMENT", 0, 22], ["the GC reaction", "PROBLEM", 47, 62]]], ["Here we use the modified Gillespie algorithm to account for the following reactions: (i) CB division, (ii) CB migration, (iii) CC-T FH binding, (iv) CC competition for T FH help, and (v) CC spontaneous unbinding.", [["CC", "CHEMICAL", 127, 129], ["CC", "CHEMICAL", 149, 151], ["CC", "CHEMICAL", 187, 189], ["T FH", "GENE_OR_GENE_PRODUCT", 168, 172], ["the modified Gillespie algorithm", "TREATMENT", 12, 44], ["CC spontaneous unbinding", "PROBLEM", 187, 211]]], ["A brief description of each one of the cellular interactions follows:Stochastic Model of the GCGC initiation and founder cells: NB r activation \u2212\u2212\u2212\u2212\u2192 CB A GC starts roughly 4 days after initial exposure to an antigen, after naive B cells are activated by exposure to exogenous antigen within the lymph nodes.", [["cellular", "ANATOMY", 39, 47], ["cells", "ANATOMY", 121, 126], ["NB r activation \u2212\u2212\u2212\u2212\u2192 CB", "ANATOMY", 128, 152], ["B cells", "ANATOMY", 230, 237], ["lymph nodes", "ANATOMY", 296, 307], ["cellular", "CELL", 39, 47], ["GCGC", "CANCER", 93, 97], ["founder cells", "CELL", 113, 126], ["NB", "CELL", 128, 130], ["B cells", "CELL", 230, 237], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 296, 307], ["founder cells", "CELL_LINE", 113, 126], ["naive B cells", "CELL_TYPE", 224, 237], ["exogenous antigen", "PROTEIN", 267, 284], ["NB r activation", "TEST", 128, 143], ["A GC", "TEST", 153, 157], ["an antigen", "TEST", 206, 216], ["naive B cells", "TREATMENT", 224, 237], ["lymph nodes", "OBSERVATION", 296, 307]]], ["Early interclonal competition for T cell signals selects a subset of B cells with the highest relative affinity to enter the GC reaction, contributing to the early establishment of the oligoclonality in the GC [34] .", [["T cell", "ANATOMY", 34, 40], ["B cells", "ANATOMY", 69, 76], ["T cell", "CELL", 34, 40], ["B cells", "CELL", 69, 76], ["B cells", "CELL_TYPE", 69, 76], ["T cell signals", "PROBLEM", 34, 48], ["B cells", "PROBLEM", 69, 76], ["the GC reaction", "PROBLEM", 121, 136]]], ["Our GC model starts empty at day 4 after immunization, after which time B cells start to enter the GC reaction at a rate of r activation per hour during the next 5 days (implying 5 \u00b7 24 \u00b7 r activation seeder cells) [22, 35] .", [["B cells", "ANATOMY", 72, 79], ["seeder cells", "ANATOMY", 201, 213], ["B cells", "CELL", 72, 79], ["seeder cells", "CELL", 201, 213], ["B cells", "CELL_TYPE", 72, 79], ["seeder cells", "CELL_TYPE", 201, 213], ["immunization", "TREATMENT", 41, 53], ["the GC reaction", "PROBLEM", 95, 110]]], ["The propensity of this reaction can be computed as: propensity = r activation , between day 4 and day 9, 0 , otherwise.Stochastic Model of the GCIn our simulation, we use a division counter [14] that takes values between 0 and 6, and is reduced by one each time a B cell divides.", [["B cell", "ANATOMY", 264, 270], ["B cell", "CELL", 264, 270], ["B cell", "CELL_TYPE", 264, 270], ["this reaction", "PROBLEM", 18, 31]]], ["Once the division counter falls to zero, the cell can no longer divide and migrates to the LZ.", [["cell", "ANATOMY", 45, 49], ["cell", "CELL", 45, 49], ["no longer", "UNCERTAINTY", 54, 63], ["LZ", "ANATOMY", 91, 93]]], ["Founding cells are initialized with the maximum division counter, i.e., 6.", [["cells", "ANATOMY", 9, 14], ["cells", "CELL", 9, 14]]], ["We assume an initial affinity for BCRs 0.4 (see Supplementary Information for discussion about the choice of parameters).Stochastic Model of the GCCentroblast division: CB r division \u2212 \u2212\u2212\u2212 \u2192 2CB CBs proliferate up to 6 times in the DZ [14] , and randomly acquire mutations in their BCR genes through SHM after each division.", [["CBs", "ANATOMY", 195, 198], ["DZ", "CHEMICAL", 232, 234], ["BCR", "GENE_OR_GENE_PRODUCT", 282, 285], ["CB r division \u2212 \u2212\u2212\u2212 \u2192 2CB CBs", "CELL_LINE", 169, 198], ["BCR genes", "DNA", 282, 291], ["SHM", "DNA", 300, 303], ["CB r division", "TEST", 169, 182]]], ["Similarly to seeder cells, we endow CBs with a division counter, which allows them to divide up to 6 times depending on the amount of T FH help received.", [["seeder cells", "ANATOMY", 13, 25], ["CBs", "ANATOMY", 36, 39], ["seeder cells", "CELL", 13, 25], ["CBs", "CELLULAR_COMPONENT", 36, 39], ["T FH", "GENE_OR_GENE_PRODUCT", 134, 138], ["seeder cells", "CELL_TYPE", 13, 25], ["seeder cells", "PROBLEM", 13, 25], ["a division counter", "TREATMENT", 45, 63], ["seeder cells", "OBSERVATION", 13, 25]]], ["Cells are only allowed to migrate to the LZ once the counter has fallen to 0.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5]]], ["The propensity of this reaction is:Stochastic Model of the GCEach daughter CB undergoes apoptosis (CB \u2212 \u2192 \u2205) with probability \u03b4 per mutation (see Section 2.2).Stochastic Model of the GCCentroblast migration DZ \u2192 LZ: CB r migration \u2212\u2212\u2212\u2212\u2192 CC Once a CB division counter drops to 0, the cell can migrate to the LZ, where its regulatory program significantly changes.", [["GCEach daughter CB", "ANATOMY", 59, 77], ["cell", "ANATOMY", 283, 287], ["DZ", "CHEMICAL", 207, 209], ["CC", "CHEMICAL", 237, 239], ["cell", "CELL", 283, 287], ["GCEach daughter CB", "CELL_LINE", 59, 77], ["this reaction", "PROBLEM", 18, 31], ["apoptosis", "PROBLEM", 88, 97], ["a CB division counter drops", "TREATMENT", 245, 272], ["migration DZ", "OBSERVATION", 197, 209], ["CB", "ANATOMY", 216, 218], ["migration", "OBSERVATION", 221, 230], ["LZ", "ANATOMY", 307, 309]]], ["The propensity of this reaction is:Stochastic Model of the GCExperiments suggest that class II MHC molecules are rapidly turned over on DZ B cells by ubiquitin-mediated degradation, ensuring that the peptide-MHC II density is reset after every LZ-DZ cycle [36] .", [["DZ B cells", "ANATOMY", 136, 146], ["DZ B", "CHEMICAL", 136, 140], ["DZ", "CHEMICAL", 247, 249], ["LZ-DZ", "CHEMICAL", 244, 249], ["class II MHC", "GENE_OR_GENE_PRODUCT", 86, 98], ["DZ B cells", "CELL", 136, 146], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 150, 159], ["class II MHC molecules", "PROTEIN", 86, 108], ["DZ B cells", "CELL_LINE", 136, 146], ["ubiquitin", "PROTEIN", 150, 159], ["MHC II", "PROTEIN", 208, 214], ["this reaction", "PROBLEM", 18, 31], ["class II MHC molecules", "PROBLEM", 86, 108], ["DZ B cells", "TREATMENT", 136, 146], ["ubiquitin-mediated degradation", "PROBLEM", 150, 180]]], ["Therefore, we assume that the number of antigen-MHC complexes is reset to 0 at the time of migration, which ensures fair selection against other newly activated CCs in the LZ.Stochastic Model of the GCCentrocyte antigen uptake from FDC: CC + FDC r FDC:CC \u2212 \u2212\u2212\u2212 \u2192 CC(pMHC) + FDC Centrocytes diffuse in the LZ until they encounter an FDC.", [["CCs", "ANATOMY", 161, 164], ["FDC", "ANATOMY", 232, 235], ["FDC", "ANATOMY", 242, 245], ["CC \u2212 \u2212\u2212\u2212 \u2192 CC(pMHC) + FDC", "ANATOMY", 252, 277], ["FDC", "ANATOMY", 332, 335], ["CC", "CHEMICAL", 237, 239], ["CC", "CHEMICAL", 252, 254], ["CC", "CHEMICAL", 263, 265], ["antigen-MHC", "GENE_OR_GENE_PRODUCT", 40, 51], ["CCs", "CELL", 161, 164], ["GCCentrocyte antigen", "GENE_OR_GENE_PRODUCT", 199, 219], ["FDC", "CELL", 232, 235], ["antigen-MHC complexes", "PROTEIN", 40, 61], ["GCCentrocyte antigen", "PROTEIN", 199, 219], ["FDC", "CELL_TYPE", 232, 235], ["CC", "CELL_TYPE", 237, 239], ["FDC", "CELL_TYPE", 242, 245], ["FDC", "CELL_TYPE", 248, 251], ["FDC", "CELL_TYPE", 274, 277], ["FDC", "CELL_TYPE", 332, 335], ["antigen-MHC complexes", "TREATMENT", 40, 61], ["other newly activated CCs in the LZ", "PROBLEM", 139, 174], ["Stochastic Model", "TEST", 175, 191], ["the GCCentrocyte antigen uptake", "TEST", 195, 226], ["FDC", "TEST", 232, 235], ["CC", "TEST", 237, 239], ["FDC", "TEST", 242, 245], ["FDC", "TEST", 248, 251], ["CC", "TEST", 252, 254], ["\u2212", "TEST", 255, 256], ["\u2212\u2212\u2212", "TEST", 257, 260], ["CC", "TEST", 263, 265], ["pMHC", "TEST", 266, 270], ["FDC", "TEST", 274, 277], ["Centrocytes", "TEST", 278, 289], ["diffuse in the LZ", "PROBLEM", 290, 307], ["LZ", "ANATOMY", 172, 174], ["diffuse", "OBSERVATION_MODIFIER", 290, 297], ["LZ", "ANATOMY", 305, 307], ["FDC", "OBSERVATION", 332, 335]]], ["Since the encounter rate is inversely proportional to the LZ volume, r FDC-CC \u221d 1/vol LZ , i.e., it is more likely for a CC to encounter a given FDC when the GC volume is small.", [["CC", "CHEMICAL", 75, 77], ["CC", "CHEMICAL", 121, 123], ["FDC", "CELL", 145, 148], ["FDC", "CELL_TYPE", 145, 148], ["the LZ volume", "TEST", 54, 67], ["the GC volume", "TEST", 154, 167], ["more likely", "UNCERTAINTY", 103, 114], ["GC volume", "OBSERVATION", 158, 167], ["small", "OBSERVATION_MODIFIER", 171, 176]]], ["As vol LZ is proportional to the number of CCs, N CC , the propensity can be written as:Stochastic Model of the GCWe assume that antigen uptake occurs when a CC encounters an FDC, upon which, the CC acquires antigens in an affinity-dependent manner and re-exposes on its surface as a pMHC complex.", [["FDC", "ANATOMY", 175, 178], ["surface", "ANATOMY", 271, 278], ["CC", "CHEMICAL", 50, 52], ["CC", "CHEMICAL", 158, 160], ["CC", "CHEMICAL", 196, 198], ["vol LZ", "GENE_OR_GENE_PRODUCT", 3, 9], ["CCs", "CELL", 43, 46], ["antigen", "GENE_OR_GENE_PRODUCT", 129, 136], ["FDC", "CELL", 175, 178], ["surface", "CELLULAR_COMPONENT", 271, 278], ["pMHC", "GENE_OR_GENE_PRODUCT", 284, 288], ["GCWe", "PROTEIN", 112, 116], ["FDC", "CELL_TYPE", 175, 178], ["pMHC complex", "PROTEIN", 284, 296], ["antigen uptake", "PROBLEM", 129, 143], ["the CC acquires antigens", "TEST", 192, 216]]], ["Mature B cells have been reported to carry up to 10 5 BCRs on their cell surface [37] , and FDCs present a very large amount of antigen [38] , hence we assume that there is no competition for antigen and a B cell can acquire as much antigen as the affinity of its BCR allows.", [["B cells", "ANATOMY", 7, 14], ["cell surface", "ANATOMY", 68, 80], ["FDCs", "ANATOMY", 92, 96], ["B cell", "ANATOMY", 206, 212], ["B cells", "CELL", 7, 14], ["BCRs", "GENE_OR_GENE_PRODUCT", 54, 58], ["cell", "CELL", 68, 72], ["FDCs", "CELL", 92, 96], ["B cell", "CELL", 206, 212], ["BCR", "GENE_OR_GENE_PRODUCT", 264, 267], ["B cells", "CELL_TYPE", 7, 14], ["BCRs", "PROTEIN", 54, 58], ["FDCs", "CELL_TYPE", 92, 96], ["B cell", "CELL_TYPE", 206, 212], ["BCR", "PROTEIN", 264, 267], ["Mature B cells", "PROBLEM", 0, 14], ["antigen", "PROBLEM", 192, 199], ["a B cell", "PROBLEM", 204, 212]]], ["Therefore, upon contact with an FDC, the pMHC complex of the centrocyte is updated with pMHC = affinity CC .", [["FDC", "ANATOMY", 32, 35], ["centrocyte", "ANATOMY", 61, 71], ["CC", "CHEMICAL", 104, 106], ["FDC", "CELL", 32, 35], ["pMHC", "GENE_OR_GENE_PRODUCT", 41, 45], ["centrocyte", "CANCER", 61, 71], ["pMHC", "GENE_OR_GENE_PRODUCT", 88, 92], ["FDC", "CELL_TYPE", 32, 35], ["pMHC complex", "PROTEIN", 41, 53], ["pMHC", "PROTEIN", 88, 92]]], ["In the event of the CC having previously acquired antigens from another FDC, the pMHC complex is replaced.", [["FDC", "ANATOMY", 72, 75], ["CC", "CHEMICAL", 20, 22], ["CC", "CANCER", 20, 22], ["FDC", "CELL", 72, 75], ["pMHC", "GENE_OR_GENE_PRODUCT", 81, 85], ["FDC", "CELL_TYPE", 72, 75], ["pMHC complex", "PROTEIN", 81, 93], ["previously acquired antigens", "PROBLEM", 30, 58]]], ["The interaction of GC B cells with FDCs is of the order of a second [6, 39] , and hence, we do not explicitly model the binding time between B cells and FDCs.", [["GC B cells", "ANATOMY", 19, 29], ["FDCs", "ANATOMY", 35, 39], ["B cells", "ANATOMY", 141, 148], ["FDCs", "ANATOMY", 153, 157], ["GC B cells", "CELL", 19, 29], ["FDCs", "CELL", 35, 39], ["B cells", "CELL", 141, 148], ["FDCs", "CELL", 153, 157], ["GC B cells", "CELL_TYPE", 19, 29], ["FDCs", "CELL_TYPE", 35, 39], ["B cells", "CELL_TYPE", 141, 148], ["FDCs", "CELL_TYPE", 153, 157]]], ["Alternative models that take into account spatial motion have included a refractory time during which a B cell cannot attempt antigen binding again [22] .", [["B cell", "ANATOMY", 104, 110], ["B cell", "CELL", 104, 110], ["B cell", "CELL_TYPE", 104, 110], ["a B cell", "TREATMENT", 102, 110]]], ["This interval is necessary to give time for the CC to diffuse away from the FDC and prevent repetitive binding.", [["FDC", "ANATOMY", 76, 79], ["CC", "CHEMICAL", 48, 50], ["FDC", "CELL", 76, 79], ["FDC", "CELL_TYPE", 76, 79], ["repetitive binding", "PROBLEM", 92, 110], ["diffuse", "OBSERVATION_MODIFIER", 54, 61]]], ["However this is not necessary in our model, as the Gillespie algorithm models cellular distributions, and the probability of the same CC-FDC pair binding more than once is very small, \u223c (r FDC:CC / \u2211 i propensity (reaction i )) 2 .", [["cellular", "ANATOMY", 78, 86], ["CC", "CHEMICAL", 134, 136], ["cellular", "CELL", 78, 86], ["FDC", "CELL_TYPE", 137, 140], ["not necessary", "UNCERTAINTY", 16, 29], ["cellular distributions", "OBSERVATION", 78, 100]]], ["Centrocyte-T FH binding: CC + T FH r TC:CC \u2212\u2212\u2212\u2192 [CCTC] After acquiring antigen, CCs diffuse into the LZ until they encounter a free T FH .", [["CC", "CHEMICAL", 25, 27], ["CC", "CHEMICAL", 40, 42], ["FH", "DISEASE", 134, 136], ["Centrocyte-T FH", "GENE_OR_GENE_PRODUCT", 0, 15], ["T FH", "CANCER", 132, 136], ["Centrocyte-", "TEST", 0, 11], ["CC", "TEST", 25, 27], ["TC", "TEST", 37, 39], ["CC", "TEST", 40, 42], ["\u2212\u2212\u2212\u2192", "TEST", 43, 47], ["CCTC", "TEST", 49, 53], ["acquiring antigen", "TEST", 61, 78], ["CCs diffuse into the LZ", "PROBLEM", 80, 103], ["LZ", "ANATOMY", 101, 103]]], ["Upon encounter, CCs attempt to bind their pMHCs ligands to the T cell receptors expressed on the surface of the T FHs .", [["T cell", "ANATOMY", 63, 69], ["surface", "ANATOMY", 97, 104], ["T FHs", "ANATOMY", 112, 117], ["pMHCs", "GENE_OR_GENE_PRODUCT", 42, 47], ["T cell receptors", "GENE_OR_GENE_PRODUCT", 63, 79], ["surface", "CELLULAR_COMPONENT", 97, 104], ["T FHs", "GENE_OR_GENE_PRODUCT", 112, 117], ["pMHCs", "PROTEIN", 42, 47], ["T cell receptors", "PROTEIN", 63, 79], ["T FHs", "CELL_TYPE", 112, 117], ["the T cell receptors", "TREATMENT", 59, 79]]], ["The propensity is derived in the same manner as for the encouters with FDCs:Stochastic Model of the GCRegarding the number of unbound T FHs , T FHs enter and leave the GC during the whole reaction [40] .", [["T FHs", "GENE_OR_GENE_PRODUCT", 134, 139], ["T FHs", "GENE_OR_GENE_PRODUCT", 142, 147], ["FDCs", "CELL_TYPE", 71, 75], ["unbound T FHs", "PROTEIN", 126, 139], ["T FHs", "PROTEIN", 142, 147]]], ["Therefore, our model assumes that a homeostatic flow of T FHs has been established that leads to an approximately constant density of T FHs during the whole reaction [18] (see Section 2.4 for a more detailed discussion).", [["T FHs", "CHEMICAL", 56, 61], ["T FHs", "GENE_OR_GENE_PRODUCT", 56, 61], ["T FHs", "GENE_OR_GENE_PRODUCT", 134, 139], ["T FHs", "PROTEIN", 56, 61], ["T FHs", "PROTEIN", 134, 139]]], ["Since the volume of the LZ is proportional to the number of CCs, we can write:Stochastic Model of the GCTo implement this constraint, we dynamically adjust the number of T FHs at every iteration of the Gillespie algorithm such that the above equation is always verified.Centrocyte competition for TTC] Two-photon microscopy imaging reveals that the majority of T FHs in GCs are not engaged in stable interactions with B cells, but instead, most contacts between GC B cells and T FHs are of short duration (<5 min) [6] .", [["T FHs", "ANATOMY", 361, 366], ["GCs", "ANATOMY", 370, 373], ["B cells", "ANATOMY", 418, 425], ["GC B cells", "ANATOMY", 462, 472], ["T FHs", "ANATOMY", 477, 482], ["T FHs", "GENE_OR_GENE_PRODUCT", 170, 175], ["T FHs", "GENE_OR_GENE_PRODUCT", 361, 366], ["GCs", "CELL", 370, 373], ["B cells", "CELL", 418, 425], ["GC B cells", "CELL", 462, 472], ["T FHs", "GENE_OR_GENE_PRODUCT", 477, 482], ["LZ", "PROTEIN", 24, 26], ["T FHs", "PROTEIN", 170, 175], ["T FHs", "PROTEIN", 361, 366], ["B cells", "CELL_TYPE", 418, 425], ["GC B cells", "CELL_TYPE", 462, 472], ["T FHs", "CELL_TYPE", 477, 482], ["the Gillespie algorithm", "TREATMENT", 198, 221], ["the above equation", "TEST", 232, 250], ["Two-photon microscopy imaging", "TEST", 302, 331], ["B cells", "PROBLEM", 418, 425], ["stable", "OBSERVATION_MODIFIER", 393, 399]]], ["In our model, we replicate this phenomenon by introducing a competition between the CCs to bind to T FHs .", [["T FHs", "ANATOMY", 99, 104], ["T FHs", "GENE_OR_GENE_PRODUCT", 99, 104], ["T FHs", "PROTEIN", 99, 104], ["this phenomenon", "TREATMENT", 27, 42]]], ["We assume that, if during the time a CC 1 is bound to a T FHs a second CC 2 attempts to bind to the same T FH , the CC with the larger amount of pMHC will remain bound and the other CC will be rejected [20] .", [["CC", "CHEMICAL", 37, 39], ["CC", "CHEMICAL", 71, 73], ["CC", "CHEMICAL", 116, 118], ["CC", "CHEMICAL", 182, 184], ["T FH", "GENE_OR_GENE_PRODUCT", 105, 109], ["pMHC", "GENE_OR_GENE_PRODUCT", 145, 149], ["T FHs", "PROTEIN", 56, 61], ["T FH", "PROTEIN", 105, 109], ["pMHC", "PROTEIN", 145, 149], ["a T FHs a second CC 2 attempts", "TREATMENT", 54, 84]]], ["The propensity can be written as:Centrocyte competition for TAs a result of this competition, a CC can interact with a T FH multiple times for shorter amounts of time in our model.", [["CC", "CHEMICAL", 96, 98], ["T FH", "GENE_OR_GENE_PRODUCT", 119, 123], ["a T FH", "TREATMENT", 117, 123]]], ["We assume that all these signals are cumulative and contribute towards fate decision [23, 41] .Centrocyte competition for TFurthermore, a CC substitution reaction happens in the timescale of a diffusion process, which is typically much faster than the timescale of the GC reaction.", [["TFurthermore", "CHEMICAL", 122, 134], ["CC", "CHEMICAL", 138, 140], ["TFurthermore", "TREATMENT", 122, 134], ["a CC substitution reaction", "TREATMENT", 136, 162], ["a diffusion process", "PROBLEM", 191, 210], ["the GC reaction", "PROBLEM", 265, 280]]], ["Hence, we neglect the time associated with the unbinding of CC 1 and binding of CC 2 , and assume that this reaction has the same rate as a standard CC-T FH binding.", [["CC", "CHEMICAL", 60, 62], ["CC", "CHEMICAL", 80, 82], ["CC", "CHEMICAL", 149, 151], ["CC 1", "GENE_OR_GENE_PRODUCT", 60, 64], ["this reaction", "PROBLEM", 103, 116]]], ["Once a CC and T FH unbind after the CC has received enough T FH signal, the T FH cell is released and the CC switches to the state selected.", [["T FH cell", "ANATOMY", 76, 85], ["CC", "CHEMICAL", 7, 9], ["CC", "CHEMICAL", 36, 38], ["CC", "CHEMICAL", 106, 108], ["T FH cell", "CELL", 76, 85], ["T FH cell", "CELL_TYPE", 76, 85], ["FH cell", "OBSERVATION", 78, 85]]], ["Centrocyte apoptosis: CC r apoptosis \u2212\u2212\u2212\u2212\u2192 \u2205 All CCs are subjected to a timed program regardless of their BCR affinity, and undergo apoptosis with rate r apoptosis if not rescued by T FH signals:Centrocyte-T FH spontaneous unbinding: [CCTC]Centrocyte recirculation: CC sel r recirculate \u2212 \u2212\u2212\u2212\u2212 \u2192 CB Selected CCs can recircule into the DZ for additional rounds of division and affinity maturation.", [["Centrocyte", "ANATOMY", 0, 10], ["CCs", "ANATOMY", 49, 52], ["CCs", "ANATOMY", 308, 311], ["CC", "CHEMICAL", 22, 24], ["CC", "CHEMICAL", 266, 268], ["DZ", "CHEMICAL", 335, 337], ["Centrocyte", "CELL", 0, 10], ["CCs", "CELL", 49, 52], ["BCR", "GENE_OR_GENE_PRODUCT", 106, 109], ["T FH", "GENE_OR_GENE_PRODUCT", 182, 186], ["Centrocyte-T FH", "GENE_OR_GENE_PRODUCT", 195, 210], ["DZ", "SIMPLE_CHEMICAL", 335, 337], ["CCs", "CELL_TYPE", 49, 52], ["BCR", "PROTEIN", 106, 109], ["Centrocyte apoptosis", "TEST", 0, 20], ["their BCR affinity", "PROBLEM", 100, 118], ["apoptosis", "PROBLEM", 132, 141], ["rate r apoptosis", "TEST", 147, 163], ["Centrocyte", "TEST", 195, 205], ["CCTC", "TEST", 235, 239], ["Centrocyte recirculation", "TEST", 240, 264], ["affinity maturation", "TREATMENT", 376, 395], ["CC r", "OBSERVATION_MODIFIER", 22, 26], ["apoptosis", "OBSERVATION", 27, 36], ["DZ", "OBSERVATION", 335, 337]]], ["Their division counter is reset to 1-6 depending on the amount of T FH signals received (Section 2.6).Centrocyte-T FH spontaneous unbinding: [CCTC]Centrocyte exit: CC sel r exit \u2212 \u2212 \u2192 MBC or PC Similarly, CC sel can terminally differentiate as a PC or MBC with the following propensity:Centrocyte-T FH spontaneous unbinding: [CCTC]We assume that once a CC has been selected to differentiate, it becomes a PM or a MBC in a pMHC-dependent manner.", [["PC", "ANATOMY", 191, 193], ["PC", "ANATOMY", 246, 248], ["MBC", "ANATOMY", 252, 255], ["PM", "ANATOMY", 405, 407], ["MBC", "ANATOMY", 413, 416], ["CC", "CHEMICAL", 164, 166], ["MBC", "CHEMICAL", 184, 187], ["CC", "CHEMICAL", 205, 207], ["CC", "CHEMICAL", 353, 355], ["MBC", "CHEMICAL", 413, 416], ["Centrocyte-T FH", "GENE_OR_GENE_PRODUCT", 102, 117], ["PC", "CANCER", 246, 248], ["MBC", "CANCER", 252, 255], ["MBC", "CANCER", 413, 416], ["pMHC", "GENE_OR_GENE_PRODUCT", 422, 426], ["CC", "PROTEIN", 353, 355], ["pMHC", "PROTEIN", 422, 426], ["Centrocyte", "TEST", 102, 112], ["CCTC", "TEST", 142, 146], ["MBC", "TEST", 184, 187], ["PC", "PROBLEM", 191, 193], ["a PC", "TEST", 244, 248], ["Centrocyte", "TEST", 286, 296], ["a MBC", "TEST", 411, 416]]], ["In Section 2.7, we computationally investigate three alternative scenarios to determine fate choice.Cell Fate after Somatic HypermutationMost of the variability of an antibody is concentrated into three hypervariable loops called complementarity determining regions, CDR1, CDR2, and CDR3, which are responsible for the extensive range of antigens with which antibodies can interact [42] .", [["Cell", "ANATOMY", 100, 104], ["Cell", "CELL", 100, 104], ["CDR1", "GENE_OR_GENE_PRODUCT", 267, 271], ["CDR2", "GENE_OR_GENE_PRODUCT", 273, 277], ["CDR3", "GENE_OR_GENE_PRODUCT", 283, 287], ["complementarity determining regions", "DNA", 230, 265], ["CDR1", "DNA", 267, 271], ["CDR2", "DNA", 273, 277], ["CDR3", "DNA", 283, 287], ["antigens", "PROTEIN", 338, 346], ["antibodies", "PROTEIN", 358, 368], ["Somatic Hypermutation", "PROBLEM", 116, 137], ["an antibody", "TEST", 164, 175], ["CDR1", "PROBLEM", 267, 271], ["CDR2", "TEST", 273, 277], ["CDR3", "TEST", 283, 287], ["the extensive range of antigens", "PROBLEM", 315, 346], ["Somatic Hypermutation", "OBSERVATION", 116, 137], ["hypervariable loops", "OBSERVATION", 203, 222]]], ["A mutation in the CDR typically modifies the antigen binding properties of the BCR [43] , while a mutation in the surrounding framework regions (FWR) might compromise its structural support and potentially lead to apoptosis.", [["BCR", "GENE_OR_GENE_PRODUCT", 79, 82], ["CDR", "DNA", 18, 21], ["BCR", "PROTEIN", 79, 82], ["FWR", "DNA", 145, 148], ["A mutation in the CDR", "PROBLEM", 0, 21], ["a mutation", "PROBLEM", 96, 106], ["apoptosis", "PROBLEM", 214, 223]]], ["Not surprisingly, CDR chains show higher variability than FWR chains [44] , although this might be due to posterior selection [6] .Cell Fate after Somatic HypermutationWe model the effect of a mutation using a decision tree [24] .", [["Cell", "ANATOMY", 131, 135], ["CDR chains", "GENE_OR_GENE_PRODUCT", 18, 28], ["Cell", "CELL", 131, 135], ["CDR chains", "PROTEIN", 18, 28], ["FWR chains", "PROTEIN", 58, 68], ["CDR chains", "TEST", 18, 28], ["higher variability than FWR chains", "PROBLEM", 34, 68], ["a mutation", "PROBLEM", 191, 201], ["higher", "OBSERVATION_MODIFIER", 34, 40], ["variability", "OBSERVATION_MODIFIER", 41, 52], ["might be due to", "UNCERTAINTY", 90, 105], ["posterior", "ANATOMY_MODIFIER", 106, 115]]], ["In this representation, a nucleotide change can either: (1) be neutral or silent, i.e., the mutation has no impact on affinity, with probability \u03c3; (2) result in a nonproductive BCR that leads to apoptosis with probability \u03b4; or (3) change the affinity of the BCR with probability \u03b2 = 1 \u2212 \u03c3 \u2212 \u03b4 ( Figure 2 ).", [["nucleotide", "CHEMICAL", 26, 36], ["nucleotide", "CHEMICAL", 26, 36], ["BCR", "GENE_OR_GENE_PRODUCT", 178, 181], ["BCR", "GENE_OR_GENE_PRODUCT", 260, 263], ["BCR", "PROTEIN", 178, 181], ["BCR", "PROTEIN", 260, 263], ["a nucleotide change", "PROBLEM", 24, 43], ["the mutation", "PROBLEM", 88, 100], ["a nonproductive BCR", "PROBLEM", 162, 181], ["apoptosis", "PROBLEM", 196, 205], ["the BCR", "TEST", 256, 263], ["probability", "TEST", 269, 280], ["silent", "OBSERVATION", 74, 80]]], ["In our simulation, we assume that a mutation can happen in both the FWR and CDR regions, although only mutations in the CDR region can lead to a change in affinity.", [["FWR", "GENE_OR_GENE_PRODUCT", 68, 71], ["FWR and CDR regions", "DNA", 68, 87], ["CDR region", "DNA", 120, 130], ["a mutation", "PROBLEM", 34, 44], ["mutations in the CDR region", "PROBLEM", 103, 130], ["a change in affinity", "PROBLEM", 143, 163]]], ["To model the effect of a mutation, we draw two random numbers.", [["a mutation", "PROBLEM", 23, 33]]], ["The first number determines the number of single nucleotide changes in the whole BCR sequence according to a binomial distribution with parameters N BCR = 660 [45] and p SHM = 1 \u00d7 10 \u22123 [46] .", [["nucleotide", "CHEMICAL", 49, 59], ["nucleotide", "CHEMICAL", 49, 59], ["BCR", "GENE_OR_GENE_PRODUCT", 81, 84], ["BCR sequence", "DNA", 81, 93], ["single nucleotide changes", "PROBLEM", 42, 67], ["the whole BCR sequence", "TREATMENT", 71, 93], ["BCR", "TEST", 149, 152], ["SHM", "TEST", 170, 173]]], ["The second random number determines the impact of each mutation according to Figure 2 . .", [["each mutation", "TREATMENT", 50, 63]]], ["The number of mutations in the BCR after each centroblast division is sampled from a binomial distribution.", [["BCR", "GENE_OR_GENE_PRODUCT", 31, 34], ["BCR", "PROTEIN", 31, 34], ["mutations in the BCR", "PROBLEM", 14, 34], ["mutations", "OBSERVATION", 14, 23], ["binomial distribution", "OBSERVATION", 85, 106]]], ["Each mutation can produce a BCR of similar affinity, lead to cell apoptosis or produce a BCR of different affinity with probability \u03c3, \u03b4, and \u03b2 respectively.B Cell Receptor Affinity to EpitoteTo model changes in affinity, we only consider the sequence S CDR of the CDR region of each BCR.", [["cell", "ANATOMY", 61, 65], ["Cell", "ANATOMY", 159, 163], ["BCR", "GENE_OR_GENE_PRODUCT", 28, 31], ["cell", "CELL", 61, 65], ["BCR", "GENE_OR_GENE_PRODUCT", 89, 92], ["\u03c3", "GENE_OR_GENE_PRODUCT", 132, 133], ["\u03b4", "GENE_OR_GENE_PRODUCT", 135, 136], ["\u03b2", "GENE_OR_GENE_PRODUCT", 142, 143], ["Cell", "CELL", 159, 163], ["BCR", "GENE_OR_GENE_PRODUCT", 284, 287], ["BCR", "PROTEIN", 28, 31], ["BCR", "PROTEIN", 89, 92], ["\u03c3", "PROTEIN", 132, 133], ["\u03b4", "PROTEIN", 135, 136], ["\u03b2", "PROTEIN", 142, 143], ["CDR region", "DNA", 265, 275], ["BCR", "PROTEIN", 284, 287], ["Each mutation", "PROBLEM", 0, 13], ["a BCR", "PROBLEM", 26, 31], ["similar affinity", "PROBLEM", 35, 51], ["cell apoptosis", "PROBLEM", 61, 75], ["a BCR of different affinity", "PROBLEM", 87, 114], ["model changes in affinity", "PROBLEM", 195, 220], ["the sequence S CDR", "TEST", 239, 257], ["each BCR", "PROBLEM", 279, 287], ["cell apoptosis", "OBSERVATION", 61, 75], ["BCR", "OBSERVATION", 284, 287]]], ["Each sequence S CDR is composed of N CDR sites that can take 4 possibles values \u2208 [A, T, G, C].", [["N CDR sites", "DNA", 35, 46], ["Each sequence S CDR", "TEST", 0, 19], ["N CDR sites", "PROBLEM", 35, 46]]], ["To simplify sequence comparison, we further assume that all the BCRs sequences are of the same length (N CDR = 25).", [["BCRs", "GENE_OR_GENE_PRODUCT", 64, 68], ["BCRs sequences", "DNA", 64, 78], ["all the BCRs sequences", "TEST", 56, 78], ["CDR", "TEST", 105, 108]]], ["We define the affinity of a sequence by using the normalized Hamming distance between the sequence S CDR and the optimal CDR sequence S 0 to bind the target antigen, as follows:B Cell Receptor Affinity to EpitoteWhile this representation does not consider the structural properties of the BCR, it has the advantage of modelling the effect of individual nucleotide changes and being computationally very cheap to compute, which enables the running of exhaustive simulations of the GC with a realistic number of cells.", [["Cell", "ANATOMY", 179, 183], ["cells", "ANATOMY", 510, 515], ["nucleotide", "CHEMICAL", 353, 363], ["nucleotide", "CHEMICAL", 353, 363], ["Cell", "CELL", 179, 183], ["BCR", "GENE_OR_GENE_PRODUCT", 289, 292], ["cells", "CELL", 510, 515], ["sequence S CDR", "DNA", 90, 104], ["CDR sequence S 0", "DNA", 121, 137], ["BCR", "PROTEIN", 289, 292], ["the sequence S CDR", "TEST", 86, 104], ["the optimal CDR sequence S", "TEST", 109, 135], ["the BCR", "PROBLEM", 285, 292], ["individual nucleotide changes", "PROBLEM", 342, 371], ["BCR", "OBSERVATION", 289, 292]]], ["Furthermore, Equation (1) is bounded by 0 \u2264 a CDR \u2264 1, and hence, a CDR is endowed with the general properties expected of any physiologically relevant affinity function.", [["a CDR", "TEST", 66, 71]]], ["For instance, it becomes probabilistically less likely to increase the affinity of a sequence that is close to the upper bound.", [["upper", "ANATOMY_MODIFIER", 115, 120]]], ["Conversely, if a sequence exhibits low affinity, there is a wide range of mutations that can significantly increase the affinity.", [["low affinity", "PROBLEM", 35, 47], ["a wide range of mutations", "PROBLEM", 58, 83]]], ["Our definition of affinity has strong similarities with previously postulated affinity measures [47] , with the important difference being that we use the Hamming distance instead of the Euclidean distance, which is more adequate to work with strings of characters (nucleotides).", [["nucleotides", "CHEMICAL", 266, 277]]], ["It also agrees with other postulated properties of the affinity function such as: homogeneity, i.e., the function applies equally well to all regions of the shape space; complementarity, i.e., the optimal sequence can also be represented as a sequence, where shortest distance to the antigen sequence corresponds to greater affinity; and smoothness, i.e., small changes in the distance correspond to small changes in the affinity [48] .T FH DynamicsTwo-photon microscopy experiments have shown that T FHs exist in a state of dynamic exchange between different GCs in a lymph node, and newly activated T FHs can invade pre-established GCs and contribute to B cell selection and plasmablast differentiation [40] .", [["GCs", "ANATOMY", 560, 563], ["lymph node", "ANATOMY", 569, 579], ["T FHs", "ANATOMY", 601, 606], ["GCs", "ANATOMY", 634, 637], ["B cell", "ANATOMY", 656, 662], ["plasmablast", "ANATOMY", 677, 688], ["T FHs", "GENE_OR_GENE_PRODUCT", 499, 504], ["GCs", "CELL", 560, 563], ["lymph node", "MULTI-TISSUE_STRUCTURE", 569, 579], ["T FHs", "GENE_OR_GENE_PRODUCT", 601, 606], ["GCs", "CELL", 634, 637], ["B cell", "CELL", 656, 662], ["antigen sequence", "PROTEIN", 284, 300], ["T FHs", "PROTEIN", 499, 504], ["T FHs", "CELL_TYPE", 601, 606], ["a sequence", "TEST", 241, 251], ["the antigen sequence", "TEST", 280, 300], ["small changes in the distance", "PROBLEM", 356, 385], ["small changes in the affinity", "PROBLEM", 400, 429], ["photon microscopy experiments", "TEST", 453, 482], ["a lymph node", "PROBLEM", 567, 579], ["B cell selection", "TREATMENT", 656, 672], ["shape", "OBSERVATION_MODIFIER", 157, 162], ["greater affinity", "OBSERVATION_MODIFIER", 316, 332], ["small", "OBSERVATION_MODIFIER", 356, 361], ["changes", "OBSERVATION", 362, 369], ["small", "OBSERVATION_MODIFIER", 400, 405], ["lymph node", "OBSERVATION", 569, 579], ["cell selection", "OBSERVATION", 658, 672]]], ["Furthermore, T FHs also proliferate [18] , which results in cell count variability across time points.", [["T FHs", "ANATOMY", 13, 18], ["cell", "ANATOMY", 60, 64], ["T FHs", "GENE_OR_GENE_PRODUCT", 13, 18], ["cell", "CELL", 60, 64], ["T FHs", "PROTEIN", 13, 18], ["cell count variability", "PROBLEM", 60, 82], ["cell count", "OBSERVATION", 60, 70]]], ["However, the ratio of GC B cells to T FHs in the LZ appears to be maintained at a relatively constant ratio of \u223c7:1 through the entire GC reaction [18] .", [["GC B cells", "ANATOMY", 22, 32], ["GC B cells", "CELL", 22, 32], ["T FHs", "GENE_OR_GENE_PRODUCT", 36, 41], ["GC B cells", "CELL_TYPE", 22, 32], ["T FHs", "PROTEIN", 36, 41], ["the ratio", "TEST", 9, 18], ["GC B cells", "PROBLEM", 22, 32], ["LZ", "ANATOMY", 49, 51], ["appears to be", "UNCERTAINTY", 52, 65]]], ["We also note that a constant ratio of CC:T FHs results in an approximately constant probability of a CC encountering a T FH through the whole GC response.T FH DynamicsIn a typical GC, T FHs are activated by a variety of different antigens, and hence, CCs can only successfully bind to a subset of the available T FHs .", [["GC", "ANATOMY", 180, 182], ["T FHs", "ANATOMY", 184, 189], ["CC", "CHEMICAL", 38, 40], ["CC", "CHEMICAL", 101, 103], ["T FH", "GENE_OR_GENE_PRODUCT", 119, 123], ["GC", "CELL", 180, 182], ["T FHs", "GENE_OR_GENE_PRODUCT", 184, 189], ["T FHs", "GENE_OR_GENE_PRODUCT", 311, 316], ["T FHs", "CELL_TYPE", 184, 189], ["antigens", "PROTEIN", 230, 238], ["T FHs", "PROTEIN", 311, 316]]], ["Since our model assumes that only one type of antigen is presented by the FDCs and acquired by CCs, we decrease the experimentally determined CC:T FHs ratio to a lower number, which we optimise using time resolved measurements on GC kinetics data (Section 2.10).", [["FDCs", "ANATOMY", 74, 78], ["CC", "CHEMICAL", 142, 144], ["FDCs", "CELL", 74, 78], ["T FHs", "GENE_OR_GENE_PRODUCT", 145, 150], ["FDCs", "CELL_TYPE", 74, 78], ["GC kinetics data", "TEST", 230, 246]]], ["Our estimation is that the optimal effective ratio is \u22481/46, suggesting that only 15% of measured T FHs are specialized to a specific antigen.T FH Survival SignalsThe signaling interaction between a CC and a T FH is non-linear: ICOSL on B cells promotes upregulation of CD40L on T cells, which in turn further upregulates ICOSL on the B cell, creating a positive feedback loop that promotes a mode of intimate contact in which a large area of the B and T cell surfaces are juxtaposed [49] .", [["B cells", "ANATOMY", 237, 244], ["T cells", "ANATOMY", 279, 286], ["B cell", "ANATOMY", 335, 341], ["B", "ANATOMY", 447, 448], ["T cell surfaces", "ANATOMY", 453, 468], ["CC", "CHEMICAL", 199, 201], ["T FHs", "GENE_OR_GENE_PRODUCT", 98, 103], ["CC", "CANCER", 199, 201], ["T FH", "GENE_OR_GENE_PRODUCT", 208, 212], ["ICOSL", "GENE_OR_GENE_PRODUCT", 228, 233], ["B cells", "CELL", 237, 244], ["CD40L", "GENE_OR_GENE_PRODUCT", 270, 275], ["T cells", "CELL", 279, 286], ["ICOSL", "GENE_OR_GENE_PRODUCT", 322, 327], ["B cell", "CELL", 335, 341], ["B", "CELL", 447, 448], ["T cell", "CELL", 453, 459], ["T FHs", "PROTEIN", 98, 103], ["T FH", "PROTEIN", 208, 212], ["ICOSL", "PROTEIN", 228, 233], ["B cells", "CELL_TYPE", 237, 244], ["CD40L", "PROTEIN", 270, 275], ["T cells", "CELL_TYPE", 279, 286], ["ICOSL", "PROTEIN", 322, 327], ["B cell", "CELL_TYPE", 335, 341], ["B cells", "TREATMENT", 237, 244], ["CD40L on T cells", "TREATMENT", 270, 286], ["a positive feedback loop", "PROBLEM", 352, 376], ["the B and T cell surfaces", "TREATMENT", 443, 468], ["positive", "OBSERVATION_MODIFIER", 354, 362], ["feedback loop", "OBSERVATION", 363, 376], ["large", "OBSERVATION_MODIFIER", 429, 434], ["area", "OBSERVATION_MODIFIER", 435, 439]]], ["Thus, small differences in pMHC density between B cells of different affinities can be nonlinearly amplified into large differences in signaling that allow for a more efficient selection of high affinity B cells.", [["B cells", "ANATOMY", 48, 55], ["high affinity B cells", "ANATOMY", 190, 211], ["pMHC", "GENE_OR_GENE_PRODUCT", 27, 31], ["B cells", "CELL", 48, 55], ["B cells", "CELL", 204, 211], ["pMHC", "PROTEIN", 27, 31], ["B cells", "CELL_TYPE", 48, 55], ["high affinity B cells", "CELL_TYPE", 190, 211], ["small differences in pMHC density", "PROBLEM", 6, 39], ["different affinities", "PROBLEM", 59, 79], ["high affinity B cells", "PROBLEM", 190, 211], ["small", "OBSERVATION_MODIFIER", 6, 11], ["differences", "OBSERVATION_MODIFIER", 12, 23], ["pMHC density", "OBSERVATION", 27, 39], ["large", "OBSERVATION_MODIFIER", 114, 119], ["high affinity", "OBSERVATION", 190, 203]]], ["To reproduce this behavior, we describe the strength of the binding signal using a family of monotonically increasing functions with parameter n, such as:T FH Survival Signalswhere the parameter n controls the strength of the nonlinear interaction: higher values of n make it harder for cells with low or moderate affinity to acquire T FH signals (see the Supplementary Information for a more detailed discussion).", [["cells", "ANATOMY", 287, 292], ["cells", "CELL", 287, 292], ["T FH", "GENE_OR_GENE_PRODUCT", 334, 338]]], ["At every unbinding event, the cumulative signal of the CC acquired from T FH is incremented with:T FH Survival SignalsThus, in our model, the total amount of help received from a T FHs is the cumulative signal obtained by aggregating the signals received through each encounter, however small, that a CC has with a T FH in the LZ.", [["CC", "CHEMICAL", 55, 57], ["CC", "CHEMICAL", 301, 303], ["FH", "DISEASE", 317, 319], ["T FH", "GENE_OR_GENE_PRODUCT", 72, 76], ["T FH", "GENE_OR_GENE_PRODUCT", 315, 319], ["T FHs", "PROTEIN", 179, 184], ["small", "OBSERVATION_MODIFIER", 287, 292], ["LZ", "ANATOMY", 327, 329]]], ["In practice, most encounters are of short duration and typically increase the cumulative T FHs help by only a small amount (70% of the bindings last for less than 5 min).", [["T FHs", "GENE_OR_GENE_PRODUCT", 89, 94], ["short duration", "OBSERVATION_MODIFIER", 36, 50], ["increase", "OBSERVATION_MODIFIER", 65, 73], ["small", "OBSERVATION_MODIFIER", 110, 115], ["amount", "OBSERVATION_MODIFIER", 116, 122]]], ["This mimics the observation that a CC probes and attempts to bind to many different T FHs endowed with different receptors, before receiving a substantial amount of signalling from a T FH with a compatible receptor.Regulation of the Cell CycleThe process of acquiring T cell help ends when a CC unbinds spontaneously from a T FH after having received signals for \u223c30 min, upon which, the CC is considered selected and can either leave the GC and terminally differentiate into a PC or a MBC, or recirculate into the DZ for further rounds of division and BCR maturation.", [["Cell", "ANATOMY", 233, 237], ["T cell", "ANATOMY", 268, 274], ["GC", "ANATOMY", 439, 441], ["PC", "ANATOMY", 478, 480], ["MBC", "ANATOMY", 486, 489], ["CC", "CHEMICAL", 35, 37], ["CC", "CHEMICAL", 292, 294], ["CC", "CHEMICAL", 388, 390], ["MBC", "CHEMICAL", 486, 489], ["DZ", "CHEMICAL", 515, 517], ["T FHs", "GENE_OR_GENE_PRODUCT", 84, 89], ["T FH", "GENE_OR_GENE_PRODUCT", 183, 187], ["Cell", "CELL", 233, 237], ["T cell", "CELL", 268, 274], ["T FH", "CANCER", 324, 328], ["GC", "CELL", 439, 441], ["PC", "CANCER", 478, 480], ["MBC", "CANCER", 486, 489], ["DZ", "SIMPLE_CHEMICAL", 515, 517], ["BCR", "GENE_OR_GENE_PRODUCT", 553, 556], ["T FHs", "PROTEIN", 84, 89], ["T FH", "PROTEIN", 183, 187], ["T cell", "CELL_TYPE", 268, 274], ["BCR", "PROTEIN", 553, 556], ["a CC probes", "TREATMENT", 33, 44], ["different receptors", "TREATMENT", 103, 122], ["a MBC", "TEST", 484, 489], ["BCR maturation", "TREATMENT", 553, 567], ["Cell Cycle", "OBSERVATION", 233, 243], ["DZ", "OBSERVATION", 515, 517], ["BCR maturation", "OBSERVATION", 553, 567]]], ["Cells that recirculate into the DZ regulate their cell cycle speed according to the amount of T FHs help received, with cells that have received strong signals being able to replicate up to 6 times [10, 14] .", [["Cells", "ANATOMY", 0, 5], ["DZ", "ANATOMY", 32, 34], ["cell", "ANATOMY", 50, 54], ["cells", "ANATOMY", 120, 125], ["DZ", "CHEMICAL", 32, 34], ["Cells", "CELL", 0, 5], ["DZ", "SIMPLE_CHEMICAL", 32, 34], ["cell", "CELL", 50, 54], ["T FHs", "GENE_OR_GENE_PRODUCT", 94, 99], ["cells", "CELL", 120, 125], ["T FHs", "PROTEIN", 94, 99], ["DZ", "OBSERVATION", 32, 34]]], ["The regulation of the cell cycle is likely to be induced by MYC [11, 13] , a cell-cycle regulator that is upregulated by T FH help in cells selected for reentry into the DZ [12] .", [["cell", "ANATOMY", 22, 26], ["cell", "ANATOMY", 77, 81], ["cells", "ANATOMY", 134, 139], ["DZ", "CHEMICAL", 170, 172], ["cell", "CELL", 22, 26], ["MYC [11, 13", "GENE_OR_GENE_PRODUCT", 60, 71], ["cell", "CELL", 77, 81], ["T FH", "GENE_OR_GENE_PRODUCT", 121, 125], ["cells", "CELL", 134, 139], ["MYC", "PROTEIN", 60, 63], ["cell-cycle regulator", "PROTEIN", 77, 97], ["a cell-cycle regulator", "TREATMENT", 75, 97], ["cell cycle", "OBSERVATION", 22, 32], ["likely to be", "UNCERTAINTY", 36, 48], ["DZ", "OBSERVATION", 170, 172]]], ["MYC is also known to play a critical role in the regulation of division bursts in the DZ [11] .Regulation of the Cell CycleTo reproduce the regulation of the cell cycle, we use a division counter [14] that takes values between 1 and 6 depending on the amount of T FH help received.", [["Cell", "ANATOMY", 113, 117], ["cell", "ANATOMY", 158, 162], ["DZ", "CHEMICAL", 86, 88], ["MYC", "GENE_OR_GENE_PRODUCT", 0, 3], ["Cell", "CELL", 113, 117], ["cell", "CELL", 158, 162], ["T FH", "GENE_OR_GENE_PRODUCT", 262, 266], ["MYC", "PROTEIN", 0, 3], ["the Cell CycleTo", "TREATMENT", 109, 125], ["the cell cycle", "TREATMENT", 154, 168], ["a division counter", "TREATMENT", 177, 195], ["Cell CycleTo", "OBSERVATION", 113, 125], ["cell cycle", "OBSERVATION", 158, 168]]], ["To implement the division counter, we first run a short simulation to precompute the distribution of cumulative help from T FH .", [["FH", "DISEASE", 124, 126], ["T FH", "GENE_OR_GENE_PRODUCT", 122, 126]]], ["This initial distribution is kept fixed throughout the GC simulation and used to define 6 equal percentiles, such that a cell in the nth percentile undergoes n divisions ( Figure 3 ).", [["cell", "ANATOMY", 121, 125], ["cell", "CELL", 121, 125]]], ["Such definition corresponds to an average of \u223c3.5 divisions per recirculating cell in our model, very close to the experimentally determined average of 3 divisions per recirculating cell [14] .", [["cell", "ANATOMY", 78, 82], ["cell", "ANATOMY", 182, 186], ["cell", "CELL", 78, 82], ["cell", "CELL", 182, 186], ["recirculating cell", "CELL_TYPE", 64, 82], ["average", "OBSERVATION_MODIFIER", 34, 41], ["recirculating cell", "OBSERVATION", 64, 82]]], ["Besides increasing in number due to the higher number of cellular divisions, high-affinity cells also acquire a higher number of mutations than those that undergo fewer divisions [14] , which enhances their chances of developing more effective BCRs.Plasma Cell and Memory B Cell DifferentiationUpon exit from the GC, B cells terminally differentiate into PCs or MBCs.", [["cellular", "ANATOMY", 57, 65], ["high-affinity cells", "ANATOMY", 77, 96], ["Cell", "ANATOMY", 256, 260], ["Cell", "ANATOMY", 274, 278], ["GC", "ANATOMY", 313, 315], ["B cells", "ANATOMY", 317, 324], ["PCs", "ANATOMY", 355, 358], ["MBCs", "ANATOMY", 362, 366], ["cellular", "CELL", 57, 65], ["cells", "CELL", 91, 96], ["BCRs", "PATHOLOGICAL_FORMATION", 244, 248], ["Plasma", "ORGANISM_SUBSTANCE", 249, 255], ["Cell", "CELL", 256, 260], ["Memory B Cell", "CELL", 265, 278], ["GC", "CELL", 313, 315], ["B cells", "CELL", 317, 324], ["PCs", "CELL", 355, 358], ["MBCs", "CELL", 362, 366], ["high-affinity cells", "CELL_TYPE", 77, 96], ["B cells", "CELL_TYPE", 317, 324], ["PCs", "CELL_TYPE", 355, 358], ["MBCs", "CELL_TYPE", 362, 366], ["high-affinity cells", "PROBLEM", 77, 96], ["Plasma Cell", "TEST", 249, 260], ["MBCs", "TEST", 362, 366], ["increasing", "OBSERVATION_MODIFIER", 8, 18], ["cellular divisions", "OBSERVATION", 57, 75], ["affinity cells", "OBSERVATION", 82, 96], ["Memory B Cell DifferentiationUpon", "OBSERVATION", 265, 298]]], ["Temporal data has demonstrated the existence of a temporal switch, where MBCs tend to be produced during the early phases and PCs are produced at later times of the response [50] .", [["MBCs", "ANATOMY", 73, 77], ["MBCs", "CANCER", 73, 77], ["MBCs", "CELL_TYPE", 73, 77], ["Temporal data", "TEST", 0, 13], ["a temporal switch", "TREATMENT", 48, 65], ["MBCs", "PROBLEM", 73, 77]]], ["The precise mechanism that determines whether a cell differentiates into a PC or MBC is not completely understood [1] , although recent work suggests that affinity to antigen plays a central role in selecting the cells that enter the PC pool, while lower affinity selected B cells progress to MBCs [51] .", [["cell", "ANATOMY", 48, 52], ["PC", "ANATOMY", 75, 77], ["MBC", "ANATOMY", 81, 84], ["cells", "ANATOMY", 213, 218], ["PC pool", "ANATOMY", 234, 241], ["B cells", "ANATOMY", 273, 280], ["MBCs", "ANATOMY", 293, 297], ["MBCs", "CHEMICAL", 293, 297], ["cell", "CELL", 48, 52], ["PC", "CANCER", 75, 77], ["MBC", "CANCER", 81, 84], ["cells", "CELL", 213, 218], ["PC", "CANCER", 234, 236], ["B cells", "CELL", 273, 280], ["B cells", "CELL_TYPE", 273, 280], ["a PC or MBC", "PROBLEM", 73, 84], ["the PC pool", "TEST", 230, 241], ["MBCs", "TEST", 293, 297]]], ["In this scenario, T FH help stimulates CD40 signaling and IRF4 transcription, which in turn regulates, in a dose-dependent manner, the choice between differentiating into a PC or cycling back into the DZ [52] .", [["PC", "ANATOMY", 173, 175], ["DZ", "CHEMICAL", 201, 203], ["T FH", "GENE_OR_GENE_PRODUCT", 18, 22], ["CD40", "GENE_OR_GENE_PRODUCT", 39, 43], ["IRF4", "GENE_OR_GENE_PRODUCT", 58, 62], ["PC", "CANCER", 173, 175], ["CD40", "PROTEIN", 39, 43], ["IRF4", "PROTEIN", 58, 62], ["IRF4 transcription", "TREATMENT", 58, 76], ["a PC", "TREATMENT", 171, 175]]], ["This model has been computationally investigated using a multi-scale probabilistic model and shown to lead to good agreement with the experimentally determined GC output [20] .", [["a multi-scale probabilistic model", "TREATMENT", 55, 88], ["GC output", "TEST", 160, 169]]], ["Regarding the differentiation into MBCs, the determinants that predispose cells to enter the MBC pool or the markers that identify cells committed to the MBC lineage are not known.", [["MBCs", "ANATOMY", 35, 39], ["cells", "ANATOMY", 74, 79], ["MBC pool", "ANATOMY", 93, 101], ["cells", "ANATOMY", 131, 136], ["MBC lineage", "ANATOMY", 154, 165], ["MBCs", "CANCER", 35, 39], ["cells", "CELL", 74, 79], ["MBC", "CANCER", 93, 96], ["cells", "CELL", 131, 136], ["MBC lineage", "CELL", 154, 165], ["MBCs", "CELL_TYPE", 35, 39], ["MBC lineage", "CELL_TYPE", 154, 165], ["predispose cells", "PROBLEM", 63, 79], ["the markers", "TEST", 105, 116]]], ["A fraction of LZ B cells with lower affinity are prone to progress to resting MBCs in a Bach2 TF-dependent manner [53, 54] , although high-affinity cells might also become MBCs.", [["LZ B cells", "ANATOMY", 14, 24], ["MBCs", "ANATOMY", 78, 82], ["high-affinity cells", "ANATOMY", 134, 153], ["MBCs", "ANATOMY", 172, 176], ["LZ B cells", "CELL", 14, 24], ["MBCs", "CELL", 78, 82], ["Bach2", "GENE_OR_GENE_PRODUCT", 88, 93], ["TF", "GENE_OR_GENE_PRODUCT", 94, 96], ["cells", "CELL", 148, 153], ["MBCs", "CELL", 172, 176], ["LZ B cells", "CELL_TYPE", 14, 24], ["resting MBCs", "CELL_TYPE", 70, 82], ["Bach2 TF", "PROTEIN", 88, 96], ["MBCs", "CELL_TYPE", 172, 176], ["A fraction of LZ B cells", "TREATMENT", 0, 24], ["lower affinity", "PROBLEM", 30, 44], ["resting MBCs", "TEST", 70, 82], ["a Bach2 TF", "TEST", 86, 96], ["high-affinity cells", "PROBLEM", 134, 153], ["MBCs", "PROBLEM", 172, 176], ["lower affinity", "OBSERVATION", 30, 44]]], ["This suggests that stochastic effects might be at play in the selection of the MBC fate.", [["MBC", "CHEMICAL", 79, 82], ["MBC", "CANCER", 79, 82], ["stochastic effects", "PROBLEM", 19, 37], ["stochastic effects", "OBSERVATION", 19, 37]]], ["Similarly to previous work, we assume that IRF4 regulates cell fate in a dose-dependent manner, where high-affinity cells that express high amounts of IRF4 are directed to the PC pool, and medium affinity cells either cycle back into the DZ or differentiate as a MBC.", [["cell", "ANATOMY", 58, 62], ["cells", "ANATOMY", 116, 121], ["PC pool", "ANATOMY", 176, 183], ["cells", "ANATOMY", 205, 210], ["DZ", "ANATOMY", 238, 240], ["MBC", "ANATOMY", 263, 266], ["DZ", "CHEMICAL", 238, 240], ["MBC", "CHEMICAL", 263, 266], ["IRF4", "GENE_OR_GENE_PRODUCT", 43, 47], ["cell", "CELL", 58, 62], ["cells", "CELL", 116, 121], ["IRF4", "GENE_OR_GENE_PRODUCT", 151, 155], ["cells", "CELL", 205, 210], ["MBC", "CANCER", 263, 266], ["IRF4", "PROTEIN", 43, 47], ["high-affinity cells", "CELL_LINE", 102, 121], ["IRF4", "PROTEIN", 151, 155], ["medium affinity cells", "CELL_LINE", 189, 210], ["IRF4 regulates cell fate", "TREATMENT", 43, 67], ["high-affinity cells", "PROBLEM", 102, 121], ["IRF4", "TREATMENT", 151, 155], ["the PC pool", "TEST", 172, 183], ["medium affinity cells", "TREATMENT", 189, 210], ["a MBC", "PROBLEM", 261, 266]]], ["Once a cell is positively selected, we simulate and analyse three possible differentiation scenarios:Plasma Cell and Memory B Cell Differentiation\u2022 Antigen-driven differentiation model (model 1): In this first scenario, we consider that affinity determines B cell fate in a deterministic manner.", [["cell", "ANATOMY", 7, 11], ["Cell", "ANATOMY", 108, 112], ["Cell", "ANATOMY", 126, 130], ["B cell", "ANATOMY", 257, 263], ["cell", "CELL", 7, 11], ["Plasma", "ORGANISM_SUBSTANCE", 101, 107], ["Cell", "CELL", 108, 112], ["Memory B Cell", "CELL", 117, 130], ["B cell", "CELL", 257, 263], ["Plasma Cell", "TEST", 101, 112], ["Antigen", "TEST", 148, 155], ["Memory B Cell Differentiation", "OBSERVATION", 117, 146]]], ["Namely, there is a threshold pMHC thresh above which a CC becomes a PC.", [["CC", "CHEMICAL", 55, 57], ["PC", "CANCER", 68, 70], ["pMHC", "PROTEIN", 29, 33]]], ["Below that threshold, a cell becomes a MBC. \u2022 Dynamic antigen-driven differentiation model (model 2): A more sophisticated hypothesis is that T cells progressively become less sensitive to the pMHC complex and, as the average affinity of B cells increases in the GC, a larger amount of pMHC is needed to induce the same amount of IRF4.", [["cell", "ANATOMY", 24, 28], ["MBC", "ANATOMY", 39, 42], ["T cells", "ANATOMY", 142, 149], ["B cells", "ANATOMY", 238, 245], ["MBC", "DISEASE", 39, 42], ["cell", "CELL", 24, 28], ["MBC", "CANCER", 39, 42], ["T cells", "CELL", 142, 149], ["pMHC", "GENE_OR_GENE_PRODUCT", 193, 197], ["B cells", "CELL", 238, 245], ["pMHC", "GENE_OR_GENE_PRODUCT", 286, 290], ["IRF4", "GENE_OR_GENE_PRODUCT", 330, 334], ["T cells", "CELL_TYPE", 142, 149], ["pMHC complex", "PROTEIN", 193, 205], ["B cells", "CELL_TYPE", 238, 245], ["pMHC", "PROTEIN", 286, 290], ["IRF4", "PROTEIN", 330, 334], ["a MBC", "PROBLEM", 37, 42], ["Dynamic antigen", "TEST", 46, 61], ["A more sophisticated hypothesis", "PROBLEM", 102, 133], ["T cells", "PROBLEM", 142, 149], ["B cells", "PROBLEM", 238, 245], ["IRF4", "OBSERVATION", 330, 334]]], ["In the second scenario, the choice between PC and MBC is also deterministic, although according to a dynamic threshold that increases linearly with time, i.e., pMHC thresh = affinity GC (t \u2212 t 0 ) + a 0 . \u2022 Stochastic differentiation model (model 3): Finally, we also investigate a probabilistic scenario where, once a B cell has been selected for differentiation, it becomes a PC or MBC according to some fixed probabilities that depend on the amount of expressed pMHC as follows: p MBC = e \u2212k(pMHC\u2212p 0 ) and p PC = 1 \u2212 p MBC .Plasma Cell and Memory B Cell DifferentiationIn all three scenarios, apoptosis occurs irrespective of affinity.", [["B cell", "ANATOMY", 319, 325], ["Cell", "ANATOMY", 535, 539], ["Cell", "ANATOMY", 553, 557], ["MBC", "CHEMICAL", 50, 53], ["PC", "CANCER", 43, 45], ["MBC", "SIMPLE_CHEMICAL", 50, 53], ["B cell", "CELL", 319, 325], ["PC", "CANCER", 378, 380], ["MBC", "CANCER", 384, 387], ["pMHC", "GENE_OR_GENE_PRODUCT", 465, 469], ["Plasma", "ORGANISM_SUBSTANCE", 528, 534], ["Cell", "CELL", 535, 539], ["Memory B Cell", "CELL", 544, 557], ["pMHC", "PROTEIN", 160, 164], ["B cell", "CELL_TYPE", 319, 325], ["pMHC", "PROTEIN", 465, 469], ["PC and MBC", "TREATMENT", 43, 53], ["pMHC", "TEST", 160, 164], ["GC", "TEST", 183, 185], ["a B cell", "TREATMENT", 317, 325], ["a PC or MBC", "PROBLEM", 376, 387], ["some fixed probabilities", "PROBLEM", 401, 425], ["MBC", "TEST", 484, 487], ["pMHC\u2212p", "TEST", 495, 501], ["PC", "TEST", 512, 514], ["MBC", "TEST", 523, 526], ["Plasma Cell", "TEST", 528, 539], ["apoptosis", "PROBLEM", 597, 606], ["Memory B Cell", "OBSERVATION", 544, 557]]], ["Namely, apoptosis is modelled in the Gillespie algorithm as a reaction channel with constant kinetic rate, and hence, its probability of happening only depends on the total number of CCs.", [["a reaction channel", "PROBLEM", 60, 78], ["constant kinetic rate", "TEST", 84, 105]]], ["We note, however, that CCs carrying high-affinity BCRs are more likely to be positively selected and differentiate or recirculate, while lower affinity CCs are more likely to stay in the GC and undergo apoptosis, which might result in an indirect association between low affinity and apoptosis [55] .", [["CCs", "ANATOMY", 23, 26], ["GC", "ANATOMY", 187, 189], ["CCs", "CELL", 23, 26], ["BCRs", "GENE_OR_GENE_PRODUCT", 50, 54], ["GC", "CELL", 187, 189], ["BCRs", "PROTEIN", 50, 54], ["CCs carrying high-affinity BCRs", "PROBLEM", 23, 54], ["lower affinity CCs", "PROBLEM", 137, 155], ["apoptosis", "PROBLEM", 202, 211], ["low affinity", "PROBLEM", 267, 279], ["apoptosis", "PROBLEM", 284, 293], ["apoptosis", "OBSERVATION", 202, 211], ["low affinity", "OBSERVATION_MODIFIER", 267, 279]]], ["Regarding recirculation, it happens stochastically according to a Gillespie channel of constant kinetic rate once a CC has been selected, and hence, recirculation after selection is an affinity-independent event.", [["CC", "CHEMICAL", 116, 118]]], ["In all scenarios, the amount of received T cell signaling is only important to stop apoptosis and to decide on the number of divisions for cells that recirculate into the DZ.", [["T cell", "ANATOMY", 41, 47], ["cells", "ANATOMY", 139, 144], ["DZ", "CHEMICAL", 171, 173], ["T cell", "CELL", 41, 47], ["cells", "CELL", 139, 144], ["DZ", "SIMPLE_CHEMICAL", 171, 173], ["T cell signaling", "TREATMENT", 41, 57], ["apoptosis", "PROBLEM", 84, 93], ["cells", "PROBLEM", 139, 144], ["the DZ", "PROBLEM", 167, 173], ["amount", "OBSERVATION_MODIFIER", 22, 28], ["DZ", "OBSERVATION", 171, 173]]], ["In that respect, all models are based on antigen-driven selection mechanisms.Phylogenetic Trees RepresentationWe use phylogenetic trees to visualize the evolution of the CDR sequences through SHM.", [["antigen", "GENE_OR_GENE_PRODUCT", 41, 48], ["CDR sequences", "DNA", 170, 183], ["SHM", "DNA", 192, 195], ["antigen", "TEST", 41, 48], ["the CDR sequences", "TEST", 166, 183]]], ["In such a representation, each founder cell, associated with a unique V, D and J combination, defines the unmutated germline of a new tree, and newly acquired mutations are represented as downstream nodes.", [["cell", "ANATOMY", 39, 43], ["founder cell", "CELL", 31, 43], ["unmutated germline", "DNA", 106, 124], ["D and J combination", "TREATMENT", 73, 92], ["newly acquired mutations", "PROBLEM", 144, 168], ["unmutated germline", "OBSERVATION", 106, 124], ["new", "OBSERVATION_MODIFIER", 130, 133], ["tree", "OBSERVATION_MODIFIER", 134, 138], ["downstream", "OBSERVATION_MODIFIER", 188, 198], ["nodes", "OBSERVATION", 199, 204]]], ["Different approaches to represent clonal trees are possible.", [["clonal trees", "PROBLEM", 34, 46], ["clonal trees", "OBSERVATION", 34, 46]]], ["Here, we chose to associate each leaf with a sequenced cell and each internal node with an unique mutation of the BCR.", [["leaf", "ANATOMY", 33, 37], ["cell", "ANATOMY", 55, 59], ["internal node", "ANATOMY", 69, 82], ["leaf", "ORGAN", 33, 37], ["cell", "CELL", 55, 59], ["internal node", "MULTI-TISSUE_STRUCTURE", 69, 82], ["BCR", "GENE_OR_GENE_PRODUCT", 114, 117], ["BCR", "PROTEIN", 114, 117], ["a sequenced cell and each internal node", "PROBLEM", 43, 82], ["the BCR", "PROBLEM", 110, 117], ["internal node", "ANATOMY", 69, 82], ["BCR", "OBSERVATION", 114, 117]]], ["Using our simulated data, it is trivial to reconstruct lineage trees, as we can follow each founder cell and its progeny through the whole GC reaction.", [["cell", "ANATOMY", 100, 104], ["cell", "CELL", 100, 104], ["the whole GC reaction", "PROBLEM", 129, 150], ["lineage trees", "OBSERVATION", 55, 68]]], ["Then, the topological properties of each phylogenetic tree, such as number of nodes, average depth of the leaves, trunk length, etc provide important information about the affinity maturation [29, 56] , and can be used to compare simulated trees to trees inferred from experimental data.Phylogenetic Trees RepresentationTo construct trees from experimental data, i.e., repertoire sequencing data, we first align the variable (V), diversity (D) and joining (J) gene segments of each sequence using the IMGT [57] (for V,D,J) and VBASE2 (for V) [58] databases with BLAST [59] .", [["leaves", "ANATOMY", 106, 112], ["trunk", "ANATOMY", 114, 119], ["trunk", "ORGANISM_SUBDIVISION", 114, 119], ["joining (J) gene segments", "DNA", 448, 473], ["experimental data", "TEST", 344, 361], ["repertoire sequencing data", "TEST", 369, 395], ["diversity (D) and joining (J) gene segments of each sequence", "TREATMENT", 430, 490], ["the IMGT", "TEST", 497, 505], ["BLAST", "TEST", 562, 567], ["phylogenetic tree", "OBSERVATION", 41, 58], ["nodes", "OBSERVATION", 78, 83], ["leaves", "ANATOMY_MODIFIER", 106, 112], ["trunk", "ANATOMY", 114, 119]]], ["In the case of discrepancy between V segment assignments from the two databases, the assignment leading to the lowest number of somatic mutations is chosen.", [["V segment", "DNA", 35, 44], ["discrepancy between V segment assignments", "PROBLEM", 15, 56], ["somatic mutations", "PROBLEM", 128, 145], ["somatic mutations", "OBSERVATION", 128, 145]]], ["As cells have at most 20 mutations, all assignments were unambiguous with a V(D)J alignment score over 95%.", [["cells", "ANATOMY", 3, 8], ["cells", "CELL", 3, 8], ["a V(D)J alignment score", "TEST", 74, 97]]], ["Next, functional V(D)J sequences are grouped together into clones if they shared the same V, J and D gene segments.", [["V(D)J", "GENE_OR_GENE_PRODUCT", 17, 22], ["functional V(D)J sequences", "DNA", 6, 32], ["V, J and D gene segments", "DNA", 90, 114], ["functional V(D)J sequences", "TREATMENT", 6, 32], ["segments", "ANATOMY_MODIFIER", 106, 114]]], ["The grouped sequences from each clone are then aligned with ClustalW [60] .", [["clone", "CELL", 32, 37]]], ["This second alignment is necessary to infer a mutation matrix, as tree inference algorithms typically require sequences to be aligned and of the same length, while experimentally determined sequences have different lengths, and include insertions and deletions.", [["a mutation matrix", "PROBLEM", 44, 61], ["insertions and deletions", "TREATMENT", 236, 260]]], ["The corresponding trees are computed with SCITE [61] , a stochastic search algorithm based on Markov chain Monte Carlo sampling.", [["a stochastic search algorithm", "TEST", 55, 84]]], ["The root node is defined by taking the unmutated V(D)J germline and filling the remaining junction region with the consensus sequence of all available sequences.", [["root node", "ANATOMY", 4, 13], ["root node", "MULTI-TISSUE_STRUCTURE", 4, 13], ["unmutated V(D)J germline", "DNA", 39, 63], ["consensus sequence", "DNA", 115, 133], ["the unmutated V(D)J germline", "TREATMENT", 35, 63], ["root", "OBSERVATION_MODIFIER", 4, 8], ["node", "OBSERVATION", 9, 13], ["remaining", "ANATOMY_MODIFIER", 80, 89], ["junction", "ANATOMY_MODIFIER", 90, 98]]], ["Finally, the obtained trees are analyzed with the BioPhylo Python library [62] to compute the main topological tree properties, such as number of leaves, internal nodes, branches, trunk, etc.Clonal DiversityClonal diversity has been measured using a multi-color fate mapping technology that permanently tags individual B cells and their progeny with different combinations of fluorescent proteins.", [["leaves", "ANATOMY", 146, 152], ["internal nodes", "ANATOMY", 154, 168], ["branches", "ANATOMY", 170, 178], ["trunk", "ANATOMY", 180, 185], ["B cells", "ANATOMY", 319, 326], ["internal nodes", "MULTI-TISSUE_STRUCTURE", 154, 168], ["trunk", "ORGANISM_SUBDIVISION", 180, 185], ["B cells", "CELL", 319, 326], ["B cells", "CELL_TYPE", 319, 326], ["fluorescent proteins", "PROTEIN", 376, 396], ["internal nodes, branches, trunk, etc", "PROBLEM", 154, 190], ["Clonal Diversity", "PROBLEM", 191, 207], ["Clonal diversity", "PROBLEM", 207, 223], ["a multi-color fate mapping technology", "TREATMENT", 248, 285], ["fluorescent proteins", "PROBLEM", 376, 396], ["main topological", "OBSERVATION", 94, 110], ["tree properties", "OBSERVATION", 111, 126], ["leaves", "ANATOMY_MODIFIER", 146, 152], ["internal nodes", "ANATOMY", 154, 168], ["branches", "ANATOMY_MODIFIER", 170, 178], ["trunk", "ANATOMY", 180, 185], ["Diversity", "OBSERVATION_MODIFIER", 198, 207]]], ["A Normalized Dominance Score (NDS), defined as the fraction of all B cells in a GC that carry the dominant color combination, was used to characterize clonal diversity [15, 63] .", [["B cells", "ANATOMY", 67, 74], ["B cells", "CELL", 67, 74], ["B cells", "CELL_TYPE", 67, 74], ["A Normalized Dominance Score", "TEST", 0, 28], ["Normalized", "OBSERVATION_MODIFIER", 2, 12], ["Dominance", "OBSERVATION", 13, 22]]], ["To simulate this experiment, we cluster founders into 10 groups, and define an NDS score as the ratio between the cell count of the dominant cluster over the total number of cells.", [["cell", "ANATOMY", 114, 118], ["cells", "ANATOMY", 174, 179], ["cell", "CELL", 114, 118], ["cells", "CELL", 174, 179], ["an NDS score", "TEST", 76, 88], ["the ratio", "TEST", 92, 101], ["the cell count", "TEST", 110, 124], ["cell count", "OBSERVATION", 114, 124], ["dominant", "OBSERVATION_MODIFIER", 132, 140], ["cluster", "OBSERVATION_MODIFIER", 141, 148]]], ["The NDS is used only for a direct comparison with measurements, but not for other characterisations of the clonal diversity.", [["clonal", "CELL", 107, 113], ["the clonal diversity", "PROBLEM", 103, 123], ["clonal diversity", "OBSERVATION", 107, 123]]], ["Later in the paper, we use the clonal dominance (CD), which is simply the ratio between the cell count of a clone cluster and the total number of cells.Parameter OptimizationOur models include 17 free parameters that need to be optimised.", [["cell", "ANATOMY", 92, 96], ["cells", "ANATOMY", 146, 151], ["cell", "CELL", 92, 96], ["clone", "CELL", 108, 113], ["cells", "CELL", 146, 151], ["the ratio", "TEST", 70, 79], ["the cell count", "TEST", 88, 102], ["a clone cluster", "PROBLEM", 106, 121], ["Parameter OptimizationOur models", "TEST", 152, 184], ["clonal dominance", "OBSERVATION", 31, 47], ["cell count", "OBSERVATION", 92, 102], ["clone cluster", "OBSERVATION", 108, 121], ["total", "OBSERVATION_MODIFIER", 130, 135]]], ["As the amount of quantitative information about the GC dynamics is still limited, we exploit the recent literature to obtain reasonable estimates about the value of some parameters as well as variability bounds (Lower bound and Upper bound columns in Table 2 ).", [["the GC dynamics", "TEST", 48, 63], ["variability bounds (Lower bound", "PROBLEM", 192, 223], ["Upper", "ANATOMY_MODIFIER", 228, 233]]], ["Further details can be found in the Supplementary Information.Parameter OptimizationIn addition, many recent works have experimentally characterized the GC, and we use these data to constrain different properties of the GC response, such as GC kinetics, output cell counts, etc. We further use data from mice experiments when human experiments are not available.", [["cell", "ANATOMY", 261, 265], ["cell", "CELL", 261, 265], ["mice", "ORGANISM", 304, 308], ["human", "ORGANISM", 326, 331], ["mice", "SPECIES", 304, 308], ["human", "SPECIES", 326, 331], ["mice", "SPECIES", 304, 308], ["human", "SPECIES", 326, 331], ["these data", "TEST", 168, 178], ["GC kinetics", "TEST", 241, 252], ["output cell counts", "TEST", 254, 272], ["human experiments", "TEST", 326, 343], ["output cell counts", "OBSERVATION", 254, 272]]], ["We briefly discuss here the constraint bounds on each GC property.\u2022 Number of GC B cells: A time-resolved study of 3457 GC sections from mice providedinformation about the GC area A GC throughout the GC reaction [18] .", [["GC B cells", "ANATOMY", 78, 88], ["GC sections", "ANATOMY", 120, 131], ["GC area", "ANATOMY", 172, 179], ["GC B cells", "CELL", 78, 88], ["GC sections", "CANCER", 120, 131], ["mice", "ORGANISM", 137, 141], ["GC B cells", "CELL_TYPE", 78, 88], ["mice", "SPECIES", 137, 141], ["mice", "SPECIES", 137, 141], ["study", "TEST", 106, 111], ["GC sections", "TEST", 120, 131], ["the GC reaction", "TEST", 196, 211]]], ["Assuming that GC are spherical, then A GC = \u03c0 r 2 GC , from where the radius of the GC, r GC , can be estimated.", [["A GC", "TEST", 37, 41], ["GC", "TEST", 50, 52], ["radius", "ANATOMY_MODIFIER", 70, 76], ["GC", "ANATOMY", 84, 86]]], ["If we further assume that B cells are the predominant cellular type in the GC, we can estimate the number of B cells in the GC as:\u2022 Number of GC B cells: A time-resolved study of 3457 GC sections from mice providedwhere we have considered cells to be spherical.", [["B cells", "ANATOMY", 26, 33], ["cellular type", "ANATOMY", 54, 67], ["GC", "ANATOMY", 75, 77], ["B cells", "ANATOMY", 109, 116], ["GC", "ANATOMY", 124, 126], ["GC B cells", "ANATOMY", 142, 152], ["GC sections", "ANATOMY", 184, 195], ["cells", "ANATOMY", 239, 244], ["B cells", "CELL", 26, 33], ["cellular type", "CELL", 54, 67], ["GC", "CELL", 75, 77], ["B cells", "CELL", 109, 116], ["GC B cells", "CELL", 142, 152], ["GC sections", "CANCER", 184, 195], ["mice", "ORGANISM", 201, 205], ["cells", "CELL", 239, 244], ["B cells", "CELL_TYPE", 26, 33], ["B cells", "CELL_TYPE", 109, 116], ["GC B cells", "CELL_TYPE", 142, 152], ["mice", "SPECIES", 201, 205], ["mice", "SPECIES", 201, 205], ["B cells", "PROBLEM", 26, 33], ["GC sections", "TEST", 184, 195], ["predominant", "OBSERVATION_MODIFIER", 42, 53], ["cellular type", "OBSERVATION", 54, 67]]], ["Taking r B cell = 6.2 \u00b5m [64] and r GC = 80 \u00b5m (day 9) [18] , we get an average of N B cell \u2248 2000 at the GC peak.", [["B cell", "ANATOMY", 9, 15], ["N B cell", "ANATOMY", 83, 91], ["B cell", "CELL", 85, 91], ["Taking r B cell", "TEST", 0, 15], ["r GC", "TEST", 34, 38]]], ["As most histological sections do not go cut GCs through the centre, estimations of individual GC volumes are only approximated.", [["sections", "ANATOMY", 21, 29], ["most histological sections", "TEST", 3, 29], ["individual GC volumes", "TEST", 83, 104], ["GC volumes", "OBSERVATION", 94, 104]]], ["Nevertheless, it has been shown that cross-sectional area distributions of spleen sections reflect accurately the broad real-size distributions of GCs [65] .", [["spleen sections", "ANATOMY", 75, 90], ["spleen sections", "MULTI-TISSUE_STRUCTURE", 75, 90], ["spleen sections", "TEST", 75, 90], ["GCs", "TEST", 147, 150], ["cross-sectional", "OBSERVATION_MODIFIER", 37, 52], ["area", "OBSERVATION_MODIFIER", 53, 57], ["spleen", "ANATOMY", 75, 81], ["broad", "OBSERVATION_MODIFIER", 114, 119], ["size", "OBSERVATION_MODIFIER", 125, 129]]], ["Moreover, as there is significant variability in GC B cell sizes, notably during the cell division cycle [66, 67] ), the previous number has to be considered only an order of magnitude approximation to the total number of cells.", [["GC B cell", "ANATOMY", 49, 58], ["cell", "ANATOMY", 85, 89], ["cells", "ANATOMY", 222, 227], ["GC B cell", "CELL", 49, 58], ["cell", "CELL", 85, 89], ["cells", "CELL", 222, 227], ["significant variability in GC B cell sizes", "PROBLEM", 22, 64], ["significant", "OBSERVATION_MODIFIER", 22, 33], ["variability", "OBSERVATION_MODIFIER", 34, 45], ["GC B cell", "OBSERVATION", 49, 58], ["sizes", "OBSERVATION_MODIFIER", 59, 64]]], ["Interestingly, the same study found that GC undergo a fast expansion phase from day 4 to 9, and then progressively decrease in volume by a factor of 2, roughly 10 days after the initial expansion [18] . \u2022 DZ/LZ ratio: Despite high variability in size, a typical cellular composition with relatively stable cell ratios of resident T FHs , macrophages, proliferating cells, and apoptotic nuclei seems to be maintained during the established phase of the response [18] .", [["cellular", "ANATOMY", 262, 270], ["cell", "ANATOMY", 306, 310], ["T FHs", "ANATOMY", 330, 335], ["macrophages", "ANATOMY", 338, 349], ["cells", "ANATOMY", 365, 370], ["nuclei", "ANATOMY", 386, 392], ["DZ", "CHEMICAL", 205, 207], ["DZ", "SIMPLE_CHEMICAL", 205, 207], ["cellular", "CELL", 262, 270], ["cell", "CELL", 306, 310], ["T FHs", "CELL", 330, 335], ["macrophages", "CELL", 338, 349], ["cells", "CELL", 365, 370], ["nuclei", "CELLULAR_COMPONENT", 386, 392], ["resident T FHs", "CELL_TYPE", 321, 335], ["macrophages", "CELL_TYPE", 338, 349], ["proliferating cells", "CELL_TYPE", 351, 370], ["the same study", "TEST", 15, 29], ["a fast expansion phase", "TEST", 52, 74], ["progressively decrease in volume", "PROBLEM", 101, 133], ["DZ/LZ ratio", "TEST", 205, 216], ["high variability in size", "PROBLEM", 226, 250], ["a typical cellular composition", "PROBLEM", 252, 282], ["macrophages", "PROBLEM", 338, 349], ["proliferating cells", "PROBLEM", 351, 370], ["apoptotic nuclei", "PROBLEM", 376, 392], ["progressively", "OBSERVATION_MODIFIER", 101, 114], ["decrease", "OBSERVATION_MODIFIER", 115, 123], ["volume", "OBSERVATION_MODIFIER", 127, 133], ["DZ", "OBSERVATION", 205, 207], ["LZ", "ANATOMY", 208, 210], ["high variability", "OBSERVATION_MODIFIER", 226, 242], ["size", "OBSERVATION_MODIFIER", 246, 250], ["cellular composition", "OBSERVATION", 262, 282], ["relatively", "OBSERVATION_MODIFIER", 288, 298], ["stable", "OBSERVATION_MODIFIER", 299, 305], ["cell", "OBSERVATION", 306, 310], ["macrophages", "ANATOMY", 338, 349], ["proliferating cells", "OBSERVATION", 351, 370], ["apoptotic nuclei", "OBSERVATION", 376, 392]]], ["Time-resolved data about the relative size of DZ to LZ is also available from the same study.", [["DZ", "CHEMICAL", 46, 48], ["DZ", "SIMPLE_CHEMICAL", 46, 48], ["the same study", "TEST", 78, 92], ["size", "OBSERVATION_MODIFIER", 38, 42], ["DZ", "OBSERVATION", 46, 48], ["LZ", "ANATOMY", 52, 54]]], ["While the variability in the relative volumes of DZ and LZ is considerably high at all sampled time points ( Figure 4B ), it stabilizes after the phase of monoclonal expansion to an average of \u223c 1 during the entire GC reaction [18] .", [["DZ", "CHEMICAL", 49, 51], ["DZ", "SIMPLE_CHEMICAL", 49, 51], ["DZ", "PROBLEM", 49, 51], ["monoclonal expansion", "PROBLEM", 155, 175], ["the entire GC reaction", "PROBLEM", 204, 226], ["variability", "OBSERVATION_MODIFIER", 10, 21], ["volumes", "OBSERVATION_MODIFIER", 38, 45], ["DZ", "OBSERVATION", 49, 51], ["LZ", "ANATOMY", 56, 58], ["considerably", "OBSERVATION_MODIFIER", 62, 74], ["high", "OBSERVATION_MODIFIER", 75, 79], ["monoclonal expansion", "OBSERVATION", 155, 175]]], ["The high variability is consistent with some other studies that found a ratio of 2 [9] .", [["some other studies", "TEST", 40, 58], ["a ratio", "TEST", 70, 77], ["high variability", "OBSERVATION", 4, 20], ["consistent with", "UNCERTAINTY", 24, 39]]], ["In our simulation, the DZ/LZ ratio is defined as the number of CBs over the number of CCs; however, we only estimate this ratio after day 9 after immunization, hence avoiding the early days of the GC establishment, where the DZ and LZ are still not spatially separated. \u2022 Cell death: Apoptosis is prevalent in the GC, with up to half of all GC B cells dying every 6 h [55] .\u2022 Number of GC B cells: A time-resolved study of 3457 GC sections from mice providedWe use a relatively constant cell death rate of 8%/h in both the DZ and LZ through the entire GC response. \u2022 SHM mutations: Time-resolved data on sequenced BCR mutations, obtained by comparing sequences to the closest known V,D,J germline sequences, suggest that B cell clones undergo roughly 5 mutations every 10 days, and [6, 44] .", [["CBs", "ANATOMY", 63, 66], ["Cell", "ANATOMY", 272, 276], ["GC", "ANATOMY", 314, 316], ["GC B cells", "ANATOMY", 341, 351], ["GC B cells", "ANATOMY", 386, 396], ["GC sections", "ANATOMY", 428, 439], ["cell", "ANATOMY", 487, 491], ["B cell clones", "ANATOMY", 721, 734], ["DZ", "CHEMICAL", 23, 25], ["DZ", "CHEMICAL", 225, 227], ["death", "DISEASE", 277, 282], ["death", "DISEASE", 492, 497], ["DZ", "CHEMICAL", 523, 525], ["DZ", "SIMPLE_CHEMICAL", 23, 25], ["CBs", "CELLULAR_COMPONENT", 63, 66], ["Cell", "CELL", 272, 276], ["GC", "CELL", 314, 316], ["GC B cells", "CELL", 341, 351], ["GC B cells", "CELL", 386, 396], ["GC sections", "CANCER", 428, 439], ["mice", "ORGANISM", 445, 449], ["cell", "CELL", 487, 491], ["DZ", "SIMPLE_CHEMICAL", 523, 525], ["BCR", "GENE_OR_GENE_PRODUCT", 614, 617], ["D", "GENE_OR_GENE_PRODUCT", 684, 685], ["B cell clones", "CELL", 721, 734], ["GC B cells", "CELL_TYPE", 341, 351], ["GC B cells", "CELL_TYPE", 386, 396], ["BCR mutations", "DNA", 614, 627], ["V,D,J germline sequences", "DNA", 682, 706], ["B cell clones", "CELL_LINE", 721, 734], ["mice", "SPECIES", 445, 449], ["mice", "SPECIES", 445, 449], ["the DZ/LZ ratio", "TEST", 19, 34], ["immunization", "TREATMENT", 146, 158], ["the GC establishment", "TEST", 193, 213], ["the DZ and LZ", "PROBLEM", 221, 234], ["Cell death", "PROBLEM", 272, 282], ["Apoptosis", "PROBLEM", 284, 293], ["GC sections", "TEST", 428, 439], ["a relatively constant cell death rate", "TREATMENT", 465, 502], ["sequenced BCR mutations", "PROBLEM", 604, 627], ["J germline sequences", "TEST", 686, 706], ["B cell clones", "TREATMENT", 721, 734], ["LZ", "ANATOMY", 26, 28], ["DZ", "OBSERVATION", 225, 227], ["LZ", "ANATOMY", 232, 234], ["DZ", "ANATOMY", 523, 525], ["LZ", "ANATOMY", 530, 532]]], ["We use these data to further constrain our model. \u2022 GC cellular output: Finally, we use time-resolve data of the GC cellular output [50] to constrain our model.", [["cellular", "ANATOMY", 55, 63], ["cellular", "ANATOMY", 116, 124], ["GC cellular", "CELL", 52, 63], ["GC cellular", "CELL", 113, 124], ["these data", "TEST", 7, 17], ["GC cellular output", "TEST", 52, 70], ["the GC cellular output", "TEST", 109, 131], ["cellular output", "OBSERVATION", 55, 70]]], ["Because the experiment only measured relative abundances rather than direct cell counts, we scale both the model predictions and experimental measures by the maximum value.\u2022 Number of GC B cells: A time-resolved study of 3457 GC sections from mice providedNext, we compute an error for each set of parameters, defined as the sum of the root mean square deviation (RMSD) between the model prediction and experimental results.", [["cell", "ANATOMY", 76, 80], ["GC B cells", "ANATOMY", 184, 194], ["GC sections", "ANATOMY", 226, 237], ["cell", "CELL", 76, 80], ["GC B cells", "CELL", 184, 194], ["GC sections", "CANCER", 226, 237], ["mice", "ORGANISM", 243, 247], ["GC B cells", "CELL_TYPE", 184, 194], ["mice", "SPECIES", 243, 247], ["mice", "SPECIES", 243, 247], ["direct cell counts", "TEST", 69, 87], ["experimental measures", "TREATMENT", 129, 150], ["resolved study", "TEST", 203, 217], ["GC sections", "TEST", 226, 237], ["the model prediction", "TEST", 378, 398], ["root", "OBSERVATION_MODIFIER", 336, 340]]], ["For a fair measurement of the fitting performances across heterogeneous GCs, the RMSD is normalized by dividing it by the standard deviation of the experimental data averaged over the different time-points-we also average over same time-point replicates, when available, to reduce variability.", [["GCs", "CELL", 72, 75], ["heterogeneous", "OBSERVATION_MODIFIER", 58, 71], ["normalized", "OBSERVATION", 89, 99]]], ["As no measurement of the cell death standard deviation is available, we arbitrarily assume a standard deviation of 1% cell death/h (measured rate is 8% cell death/h).", [["cell", "ANATOMY", 25, 29], ["cell", "ANATOMY", 118, 122], ["cell", "ANATOMY", 152, 156], ["death", "DISEASE", 123, 128], ["death", "DISEASE", 157, 162], ["cell", "CELL", 25, 29], ["cell", "CELL", 118, 122], ["cell", "CELL", 152, 156], ["the cell death", "PROBLEM", 21, 35], ["a standard deviation of 1% cell death", "PROBLEM", 91, 128], ["rate", "TEST", 141, 145]]], ["For each one of the 4 properties for which data is available, i.e., cell count, DZ/LZ ratio, cell death and number of mutations, we compute an independent NRMSD.", [["cell", "ANATOMY", 68, 72], ["cell", "ANATOMY", 93, 97], ["DZ", "CHEMICAL", 80, 82], ["death", "DISEASE", 98, 103], ["cell", "CELL", 68, 72], ["cell", "CELL", 93, 97], ["cell count", "TEST", 68, 78], ["DZ/LZ ratio", "TEST", 80, 91], ["cell death", "PROBLEM", 93, 103], ["mutations", "PROBLEM", 118, 127], ["LZ", "ANATOMY", 83, 85], ["cell death", "OBSERVATION", 93, 103]]], ["A NRMSD lower than one indicates that the simulation error is lower than the uncertainties intrinsic to experiments.\u2022 Number of GC B cells: A time-resolved study of 3457 GC sections from mice providedThe score function is minimized with the maxLIPO algorithm [68] , which is both parameter free and provably better than a random search.", [["GC B cells", "ANATOMY", 128, 138], ["GC sections", "ANATOMY", 170, 181], ["GC B cells", "CELL", 128, 138], ["GC sections", "CANCER", 170, 181], ["mice", "ORGANISM", 187, 191], ["GC B cells", "CELL_TYPE", 128, 138], ["mice", "SPECIES", 187, 191], ["mice", "SPECIES", 187, 191], ["resolved study", "TEST", 147, 161], ["GC sections", "TEST", 170, 181], ["The score function", "TEST", 200, 218], ["the maxLIPO algorithm", "TEST", 237, 258]]], ["Due to the high computational cost required for parameter optimization with high dimensionality, a simplified ODE system was also used to speed up the maxLIPO search (described in the Supplementary Information).Germinal Center DynamicsWe simulate our GC model using a modified Gillespie algorithm [20] and the parameters optimised as discussed in Section 2.10.", [["parameter optimization", "TREATMENT", 48, 70], ["high dimensionality", "PROBLEM", 76, 95], ["a simplified ODE system", "TREATMENT", 97, 120], ["a modified Gillespie algorithm", "TREATMENT", 266, 296]]], ["Namely, 1000 simulations were run and the normalized root mean square deviation (NRMSE) of each optimised GC property was computed.", [["root", "ANATOMY", 53, 57], ["root", "OBSERVATION_MODIFIER", 53, 57]]], ["For instance, the NRMSD of the GC B cell count is 0.13, indicating a smaller deviation than the standard deviation of the experimentally determined number of GC output cells.", [["GC B cell", "ANATOMY", 31, 40], ["GC output cells", "ANATOMY", 158, 173], ["GC B cell", "CELL", 31, 40], ["GC output cells", "CELL", 158, 173], ["GC output cells", "CELL_TYPE", 158, 173], ["the GC B cell count", "TEST", 27, 46], ["a smaller deviation", "PROBLEM", 67, 86], ["GC output cells", "PROBLEM", 158, 173], ["cell count", "OBSERVATION", 36, 46], ["smaller", "OBSERVATION_MODIFIER", 69, 76], ["deviation", "OBSERVATION", 77, 86], ["GC output cells", "OBSERVATION", 158, 173]]], ["A reason for this disparity is the high heterogeneity of GCs in terms of size and cell count [18, 65] , with measured GCs ranging from \u223c500 to \u223c10,000 B cells in size.", [["cell", "ANATOMY", 82, 86], ["B cells", "ANATOMY", 151, 158], ["GCs", "CELL", 57, 60], ["cell", "CELL", 82, 86], ["B cells", "CELL", 151, 158], ["B cells", "CELL_TYPE", 151, 158], ["this disparity", "PROBLEM", 13, 27], ["the high heterogeneity of GCs", "PROBLEM", 31, 60], ["cell count", "TEST", 82, 92], ["GCs", "TEST", 118, 121], ["size", "OBSERVATION_MODIFIER", 73, 77], ["cells", "OBSERVATION", 153, 158], ["size", "OBSERVATION_MODIFIER", 162, 166]]], ["As our model is trained to replicate the mean experimental values, it is expected to show lower standard deviation.", [["lower standard deviation", "PROBLEM", 90, 114], ["lower", "OBSERVATION_MODIFIER", 90, 95], ["standard deviation", "OBSERVATION", 96, 114]]], ["Despite this difference, our model recapitulates well the general trends of experimental measurements, e.g., the reduction of GC volume by half in \u223c5 days [65] , and the shutdown of the GC at around day 40.", [["experimental measurements", "TEST", 76, 101], ["the reduction of GC volume", "TREATMENT", 109, 135]]], ["Figures (A,B) depict simulations and experimental data about cell count and DZ/LZ volumetric ratio respectively, the latter derived from [18] .", [["cell", "ANATOMY", 61, 65], ["DZ", "CHEMICAL", 76, 78], ["cell", "CELL", 61, 65], ["experimental data", "TEST", 37, 54], ["cell count", "TEST", 61, 71], ["DZ/LZ volumetric ratio", "TEST", 76, 98]]], ["Figure (C) shows the death rate percentages of B cells in both the DZ and LZ (8 %/h) [55] .", [["B cells", "ANATOMY", 47, 54], ["death", "DISEASE", 21, 26], ["DZ", "CHEMICAL", 67, 69], ["B cells", "CELL", 47, 54], ["B cells", "CELL_TYPE", 47, 54], ["the death rate", "TEST", 17, 31], ["B cells", "OBSERVATION", 47, 54], ["DZ", "ANATOMY", 67, 69], ["LZ", "ANATOMY", 74, 76]]], ["Figure (D) shows the mutation rates at different time points, and roughly corresponds to 5 mutations every 10 days [6, 44] .", [["the mutation rates", "PROBLEM", 17, 35]]], ["Figures (E,F) illustrate the temporal switch from memory B cell to plasma cell production simulated with our model using 3 different differentiation scenarios and experimentally measured [50] .Germinal Center DynamicsRegarding PC/MBC differentiation, the time-dependent GC output of the three models investigated in Section 2.7 reproduces the temporal switch experimentally observed ( Figure 4E,F) , where memory cell models are produced during the first two weeks of the GC reaction, and plasma cells are produced afterwards [50] .", [["memory B cell", "ANATOMY", 50, 63], ["plasma cell", "ANATOMY", 67, 78], ["memory cell", "ANATOMY", 406, 417], ["plasma cells", "ANATOMY", 489, 501], ["MBC", "CHEMICAL", 230, 233], ["memory B cell", "CELL", 50, 63], ["plasma cell", "CELL", 67, 78], ["memory cell", "CELL", 406, 417], ["plasma cells", "CELL", 489, 501], ["memory B cell", "CELL_TYPE", 50, 63], ["plasma cells", "CELL_TYPE", 489, 501], ["the temporal switch", "PROBLEM", 25, 44], ["memory B cell to plasma cell production", "TREATMENT", 50, 89], ["GC output", "TEST", 270, 279], ["memory cell models", "TEST", 406, 424], ["the GC reaction", "PROBLEM", 468, 483], ["plasma cells", "TEST", 489, 501], ["MBC differentiation", "OBSERVATION", 230, 249]]], ["The model based on a fixed threshold has the lowest agreement with experiments, as this model does not lead to a substantial production of MBCs after 2 weeks, while MBCs are produced during the whole GC reaction, albeit at a moderate rate at late time-points.", [["MBCs", "ANATOMY", 139, 143], ["MBCs", "ANATOMY", 165, 169], ["MBCs", "CHEMICAL", 139, 143], ["MBCs", "CHEMICAL", 165, 169], ["MBCs", "CELL", 139, 143], ["MBCs", "SIMPLE_CHEMICAL", 165, 169], ["MBCs", "CELL_TYPE", 165, 169], ["a substantial production of MBCs", "PROBLEM", 111, 143], ["MBCs", "TEST", 165, 169], ["the whole GC reaction", "PROBLEM", 190, 211], ["substantial", "OBSERVATION_MODIFIER", 113, 124], ["production", "OBSERVATION_MODIFIER", 125, 135]]], ["On the other hand, both the dynamic threshold and stochastic differentiation model are compatible with experimental data (average NRMSD = 0.52 and 0.59), with the stochastic model fitting the data slightly better.Germinal Center DynamicsTo gain insight into which parameters have a higher impact on the GC dynamics, we perform a stability analysis (Supplementary Information).", [["NRMSD", "TEST", 130, 135], ["a stability analysis", "TEST", 327, 347], ["stochastic differentiation", "OBSERVATION", 50, 76], ["compatible with", "UNCERTAINTY", 87, 102]]], ["The analysis reveals that the GC kinetics is most sensitive to changes in the parameters that regulate the selection process by T FHs , such as the amount of T FHs signals necessary for a LZ B cell to recirculate into the DZ, as well as the amount of cellular divisions it undergoes once there.", [["LZ B cell", "ANATOMY", 188, 197], ["DZ", "ANATOMY", 222, 224], ["cellular", "ANATOMY", 251, 259], ["DZ", "CHEMICAL", 222, 224], ["T FHs", "GENE_OR_GENE_PRODUCT", 128, 133], ["T FHs", "GENE_OR_GENE_PRODUCT", 158, 163], ["LZ B cell", "CELL", 188, 197], ["DZ", "MULTI-TISSUE_STRUCTURE", 222, 224], ["cellular", "CELL", 251, 259], ["T FHs", "PROTEIN", 128, 133], ["T FHs", "PROTEIN", 158, 163], ["LZ B cell", "CELL_TYPE", 188, 197], ["The analysis", "TEST", 0, 12], ["the GC kinetics", "PROBLEM", 26, 41], ["a LZ B cell", "PROBLEM", 186, 197], ["the DZ", "PROBLEM", 218, 224], ["DZ", "OBSERVATION", 222, 224], ["amount", "OBSERVATION_MODIFIER", 241, 247], ["cellular divisions", "OBSERVATION", 251, 269]]], ["Similarly, the probability \u03b4 of dying in the DZ after a mutation leads to a nonproductive receptor critically influences the number of cells in the GC.Germinal Center DynamicsWe also perform a sensitivity analysis to quantify the effect of changes in the parameters in the simulation output.", [["cells", "ANATOMY", 135, 140], ["GC", "ANATOMY", 148, 150], ["DZ", "CHEMICAL", 45, 47], ["cells", "CELL", 135, 140], ["GC", "CELL", 148, 150], ["nonproductive receptor", "PROTEIN", 76, 98], ["the DZ", "PROBLEM", 41, 47], ["a mutation", "PROBLEM", 54, 64], ["a sensitivity analysis", "TEST", 191, 213], ["the simulation output", "TEST", 269, 290], ["DZ", "OBSERVATION", 45, 47]]], ["The changes in the model output are quantified by measuring the change in NRMSE total over all quantified GC properties ( Table 2) .", [["The changes in the model output", "PROBLEM", 0, 31], ["model", "OBSERVATION_MODIFIER", 19, 24], ["output", "OBSERVATION_MODIFIER", 25, 31], ["change", "OBSERVATION_MODIFIER", 64, 70]]], ["Some parameter changes mainly affect the GC kinetics, e.g., the GC B cell counts and the DZ/LZ ratio, while others have an impact on the affinity maturation process, e.g., clonal diversity and number of acquired mutations.", [["GC B cell", "ANATOMY", 64, 73], ["DZ", "CHEMICAL", 89, 91], ["GC B cell", "CELL", 64, 73], ["LZ", "GENE_OR_GENE_PRODUCT", 92, 94], ["Some parameter changes", "PROBLEM", 0, 22], ["the GC kinetics", "TEST", 37, 52], ["the GC B cell counts", "TEST", 60, 80], ["the DZ/LZ ratio", "TEST", 85, 100], ["the affinity maturation process", "PROBLEM", 133, 164], ["acquired mutations", "PROBLEM", 203, 221], ["LZ", "ANATOMY", 92, 94], ["clonal diversity", "OBSERVATION", 172, 188]]], ["As an example, the lethal mutation probability \u03b4 has a strong impact on the GC kinetics, as a 10% decrease leads to a 660% change in the total NRMSD.", [["the lethal mutation probability", "PROBLEM", 15, 46], ["total", "OBSERVATION_MODIFIER", 137, 142]]], ["On the other hand, the silent mutation probability \u03c3 has a low impact, as a 10% decrease only leads to a change in the total NRMSD of <10% (Table S1 in the Supplementary Information).Comparison of Simulated and Experimentally Determined BCR SequencesA direct comparison of sequences between sequenced GC B cell repertoires and sequences inferred with our model is not possible due to our abstract representation of the variable region of the BCR.Comparison of Simulated and Experimentally Determined BCR SequencesAs an alternative, we use phylogenetic trees to visualize the somatic evolution of B cells during the GC response.", [["GC B cell", "ANATOMY", 301, 310], ["B cells", "ANATOMY", 596, 603], ["BCR", "GENE_OR_GENE_PRODUCT", 237, 240], ["GC B cell", "CELL", 301, 310], ["BCR", "GENE_OR_GENE_PRODUCT", 442, 445], ["BCR", "GENE_OR_GENE_PRODUCT", 500, 503], ["B cells", "CELL", 596, 603], ["BCR", "PROTEIN", 237, 240], ["BCR", "PROTEIN", 442, 445], ["BCR", "PROTEIN", 500, 503], ["B cells", "CELL_TYPE", 596, 603], ["the silent mutation probability", "PROBLEM", 19, 50], ["a change", "PROBLEM", 103, 111], ["the total NRMSD", "TEST", 115, 130], ["GC B cell repertoires", "TEST", 301, 322], ["the BCR", "PROBLEM", 438, 445], ["phylogenetic trees", "TREATMENT", 539, 557], ["B cells", "PROBLEM", 596, 603], ["low impact", "OBSERVATION_MODIFIER", 59, 69], ["change", "OBSERVATION_MODIFIER", 105, 111], ["BCR", "OBSERVATION", 442, 445], ["B cells", "OBSERVATION", 596, 603]]], ["To construct experimental trees, we use single-cell BCR sequencing data obtained from individual GCs [15] .", [["cell", "ANATOMY", 47, 51], ["cell", "CELL", 47, 51], ["BCR", "PROTEIN", 52, 55], ["single-cell BCR sequencing data", "TEST", 40, 71], ["individual GCs", "TEST", 86, 100]]], ["Specifically, the sequences of the Ig heavy chain of \u223c1500 single B cells from 18 distinct GCs-with an average of roughly 80 cells per GC-were used to build 266 trees containing at least 2 cells.", [["B cells", "ANATOMY", 66, 73], ["GCs", "ANATOMY", 91, 94], ["cells", "ANATOMY", 125, 130], ["cells", "ANATOMY", 189, 194], ["Ig heavy chain", "GENE_OR_GENE_PRODUCT", 35, 49], ["B cells", "CELL", 66, 73], ["GCs", "CELL", 91, 94], ["cells", "CELL", 125, 130], ["GC", "CELL", 135, 137], ["cells", "CELL", 189, 194], ["Ig heavy chain", "PROTEIN", 35, 49], ["B cells", "CELL_TYPE", 66, 73], ["single B cells", "TEST", 59, 73], ["GCs", "TEST", 91, 94], ["GC", "TEST", 135, 137]]], ["All measurements were performed on mice at day 15 after immunization with different antigens.", [["mice", "ORGANISM", 35, 39], ["mice", "SPECIES", 35, 39], ["mice", "SPECIES", 35, 39], ["All measurements", "TEST", 0, 16], ["immunization", "TREATMENT", 56, 68]]], ["By sampling midway through the GC reaction, intermediate BCRs that might have populated the GC at earlier time-points are lost, and the inference sometimes shows long trunks, representing the pruned evolutionary process of the sampled cells, in agreement with earlier observations [29] .", [["long trunks", "ANATOMY", 162, 173], ["cells", "ANATOMY", 235, 240], ["BCRs", "GENE_OR_GENE_PRODUCT", 57, 61], ["trunks", "MULTI-TISSUE_STRUCTURE", 167, 173], ["cells", "CELL", 235, 240], ["the GC reaction", "PROBLEM", 27, 42], ["intermediate BCRs", "PROBLEM", 44, 61], ["long trunks", "PROBLEM", 162, 173], ["intermediate BCRs", "OBSERVATION", 44, 61]]], ["Co-existing clones are only seen close to the tree leaves ( Figure 5A) , where selection is currently taking place.", [["clones", "ANATOMY", 12, 18], ["leaves", "ANATOMY", 51, 57], ["clones", "CELL", 12, 18], ["Co-existing clones", "PROBLEM", 0, 18], ["clones", "OBSERVATION", 12, 18]]], ["To reproduce the experimental sampling conditions with the simulated data, we uniformly sampled 80 cells at day 15 after immunization from our model.Comparison of Simulated and Experimentally Determined BCR SequencesThe experimental and simulated trees were analyzed with the BioPhylo python library [62] to compute important topological properties, such as number of leaves, average leaf depth, and trunk length.", [["cells", "ANATOMY", 99, 104], ["leaves", "ANATOMY", 368, 374], ["leaf", "ANATOMY", 384, 388], ["trunk", "ANATOMY", 400, 405], ["cells", "CELL", 99, 104], ["BCR", "GENE_OR_GENE_PRODUCT", 203, 206], ["leaf", "ORGANISM_SUBDIVISION", 384, 388], ["trunk", "ORGANISM_SUBDIVISION", 400, 405], ["BCR Sequences", "DNA", 203, 216], ["the experimental sampling conditions", "PROBLEM", 13, 49], ["immunization", "TREATMENT", 121, 133], ["BCR Sequences", "TEST", 203, 216], ["leaf depth", "OBSERVATION", 384, 394], ["trunk", "ANATOMY", 400, 405], ["length", "OBSERVATION_MODIFIER", 406, 412]]], ["The distributions of these properties in both the simulated and the experimental tress are shown in Figure 5B -D.", [["distributions", "OBSERVATION_MODIFIER", 4, 17]]], ["However, experiments suggest that the density function of cell mutations per tree is broader than what our model predicts.", [["cell", "ANATOMY", 58, 62], ["cell", "CELL", 58, 62], ["the density function of cell mutations", "PROBLEM", 34, 72], ["density", "OBSERVATION", 38, 45], ["cell mutations", "OBSERVATION", 58, 72]]], ["This could be explained by the fact that all mutations have equal contributions in our model, where one mutation can only increment the affinity by 1 N CDR , with N CDR = 25.", [["all mutations", "PROBLEM", 41, 54], ["N CDR", "TEST", 163, 168], ["could be explained", "UNCERTAINTY", 5, 23]]], ["Such limitation prevents cells with a low number of mutations from having a high-affinity BCR, thus constraining the simulated density function to be narrower.", [["cells", "ANATOMY", 25, 30], ["cells", "CELL", 25, 30], ["BCR", "GENE_OR_GENE_PRODUCT", 90, 93], ["BCR", "PROTEIN", 90, 93], ["Such limitation prevents cells", "PROBLEM", 0, 30], ["a low number of mutations", "PROBLEM", 36, 61], ["a high-affinity BCR", "PROBLEM", 74, 93], ["low number", "OBSERVATION_MODIFIER", 38, 48], ["density", "OBSERVATION", 127, 134], ["narrower", "OBSERVATION_MODIFIER", 150, 158]]], ["Another contributing factor could be the fact that our simulation only considers the CDR region, and does not keep track of silent mutations that might occur in the FWR region.", [["CDR region", "DNA", 85, 95], ["FWR region", "DNA", 165, 175], ["silent mutations", "PROBLEM", 124, 140]]], ["Figure 6A depicts the evolution of the average affinity in the GC through its lifespan.", [["the average affinity", "PROBLEM", 35, 55]]], ["Noticeably, affinity does not substantially improve during the first days of the GC reaction, corresponding to the phase of monoclonal expansion where B cells divide without selection pressure.", [["B cells", "ANATOMY", 151, 158], ["B cells", "CELL", 151, 158], ["B cells", "CELL_TYPE", 151, 158], ["the GC reaction", "PROBLEM", 77, 92], ["monoclonal expansion", "PROBLEM", 124, 144], ["B cells", "TREATMENT", 151, 158], ["selection pressure", "TEST", 174, 192], ["monoclonal expansion", "OBSERVATION", 124, 144]]], ["After day 10, affinity increases linearly throughout most of the lifespan of the GC, only showing slower improvement rates near the end of the GC reaction, where the remaining B cells have presumably developed good receptors against the exposed antigens, and new mutations are likely to be detrimental to the overall affinity.Visualizing Affinity MaturationFor visualization purposes, we randomly sampled two cells every day from the dominant clone, where dominance was established by analyzing clonal cell counts at the end of the simulation, and computed a tree from the obtained set of BCR sequences ( Figure 6B ).", [["GC", "ANATOMY", 81, 83], ["B cells", "ANATOMY", 176, 183], ["cells", "ANATOMY", 409, 414], ["clone", "ANATOMY", 443, 448], ["cell", "ANATOMY", 502, 506], ["B cells", "CELL", 176, 183], ["cells", "CELL", 409, 414], ["clone", "CELL", 443, 448], ["clonal cell", "CELL", 495, 506], ["BCR", "GENE_OR_GENE_PRODUCT", 589, 592], ["B cells", "CELL_TYPE", 176, 183], ["exposed antigens", "PROTEIN", 237, 253], ["BCR sequences", "DNA", 589, 602], ["the GC reaction", "PROBLEM", 139, 154], ["the exposed antigens", "PROBLEM", 233, 253], ["new mutations", "PROBLEM", 259, 272], ["visualization purposes", "TEST", 361, 383], ["analyzing clonal cell counts", "TEST", 485, 513], ["BCR sequences", "TEST", 589, 602], ["slower", "OBSERVATION_MODIFIER", 98, 104], ["improvement", "OBSERVATION_MODIFIER", 105, 116], ["dominant", "OBSERVATION_MODIFIER", 434, 442], ["clone", "OBSERVATION", 443, 448], ["clonal cell counts", "OBSERVATION", 495, 513]]], ["Since we sample uniformly throughout the lifespan of the GC, we do not observe the long trunk found in experimentally inferred trees due to pruned clones.", [["trunk", "ANATOMY", 88, 93], ["clones", "ANATOMY", 147, 153], ["trunk", "ORGANISM_SUBDIVISION", 88, 93], ["clones", "CELL", 147, 153], ["pruned clones", "CELL_LINE", 140, 153], ["pruned clones", "PROBLEM", 140, 153], ["pruned clones", "OBSERVATION", 140, 153]]], ["Although the specific structure of the tree shows high variability as a consequence of the strong undersamplig, the tree clearly shows how affinity maturates as a result of clonal evolution.", [["clonal", "CELL", 173, 179], ["high variability", "PROBLEM", 50, 66], ["tree", "ANATOMY_MODIFIER", 39, 43], ["high variability", "OBSERVATION", 50, 66], ["clonal evolution", "OBSERVATION", 173, 189]]], ["Noticeable also is the clear correlation between increased affinity and number of SHMs (the number of mutations is equal to the number of nodes connecting the root cell and a leaf).", [["nodes", "ANATOMY", 138, 143], ["root cell", "ANATOMY", 159, 168], ["leaf", "ANATOMY", 175, 179], ["SHMs", "GENE_OR_GENE_PRODUCT", 82, 86], ["root cell", "CELL", 159, 168], ["leaf", "ORGAN", 175, 179], ["SHMs", "PROTEIN", 82, 86], ["increased affinity", "PROBLEM", 49, 67], ["mutations", "PROBLEM", 102, 111], ["increased", "OBSERVATION_MODIFIER", 49, 58], ["affinity", "OBSERVATION_MODIFIER", 59, 67], ["number", "OBSERVATION_MODIFIER", 72, 78], ["nodes", "OBSERVATION", 138, 143], ["root cell", "OBSERVATION", 159, 168], ["leaf", "ANATOMY", 175, 179]]], ["Resampling the BCR set multiple times did not significantly change the properties of the tree.Visualizing Clonal Competition and Clonal BurstTo better understand the complex process of clonal competition and the mechanisms behind clonal bursts observed in a subset of GCs [15] , we plot the evolution of the number of clonal families in the GC as a function of time ( Figure 7A) , where clonal families are defined in our simulations as the cells descending from the same founder cell.", [["cells", "ANATOMY", 441, 446], ["cell", "ANATOMY", 480, 484], ["BCR", "GENE_OR_GENE_PRODUCT", 15, 18], ["clonal", "CELL", 185, 191], ["cells", "CELL", 441, 446], ["cell", "CELL", 480, 484], ["BCR", "PROTEIN", 15, 18], ["clonal bursts", "PROBLEM", 230, 243], ["tree", "ANATOMY_MODIFIER", 89, 93], ["founder cell", "OBSERVATION", 472, 484]]], ["Our model reveals that the number of clones increases until day 8, corresponding to the continuous entry of new founder cells in the GC.", [["clones", "ANATOMY", 37, 43], ["cells", "ANATOMY", 120, 125], ["GC", "ANATOMY", 133, 135], ["clones", "CELL", 37, 43], ["cells", "CELL", 120, 125], ["GC", "CELL", 133, 135], ["founder cells", "CELL_TYPE", 112, 125]]], ["Then, shortly after the monoclonal expansion phase, the GC experiences a rapid loss of clonal diversity due to the high selection pressure exerted in the LZ on the still immature CCs, followed by a more moderate decrease that lasts until the end of the GC reaction.", [["CCs", "ANATOMY", 179, 182], ["CCs", "CELL", 179, 182], ["the monoclonal expansion phase", "TEST", 20, 50], ["a rapid loss of clonal diversity", "PROBLEM", 71, 103], ["the GC reaction", "PROBLEM", 249, 264], ["clonal diversity", "OBSERVATION", 87, 103], ["high selection", "OBSERVATION", 115, 129], ["pressure", "OBSERVATION_MODIFIER", 130, 138], ["LZ", "ANATOMY", 154, 156], ["immature CCs", "OBSERVATION", 170, 182], ["more moderate", "OBSERVATION_MODIFIER", 198, 211], ["decrease", "OBSERVATION", 212, 220]]], ["These results are consistent with experimental characterizations that have revealed that clonal diversity is relatively high during the early days of the GC, followed by a phase lasting several weeks where a few clones quickly dominate the reaction [15] .Visualizing Clonal Competition and Clonal BurstWhile the evolution of the number of clones in the GC has not been measured quantitatively, clonal diversity has been characterized using a Normalized Dominance Score (NDS) [15] (Section 2.9).", [["clonal", "CELL", 89, 95], ["clones", "CELL", 339, 345], ["GC", "CELL", 353, 355], ["experimental characterizations", "TEST", 34, 64], ["clonal diversity", "PROBLEM", 89, 105], ["a few clones", "PROBLEM", 206, 218], ["the reaction", "PROBLEM", 236, 248], ["consistent with", "UNCERTAINTY", 18, 33], ["clonal diversity", "OBSERVATION", 89, 105], ["relatively", "OBSERVATION_MODIFIER", 109, 119], ["high", "OBSERVATION_MODIFIER", 120, 124], ["Clonal Competition", "OBSERVATION", 267, 285], ["Clonal", "OBSERVATION_MODIFIER", 290, 296], ["number", "OBSERVATION_MODIFIER", 329, 335], ["clones", "OBSERVATION", 339, 345], ["clonal diversity", "OBSERVATION", 394, 410]]], ["An interesting finding of this study is that, while most GCs retain substantial clonal diversity within the 3-week lifetime of the GC response, rapid and massive expansion of higher-affinity SHM variants (clonal bursts) leads to substantial loss of diversity in a subset of GCs.", [["GCs", "ANATOMY", 57, 60], ["GCs", "ANATOMY", 274, 277], ["GCs", "CELL", 57, 60], ["clonal", "CELL", 80, 86], ["GCs", "CELL", 274, 277], ["SHM variants", "DNA", 191, 203], ["this study", "TEST", 26, 36], ["the GC response", "TEST", 127, 142], ["massive expansion of higher-affinity SHM variants", "PROBLEM", 154, 203], ["clonal bursts)", "PROBLEM", 205, 219], ["substantial loss of diversity", "PROBLEM", 229, 258], ["substantial", "OBSERVATION_MODIFIER", 68, 79], ["clonal diversity", "OBSERVATION", 80, 96], ["GC response", "OBSERVATION", 131, 142], ["massive", "OBSERVATION_MODIFIER", 154, 161], ["expansion", "OBSERVATION_MODIFIER", 162, 171], ["higher", "OBSERVATION_MODIFIER", 175, 181], ["substantial", "OBSERVATION_MODIFIER", 229, 240], ["loss", "OBSERVATION_MODIFIER", 241, 245], ["diversity", "OBSERVATION_MODIFIER", 249, 258]]], ["As illustrated in Figure 7B , our model quantitatively reproduces the measured NDS with a low NRMSD (0.40).", [["a low NRMSD", "PROBLEM", 88, 99], ["low", "OBSERVATION_MODIFIER", 90, 93]]], ["Both the simulations and the experimental characterizations reveal a high variance in the NDS score.", [["the experimental characterizations", "TEST", 25, 59], ["a high variance in the NDS score", "PROBLEM", 67, 99], ["high variance", "OBSERVATION", 69, 82]]], ["For instance, our model predicts that 2.5% of GCs reach clonal dominance (NDS = 1) at day 30, and 25% at day 40.", [["GCs", "ANATOMY", 46, 49], ["GCs", "CELL", 46, 49], ["clonal", "CELL", 56, 62], ["GCs", "TEST", 46, 49], ["NDS", "TEST", 74, 77]]], ["This is expected if stochastic effects play a fundamental role in the emergence of dominance.", [["stochastic effects", "PROBLEM", 20, 38]]], ["To investigate the emergence of clonal dominance in more detail, we plot the Clonal Dominance (CD), which clusters cells that descend from the same founder cell (Section 2.9), of individual families in two representative simulations in Figure 8A ,C. The first simulation (1) shows a GC with no observable clonal bursts.", [["cells", "ANATOMY", 115, 120], ["cell", "ANATOMY", 156, 160], ["clonal", "CELL", 32, 38], ["cells", "CELL", 115, 120], ["founder cell", "CELL", 148, 160], ["clonal", "CELL", 305, 311], ["a GC", "TEST", 281, 285], ["observable clonal bursts", "PROBLEM", 294, 318], ["clonal dominance", "OBSERVATION", 32, 48], ["Clonal Dominance", "OBSERVATION", 77, 93], ["clonal bursts", "OBSERVATION", 305, 318]]], ["The CD of the dominant clone (green line) only becomes dominant after day 15, but other competing clones are still significantly present until much later (\u223c30 days).", [["clone", "ANATOMY", 23, 28], ["clones", "ANATOMY", 98, 104], ["clone", "CELL", 23, 28], ["green line", "CELL", 30, 40], ["clones", "CELL", 98, 104], ["dominant clone", "CELL_LINE", 14, 28], ["the dominant clone (green line", "PROBLEM", 10, 40], ["CD", "OBSERVATION", 4, 6], ["dominant", "OBSERVATION_MODIFIER", 14, 22], ["clone", "OBSERVATION", 23, 28], ["green line", "OBSERVATION", 30, 40], ["dominant", "OBSERVATION_MODIFIER", 55, 63]]], ["In the second simulation (2), the dominant clones (brown line) outcompete other clones as early as day 10, with most of the co-existing clones disappearing by day 25.", [["clones", "ANATOMY", 43, 49], ["brown line", "ANATOMY", 51, 61], ["clones", "ANATOMY", 80, 86], ["clones", "ANATOMY", 136, 142], ["clones", "CELL", 43, 49], ["brown line", "CELL", 51, 61], ["clones", "CELL", 80, 86], ["clones", "CELL", 136, 142], ["dominant clones", "CELL_LINE", 34, 49], ["the dominant clones (brown line)", "PROBLEM", 30, 62], ["dominant", "OBSERVATION_MODIFIER", 34, 42], ["clones", "OBSERVATION", 43, 49], ["brown line", "OBSERVATION", 51, 61]]], ["It is interesting to notice that in the latter scenario, representing a GC that underwent a clonal burst, the winning clone acquired an early advantage (before day 10) in terms of affinity ( Figure 8D ), which enabled the clone to proliferate and gain dominance.", [["clone", "CELL", 118, 123], ["clone", "CELL", 222, 227], ["winning clone", "CELL_LINE", 110, 123], ["a clonal burst", "PROBLEM", 90, 104]]], ["Although other clones reached higher levels of affinity at later time points, e.g., from days 15 to 25, the early advantage that led to a higher proliferation rate was sufficient to ensure dominance throughout the whole GC reaction.Visualizing Clonal Competition and Clonal BurstThe simulation shown in Figure 8 (2) seems to suggest that there is a time delay of roughly 7 days between the initial clonal affinity advantage and the clonal burst induced by it, corresponding to multiple LZ-DZ cell cycles-in our model, a full DZ-LZ cycle lasts \u223c1-2 days depending on the number of divisions in the DZ.", [["cell", "ANATOMY", 492, 496], ["DZ", "CHEMICAL", 489, 491], ["DZ", "CHEMICAL", 525, 527], ["DZ", "CHEMICAL", 597, 599], ["clones", "CELL", 15, 21], ["LZ-DZ cell", "CELL", 486, 496], ["DZ", "SIMPLE_CHEMICAL", 597, 599], ["other clones", "PROBLEM", 9, 21], ["higher levels of affinity", "PROBLEM", 30, 55], ["a higher proliferation rate", "PROBLEM", 136, 163], ["the whole GC reaction", "PROBLEM", 210, 231], ["multiple LZ-DZ cell cycles", "TREATMENT", 477, 503], ["Clonal Burst", "OBSERVATION", 267, 279], ["DZ cell cycles", "OBSERVATION", 489, 503], ["DZ", "OBSERVATION", 597, 599]]], ["To better quantify the delay between the increase in affinity and the appearance of clonal dominance, we performed a Time Lagged Cross Correlation analysis [70] between the clonal affinity and the clonal dominance time series of each clone.", [["clone", "ANATOMY", 234, 239], ["clonal", "CELL", 84, 90], ["clone", "CELL", 234, 239], ["the delay", "PROBLEM", 19, 28], ["the increase in affinity", "PROBLEM", 37, 61], ["Correlation analysis", "TEST", 135, 155], ["the clonal affinity", "TEST", 169, 188], ["increase", "OBSERVATION_MODIFIER", 41, 49], ["clonal dominance", "OBSERVATION", 84, 100], ["clonal dominance", "OBSERVATION", 197, 213]]], ["Briefly, the analysis computes the Pearson correlation of one time series with the respect to the second one shifted by a time offset.", [["the analysis", "TEST", 9, 21]]], ["We collected time series data from 1000 clone dominance-affinity pairs by taking the 10 most abundant clones of 100 GC simulations.", [["series data", "TEST", 18, 29]]], ["The results obtained, highlighted in Figure 9 , confirm that the correlation is maximized for a time delay of 7.1 days, which suggests a causal relationship between a random increase in affinity and the emergent appearance of dominance one week later.", [["a random increase in affinity", "PROBLEM", 165, 194]]], ["A delay of 7 days corresponds to roughly 3-4 rounds of DZ-LZ B cell cycles.", [["DZ-LZ B cell", "ANATOMY", 55, 67], ["DZ", "CHEMICAL", 55, 57], ["DZ-LZ B cell", "CELL", 55, 67], ["DZ", "TEST", 55, 57], ["LZ B cell cycles", "TREATMENT", 58, 74], ["LZ", "ANATOMY", 58, 60], ["cell cycles", "OBSERVATION", 63, 74]]], ["This delay is consistent with the expectation that the production of high-affinity antibodies requires several rounds of cell division and affinity maturation.", [["cell", "ANATOMY", 121, 125], ["cell", "CELL", 121, 125], ["high-affinity antibodies", "PROTEIN", 69, 93], ["This delay", "PROBLEM", 0, 10], ["high-affinity antibodies", "PROBLEM", 69, 93], ["cell division", "TREATMENT", 121, 134], ["affinity maturation", "TREATMENT", 139, 158], ["consistent with", "UNCERTAINTY", 14, 29]]], ["More specifically, with an average of three divisions per DZ-LZ cycle, our model suggests that one round of somatic hyperpermutation is not enough to achieve clonal dominance.DiscussionWe have presented a stochastic multiscale model of the GC that combines an abstract representation of individual B cell receptors (BCRs) as strings of nucleotides, a deterministic regulatory representation of the transcriptional program associated with B cell differentiation [20] and a stochastic representation of the cellular interactions that shape the GC reaction.", [["B cell", "ANATOMY", 298, 304], ["B cell", "ANATOMY", 438, 444], ["cellular", "ANATOMY", 505, 513], ["DZ", "CHEMICAL", 58, 60], ["nucleotides", "CHEMICAL", 336, 347], ["clonal", "CELL", 158, 164], ["B cell receptors", "GENE_OR_GENE_PRODUCT", 298, 314], ["BCRs", "GENE_OR_GENE_PRODUCT", 316, 320], ["B cell", "CELL", 438, 444], ["cellular", "CELL", 505, 513], ["B cell receptors", "PROTEIN", 298, 314], ["BCRs", "PROTEIN", 316, 320], ["somatic hyperpermutation", "PROBLEM", 108, 132], ["individual B cell receptors", "PROBLEM", 287, 314], ["strings of nucleotides", "PROBLEM", 325, 347], ["B cell differentiation", "PROBLEM", 438, 460], ["the cellular interactions", "PROBLEM", 501, 526], ["the GC reaction", "PROBLEM", 538, 553], ["one", "OBSERVATION_MODIFIER", 95, 98], ["round", "OBSERVATION_MODIFIER", 99, 104], ["somatic hyperpermutation", "OBSERVATION", 108, 132], ["cellular interactions", "OBSERVATION", 505, 526], ["GC reaction", "OBSERVATION", 542, 553]]], ["The model parameters were optimised using time-resolved data from various experimental characterizations of the GC kinetics and GC clonal diversity [15, 18, 44, 50, 55] .", [["The model parameters", "TEST", 0, 20], ["the GC kinetics", "TEST", 108, 123]]], ["Overall, our model recapitulates the GC dynamics characterized experimentally, including the GC B cell counts at different times of the GC reaction, the DZ/LZ volumetric ratio, the cell death and accumulation of mutations as a result of SHM.", [["GC B cell", "ANATOMY", 93, 102], ["cell", "ANATOMY", 181, 185], ["DZ", "CHEMICAL", 153, 155], ["death", "DISEASE", 186, 191], ["GC B cell", "CELL", 93, 102], ["cell", "CELL", 181, 185], ["the GC dynamics", "TEST", 33, 48], ["the GC B cell counts", "TEST", 89, 109], ["the GC reaction", "PROBLEM", 132, 147], ["the DZ/LZ volumetric ratio", "TEST", 149, 175], ["the cell death", "PROBLEM", 177, 191], ["accumulation of mutations", "PROBLEM", 196, 221], ["SHM", "PROBLEM", 237, 240], ["cell death", "OBSERVATION", 181, 191]]], ["Compared to existing models, our model accounts for a broader range of important biological processes, e.g., centroblast apoptosis, a more realistic description of antigen capture, and faithfully replicates experimental data.", [["centroblast", "ANATOMY", 109, 120], ["centroblast apoptosis", "PROBLEM", 109, 130]]], ["A sensitivity analysis reveals that the GC kinetics is very sensitive to small changes in some key parameters, indicating that the B cell maturation is a tightly regulated program.", [["B cell", "ANATOMY", 131, 137], ["B cell", "CELL", 131, 137], ["A sensitivity analysis", "TEST", 0, 22], ["the GC kinetics", "TEST", 36, 51], ["small changes", "PROBLEM", 73, 86], ["the B cell maturation", "PROBLEM", 127, 148], ["cell maturation", "OBSERVATION", 133, 148]]], ["In particular, slight differences in the T FH selection process have a high impact in the GC dynamics, and can potentially lead to a drastic increase in both the number of dividing centroblasts as well as differentiating cells.", [["centroblasts", "ANATOMY", 181, 193], ["cells", "ANATOMY", 221, 226], ["T FH", "GENE_OR_GENE_PRODUCT", 41, 45], ["centroblasts", "CANCER", 181, 193], ["cells", "CELL", 221, 226], ["dividing centroblasts", "CELL_TYPE", 172, 193], ["differentiating cells", "CELL_TYPE", 205, 226], ["a drastic increase", "PROBLEM", 131, 149], ["slight", "OBSERVATION_MODIFIER", 15, 21], ["differences", "OBSERVATION_MODIFIER", 22, 33], ["high", "OBSERVATION_MODIFIER", 71, 75], ["drastic", "OBSERVATION_MODIFIER", 133, 140], ["increase", "OBSERVATION_MODIFIER", 141, 149], ["both", "OBSERVATION_MODIFIER", 153, 157]]], ["Such sensitivity could explain the high variability observed in the GC sizes [18] .", [["Such sensitivity", "TEST", 0, 16], ["the high variability", "PROBLEM", 31, 51], ["high variability", "OBSERVATION", 35, 51]]], ["Our optimisation approach enables the easy integration of new experimental data that might become available in the near future.DiscussionWith the help of our model, we computationally investigated three candidate mechanisms that might potentially govern the terminal differentiation of GC B cells into PCs or MBCs.", [["GC B cells", "ANATOMY", 286, 296], ["PCs", "ANATOMY", 302, 305], ["MBCs", "ANATOMY", 309, 313], ["GC B cells", "CELL", 286, 296], ["PCs", "CELL", 302, 305], ["MBCs", "CELL", 309, 313], ["GC B cells", "CELL_TYPE", 286, 296], ["PCs", "CELL_TYPE", 302, 305], ["MBCs", "CELL_TYPE", 309, 313], ["new experimental data", "TEST", 58, 79], ["MBCs", "PROBLEM", 309, 313]]], ["Namely, (i) a deterministic scenario, where the amount of captured antigen determines cell fate; (ii) a dynamic model, similar to the deterministic model, but where the threshold of captured antigen to become a PC increases with the lifespan of the GC; and (iii) a probabilistic scenario, where the amount of exposed antigen determines the cellular outcome in a probabilistic fashion, i.e., cells with high and low amounts of antigen have a non-zero probability of becoming either a PC or a MBC.", [["cell", "ANATOMY", 86, 90], ["PC", "ANATOMY", 211, 213], ["cellular", "ANATOMY", 340, 348], ["cells", "ANATOMY", 391, 396], ["PC", "ANATOMY", 483, 485], ["MBC", "ANATOMY", 491, 494], ["MBC", "DISEASE", 491, 494], ["cell", "CELL", 86, 90], ["PC", "CANCER", 211, 213], ["cellular", "CELL", 340, 348], ["cells", "CELL", 391, 396], ["PC", "CANCER", 483, 485], ["MBC", "CANCER", 491, 494], ["exposed antigen", "PROTEIN", 309, 324], ["a PC", "PROBLEM", 209, 213], ["exposed antigen", "PROBLEM", 309, 324], ["high and low amounts of antigen", "PROBLEM", 402, 433], ["a MBC", "PROBLEM", 489, 494], ["cellular outcome", "OBSERVATION", 340, 356], ["high", "OBSERVATION_MODIFIER", 402, 406], ["low amounts", "OBSERVATION_MODIFIER", 411, 422]]], ["Although the three models perform reasonably well and reproduce the observed temporal switch from memory cells to plasma cell production accurately [50] , the stochastic differentiation model has the best agreement with experimental data ( Figure 4E ,F).", [["memory cells", "ANATOMY", 98, 110], ["plasma cell", "ANATOMY", 114, 125], ["cells", "CELL", 105, 110], ["plasma cell", "CELL", 114, 125], ["memory cells", "CELL_TYPE", 98, 110], ["plasma cell production", "TEST", 114, 136]]], ["One important point is that while the three models differ in the absolute counts of PCs and MBCs produced (Supplementary Figure S2) , the experimental data only reports relative changes across time-points, which might hide global changes in cellular output.", [["cellular", "ANATOMY", 241, 249], ["PCs", "CELL", 84, 87], ["cellular", "CELL", 241, 249], ["PCs", "CELL_TYPE", 84, 87], ["MBCs", "CELL_TYPE", 92, 96], ["PCs", "TEST", 84, 87], ["MBCs", "TEST", 92, 96], ["the experimental data", "TEST", 134, 155], ["global changes in cellular output", "PROBLEM", 223, 256], ["cellular output", "OBSERVATION", 241, 256]]], ["Additional experimental data on the GC output will help further differentiate between the 3 considered scenarios.DiscussionThe amount of T FHs plays a critical role in determining the GC outcome.", [["T FHs", "GENE_OR_GENE_PRODUCT", 137, 142], ["T FHs", "PROTEIN", 137, 142], ["the GC output", "TEST", 32, 45]]], ["Models where the number of T FHs is fixed at a constant value tend to be stable, with the GC reaching a steady state upon which it does not decreases or increases in size, contrary to observations ( Figure 4A ).", [["T FHs", "GENE_OR_GENE_PRODUCT", 27, 32], ["T FHs", "PROTEIN", 27, 32], ["stable", "OBSERVATION_MODIFIER", 73, 79], ["decreases", "OBSERVATION_MODIFIER", 140, 149], ["increases", "OBSERVATION_MODIFIER", 153, 162], ["size", "OBSERVATION_MODIFIER", 166, 170]]], ["We therefore assume that T FHs can enter and leave the GC during the whole reaction [40] , which leads to having an approximately constant density of T FHs [18] .", [["T FHs", "GENE_OR_GENE_PRODUCT", 25, 30], ["T FHs", "PROTEIN", 25, 30]]], ["With this assumption, the sizes of our simulated GCs closely resemble experimental determinations, and the GCs naturally become extinguished by day \u223c40 ( Figure 4A ).", [["GCs", "CELL", 49, 52], ["experimental determinations", "TEST", 70, 97], ["sizes", "OBSERVATION_MODIFIER", 26, 31]]], ["Indeed, a very rough estimation of the rate of variation of the total number of GB B cells,\u1e44 B , shows that this number approximately evolves according to\u1e44 B 0.6 \u00b7 r division \u00b7 N CB \u2212 r apoptosis \u00b7 N CC \u2212 N CC sel \u00b7 r exit , where 0.6 is a correction factor that accounts for apoptotic and non-dividing centroblasts.", [["GB B cells", "ANATOMY", 80, 90], ["centroblasts", "ANATOMY", 303, 315], ["CC", "CHEMICAL", 200, 202], ["GB B cells", "CELL", 80, 90], ["\u1e44 B", "CELL", 91, 94], ["centroblasts", "CELL", 303, 315], ["GB B cells", "CELL_TYPE", 80, 90], ["apoptotic and non-dividing centroblasts", "CELL_TYPE", 276, 315], ["B", "TEST", 156, 157], ["division", "TEST", 166, 174], ["N", "TEST", 177, 178], ["CB", "TEST", 179, 181], ["\u2212", "TEST", 182, 183], ["apoptosis", "TEST", 186, 195], ["\u00b7", "TEST", 196, 197], ["CC", "TEST", 200, 202], ["CC sel", "TEST", 207, 213], ["r exit", "TEST", 216, 222], ["a correction factor", "PROBLEM", 238, 257], ["apoptotic", "PROBLEM", 276, 285], ["very", "OBSERVATION_MODIFIER", 10, 14], ["rough", "OBSERVATION_MODIFIER", 15, 20], ["GB B cells", "OBSERVATION", 80, 90]]], ["Taking N CC /N CC sel N CB /N CC sel 100, as predicted by our model, our choice of parameters leads t\u022f N B \u22120.4 N CC sel < 0, explaining the observed reduction in N B after day 9 (a detailed ODE analysis can be found in the Supplementary Information) .", [["CC", "CHEMICAL", 9, 11], ["CC", "CHEMICAL", 15, 17], ["CC", "CHEMICAL", 30, 32], ["CC", "CHEMICAL", 114, 116], ["N B", "CHEMICAL", 103, 106], ["N B", "CHEMICAL", 163, 166], ["N B", "PROTEIN", 103, 106], ["N B", "PROTEIN", 163, 166], ["N CC /N CC sel N CB /N CC sel", "TREATMENT", 7, 36], ["parameters leads", "TEST", 83, 99]]], ["Hence, after the initial phase of monoclonal expansion, our simulated GCs enter a phase of slow decrease in size until they naturally shutdown around day 40.", [["GCs", "ANATOMY", 70, 73], ["GCs", "CELL", 70, 73], ["monoclonal expansion", "TEST", 34, 54], ["our simulated GCs", "TEST", 56, 73], ["slow decrease in size", "PROBLEM", 91, 112], ["monoclonal expansion", "OBSERVATION", 34, 54], ["slow", "OBSERVATION_MODIFIER", 91, 95], ["decrease", "OBSERVATION_MODIFIER", 96, 104], ["size", "OBSERVATION_MODIFIER", 108, 112]]], ["Of course, additional mechanisms may be at play in terminating the GC reaction, such as antibody feedback [71] .", [["the GC reaction", "PROBLEM", 63, 78], ["antibody feedback", "TEST", 88, 105]]], ["Similarly, asynchronous onset and intercommunication between GCs might alter the efficiency of antibody response and lead to compromised efficiency and earlier termination of late initialized GCs [21] .", [["asynchronous onset", "PROBLEM", 11, 29], ["intercommunication between GCs", "PROBLEM", 34, 64], ["antibody response", "PROBLEM", 95, 112], ["compromised efficiency", "PROBLEM", 125, 147]]], ["Future renditions of our work will explicitly investigate the mechanisms by which affinity influences antigen uptake and antigen presentation, including its contribution to the termination of the GC reaction.DiscussionWe also generated BCR sequences from our simulations and compare the simulated sequences with single-cell BCR sequencing data from individual GCs by means of phylogenetic trees.", [["cell", "ANATOMY", 319, 323], ["antigen", "GENE_OR_GENE_PRODUCT", 102, 109], ["BCR", "GENE_OR_GENE_PRODUCT", 236, 239], ["cell", "CELL", 319, 323], ["BCR sequences", "DNA", 236, 249], ["BCR", "PROTEIN", 324, 327], ["antigen presentation", "TEST", 121, 141], ["the GC reaction", "PROBLEM", 192, 207], ["BCR sequences", "TEST", 236, 249], ["our simulations", "TEST", 255, 270], ["the simulated sequences", "TEST", 283, 306], ["single-cell BCR sequencing data", "TEST", 312, 343], ["individual GCs", "TEST", 349, 363]]], ["Each tree represents the evolutionary process that took place in the GC and the acquisition of new mutations that conferred higher affinity to the most fitting clones.", [["clones", "CELL", 160, 166], ["new mutations", "PROBLEM", 95, 108], ["evolutionary process", "OBSERVATION", 25, 45]]], ["The comparison of important tree topological properties, such as the number of leaves, the average depth, or the length of the trunk, reveals good agreement between our model and experiments.", [["trunk", "ANATOMY", 127, 132], ["trunk", "ORGANISM_SUBDIVISION", 127, 132], ["tree topological properties", "OBSERVATION", 28, 55], ["trunk", "ANATOMY", 127, 132], ["good agreement", "OBSERVATION", 142, 156]]], ["We find our predicted distribution of mutations per cell to be narrower than experimentally characterized ( Figure 5 ), which could indicate that our current model of affinity, where one mutation can only increment the affinity by 1 N CDR , constrains the density function of the mutations count to be narrower.", [["cell", "ANATOMY", 52, 56], ["cell", "CELL", 52, 56], ["mutations per cell", "PROBLEM", 38, 56], ["the mutations count", "TEST", 276, 295], ["density", "OBSERVATION", 256, 263], ["narrower", "OBSERVATION_MODIFIER", 302, 310]]], ["Furthermore, because of our explicit modelling of the BCR sequences, our model enables the investigation of the clonal diversity within the GC and the emergence of dominance.", [["BCR", "GENE_OR_GENE_PRODUCT", 54, 57], ["BCR sequences", "DNA", 54, 67], ["the BCR sequences", "TEST", 50, 67], ["the clonal diversity", "PROBLEM", 108, 128], ["clonal diversity", "OBSERVATION", 112, 128], ["dominance", "OBSERVATION", 164, 173]]], ["A first observation is that B cells with the same affinity can have very different outcomes, resulting in a high variability of the evolution of clonal diversity across simulations, which matches experimental observations [15] (Figure 7) .", [["B cells", "ANATOMY", 28, 35], ["B cells", "CELL", 28, 35], ["B cells", "CELL_TYPE", 28, 35], ["B cells", "PROBLEM", 28, 35], ["clonal diversity across simulations", "PROBLEM", 145, 180], ["high variability", "OBSERVATION_MODIFIER", 108, 124], ["clonal diversity", "OBSERVATION", 145, 161]]], ["Interestingly, a deeper investigation of the emergence of clonal dominance demonstrates that small advantages in the affinity to antigen acquired through random mutations are amplified and result in clonal dominance within a week (Figures 8 and 9 ).", [["clonal", "CELL", 58, 64], ["a deeper investigation", "TEST", 15, 37], ["small advantages in the affinity", "PROBLEM", 93, 125], ["random mutations", "PROBLEM", 154, 170], ["clonal dominance", "OBSERVATION", 58, 74], ["small", "OBSERVATION_MODIFIER", 93, 98], ["clonal dominance", "OBSERVATION", 199, 215]]], ["This delayed correlation might explain why previous computational models found limited correlation between clone abundance and affinity throughout the GC lifespan [24] .DiscussionAs future work, we would like to investigate approaches to overcome technical limitations of the Gillespie algorithm, such as the assumption that random interactions can be modelled as a memoryless Poissonian process.", [["clone", "CELL", 107, 112], ["clone abundance", "TEST", 107, 122], ["a memoryless Poissonian process", "PROBLEM", 364, 395]]], ["This hypothesis might not be accurate for some biological programs, such as apoptosis or cell division, which tend to be better represented using log-normal distributions [72, 73] .", [["cell", "ANATOMY", 89, 93], ["cell", "CELL", 89, 93], ["apoptosis", "PROBLEM", 76, 85], ["might not be", "UNCERTAINTY", 16, 28]]], ["We also plan to explore generalizations of the Gillespie algorithm that incorporate both individual properties and non-Poissonian processes, while still being statistically correct.DiscussionOur model does not include regulation by T follicular regulatory, T FR , cells.", [["T follicular", "ANATOMY", 232, 244], ["cells", "ANATOMY", 264, 269], ["T follicular", "CELL", 232, 244], ["T FR", "GENE_OR_GENE_PRODUCT", 257, 261], ["cells", "CELL", 264, 269], ["T follicular regulatory, T FR , cells", "CELL_TYPE", 232, 269], ["the Gillespie algorithm", "TREATMENT", 43, 66]]], ["T FR cells have been implicated in the negative regulation of GC B cell activation, affinity maturation and the differentiation of plasma cells [74] .", [["T FR cells", "ANATOMY", 0, 10], ["GC B cell", "ANATOMY", 62, 71], ["plasma cells", "ANATOMY", 131, 143], ["T FR cells", "CELL", 0, 10], ["GC B cell", "CELL", 62, 71], ["plasma cells", "CELL", 131, 143], ["T FR cells", "CELL_LINE", 0, 10], ["plasma cells", "CELL_TYPE", 131, 143], ["T FR cells", "TREATMENT", 0, 10], ["GC B cell activation", "PROBLEM", 62, 82], ["affinity maturation", "PROBLEM", 84, 103], ["plasma cells", "TEST", 131, 143]]], ["Furthermore, T FRs may have a role in the negative selection of autoreactive B cells that make up a significant part of GC B cells (8% according to [55] ).", [["autoreactive B cells", "ANATOMY", 64, 84], ["GC B cells", "ANATOMY", 120, 130], ["T FRs", "GENE_OR_GENE_PRODUCT", 13, 18], ["autoreactive B cells", "CELL", 64, 84], ["GC B cells", "CELL", 120, 130], ["T FRs", "PROTEIN", 13, 18], ["autoreactive B cells", "CELL_TYPE", 64, 84], ["GC B cells", "CELL_TYPE", 120, 130], ["autoreactive B cells", "PROBLEM", 64, 84], ["GC B cells", "TEST", 120, 130]]], ["Indeed, ex vivo TCR repertoire analysis shows that T FHs and T FRs cells exhibit different TCR repertoires, with the latter more closely resembling that of regulatory T cells and being skewed toward self-antigens [75] .", [["T FHs", "ANATOMY", 51, 56], ["T FRs cells", "ANATOMY", 61, 72], ["regulatory T cells", "ANATOMY", 156, 174], ["TCR", "GENE_OR_GENE_PRODUCT", 16, 19], ["T FHs", "CELL", 51, 56], ["T FRs cells", "CELL", 61, 72], ["TCR", "GENE_OR_GENE_PRODUCT", 91, 94], ["T cells", "CELL", 167, 174], ["TCR", "PROTEIN", 16, 19], ["T FHs", "CELL_TYPE", 51, 56], ["T FRs cells", "CELL_TYPE", 61, 72], ["TCR repertoires", "PROTEIN", 91, 106], ["regulatory T cells", "CELL_TYPE", 156, 174], ["ex vivo TCR repertoire analysis", "TEST", 8, 39], ["T FHs and T FRs cells", "PROBLEM", 51, 72], ["different TCR repertoires", "PROBLEM", 81, 106], ["TCR repertoires", "OBSERVATION", 91, 106]]], ["This finding leads to the hypothesis that T FRs might negatively regulate potentially autoreactive B cells to suppress autoimmunity [76] .", [["autoreactive B cells", "ANATOMY", 86, 106], ["autoimmunity", "DISEASE", 119, 131], ["T FRs", "GENE_OR_GENE_PRODUCT", 42, 47], ["autoreactive B cells", "CELL", 86, 106], ["T FRs", "PROTEIN", 42, 47], ["autoreactive B cells", "CELL_TYPE", 86, 106], ["autoreactive B cells", "PROBLEM", 86, 106], ["autoimmunity", "PROBLEM", 119, 131]]], ["Further work will integrate T FRs and autoreactive B cells to our model, and will provide more insight behind the mechanism of autoimmunity.DiscussionFinally, an improved model to compute BCR affinity that integrates information about BCR sequences and about the structural shape of both the antibody variable region and the antigen can significantly enhance our knowledge of the mechanisms involved in the adaptive immune response [45] .", [["autoreactive B cells", "ANATOMY", 38, 58], ["autoimmunity", "DISEASE", 127, 139], ["T FRs", "CELL", 28, 33], ["autoreactive B cells", "CELL", 38, 58], ["BCR", "GENE_OR_GENE_PRODUCT", 188, 191], ["BCR", "GENE_OR_GENE_PRODUCT", 235, 238], ["T FRs", "CELL_TYPE", 28, 33], ["autoreactive B cells", "CELL_TYPE", 38, 58], ["BCR", "PROTEIN", 188, 191], ["BCR sequences", "DNA", 235, 248], ["antibody variable region", "PROTEIN", 292, 316], ["autoreactive B cells", "TREATMENT", 38, 58], ["autoimmunity", "PROBLEM", 127, 139], ["BCR sequences", "TEST", 235, 248]]], ["Attempts in this direction have already been made, for instance by representing BCRs as a chain of 10 amino acids on a rigid lattice [28] .", [["amino acids", "CHEMICAL", 102, 113], ["amino acids", "CHEMICAL", 102, 113], ["BCRs", "GENE_OR_GENE_PRODUCT", 80, 84], ["amino acids", "AMINO_ACID", 102, 113], ["BCRs", "PROTEIN", 80, 84], ["a rigid lattice", "TREATMENT", 117, 132]]], ["Despite these promising works, a full integration of the 3D structure of both the BCR and the antigen remains challenging.", [["BCR", "GENE_OR_GENE_PRODUCT", 82, 85], ["BCR", "PROTEIN", 82, 85], ["BCR", "OBSERVATION", 82, 85]]], ["An alternative approach is to focus on predicting binding affinity directly from sequence and transcriptomic data.", [["transcriptomic data", "TEST", 94, 113]]], ["This is already routinely performed to predict drug sensitivity, where the binding affinity between a drug compound and a protein is predicted using transcriptomic data and chemical information without explicitly accounting for the 3D structure of either molecule [77, 78] .", [["drug sensitivity", "TEST", 47, 63], ["the binding affinity", "PROBLEM", 71, 91], ["a drug compound", "PROBLEM", 100, 115], ["transcriptomic data", "TEST", 149, 168]]], ["The adaption of these models to the task of predicting the binding affinity between a receptor and an antigen or therapeutic compound, e.g., a vaccine, would open exciting opportunities for synthetic antibody engineering or vaccines in silico optimisation.", [["the binding affinity", "PROBLEM", 55, 75], ["a receptor", "TREATMENT", 84, 94], ["a vaccine", "TREATMENT", 141, 150], ["synthetic antibody engineering", "TREATMENT", 190, 220], ["vaccines", "TREATMENT", 224, 232]]], ["Work in this direction could have vast repercussions in understanding the emergence of broadly neutralizing antibodies, designing serological tests or vaccines against mutating pathogens, such as SARS-CoV-2.DiscussionSupplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/9/6/1448/s1.", [["SARS-CoV-2", "ORGANISM", 196, 206], ["neutralizing antibodies", "PROTEIN", 95, 118], ["SARS-CoV", "SPECIES", 196, 204], ["broadly neutralizing antibodies", "TREATMENT", 87, 118], ["serological tests", "TEST", 130, 147], ["vaccines", "TREATMENT", 151, 159], ["mutating pathogens", "PROBLEM", 168, 186]]], ["Figure S1 : Germinal center B cell count with different parameters for Tcell help, Figure S2 : Memory cells and plasma cells production with and without scaling, Table S1 : Sensitivity analysis.", [["Germinal center B cell", "ANATOMY", 12, 34], ["Memory cells", "ANATOMY", 95, 107], ["plasma cells", "ANATOMY", 112, 124], ["Germinal center B cell", "CELL", 12, 34], ["Memory cells", "CELL", 95, 107], ["plasma cells", "CELL", 112, 124], ["Memory cells", "CELL_TYPE", 95, 107], ["plasma cells", "CELL_TYPE", 112, 124], ["Germinal center B cell count", "TEST", 12, 40], ["different parameters", "TEST", 46, 66], ["Tcell help", "TEST", 71, 81], ["plasma cells production", "TEST", 112, 135], ["Sensitivity analysis", "TEST", 173, 193], ["Germinal", "ANATOMY", 12, 20], ["cell count", "OBSERVATION", 30, 40], ["S2", "ANATOMY", 90, 92], ["Memory cells", "OBSERVATION", 95, 107], ["plasma cells", "OBSERVATION", 112, 124]]]], "PMC7185268": [["MotivationIn December 2019, a local outbreak of pneumonia of initially unknown cause was detected in Wuhan, a city of 11 million people in central China (Li et al. 2020).", [["pneumonia", "DISEASE", 48, 57], ["people", "ORGANISM", 129, 135], ["people", "SPECIES", 129, 135], ["pneumonia", "PROBLEM", 48, 57], ["pneumonia", "OBSERVATION", 48, 57]]], ["The cause of the disease was identified as the novel severe acute respiratory syndrome coronavirus 2, SARS-CoV-2 (Gorbalenya et al. 2020).", [["acute respiratory syndrome coronavirus", "DISEASE", 60, 98], ["severe acute respiratory syndrome coronavirus", "SPECIES", 53, 98], ["SARS-CoV", "SPECIES", 102, 110], ["the disease", "PROBLEM", 13, 24], ["the novel severe acute respiratory syndrome coronavirus", "PROBLEM", 43, 98], ["SARS", "TEST", 102, 106], ["disease", "OBSERVATION", 17, 24], ["severe", "OBSERVATION_MODIFIER", 53, 59], ["acute", "OBSERVATION_MODIFIER", 60, 65], ["respiratory syndrome coronavirus", "OBSERVATION", 66, 98]]], ["Infection with the virus can be asymptomatic or can result in a mild to severe symptomatic disease, coronavirus disease 2019 or COVID-19.", [["coronavirus disease", "DISEASE", 100, 119], ["Infection", "PROBLEM", 0, 9], ["the virus", "PROBLEM", 15, 24], ["asymptomatic", "PROBLEM", 32, 44], ["a mild to severe symptomatic disease", "PROBLEM", 62, 98], ["coronavirus disease", "PROBLEM", 100, 119], ["COVID", "TEST", 128, 133], ["mild", "OBSERVATION_MODIFIER", 64, 68], ["severe", "OBSERVATION_MODIFIER", 72, 78], ["symptomatic", "OBSERVATION_MODIFIER", 79, 90], ["disease", "OBSERVATION", 91, 98], ["coronavirus disease", "OBSERVATION", 100, 119]]], ["The majority of COVID-19 cases result in mild symptoms including fever, cough, shortness of breath, and respiratory distress (Hu et al. 2019).", [["respiratory", "ANATOMY", 104, 115], ["fever", "DISEASE", 65, 70], ["cough", "DISEASE", 72, 77], ["shortness of breath", "DISEASE", 79, 98], ["respiratory distress", "DISEASE", 104, 124], ["COVID", "TEST", 16, 21], ["mild symptoms", "PROBLEM", 41, 54], ["fever", "PROBLEM", 65, 70], ["cough", "PROBLEM", 72, 77], ["shortness of breath", "PROBLEM", 79, 98], ["respiratory distress", "PROBLEM", 104, 124], ["mild", "OBSERVATION_MODIFIER", 41, 45], ["respiratory", "ANATOMY", 104, 115], ["distress", "OBSERVATION", 116, 124]]], ["Severe complications arise when the disease progresses to viral pneumonia and multi-organ failure.", [["multi-organ", "ANATOMY", 78, 89], ["pneumonia", "DISEASE", 64, 73], ["multi-organ failure", "DISEASE", 78, 97], ["multi-organ", "ORGAN", 78, 89], ["Severe complications", "PROBLEM", 0, 20], ["the disease", "PROBLEM", 32, 43], ["viral pneumonia", "PROBLEM", 58, 73], ["multi-organ failure", "PROBLEM", 78, 97], ["complications", "OBSERVATION", 7, 20], ["disease", "OBSERVATION", 36, 43], ["viral", "OBSERVATION_MODIFIER", 58, 63], ["pneumonia", "OBSERVATION", 64, 73], ["multi-organ failure", "OBSERVATION", 78, 97]]], ["The SARS-CoV-2 virus can spread quickly, mainly during close contact, but also through small droplets from coughing or sneezing (World Health Organization 2020b).", [["coughing", "DISEASE", 107, 115], ["sneezing", "DISEASE", 119, 127], ["SARS-CoV-2 virus", "ORGANISM", 4, 20], ["CoV-2 virus", "SPECIES", 9, 20], ["SARS-CoV-2 virus", "SPECIES", 4, 20], ["The SARS", "TEST", 0, 8], ["small droplets", "PROBLEM", 87, 101], ["coughing", "PROBLEM", 107, 115], ["sneezing", "PROBLEM", 119, 127]]], ["As of today, April 4, 2020, COVID-19 has affected 203 countries with a total of 1,201,483 reported cases, 64,690 deaths, and 264,467 recovered cases (Coronavirus 2020).MotivationFigure 1 illustrates a typical timeline of COVID-19 in a single person and shows how this timeline maps onto an entire population.", [["deaths", "DISEASE", 113, 119], ["COVID-19", "DNA", 221, 229], ["person", "SPECIES", 242, 248], ["COVID", "TEST", 28, 33]]], ["For this example, at day 0, a number of susceptible individuals are exposed to the virus and transition from the susceptible to the exposed state.", [["individuals", "ORGANISM", 52, 63], ["susceptible individuals", "PROBLEM", 40, 63], ["the virus", "PROBLEM", 79, 88], ["virus", "OBSERVATION", 83, 88]]], ["Around at day 3, the exposed individuals become infectious.", [["individuals", "ORGANISM", 29, 40], ["infectious", "PROBLEM", 48, 58], ["infectious", "OBSERVATION", 48, 58]]], ["During this time, they can infect others, while not showing any symptoms themselves.", [["any symptoms themselves", "PROBLEM", 60, 83]]], ["The infectious period lasts for approximately 10 days.", [["infectious", "OBSERVATION", 4, 14]]], ["Around day 5, infectious individuals become symptomatic.", [["individuals", "ORGANISM", 25, 36], ["symptomatic", "PROBLEM", 44, 55], ["symptomatic", "OBSERVATION_MODIFIER", 44, 55]]], ["This implies that they have potentially spread the disease for two days without knowing it.", [["the disease", "PROBLEM", 47, 58], ["disease", "OBSERVATION", 51, 58]]]], "23fbac9b3d8fd757900526382fb6b83dd6cc06f0": [["Middle East respiratory syndrome coronavirus (MERS-CoV) infection causes an acute respiratory illness and is associated with a high case fatality rate; however, the pathogenesis of severe and fatal MERS-CoV infection is unknown.", [["respiratory", "ANATOMY", 82, 93], ["Middle East respiratory syndrome coronavirus", "DISEASE", 0, 44], ["MERS-CoV) infection", "DISEASE", 46, 65], ["acute respiratory illness", "DISEASE", 76, 101], ["MERS-CoV infection", "DISEASE", 198, 216], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 0, 44], ["MERS-CoV", "ORGANISM", 46, 54], ["MERS-CoV", "ORGANISM", 198, 206], ["MERS-CoV", "SPECIES", 46, 54], ["Middle East respiratory syndrome coronavirus", "SPECIES", 0, 44], ["MERS-CoV", "SPECIES", 46, 54], ["MERS-CoV", "SPECIES", 198, 206], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 0, 44], ["CoV) infection", "PROBLEM", 51, 65], ["an acute respiratory illness", "PROBLEM", 73, 101], ["a high case fatality rate", "PROBLEM", 125, 150], ["severe and fatal MERS", "PROBLEM", 181, 202], ["CoV infection", "PROBLEM", 203, 216], ["respiratory syndrome", "OBSERVATION", 12, 32], ["acute", "OBSERVATION_MODIFIER", 76, 81], ["respiratory illness", "OBSERVATION", 82, 101], ["severe", "OBSERVATION_MODIFIER", 181, 187], ["fatal", "OBSERVATION_MODIFIER", 192, 197], ["MERS", "OBSERVATION", 198, 202], ["CoV infection", "OBSERVATION", 203, 216]]], ["We describe the histopathologic, immunohistochemical, and ultrastructural findings from the first autopsy performed on a fatal case of MERS-CoV in the world, which was related to a hospital outbreak in the United Arab Emirates in April 2014.", [["MERS-CoV", "ORGANISM", 135, 143], ["MERS-CoV", "SPECIES", 135, 143], ["the first autopsy", "TEST", 88, 105]]], ["The main histopathologic finding in the lungs was diffuse alveolar damage.", [["lungs", "ANATOMY", 40, 45], ["alveolar", "ANATOMY", 58, 66], ["alveolar damage", "DISEASE", 58, 73], ["lungs", "ORGAN", 40, 45], ["alveolar", "TISSUE", 58, 66], ["diffuse alveolar damage", "PROBLEM", 50, 73], ["main", "OBSERVATION_MODIFIER", 4, 8], ["histopathologic", "OBSERVATION", 9, 24], ["lungs", "ANATOMY", 40, 45], ["diffuse", "OBSERVATION_MODIFIER", 50, 57], ["alveolar damage", "OBSERVATION", 58, 73]]], ["Evidence of chronic disease, including severe peripheral vascular disease, patchy cardiac fibrosis, and hepatic steatosis, was noted in the other organs.", [["peripheral vascular", "ANATOMY", 46, 65], ["cardiac", "ANATOMY", 82, 89], ["hepatic", "ANATOMY", 104, 111], ["organs", "ANATOMY", 146, 152], ["chronic disease", "DISEASE", 12, 27], ["peripheral vascular disease", "DISEASE", 46, 73], ["cardiac fibrosis", "DISEASE", 82, 98], ["hepatic steatosis", "DISEASE", 104, 121], ["peripheral vascular", "MULTI-TISSUE_STRUCTURE", 46, 65], ["cardiac", "ORGAN", 82, 89], ["hepatic", "ORGAN", 104, 111], ["organs", "ORGAN", 146, 152], ["chronic disease", "PROBLEM", 12, 27], ["severe peripheral vascular disease", "PROBLEM", 39, 73], ["patchy cardiac fibrosis", "PROBLEM", 75, 98], ["hepatic steatosis", "PROBLEM", 104, 121], ["chronic", "OBSERVATION_MODIFIER", 12, 19], ["disease", "OBSERVATION", 20, 27], ["severe", "OBSERVATION_MODIFIER", 39, 45], ["peripheral", "ANATOMY_MODIFIER", 46, 56], ["vascular", "ANATOMY", 57, 65], ["disease", "OBSERVATION", 66, 73], ["patchy", "OBSERVATION_MODIFIER", 75, 81], ["cardiac", "ANATOMY", 82, 89], ["fibrosis", "OBSERVATION", 90, 98], ["hepatic", "ANATOMY", 104, 111], ["steatosis", "OBSERVATION", 112, 121], ["organs", "ANATOMY", 146, 152]]], ["Double staining immunoassays that used antieMERS-CoV antibodies paired with immunohistochemistry for cytokeratin and surfactant identified pneumocytes and epithelial syncytial cells as important targets of MERS-CoV antigen; double immunostaining with dipeptidyl peptidase 4 showed colocalization in scattered pneumocytes and syncytial cells.", [["pneumocytes", "ANATOMY", 139, 150], ["epithelial syncytial cells", "ANATOMY", 155, 181], ["pneumocytes", "ANATOMY", 309, 320], ["syncytial cells", "ANATOMY", 325, 340], ["antieMERS-CoV antibodies", "GENE_OR_GENE_PRODUCT", 39, 63], ["cytokeratin", "GENE_OR_GENE_PRODUCT", 101, 112], ["pneumocytes", "CELL", 139, 150], ["epithelial syncytial cells", "CELL", 155, 181], ["MERS-CoV antigen", "GENE_OR_GENE_PRODUCT", 206, 222], ["dipeptidyl peptidase 4", "GENE_OR_GENE_PRODUCT", 251, 273], ["pneumocytes", "CELL", 309, 320], ["syncytial cells", "CELL", 325, 340], ["antieMERS", "PROTEIN", 39, 48], ["CoV antibodies", "PROTEIN", 49, 63], ["cytokeratin", "PROTEIN", 101, 112], ["pneumocytes", "CELL_TYPE", 139, 150], ["epithelial syncytial cells", "CELL_TYPE", 155, 181], ["MERS-CoV antigen", "PROTEIN", 206, 222], ["dipeptidyl peptidase 4", "PROTEIN", 251, 273], ["scattered pneumocytes", "CELL_TYPE", 299, 320], ["syncytial cells", "CELL_TYPE", 325, 340], ["MERS-CoV", "SPECIES", 206, 214], ["Double staining immunoassays", "TEST", 0, 28], ["antieMERS", "TEST", 39, 48], ["CoV antibodies", "TEST", 49, 63], ["immunohistochemistry", "TEST", 76, 96], ["cytokeratin", "TEST", 101, 112], ["pneumocytes", "PROBLEM", 139, 150], ["epithelial syncytial cells", "PROBLEM", 155, 181], ["MERS", "TEST", 206, 210], ["CoV antigen", "TEST", 211, 222], ["double immunostaining", "TEST", 224, 245], ["dipeptidyl peptidase", "TEST", 251, 271], ["scattered pneumocytes and syncytial cells", "PROBLEM", 299, 340], ["epithelial syncytial cells", "OBSERVATION", 155, 181], ["scattered", "OBSERVATION_MODIFIER", 299, 308], ["pneumocytes", "OBSERVATION", 309, 320], ["syncytial cells", "OBSERVATION", 325, 340]]], ["Middle East respiratory syndrome coronavirus (MERS-CoV) was initially isolated from a sputum specimen of a patient who died of respiratory and renal failure in Saudi Arabia in 2012.", [["sputum specimen", "ANATOMY", 86, 101], ["respiratory", "ANATOMY", 127, 138], ["renal", "ANATOMY", 143, 148], ["Middle East respiratory syndrome coronavirus", "DISEASE", 0, 44], ["respiratory and renal failure", "DISEASE", 127, 156], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 0, 44], ["MERS-CoV", "ORGANISM", 46, 54], ["patient", "ORGANISM", 107, 114], ["renal", "ORGAN", 143, 148], ["patient", "SPECIES", 107, 114], ["Middle East respiratory syndrome coronavirus", "SPECIES", 0, 44], ["MERS-CoV", "SPECIES", 46, 54], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 0, 44], ["a sputum specimen", "TEST", 84, 101], ["respiratory and renal failure", "PROBLEM", 127, 156], ["respiratory syndrome", "OBSERVATION", 12, 32], ["respiratory", "ANATOMY", 127, 138], ["renal", "ANATOMY", 143, 148], ["failure", "OBSERVATION", 149, 156]]], ["1 Recent data have indicated that dromedary camels are likely to transmit MERS-CoV to humans.", [["dromedary camels", "ORGANISM", 34, 50], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 74, 82], ["humans", "ORGANISM", 86, 92], ["humans", "SPECIES", 86, 92], ["MERS-CoV", "SPECIES", 74, 82], ["humans", "SPECIES", 86, 92], ["dromedary camels", "PROBLEM", 34, 50]]], ["2, 3 Human-to-human MERS-CoV transmission is well documented, particularly in the setting of nosocomial outbreaks.", [["Human", "ORGANISM", 5, 10], ["human", "ORGANISM", 14, 19], ["MERS-CoV", "ORGANISM", 20, 28], ["Human", "SPECIES", 5, 10], ["human", "SPECIES", 14, 19], ["human MERS-CoV", "SPECIES", 14, 28], ["nosocomial outbreaks", "PROBLEM", 93, 113], ["nosocomial", "OBSERVATION", 93, 103]]], ["4, 5 As of July 7, 2015, the World Health Organization (WHO) was notified of 1368 laboratory-confirmed cases of MERS-CoV infection with 487 reported deaths (35.6%) from 26 countries, primarily in men with a median age of 50 years.", [["MERS-CoV infection", "DISEASE", 112, 130], ["deaths", "DISEASE", 149, 155], ["MERS-CoV", "ORGANISM", 112, 120], ["men", "ORGANISM", 196, 199], ["men", "SPECIES", 196, 199], ["MERS-CoV", "SPECIES", 112, 120], ["MERS", "PROBLEM", 112, 116], ["CoV infection", "PROBLEM", 117, 130]]], ["6 MERS-CoV infection can result in a wide clinical spectrum from asymptomatic infection, upper respiratory tract illness, to severe pneumonia and multiorgan failure.", [["upper respiratory tract", "ANATOMY", 89, 112], ["multiorgan", "ANATOMY", 146, 156], ["infection", "DISEASE", 11, 20], ["infection", "DISEASE", 78, 87], ["respiratory tract illness", "DISEASE", 95, 120], ["pneumonia", "DISEASE", 132, 141], ["multiorgan failure", "DISEASE", 146, 164], ["MERS-CoV", "ORGANISM", 2, 10], ["upper", "ORGANISM_SUBDIVISION", 89, 94], ["respiratory tract", "ORGANISM_SUBDIVISION", 95, 112], ["MERS-CoV", "SPECIES", 2, 10], ["CoV infection", "PROBLEM", 7, 20], ["asymptomatic infection", "PROBLEM", 65, 87], ["upper respiratory tract illness", "PROBLEM", 89, 120], ["severe pneumonia", "PROBLEM", 125, 141], ["multiorgan failure", "PROBLEM", 146, 164], ["CoV", "OBSERVATION_MODIFIER", 7, 10], ["infection", "OBSERVATION", 11, 20], ["wide", "OBSERVATION_MODIFIER", 37, 41], ["asymptomatic", "OBSERVATION_MODIFIER", 65, 77], ["infection", "OBSERVATION", 78, 87], ["upper", "ANATOMY_MODIFIER", 89, 94], ["respiratory tract", "ANATOMY", 95, 112], ["severe", "OBSERVATION_MODIFIER", 125, 131], ["pneumonia", "OBSERVATION", 132, 141], ["multiorgan failure", "OBSERVATION", 146, 164]]], ["7e9 MERS-CoV binds to dipeptidyl Supported by CDC operational funds.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 4, 12], ["dipeptidyl", "GENE_OR_GENE_PRODUCT", 22, 32], ["7e9 MERS-CoV", "SPECIES", 0, 12], ["dipeptidyl", "TREATMENT", 22, 32]]]], "53bc674e5723dc742dbdad40c2ceb0a31a4d62e6": [["IntroductionThe 2019 novel coronavirus (2019-nCoV) is the pathogen responsible for the outbreak of the acute respiratory disease in Wuhan, Hubei Province of China in December 2019.", [["respiratory", "ANATOMY", 109, 120], ["acute respiratory disease", "DISEASE", 103, 128], ["coronavirus", "ORGANISM", 27, 38], ["2019-nCoV", "ORGANISM", 40, 49], ["coronavirus", "SPECIES", 27, 38], ["the pathogen", "PROBLEM", 54, 66], ["the acute respiratory disease", "PROBLEM", 99, 128], ["acute", "OBSERVATION_MODIFIER", 103, 108], ["respiratory disease", "OBSERVATION", 109, 128]]], ["[1] Although a high proportion of infected individuals only develop mild symptoms, some cases can progress to pneumonia, multi-organ failure or even death.", [["multi-organ", "ANATOMY", 121, 132], ["pneumonia", "DISEASE", 110, 119], ["multi-organ failure", "DISEASE", 121, 140], ["death", "DISEASE", 149, 154], ["individuals", "ORGANISM", 43, 54], ["infected individuals", "PROBLEM", 34, 54], ["mild symptoms", "PROBLEM", 68, 81], ["pneumonia", "PROBLEM", 110, 119], ["multi-organ failure", "PROBLEM", 121, 140], ["even death", "PROBLEM", 144, 154], ["infected", "OBSERVATION", 34, 42], ["mild", "OBSERVATION_MODIFIER", 68, 72], ["pneumonia", "OBSERVATION", 110, 119], ["multi-organ", "ANATOMY", 121, 132], ["failure", "OBSERVATION", 133, 140]]], ["In this study, we performed a retrospective research focusing on clinical characteristics, laboratory findings, and the treatment regimens of the fatal and recovered coronavirus disease 2019 cases with an aim to investigate the characteristics of dead patients and thereby provide some insights into the treatment of this disease.Ethical approvalThis study was conducted in accordance with the Declaration of Helsinki and was approved by the medical ethics committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (No.", [["coronavirus disease", "DISEASE", 166, 185], ["patients", "ORGANISM", 252, 260], ["patients", "SPECIES", 252, 260], ["this study", "TEST", 3, 13], ["laboratory findings", "TEST", 91, 110], ["the treatment regimens", "TREATMENT", 116, 138], ["recovered coronavirus disease", "PROBLEM", 156, 185], ["this disease", "PROBLEM", 317, 329], ["Ethical approval", "TREATMENT", 330, 346], ["This study", "TEST", 346, 356], ["coronavirus disease", "OBSERVATION", 166, 185]]], ["Written informed consent was waived due to the rapid emergence of this infectious disease.Patients and study designA retrospective study focusing on patients who died due to confirmed COVID-19 during hospitalization (death group) was conducted in two tertiary hospitals in Wuhan (Hankou and Caidian branch of Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, and Hankou branch of The Central Hospital of Wuhan) from January 1, 2020 to February 21, 2020.", [["infectious disease", "DISEASE", 71, 89], ["COVID-19", "CHEMICAL", 184, 192], ["death", "DISEASE", 217, 222], ["Patients", "ORGANISM", 90, 98], ["patients", "ORGANISM", 149, 157], ["Patients", "SPECIES", 90, 98], ["patients", "SPECIES", 149, 157], ["this infectious disease", "PROBLEM", 66, 89], ["retrospective study", "TEST", 117, 136], ["COVID", "TEST", 184, 189], ["infectious", "OBSERVATION", 71, 81]]], ["Recovered patients who were discharged from the same inpatient ward during the same period were also enrolled.", [["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18]]], ["Patients were diagnosed according to the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 6), National Health Commission of the People's Republic of China.", [["Coronavirus Pneumonia", "DISEASE", 84, 105], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["Treatment Protocol", "TREATMENT", 55, 73], ["Novel Coronavirus Pneumonia", "PROBLEM", 78, 105], ["Coronavirus", "OBSERVATION_MODIFIER", 84, 95], ["Pneumonia", "OBSERVATION", 96, 105]]], ["[2] The severe cases are defined as patients with one of the following symptoms: respiratory rate \u226530 breaths/min, finger oxygen saturation 93% at rest, and arterial partial pressure of oxygen/fraction of inspired oxygen 300 mmHg.", [["respiratory", "ANATOMY", 81, 92], ["finger", "ANATOMY", 115, 121], ["arterial", "ANATOMY", 157, 165], ["oxygen", "CHEMICAL", 122, 128], ["oxygen", "CHEMICAL", 186, 192], ["oxygen", "CHEMICAL", 214, 220], ["oxygen", "CHEMICAL", 122, 128], ["oxygen", "CHEMICAL", 186, 192], ["oxygen", "CHEMICAL", 214, 220], ["patients", "ORGANISM", 36, 44], ["finger", "ORGANISM_SUBDIVISION", 115, 121], ["oxygen", "SIMPLE_CHEMICAL", 122, 128], ["arterial", "MULTI-TISSUE_STRUCTURE", 157, 165], ["oxygen", "SIMPLE_CHEMICAL", 186, 192], ["oxygen", "SIMPLE_CHEMICAL", 214, 220], ["patients", "SPECIES", 36, 44], ["The severe cases", "PROBLEM", 4, 20], ["the following symptoms", "PROBLEM", 57, 79], ["respiratory rate", "TEST", 81, 97], ["finger oxygen saturation", "TEST", 115, 139], ["arterial partial pressure", "TEST", 157, 182], ["inspired oxygen", "TREATMENT", 205, 220], ["severe", "OBSERVATION_MODIFIER", 8, 14], ["arterial", "ANATOMY", 157, 165], ["partial", "OBSERVATION_MODIFIER", 166, 173], ["pressure", "OBSERVATION_MODIFIER", 174, 182], ["300 mmHg", "OBSERVATION", 221, 229]]], ["[2] The criteria for discharge are: (1) throat swab specimens collected 24 h apart were negative for tests of 2019-nCoV; (2) body temperature was normal for three consecutive days; (3) symptoms of COVID-19 were resolved; (4) the chest computed tomography manifestations of COVID-19 significantly improved.", [["throat swab specimens", "ANATOMY", 40, 61], ["body", "ANATOMY", 125, 129], ["body", "ORGANISM_SUBDIVISION", 125, 129], ["throat swab specimens", "TEST", 40, 61], ["tests", "TEST", 101, 106], ["body temperature", "TEST", 125, 141], ["symptoms", "PROBLEM", 185, 193], ["COVID", "TEST", 197, 202], ["the chest computed tomography manifestations", "TEST", 225, 269], ["COVID", "TEST", 273, 278], ["throat", "ANATOMY", 40, 46], ["chest", "ANATOMY", 229, 234]]], ["[2] Laboratory confirmation Throat swab specimens were tested by real-time reverse transcription polymerase chain reactions for laboratory confirmation of 2019-nCoV infection as recently reported.", [["Throat swab specimens", "ANATOMY", 28, 49], ["infection", "DISEASE", 165, 174], ["Throat swab specimens", "CANCER", 28, 49], ["Laboratory confirmation", "TEST", 4, 27], ["Throat swab specimens", "TEST", 28, 49], ["laboratory confirmation", "TEST", 128, 151], ["nCoV infection", "PROBLEM", 160, 174], ["infection", "OBSERVATION", 165, 174]]], ["[3] The following primers and probe were used.", [["The following primers and probe", "TREATMENT", 4, 35]]], ["The forward primer was 5 0 -TCAGAATGCCAATCTCCCCAAC-3 0 , and the reverse primer was 5 0 -AAAGGTCCACCCGATA-CATTGA-3 0 , while the probe was 5 0 CY5-CTAGTTACAC-TAGCCATCCTTACTGC-3 0 BHQ1.", [["forward primer", "DNA", 4, 18], ["reverse primer", "DNA", 65, 79], ["TAGCCATCCTTACTGC-3 0 BHQ1", "DNA", 158, 183], ["The forward primer", "TEST", 0, 18], ["TCAGAATGCCAATCTCCCCAAC", "TEST", 28, 50], ["the reverse primer", "TEST", 61, 79], ["AAAGGTCCACCCGATA-CATTGA", "TEST", 89, 112], ["CY5", "TEST", 143, 146], ["CTAGTTACAC", "TEST", 147, 157], ["TAGCCATCCTTACTGC", "TEST", 158, 174]]], ["The amplification conditions were 50\u00b0C for 15 min and 95\u00b0C for 3 min, followed by 45 cycles of 95\u00b0C for 15 s and 60\u00b0C for 30 s.Data collectionBasic information such as age, gender, underlying diseases, clinical presentations, and complications was collected from clinical charts and nursing records of each patient.", [["patient", "ORGANISM", 307, 314], ["patient", "SPECIES", 307, 314], ["underlying diseases", "PROBLEM", 181, 200], ["complications", "PROBLEM", 230, 243]]], ["Laboratory tests were conducted at admission and after treatment, including blood cell count, alanine transaminase (ALT), aspartate transaminase (AST), creatinine, and Creactive protein (CRP).", [["blood cell", "ANATOMY", 76, 86], ["alanine", "CHEMICAL", 94, 101], ["aspartate", "CHEMICAL", 122, 131], ["creatinine", "CHEMICAL", 152, 162], ["alanine", "CHEMICAL", 94, 101], ["aspartate", "CHEMICAL", 122, 131], ["creatinine", "CHEMICAL", 152, 162], ["blood cell", "CELL", 76, 86], ["alanine transaminase", "GENE_OR_GENE_PRODUCT", 94, 114], ["ALT", "SIMPLE_CHEMICAL", 116, 119], ["aspartate transaminase", "GENE_OR_GENE_PRODUCT", 122, 144], ["AST", "SIMPLE_CHEMICAL", 146, 149], ["creatinine", "SIMPLE_CHEMICAL", 152, 162], ["Creactive protein", "GENE_OR_GENE_PRODUCT", 168, 185], ["CRP", "GENE_OR_GENE_PRODUCT", 187, 190], ["alanine transaminase", "PROTEIN", 94, 114], ["ALT", "PROTEIN", 116, 119], ["aspartate transaminase", "PROTEIN", 122, 144], ["AST", "PROTEIN", 146, 149], ["Creactive protein", "PROTEIN", 168, 185], ["CRP", "PROTEIN", 187, 190], ["Laboratory tests", "TEST", 0, 16], ["treatment", "TREATMENT", 55, 64], ["blood cell count", "TEST", 76, 92], ["alanine transaminase", "TEST", 94, 114], ["ALT", "TEST", 116, 119], ["aspartate transaminase", "TEST", 122, 144], ["AST", "TEST", 146, 149], ["creatinine", "TEST", 152, 162], ["Creactive protein", "TEST", 168, 185], ["CRP", "TEST", 187, 190]]], ["The treatment regimens including intravenous corticosteroids, intravenous gammaglobulin, anti-viral drugs, antibiotics, anti-fungal drugs, and respiratory supports were also collected from medical records.Statistical analysisThe SPSS Statistics 23.0 software (SPSS Inc., Chicago, IL, USA) was used to perform statistical analysis of the data.", [["intravenous", "ANATOMY", 33, 44], ["intravenous", "ANATOMY", 62, 73], ["gammaglobulin", "CHEMICAL", 74, 87], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 33, 44], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 62, 73], ["gammaglobulin", "SIMPLE_CHEMICAL", 74, 87], ["The treatment regimens", "TREATMENT", 0, 22], ["intravenous corticosteroids", "TREATMENT", 33, 60], ["intravenous gammaglobulin", "TREATMENT", 62, 87], ["anti-viral drugs", "TREATMENT", 89, 105], ["antibiotics", "TREATMENT", 107, 118], ["anti-fungal drugs", "TREATMENT", 120, 137], ["respiratory supports", "TREATMENT", 143, 163], ["Statistical analysis", "TEST", 205, 225], ["The SPSS Statistics", "TEST", 225, 244], ["software", "TEST", 250, 258], ["statistical analysis", "TEST", 309, 329], ["the data", "TEST", 333, 341]]], ["Categorical variables were presented as counts and percentages, and analyzed by x 2 test or Fisher exact test as appropriate.", [["Categorical variables", "TEST", 0, 21], ["percentages", "TEST", 51, 62], ["Fisher exact test", "TEST", 92, 109]]], ["A value of P < 0.05 was considered to be statistically significant.General characteristicsOne hundred and nine fatal and 116 recovered cases out of 964 COVID-19 patients admitted to two tertiary hospitals in Wuhan were enrolled in our study.", [["patients", "ORGANISM", 161, 169], ["patients", "SPECIES", 161, 169], ["A value", "TEST", 0, 7], ["our study", "TEST", 231, 240]]], ["The general information of the two groups was shown in the 2.6%, x 2 = 17.619, P < 0.001), and heart disease (11.9% vs. 3.4%, x 2 = 5.783, P = 0.031) [ Table 1 ].", [["heart", "ANATOMY", 95, 100], ["heart disease", "DISEASE", 95, 108], ["heart", "ORGAN", 95, 100], ["heart disease", "PROBLEM", 95, 108], ["P", "TEST", 139, 140], ["heart", "ANATOMY", 95, 100], ["disease", "OBSERVATION", 101, 108]]], ["Figure 1 showed the distribution of hypertension, lung disease, diabetes, heart disease, and malignancy in the two groups of COVID-19 patients [ Figure 1 ].", [["lung", "ANATOMY", 50, 54], ["heart", "ANATOMY", 74, 79], ["hypertension", "DISEASE", 36, 48], ["lung disease", "DISEASE", 50, 62], ["diabetes", "DISEASE", 64, 72], ["heart disease", "DISEASE", 74, 87], ["malignancy", "DISEASE", 93, 103], ["lung", "ORGAN", 50, 54], ["heart", "ORGAN", 74, 79], ["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142], ["hypertension", "PROBLEM", 36, 48], ["lung disease", "PROBLEM", 50, 62], ["diabetes", "PROBLEM", 64, 72], ["heart disease", "PROBLEM", 74, 87], ["malignancy", "PROBLEM", 93, 103], ["COVID", "TEST", 125, 130], ["hypertension", "OBSERVATION", 36, 48], ["lung", "ANATOMY", 50, 54], ["disease", "OBSERVATION", 55, 62], ["diabetes", "OBSERVATION", 64, 72], ["heart", "ANATOMY", 74, 79], ["disease", "OBSERVATION", 80, 87], ["malignancy", "OBSERVATION", 93, 103]]], ["More patients in the death group had more than one comorbidity.Clinical manifestationsThe baseline signs and symptoms of COVID-19 patients in the death group and the recovered group were shown in Table 2 .", [["death", "DISEASE", 21, 26], ["COVID", "DISEASE", 121, 126], ["death", "DISEASE", 146, 151], ["patients", "ORGANISM", 5, 13], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 130, 138], ["Clinical manifestations", "PROBLEM", 63, 86], ["The baseline signs", "PROBLEM", 86, 104], ["symptoms", "PROBLEM", 109, 117], ["COVID", "TEST", 121, 126]]], ["There was no significant difference in the proportion of patients with fever, myalgia or fatigue, headache, cough, hemoptysis, diarrhea, and heart palpitations at the time of admission between two groups (all P > 0.05).", [["heart", "ANATOMY", 141, 146], ["fever", "DISEASE", 71, 76], ["myalgia", "DISEASE", 78, 85], ["fatigue", "DISEASE", 89, 96], ["headache", "DISEASE", 98, 106], ["cough", "DISEASE", 108, 113], ["hemoptysis", "DISEASE", 115, 125], ["diarrhea", "DISEASE", 127, 135], ["heart palpitations", "DISEASE", 141, 159], ["patients", "ORGANISM", 57, 65], ["heart", "ORGAN", 141, 146], ["patients", "SPECIES", 57, 65], ["significant difference", "PROBLEM", 13, 35], ["fever", "PROBLEM", 71, 76], ["myalgia", "PROBLEM", 78, 85], ["fatigue", "PROBLEM", 89, 96], ["headache", "PROBLEM", 98, 106], ["cough", "PROBLEM", 108, 113], ["hemoptysis", "PROBLEM", 115, 125], ["diarrhea", "PROBLEM", 127, 135], ["heart palpitations", "PROBLEM", 141, 159], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35], ["hemoptysis", "OBSERVATION", 115, 125], ["diarrhea", "OBSERVATION", 127, 135], ["heart", "ANATOMY", 141, 146], ["palpitations", "OBSERVATION", 147, 159]]], ["However, the proportions of patients with dyspnea (70.6% vs. 19.0%, x 2 = 60.905, P < 0.001) and expectoration (32.1% vs. 12.1%, x 2 = 13.250, P < 0.001) were significantly higher in the death group as compared with the recovered group.", [["dyspnea", "DISEASE", 42, 49], ["expectoration", "DISEASE", 97, 110], ["death", "DISEASE", 187, 192], ["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["dyspnea", "PROBLEM", 42, 49], ["P", "TEST", 82, 83], ["expectoration", "TEST", 97, 110], ["P", "TEST", 143, 144], ["higher", "OBSERVATION_MODIFIER", 173, 179]]], ["The blood oxygen saturation when the patients were admitted to the hospital was significantly lower in the death group as compared with the recovered group (85 [77, 91]% vs. 97 [95, 98]%, Z = 10.625, P < 0.001).", [["blood", "ANATOMY", 4, 9], ["oxygen", "CHEMICAL", 10, 16], ["death", "DISEASE", 107, 112], ["oxygen", "CHEMICAL", 10, 16], ["blood", "ORGANISM_SUBSTANCE", 4, 9], ["oxygen", "SIMPLE_CHEMICAL", 10, 16], ["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["The blood oxygen saturation", "TEST", 0, 27], ["Z", "TEST", 188, 189], ["P", "TEST", 200, 201], ["lower", "OBSERVATION_MODIFIER", 94, 99]]], ["At the time of admission, 95 patients in the death group and nine patients in the recovered group were considered as severely ill patients.", [["death", "DISEASE", 45, 50], ["patients", "ORGANISM", 29, 37], ["patients", "ORGANISM", 66, 74], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 29, 37], ["patients", "SPECIES", 66, 74], ["patients", "SPECIES", 130, 138]]], ["The proportion of severely ill patients was significantly higher in the death group than in the recovered group (87.2% vs. 7.8%, x 2 = 142.515, P < 0.001).", [["severely ill", "DISEASE", 18, 30], ["death", "DISEASE", 72, 77], ["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["P", "TEST", 144, 145], ["severely", "OBSERVATION_MODIFIER", 18, 26], ["ill", "OBSERVATION_MODIFIER", 27, 30], ["significantly", "OBSERVATION_MODIFIER", 44, 57], ["higher", "OBSERVATION_MODIFIER", 58, 64]]], ["The median time from illness onset to hospitalization was 10.0 (6.5, 12.0) days in the death group as compared with 7.0 (5.0, 10.0) days in the recovered group (Z = 3.216, P = 0.001) [ Table 2 ].Laboratory findingsPatients in the death group exhibited significantly higher white blood cell (WBC) count ( [12, 20] vs. 8 [4, 13] days, Z = 7.858, P < 0.001) [ Table 4 ].DiscussionCoronaviruses are enveloped RNA viruses that could affect birds, humans, and other mammals, leading to respiratory, digestive, hepatic, and nervous system disorders.", [["white blood cell", "ANATOMY", 273, 289], ["WBC", "ANATOMY", 291, 294], ["respiratory", "ANATOMY", 480, 491], ["digestive", "ANATOMY", 493, 502], ["hepatic", "ANATOMY", 504, 511], ["nervous system", "ANATOMY", 517, 531], ["illness", "DISEASE", 21, 28], ["death", "DISEASE", 87, 92], ["death", "DISEASE", 230, 235], ["respiratory, digestive, hepatic, and nervous system disorders", "DISEASE", 480, 541], ["Patients", "ORGANISM", 214, 222], ["white blood cell", "CELL", 273, 289], ["WBC", "CELL", 291, 294], ["humans", "ORGANISM", 442, 448], ["digestive", "ORGAN", 493, 502], ["hepatic", "MULTI-TISSUE_STRUCTURE", 504, 511], ["nervous", "ANATOMICAL_SYSTEM", 517, 524], ["system", "ANATOMICAL_SYSTEM", 525, 531], ["Patients", "SPECIES", 214, 222], ["humans", "SPECIES", 442, 448], ["humans", "SPECIES", 442, 448], ["Z", "TEST", 161, 162], ["P", "TEST", 172, 173], ["Laboratory findings", "TEST", 195, 214], ["significantly higher white blood cell", "PROBLEM", 252, 289], ["WBC", "TEST", 291, 294], ["count", "TEST", 296, 301], ["Z", "TEST", 333, 334], ["P", "TEST", 344, 345], ["RNA viruses", "PROBLEM", 405, 416], ["respiratory, digestive, hepatic, and nervous system disorders", "PROBLEM", 480, 541], ["RNA viruses", "OBSERVATION", 405, 416], ["respiratory", "ANATOMY", 480, 491], ["digestive", "ANATOMY", 493, 502], ["hepatic", "ANATOMY", 504, 511], ["nervous system", "ANATOMY", 517, 531]]], ["[4, 5] Among the six coronaviruses known to infect humans, two of them can cause ARDS, which are the severe acute respiratory syndrome coronavirus (SARS-CoV) that caused an outbreak in 2002 in China, and the Middle East respiratory syndrome coronavirus (MERS-CoV) that caused an outbreak in the Middle East in 2012.", [["ARDS", "DISEASE", 81, 85], ["acute respiratory syndrome coronavirus", "DISEASE", 108, 146], ["SARS-CoV)", "DISEASE", 148, 157], ["respiratory syndrome coronavirus", "DISEASE", 220, 252], ["coronaviruses", "ORGANISM", 21, 34], ["humans", "ORGANISM", 51, 57], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 101, 146], ["SARS-CoV", "ORGANISM", 148, 156], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 208, 252], ["MERS-CoV", "ORGANISM", 254, 262], ["humans", "SPECIES", 51, 57], ["humans", "SPECIES", 51, 57], ["severe acute respiratory syndrome coronavirus", "SPECIES", 101, 146], ["SARS-CoV", "SPECIES", 148, 156], ["Middle East respiratory syndrome coronavirus", "SPECIES", 208, 252], ["MERS-CoV", "SPECIES", 254, 262], ["the six coronaviruses", "PROBLEM", 13, 34], ["ARDS", "PROBLEM", 81, 85], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 97, 146], ["the Middle East respiratory syndrome coronavirus", "PROBLEM", 204, 252], ["ARDS", "OBSERVATION", 81, 85], ["severe", "OBSERVATION_MODIFIER", 101, 107], ["acute", "OBSERVATION_MODIFIER", 108, 113], ["respiratory syndrome coronavirus", "OBSERVATION", 114, 146], ["outbreak", "OBSERVATION_MODIFIER", 173, 181], ["Middle", "ANATOMY_MODIFIER", 208, 214], ["respiratory syndrome", "OBSERVATION", 220, 240], ["outbreak", "OBSERVATION_MODIFIER", 279, 287], ["Middle", "ANATOMY_MODIFIER", 295, 301]]], ["[6] 2019-nCoV is also a beta coronavirus that causes ARDS and can be transmitted between humans.", [["ARDS", "DISEASE", 53, 57], ["beta coronavirus", "ORGANISM", 24, 40], ["humans", "ORGANISM", 89, 95], ["humans", "SPECIES", 89, 95], ["beta coronavirus", "SPECIES", 24, 40], ["humans", "SPECIES", 89, 95], ["a beta coronavirus", "PROBLEM", 22, 40], ["ARDS", "PROBLEM", 53, 57], ["ARDS", "OBSERVATION", 53, 57]]], ["[7] Similar to SARS-CoV, the 2019-nCoV is speculated to use the angiotensin-converting enzyme (ACE) 2 as a receptor for cell invasion.", [["cell", "ANATOMY", 120, 124], ["SARS", "DISEASE", 15, 19], ["angiotensin", "CHEMICAL", 64, 75], ["SARS-CoV", "ORGANISM", 15, 23], ["angiotensin-converting enzyme (ACE) 2", "GENE_OR_GENE_PRODUCT", 64, 101], ["cell", "CELL", 120, 124], ["2019-nCoV", "DNA", 29, 38], ["angiotensin-converting enzyme (ACE) 2", "PROTEIN", 64, 101], ["SARS-CoV", "SPECIES", 15, 23], ["the angiotensin-converting enzyme (ACE)", "TREATMENT", 60, 99], ["cell invasion", "PROBLEM", 120, 133], ["cell invasion", "OBSERVATION", 120, 133]]], ["[8] Similar to the patients infected with SARS-CoV, some of the 2019-nCoV patients showed rapid progression of lung lesions, which might lead to death.", [["lung lesions", "ANATOMY", 111, 123], ["SARS", "DISEASE", 42, 46], ["lung lesions", "DISEASE", 111, 123], ["death", "DISEASE", 145, 150], ["patients", "ORGANISM", 19, 27], ["SARS-CoV", "ORGANISM", 42, 50], ["patients", "ORGANISM", 74, 82], ["lung lesions", "PATHOLOGICAL_FORMATION", 111, 123], ["patients", "SPECIES", 19, 27], ["patients", "SPECIES", 74, 82], ["SARS-CoV", "SPECIES", 42, 50], ["SARS-CoV", "TEST", 42, 50], ["lung lesions", "PROBLEM", 111, 123], ["death", "PROBLEM", 145, 150], ["infected", "OBSERVATION", 28, 36], ["rapid", "OBSERVATION_MODIFIER", 90, 95], ["progression", "OBSERVATION_MODIFIER", 96, 107], ["lung", "ANATOMY", 111, 115], ["lesions", "OBSERVATION", 116, 123]]], ["The pre-treatment parameters were tested on the day of admission, and the post-treatment parameters were tested within 3 days before discharge or death. * P < 0.001, compared with the recovered group before treatment. \u2020 P < 0.001, compared with the death group before treatment. \u2021 P < 0.05, compared with the death group before treatment.", [["death", "DISEASE", 146, 151], ["death", "DISEASE", 249, 254], ["death", "DISEASE", 309, 314], ["The pre-treatment parameters", "TEST", 0, 28], ["the post-treatment parameters", "TEST", 70, 99], ["death", "PROBLEM", 146, 151], ["treatment", "TREATMENT", 207, 216], ["treatment", "TREATMENT", 268, 277], ["treatment", "TREATMENT", 328, 337]]], ["Chinese Medical Journal 2020;133 (11) www.cmj.org this study, we analyzed the clinical characteristics of the fatal cases and recovered cases collected from two tertiary hospitals in Wuhan while most patients were still hospitalized.", [["patients", "ORGANISM", 200, 208], ["patients", "SPECIES", 200, 208], ["this study", "TEST", 50, 60]]], ["Therefore, it is possible that more patients in the death group and fewer patients in the recovered group were severely ill patients at admission.", [["death", "DISEASE", 52, 57], ["ill", "DISEASE", 120, 123], ["patients", "ORGANISM", 36, 44], ["patients", "ORGANISM", 74, 82], ["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 74, 82], ["patients", "SPECIES", 124, 132]]], ["Differences may exist in the initial conditions of the two groups in our study.DiscussionA recent study showed that 2019-nCoV mainly infects middle-aged and elderly people.", [["people", "ORGANISM", 165, 171], ["people", "SPECIES", 165, 171], ["our study", "TEST", 69, 78], ["DiscussionA recent study", "TEST", 79, 103]]], ["[3] Similar to that study, most of the patients in the current study were middle-aged and elderly people.", [["patients", "ORGANISM", 39, 47], ["people", "ORGANISM", 98, 104], ["patients", "SPECIES", 39, 47], ["people", "SPECIES", 98, 104], ["that study", "TEST", 15, 25], ["the current study", "TEST", 51, 68]]], ["The median age of the deceased patients was 69 (62, 74) years in our study.", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["our study", "TEST", 65, 74]]], ["A previous study which enrolled 199 patients reported the median age of SARS non-survivors was 52 (25, 78) years and age (per 1-year increase) is a risk factor for death.", [["SARS", "DISEASE", 72, 76], ["death", "DISEASE", 164, 169], ["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["A previous study", "TEST", 0, 16], ["death", "PROBLEM", 164, 169]]], ["[9] Another study showed that the median age of MERS non-survivors was 62 (53, 73) years, older than the survivors [46 (35, 57) years].", [["Another study", "TEST", 4, 17]]], ["[10] One of the possible reasons for this phenomenon might be that the lung aging is associated with an inability of lung cells and multiple structural and functional changes in the respiratory tract, giving rise to decreased lung function, altered pulmonary remodeling, diminished regeneration, and enhanced susceptibility to pulmonary disease.", [["lung", "ANATOMY", 71, 75], ["lung cells", "ANATOMY", 117, 127], ["respiratory tract", "ANATOMY", 182, 199], ["lung", "ANATOMY", 226, 230], ["pulmonary", "ANATOMY", 249, 258], ["pulmonary", "ANATOMY", 327, 336], ["lung aging", "DISEASE", 71, 81], ["pulmonary disease", "DISEASE", 327, 344], ["lung", "ORGAN", 71, 75], ["lung cells", "CELL", 117, 127], ["respiratory tract", "ORGANISM_SUBDIVISION", 182, 199], ["lung", "ORGAN", 226, 230], ["pulmonary", "ORGAN", 249, 258], ["pulmonary", "ORGAN", 327, 336], ["lung cells", "CELL_TYPE", 117, 127], ["this phenomenon", "PROBLEM", 37, 52], ["an inability of lung cells", "PROBLEM", 101, 127], ["multiple structural and functional changes in the respiratory tract", "PROBLEM", 132, 199], ["decreased lung function", "PROBLEM", 216, 239], ["altered pulmonary remodeling", "PROBLEM", 241, 269], ["diminished regeneration", "PROBLEM", 271, 294], ["enhanced susceptibility to pulmonary disease", "PROBLEM", 300, 344], ["lung", "ANATOMY", 71, 75], ["aging", "OBSERVATION", 76, 81], ["lung", "ANATOMY", 117, 121], ["cells", "OBSERVATION", 122, 127], ["multiple", "OBSERVATION_MODIFIER", 132, 140], ["structural", "OBSERVATION_MODIFIER", 141, 151], ["functional changes", "OBSERVATION", 156, 174], ["respiratory tract", "ANATOMY", 182, 199], ["decreased", "OBSERVATION_MODIFIER", 216, 225], ["lung", "ANATOMY", 226, 230], ["function", "OBSERVATION", 231, 239], ["altered", "OBSERVATION_MODIFIER", 241, 248], ["pulmonary", "ANATOMY", 249, 258], ["remodeling", "OBSERVATION", 259, 269], ["diminished", "OBSERVATION_MODIFIER", 271, 281], ["regeneration", "OBSERVATION_MODIFIER", 282, 294], ["enhanced", "OBSERVATION_MODIFIER", 300, 308], ["susceptibility", "OBSERVATION_MODIFIER", 309, 323], ["pulmonary", "ANATOMY", 327, 336], ["disease", "OBSERVATION", 337, 344]]], ["[11] It is also reported that the older patients have a higher risk of ARDS development.", [["ARDS", "DISEASE", 71, 75], ["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["ARDS development", "PROBLEM", 71, 87], ["ARDS", "OBSERVATION", 71, 75]]], ["[12] The comorbidities, particularly the cardiovascular diseases and chronic pulmonary diseases, were reported to be important to predict the in-hospital mortality in critically ill patients.", [["cardiovascular", "ANATOMY", 41, 55], ["pulmonary", "ANATOMY", 77, 86], ["cardiovascular diseases", "DISEASE", 41, 64], ["chronic pulmonary diseases", "DISEASE", 69, 95], ["critically ill", "DISEASE", 167, 181], ["pulmonary", "ORGAN", 77, 86], ["patients", "ORGANISM", 182, 190], ["patients", "SPECIES", 182, 190], ["The comorbidities", "PROBLEM", 5, 22], ["the cardiovascular diseases", "PROBLEM", 37, 64], ["chronic pulmonary diseases", "PROBLEM", 69, 95], ["cardiovascular", "ANATOMY", 41, 55], ["diseases", "OBSERVATION", 56, 64], ["chronic", "OBSERVATION_MODIFIER", 69, 76], ["pulmonary", "ANATOMY", 77, 86], ["diseases", "OBSERVATION", 87, 95]]], ["[13] In our study, more patients in the death group had underlying diseases, especially hypertension, lung disease, and heart disease.", [["lung", "ANATOMY", 102, 106], ["heart", "ANATOMY", 120, 125], ["death", "DISEASE", 40, 45], ["hypertension", "DISEASE", 88, 100], ["lung disease", "DISEASE", 102, 114], ["heart disease", "DISEASE", 120, 133], ["patients", "ORGANISM", 24, 32], ["lung", "ORGAN", 102, 106], ["heart", "ORGAN", 120, 125], ["patients", "SPECIES", 24, 32], ["our study", "TEST", 8, 17], ["underlying diseases", "PROBLEM", 56, 75], ["hypertension", "PROBLEM", 88, 100], ["lung disease", "PROBLEM", 102, 114], ["heart disease", "PROBLEM", 120, 133], ["diseases", "OBSERVATION", 67, 75], ["hypertension", "OBSERVATION", 88, 100], ["lung", "ANATOMY", 102, 106], ["disease", "OBSERVATION", 107, 114], ["heart", "ANATOMY", 120, 125], ["disease", "OBSERVATION", 126, 133]]], ["Besides, more patients in the death group had more than one comorbidity.", [["death", "DISEASE", 30, 35], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22]]], ["It is thought that diabetes may increase the risk of infection and can delay the recovery of the infectious illnesses.", [["diabetes", "DISEASE", 19, 27], ["infection", "DISEASE", 53, 62], ["diabetes", "PROBLEM", 19, 27], ["infection", "PROBLEM", 53, 62], ["the infectious illnesses", "PROBLEM", 93, 117], ["diabetes", "OBSERVATION", 19, 27], ["infection", "OBSERVATION", 53, 62], ["infectious", "OBSERVATION", 97, 107]]], ["In our study, we found no significant difference between the death and recovered group in the percentage of patients complicated with diabetes.", [["death", "DISEASE", 61, 66], ["diabetes", "DISEASE", 134, 142], ["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116], ["our study", "TEST", 3, 12], ["the death", "PROBLEM", 57, 66], ["diabetes", "PROBLEM", 134, 142], ["no", "UNCERTAINTY", 23, 25], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["difference", "OBSERVATION", 38, 48], ["diabetes", "OBSERVATION", 134, 142]]], ["Recent studies also showed that diabetes has no significant correlation with the initiation, progression, and prognosis of ARDS.", [["diabetes", "DISEASE", 32, 40], ["ARDS", "DISEASE", 123, 127], ["Recent studies", "TEST", 0, 14], ["diabetes", "PROBLEM", 32, 40], ["ARDS", "PROBLEM", 123, 127], ["diabetes", "OBSERVATION", 32, 40], ["ARDS", "OBSERVATION", 123, 127]]], ["[14, 15] A hypothesis is that there are more hypertensive patients who developed the 2019-nCoV infection, which is related to the ACE inhibitors used in these patients.", [["hypertensive", "DISEASE", 45, 57], ["infection", "DISEASE", 95, 104], ["[14, 15] A", "SIMPLE_CHEMICAL", 0, 10], ["patients", "ORGANISM", 58, 66], ["ACE", "GENE_OR_GENE_PRODUCT", 130, 133], ["patients", "ORGANISM", 159, 167], ["patients", "SPECIES", 58, 66], ["patients", "SPECIES", 159, 167], ["nCoV infection", "PROBLEM", 90, 104], ["the ACE inhibitors", "TREATMENT", 126, 144], ["infection", "OBSERVATION", 95, 104]]], ["ACE inhibitors could indirectly increase the cellular ACE2 receptors, which may be the receptors for 2019-nCoV.", [["cellular", "ANATOMY", 45, 53], ["ACE", "GENE_OR_GENE_PRODUCT", 0, 3], ["cellular", "CELL", 45, 53], ["ACE2 receptors", "GENE_OR_GENE_PRODUCT", 54, 68], ["2019-nCoV", "GENE_OR_GENE_PRODUCT", 101, 110], ["cellular ACE2 receptors", "PROTEIN", 45, 68], ["ACE inhibitors", "TREATMENT", 0, 14], ["the cellular ACE2 receptors", "TREATMENT", 41, 68]]], ["We found more patients in the death group had hypertension.", [["death", "DISEASE", 30, 35], ["hypertension", "DISEASE", 46, 58], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["hypertension", "PROBLEM", 46, 58], ["more patients", "OBSERVATION_MODIFIER", 9, 22], ["hypertension", "OBSERVATION", 46, 58]]], ["However, the exact roles that age and underlying diseases played in the development and progression of novel coronavirus pneumonia require further investigation.", [["coronavirus pneumonia", "DISEASE", 109, 130], ["coronavirus", "ORGANISM", 109, 120], ["underlying diseases", "PROBLEM", 38, 57], ["novel coronavirus pneumonia", "PROBLEM", 103, 130], ["further investigation", "TEST", 139, 160], ["diseases", "OBSERVATION", 49, 57], ["coronavirus", "OBSERVATION_MODIFIER", 109, 120], ["pneumonia", "OBSERVATION", 121, 130]]], ["Furthermore, time from illness onset to hospitalization was longer in the death group.", [["illness", "DISEASE", 23, 30], ["death", "DISEASE", 74, 79]]], ["The patients in the death group tended to have a delayed medical care compared with the recovered group.DiscussionOur study found that the proportion of patients with dyspnea was significantly higher in the death group compared to the recovered group, and initial blood oxygen saturation was lower in the death group compared to the recovered group.", [["blood", "ANATOMY", 264, 269], ["death", "DISEASE", 20, 25], ["dyspnea", "DISEASE", 167, 174], ["death", "DISEASE", 207, 212], ["oxygen", "CHEMICAL", 270, 276], ["death", "DISEASE", 305, 310], ["oxygen", "CHEMICAL", 270, 276], ["patients", "ORGANISM", 4, 12], ["patients", "ORGANISM", 153, 161], ["blood", "ORGANISM_SUBSTANCE", 264, 269], ["oxygen", "SIMPLE_CHEMICAL", 270, 276], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 153, 161], ["a delayed medical care", "TREATMENT", 47, 69], ["DiscussionOur study", "TEST", 104, 123], ["dyspnea", "PROBLEM", 167, 174], ["initial blood oxygen saturation", "TEST", 256, 287], ["higher", "OBSERVATION_MODIFIER", 193, 199]]], ["It is easy to understand that the progressive hypoxemia often suggests poor prognosis in pulmonary diseases and the indicators for hypoxemia are already used to evaluate the severity of the COVID-19.", [["pulmonary", "ANATOMY", 89, 98], ["hypoxemia", "DISEASE", 46, 55], ["pulmonary diseases", "DISEASE", 89, 107], ["hypoxemia", "DISEASE", 131, 140], ["COVID-19", "CHEMICAL", 190, 198], ["pulmonary", "ORGAN", 89, 98], ["the progressive hypoxemia", "PROBLEM", 30, 55], ["pulmonary diseases", "PROBLEM", 89, 107], ["hypoxemia", "PROBLEM", 131, 140], ["the COVID", "TEST", 186, 195], ["progressive", "OBSERVATION_MODIFIER", 34, 45], ["hypoxemia", "OBSERVATION", 46, 55], ["pulmonary", "ANATOMY", 89, 98], ["diseases", "OBSERVATION", 99, 107]]], ["[3] Our study found that the WBC count increased in the death group during hospitalization, suggesting that comorbid bacterial or fungal infection might have occurred in these deceased patients.", [["WBC", "ANATOMY", 29, 32], ["death", "DISEASE", 56, 61], ["bacterial or fungal infection", "DISEASE", 117, 146], ["WBC", "CELL", 29, 32], ["patients", "ORGANISM", 185, 193], ["patients", "SPECIES", 185, 193], ["Our study", "TEST", 4, 13], ["the WBC count", "TEST", 25, 38], ["comorbid bacterial or fungal infection", "PROBLEM", 108, 146], ["comorbid", "OBSERVATION_MODIFIER", 108, 116], ["bacterial", "OBSERVATION_MODIFIER", 117, 126], ["fungal", "OBSERVATION_MODIFIER", 130, 136], ["infection", "OBSERVATION", 137, 146]]], ["However, most of the patients in this study received broad-spectrum antimicrobial drug treatment, and no etiological evidence of infection was obtained from them.", [["infection", "DISEASE", 129, 138], ["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["this study", "TEST", 33, 43], ["broad-spectrum antimicrobial drug treatment", "TREATMENT", 53, 96], ["infection", "PROBLEM", 129, 138], ["antimicrobial drug", "OBSERVATION", 68, 86], ["no etiological evidence of", "UNCERTAINTY", 102, 128], ["infection", "OBSERVATION", 129, 138]]], ["Previous studies found Chinese Medical Journal 2020;133 (11) www.cmj.org that during the acute phase of SARS-CoV infection in humans, the blood lymphocyte counts, particularly CD 4 + and CD 8 + T cell counts, were decreased.", [["blood lymphocyte", "ANATOMY", 138, 154], ["CD 8 + T cell", "ANATOMY", 187, 200], ["SARS-CoV infection", "DISEASE", 104, 122], ["SARS-CoV", "ORGANISM", 104, 112], ["humans", "ORGANISM", 126, 132], ["blood lymphocyte", "CELL", 138, 154], ["CD 4", "GENE_OR_GENE_PRODUCT", 176, 180], ["humans", "SPECIES", 126, 132], ["SARS-CoV", "SPECIES", 104, 112], ["humans", "SPECIES", 126, 132], ["Previous studies", "TEST", 0, 16], ["SARS", "PROBLEM", 104, 108], ["CoV infection in humans", "PROBLEM", 109, 132], ["the blood lymphocyte counts", "TEST", 134, 161], ["CD", "TEST", 176, 178], ["CD", "TEST", 187, 189], ["T cell counts", "TEST", 194, 207], ["SARS", "OBSERVATION", 104, 108], ["CoV", "OBSERVATION_MODIFIER", 109, 112], ["infection", "OBSERVATION", 113, 122], ["decreased", "OBSERVATION_MODIFIER", 214, 223]]], ["[16] [17] [18] Another study suggested that lymphocyte cells, especially CD 4 + and CD 8 + T cells may play protective roles in coronavirus infection.", [["lymphocyte cells", "ANATOMY", 44, 60], ["CD 4 + and CD 8 + T cells", "ANATOMY", 73, 98], ["coronavirus infection", "DISEASE", 128, 149], ["[16] [17] [18", "SIMPLE_CHEMICAL", 0, 13], ["lymphocyte cells", "CELL", 44, 60], ["CD 4", "GENE_OR_GENE_PRODUCT", 73, 77], ["CD 8", "GENE_OR_GENE_PRODUCT", 84, 88], ["coronavirus", "ORGANISM", 128, 139], ["lymphocyte cells", "CELL_TYPE", 44, 60], ["T cells", "CELL_TYPE", 91, 98], ["Another study", "TEST", 15, 28], ["lymphocyte cells", "PROBLEM", 44, 60], ["CD", "TEST", 73, 75], ["CD", "TEST", 84, 86], ["T cells", "PROBLEM", 91, 98], ["coronavirus infection", "PROBLEM", 128, 149], ["lymphocyte cells", "OBSERVATION", 44, 60], ["coronavirus", "OBSERVATION_MODIFIER", 128, 139], ["infection", "OBSERVATION", 140, 149]]], ["[19] Similar to previous studies, our study found that patients in the death group had lower lymphocyte count and lymphocyte percentage.", [["lymphocyte", "ANATOMY", 93, 103], ["lymphocyte", "ANATOMY", 114, 124], ["death", "DISEASE", 71, 76], ["patients", "ORGANISM", 55, 63], ["lymphocyte", "CELL", 93, 103], ["lymphocyte", "CELL", 114, 124], ["patients", "SPECIES", 55, 63], ["previous studies", "TEST", 16, 32], ["our study", "TEST", 34, 43], ["lower lymphocyte count", "PROBLEM", 87, 109], ["lymphocyte percentage", "TEST", 114, 135], ["lower lymphocyte count", "OBSERVATION", 87, 109], ["lymphocyte percentage", "OBSERVATION", 114, 135]]], ["During hospitalization, the lymphocyte count and lymphocyte percentage decreased in the deceased patients.", [["lymphocyte", "ANATOMY", 28, 38], ["lymphocyte", "ANATOMY", 49, 59], ["lymphocyte", "CELL", 28, 38], ["lymphocyte", "CELL", 49, 59], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["the lymphocyte count", "TEST", 24, 44], ["lymphocyte percentage", "TEST", 49, 70], ["lymphocyte count", "OBSERVATION", 28, 44], ["lymphocyte percentage", "OBSERVATION", 49, 70], ["decreased", "OBSERVATION_MODIFIER", 71, 80]]], ["This may be because the viral infection causes persistent consumption and/or insufficient regeneration of lymphocytes.DiscussionALT, AST, and creatinine levels were higher in the death group as compared to the recovered group.", [["lymphocytes", "ANATOMY", 106, 117], ["viral infection", "DISEASE", 24, 39], ["creatinine", "CHEMICAL", 142, 152], ["death", "DISEASE", 179, 184], ["creatinine", "CHEMICAL", 142, 152], ["lymphocytes", "CELL", 106, 117], ["AST", "SIMPLE_CHEMICAL", 133, 136], ["creatinine", "SIMPLE_CHEMICAL", 142, 152], ["lymphocytes", "CELL_TYPE", 106, 117], ["AST", "PROTEIN", 133, 136], ["the viral infection", "PROBLEM", 20, 39], ["persistent consumption", "PROBLEM", 47, 69], ["insufficient regeneration of lymphocytes", "PROBLEM", 77, 117], ["AST", "TEST", 133, 136], ["creatinine levels", "TEST", 142, 159], ["viral", "OBSERVATION_MODIFIER", 24, 29], ["infection", "OBSERVATION", 30, 39], ["persistent", "OBSERVATION_MODIFIER", 47, 57], ["consumption", "OBSERVATION_MODIFIER", 58, 69], ["insufficient", "OBSERVATION_MODIFIER", 77, 89], ["regeneration", "OBSERVATION_MODIFIER", 90, 102], ["lymphocytes", "OBSERVATION", 106, 117]]], ["Previous studies also showed that the transaminases were elevated in the MERS and SARS patients.", [["SARS", "DISEASE", 82, 86], ["transaminases", "SIMPLE_CHEMICAL", 38, 51], ["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95], ["Previous studies", "TEST", 0, 16], ["the transaminases", "TEST", 34, 51], ["elevated", "PROBLEM", 57, 65]]], ["[20] [21] [22] [23] A recent study showed that elderly patients infected with 2019-nCoV have higher CRP levels.", [["[20] [21] [22] [23", "SIMPLE_CHEMICAL", 0, 18], ["patients", "ORGANISM", 55, 63], ["CRP", "GENE_OR_GENE_PRODUCT", 100, 103], ["CRP", "PROTEIN", 100, 103], ["patients", "SPECIES", 55, 63], ["A recent study", "TEST", 20, 34], ["higher CRP levels", "PROBLEM", 93, 110]]], ["[7] Moreover, CRP was considered to be a significant predictor for disease severity in SARS.", [["SARS", "DISEASE", 87, 91], ["CRP", "GENE_OR_GENE_PRODUCT", 14, 17], ["CRP", "PROTEIN", 14, 17], ["CRP", "TEST", 14, 17], ["disease severity in SARS", "PROBLEM", 67, 91]]], ["[22, 24] Similar to previous studies, our study found that the CRP levels were higher in the death group compared to the recovered group at the time of admission, and the CRP levels remained high during the progression of the disease.DiscussionPatients in the death group had more complications such as ARDS, acute cardiac injury, acute kidney injury, shock, and DIC, which was consistent with the previous study of COVID-19.", [["cardiac", "ANATOMY", 315, 322], ["kidney", "ANATOMY", 337, 343], ["death", "DISEASE", 93, 98], ["death", "DISEASE", 260, 265], ["ARDS", "DISEASE", 303, 307], ["cardiac injury", "DISEASE", 315, 329], ["acute kidney injury", "DISEASE", 331, 350], ["shock", "DISEASE", 352, 357], ["DIC", "DISEASE", 363, 366], ["COVID-19", "CHEMICAL", 416, 424], ["CRP", "GENE_OR_GENE_PRODUCT", 63, 66], ["CRP", "GENE_OR_GENE_PRODUCT", 171, 174], ["cardiac", "ORGAN", 315, 322], ["kidney", "ORGAN", 337, 343], ["CRP", "PROTEIN", 63, 66], ["CRP", "PROTEIN", 171, 174], ["previous studies", "TEST", 20, 36], ["our study", "TEST", 38, 47], ["the CRP levels", "TEST", 59, 73], ["the CRP levels", "TEST", 167, 181], ["the disease", "PROBLEM", 222, 233], ["ARDS", "PROBLEM", 303, 307], ["acute cardiac injury", "PROBLEM", 309, 329], ["acute kidney injury", "PROBLEM", 331, 350], ["shock", "PROBLEM", 352, 357], ["DIC", "PROBLEM", 363, 366], ["the previous study", "TEST", 394, 412], ["COVID", "TEST", 416, 421], ["higher", "OBSERVATION_MODIFIER", 79, 85], ["high", "OBSERVATION_MODIFIER", 191, 195], ["progression", "OBSERVATION_MODIFIER", 207, 218], ["disease", "OBSERVATION", 226, 233], ["ARDS", "OBSERVATION", 303, 307], ["acute", "OBSERVATION_MODIFIER", 309, 314], ["cardiac", "ANATOMY", 315, 322], ["injury", "OBSERVATION", 323, 329], ["acute", "OBSERVATION_MODIFIER", 331, 336], ["kidney", "ANATOMY", 337, 343], ["injury", "OBSERVATION", 344, 350], ["shock", "OBSERVATION", 352, 357], ["consistent with", "UNCERTAINTY", 378, 393]]], ["[25] It is noteworthy that patients in the death group had a shorter length of hospital stay compared with the recovered group.", [["death", "DISEASE", 43, 48], ["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35]]], ["This difference probably caused by the rapid progression of COVID-19 in the death group.", [["death", "DISEASE", 76, 81], ["COVID", "TEST", 60, 65], ["probably caused", "UNCERTAINTY", 16, 31], ["rapid", "OBSERVATION_MODIFIER", 39, 44], ["progression", "OBSERVATION_MODIFIER", 45, 56]]], ["The patients in the death group were empirically given more corticosteroids, more anti-fungal drugs, and better antibiotics without solid evidence.", [["death", "DISEASE", 20, 25], ["corticosteroids", "CHEMICAL", 60, 75], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["more corticosteroids", "TREATMENT", 55, 75], ["anti-fungal drugs", "TREATMENT", 82, 99], ["better antibiotics", "TREATMENT", 105, 123]]], ["A limitation of our study is that the initial conditions of the two groups differed.", [["our study", "TEST", 16, 25]]], ["Therefore, these results do not provide conclusive data on the effects of different treatments.", [["different treatments", "TREATMENT", 74, 94]]], ["More researches are required on the necessity of prophylactically using antibiotics and the time to use them in viral pneumonia patients.", [["pneumonia", "DISEASE", 118, 127], ["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 128, 136], ["antibiotics", "TREATMENT", 72, 83], ["viral pneumonia patients", "PROBLEM", 112, 136], ["viral", "OBSERVATION_MODIFIER", 112, 117], ["pneumonia", "OBSERVATION", 118, 127]]], ["Previous studies in corticosteroid therapy suggest that high doses of corticosteroids do not diminish the mortality rate for SARS but tend to result in severe adverse reactions.", [["SARS", "DISEASE", 125, 129], ["corticosteroids", "CHEMICAL", 70, 85], ["corticosteroid", "SIMPLE_CHEMICAL", 20, 34], ["Previous studies", "TEST", 0, 16], ["corticosteroid therapy", "TREATMENT", 20, 42], ["corticosteroids", "TREATMENT", 70, 85], ["SARS", "PROBLEM", 125, 129], ["severe adverse reactions", "PROBLEM", 152, 176], ["severe", "OBSERVATION_MODIFIER", 152, 158]]], ["[26, 27] Further research is required to investigate the necessity, dose, and timing of corticosteroid therapy in 2019-nCoV infection.", [["infection", "DISEASE", 124, 133], ["corticosteroid", "SIMPLE_CHEMICAL", 88, 102], ["corticosteroid therapy", "TREATMENT", 88, 110], ["nCoV infection", "PROBLEM", 119, 133], ["infection", "OBSERVATION", 124, 133]]], ["Furthermore, it is found that 45% of patients showed signs of pulmonary fibrosis within one month after being infected with SARS-CoV.", [["pulmonary", "ANATOMY", 62, 71], ["pulmonary fibrosis", "DISEASE", 62, 80], ["SARS", "DISEASE", 124, 128], ["patients", "ORGANISM", 37, 45], ["pulmonary", "ORGAN", 62, 71], ["SARS-CoV", "ORGANISM", 124, 132], ["patients", "SPECIES", 37, 45], ["SARS-CoV", "SPECIES", 124, 132], ["pulmonary fibrosis", "PROBLEM", 62, 80], ["SARS", "PROBLEM", 124, 128], ["pulmonary", "ANATOMY", 62, 71], ["fibrosis", "OBSERVATION", 72, 80], ["infected", "OBSERVATION", 110, 118]]], ["[28] Another study found lung fibrosis in 33% of patients who have recovered from MERS-CoV.", [["lung", "ANATOMY", 25, 29], ["lung fibrosis", "DISEASE", 25, 38], ["lung", "ORGAN", 25, 29], ["patients", "ORGANISM", 49, 57], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 82, 90], ["patients", "SPECIES", 49, 57], ["MERS-CoV", "SPECIES", 82, 90], ["Another study", "TEST", 5, 18], ["lung fibrosis", "PROBLEM", 25, 38], ["lung", "ANATOMY", 25, 29], ["fibrosis", "OBSERVATION", 30, 38]]], ["[29] It is possible that pulmonary fibrosis will become one of the serious complications in patients with 2019-nCoV infection.", [["pulmonary", "ANATOMY", 25, 34], ["pulmonary fibrosis", "DISEASE", 25, 43], ["infection", "DISEASE", 116, 125], ["pulmonary", "ORGAN", 25, 34], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["pulmonary fibrosis", "PROBLEM", 25, 43], ["the serious complications", "PROBLEM", 63, 88], ["nCoV infection", "PROBLEM", 111, 125], ["is possible", "UNCERTAINTY", 8, 19], ["pulmonary", "ANATOMY", 25, 34], ["fibrosis", "OBSERVATION", 35, 43], ["serious", "OBSERVATION_MODIFIER", 67, 74], ["complications", "OBSERVATION", 75, 88], ["infection", "OBSERVATION", 116, 125]]], ["[30] Drugs for the treatment of idiopathic pulmonary fibrosis such as pirfenidone and nintedanib might be useful in preventing and treating pulmonary fibrosis in patients with 2019-nCoV infection.DiscussionIn summary, we studied the clinical data of 109 patients who died from 2019-nCoV infection and 116 patients who recovered.", [["pulmonary", "ANATOMY", 43, 52], ["pulmonary", "ANATOMY", 140, 149], ["idiopathic pulmonary fibrosis", "DISEASE", 32, 61], ["pirfenidone", "CHEMICAL", 70, 81], ["nintedanib", "CHEMICAL", 86, 96], ["pulmonary fibrosis", "DISEASE", 140, 158], ["infection", "DISEASE", 186, 195], ["infection", "DISEASE", 287, 296], ["pirfenidone", "CHEMICAL", 70, 81], ["nintedanib", "CHEMICAL", 86, 96], ["[30] Drugs", "SIMPLE_CHEMICAL", 0, 10], ["pulmonary", "ORGAN", 43, 52], ["pirfenidone", "SIMPLE_CHEMICAL", 70, 81], ["nintedanib", "SIMPLE_CHEMICAL", 86, 96], ["pulmonary", "ORGAN", 140, 149], ["patients", "ORGANISM", 162, 170], ["patients", "ORGANISM", 254, 262], ["patients", "ORGANISM", 305, 313], ["patients", "SPECIES", 162, 170], ["patients", "SPECIES", 254, 262], ["patients", "SPECIES", 305, 313], ["Drugs", "TREATMENT", 5, 10], ["idiopathic pulmonary fibrosis", "PROBLEM", 32, 61], ["pirfenidone", "TREATMENT", 70, 81], ["nintedanib", "TREATMENT", 86, 96], ["pulmonary fibrosis", "PROBLEM", 140, 158], ["nCoV infection", "PROBLEM", 181, 195], ["nCoV infection", "PROBLEM", 282, 296], ["idiopathic", "OBSERVATION_MODIFIER", 32, 42], ["pulmonary", "ANATOMY", 43, 52], ["fibrosis", "OBSERVATION", 53, 61], ["pulmonary", "ANATOMY", 140, 149], ["fibrosis", "OBSERVATION", 150, 158], ["infection", "OBSERVATION", 186, 195], ["infection", "OBSERVATION", 287, 296]]], ["Patients in the death group exhibited characteristics of advanced age, more pre-existing comorbidities, dyspnea, oxygen saturation decrease, increased WBC count, decreased lymphocytes, and elevated CRP levels.", [["WBC", "ANATOMY", 151, 154], ["lymphocytes", "ANATOMY", 172, 183], ["death", "DISEASE", 16, 21], ["dyspnea", "DISEASE", 104, 111], ["oxygen", "CHEMICAL", 113, 119], ["oxygen", "CHEMICAL", 113, 119], ["Patients", "ORGANISM", 0, 8], ["oxygen", "SIMPLE_CHEMICAL", 113, 119], ["lymphocytes", "CELL", 172, 183], ["CRP", "GENE_OR_GENE_PRODUCT", 198, 201], ["lymphocytes", "CELL_TYPE", 172, 183], ["CRP", "PROTEIN", 198, 201], ["Patients", "SPECIES", 0, 8], ["more pre-existing comorbidities", "PROBLEM", 71, 102], ["dyspnea", "PROBLEM", 104, 111], ["oxygen saturation decrease", "PROBLEM", 113, 139], ["increased WBC count", "PROBLEM", 141, 160], ["decreased lymphocytes", "PROBLEM", 162, 183], ["elevated CRP levels", "PROBLEM", 189, 208], ["dyspnea", "OBSERVATION", 104, 111], ["oxygen saturation", "OBSERVATION", 113, 130], ["decrease", "OBSERVATION_MODIFIER", 131, 139], ["increased", "OBSERVATION_MODIFIER", 141, 150], ["WBC count", "OBSERVATION", 151, 160], ["decreased lymphocytes", "OBSERVATION", 162, 183], ["elevated", "OBSERVATION_MODIFIER", 189, 197], ["CRP levels", "OBSERVATION_MODIFIER", 198, 208]]], ["We hope our study could offer some suggestions to the understanding of this disease.", [["our study", "TEST", 8, 17], ["this disease", "PROBLEM", 71, 83]]]], "PMC7094721": [["IntroductionProteome homeostasis is crucial for cell survival and involves several levels of quality control mechanisms to avoid production of aberrant protein products [1].", [["cell", "ANATOMY", 48, 52], ["cell", "CELL", 48, 52], ["aberrant protein products", "PROTEIN", 143, 168], ["IntroductionProteome homeostasis", "TREATMENT", 0, 32], ["cell survival", "TREATMENT", 48, 61], ["aberrant protein products", "PROBLEM", 143, 168]]], ["The first checkpoint during biogenesis of polypeptides is co-translational and mediated by ribosomes, which are considered a dynamic center for quality control of both mRNA and nascent proteins.", [["ribosomes", "ANATOMY", 91, 100], ["ribosomes", "CELLULAR_COMPONENT", 91, 100], ["mRNA", "RNA", 168, 172], ["nascent proteins", "PROTEIN", 177, 193], ["biogenesis of polypeptides", "TREATMENT", 28, 54], ["nascent proteins", "OBSERVATION", 177, 193]]], ["Damaged mRNAs or nascent peptides forming stable interactions with the ribosomal exit tunnel (RET) and the peptidyl-transferase center can cause translational stalling of the ribosomes [2], [3].", [["ribosomal", "ANATOMY", 71, 80], ["ribosomes", "ANATOMY", 175, 184], ["peptidyl", "CHEMICAL", 107, 115], ["ribosomal", "CELLULAR_COMPONENT", 71, 80], ["RET", "GENE_OR_GENE_PRODUCT", 94, 97], ["peptidyl-transferase", "GENE_OR_GENE_PRODUCT", 107, 127], ["Damaged mRNAs", "RNA", 0, 13], ["ribosomal exit tunnel", "PROTEIN", 71, 92], ["RET", "PROTEIN", 94, 97], ["peptidyl-transferase center", "PROTEIN", 107, 134], ["Damaged mRNAs", "PROBLEM", 0, 13], ["nascent peptides", "TREATMENT", 17, 33], ["the ribosomal exit tunnel (RET)", "TREATMENT", 67, 98], ["the peptidyl-transferase center", "TREATMENT", 103, 134], ["translational stalling of the ribosomes", "PROBLEM", 145, 184], ["stable", "OBSERVATION_MODIFIER", 42, 48], ["exit tunnel", "OBSERVATION", 81, 92]]], ["Ribosomal stalling is potentially dangerous for the cell survival, therefore different mechanisms have evolved to resolve such events.", [["cell", "ANATOMY", 52, 56], ["Ribosomal", "CELLULAR_COMPONENT", 0, 9], ["cell", "CELL", 52, 56], ["Ribosomal stalling", "PROBLEM", 0, 18], ["the cell survival", "TREATMENT", 48, 65], ["such events", "PROBLEM", 122, 133], ["cell survival", "OBSERVATION", 52, 65]]], ["Translation of erroneous mRNAs owing to a premature termination codon, the lack of termination codon or a broad range of potential stalling sequences often cause degradation of such mRNAs by nonsense-mediated decay (NMD), nonstop decay (NSD) and no-go decay (NGD) pathways, respectively [4], [5], [6].", [["mRNAs", "RNA", 25, 30], ["premature termination codon", "DNA", 42, 69], ["mRNAs", "RNA", 182, 187], ["erroneous mRNAs", "PROBLEM", 15, 30], ["a premature termination codon", "PROBLEM", 40, 69], ["termination codon", "PROBLEM", 83, 100], ["potential stalling sequences", "PROBLEM", 121, 149], ["such mRNAs", "PROBLEM", 177, 187], ["nonsense-mediated decay", "PROBLEM", 191, 214], ["erroneous mRNAs", "OBSERVATION", 15, 30]]], ["These pathways trigger either ribosomes dissociation and recycling or their degradation together with associated tRNAs and nascent polypeptides [7].", [["ribosomes", "CELLULAR_COMPONENT", 30, 39], ["ribosomes dissociation", "PROBLEM", 30, 52], ["their degradation", "PROBLEM", 70, 87], ["associated tRNAs and nascent polypeptides", "PROBLEM", 102, 143], ["ribosomes dissociation", "OBSERVATION", 30, 52]]], ["Impairments of these protein quality control pathways are involved in several pathological conditions, such as the Huntington disease [8] and other neurodegenerative diseases [9], [10].IntroductionNascent polypeptides derived from stalled ribosomes are extracted from the RET and targeted to degradation through the proteasome pathway, which involves the E3 ubiquitin ligase Ltn1/Listerin [11], [12] and the AAA ATPase Cdc48/p97 [13], [14], [15], identified in yeast and mammalian cells.", [["ribosomes", "ANATOMY", 239, 248], ["cells", "ANATOMY", 481, 486], ["Huntington disease", "DISEASE", 115, 133], ["neurodegenerative diseases", "DISEASE", 148, 174], ["Nascent polypeptides", "GENE_OR_GENE_PRODUCT", 197, 217], ["ribosomes", "CELLULAR_COMPONENT", 239, 248], ["RET", "GENE_OR_GENE_PRODUCT", 272, 275], ["E3", "GENE_OR_GENE_PRODUCT", 355, 357], ["Ltn1", "GENE_OR_GENE_PRODUCT", 375, 379], ["Listerin [11]", "GENE_OR_GENE_PRODUCT", 380, 393], ["[12]", "SIMPLE_CHEMICAL", 395, 399], ["AAA ATPase", "GENE_OR_GENE_PRODUCT", 408, 418], ["Cdc48", "GENE_OR_GENE_PRODUCT", 419, 424], ["p97", "GENE_OR_GENE_PRODUCT", 425, 428], ["[14], [15]", "SIMPLE_CHEMICAL", 435, 445], ["yeast", "CELL", 461, 466], ["mammalian cells", "CELL", 471, 486], ["RET", "DNA", 272, 275], ["proteasome", "PROTEIN", 316, 326], ["E3 ubiquitin ligase", "PROTEIN", 355, 374], ["Ltn1", "PROTEIN", 375, 379], ["Listerin [11]", "PROTEIN", 380, 393], ["AAA ATPase", "PROTEIN", 408, 418], ["Cdc48", "PROTEIN", 419, 424], ["p97", "PROTEIN", 425, 428], ["mammalian cells", "CELL_TYPE", 471, 486], ["yeast", "SPECIES", 461, 466], ["yeast", "SPECIES", 461, 466], ["Impairments of these protein quality control pathways", "PROBLEM", 0, 53], ["several pathological conditions", "PROBLEM", 70, 101], ["the Huntington disease", "PROBLEM", 111, 133], ["other neurodegenerative diseases", "PROBLEM", 142, 174], ["IntroductionNascent polypeptides", "TREATMENT", 185, 217], ["stalled ribosomes", "PROBLEM", 231, 248], ["Listerin", "TEST", 380, 388], ["the AAA ATPase Cdc48", "TEST", 404, 424], ["yeast and mammalian cells", "PROBLEM", 461, 486], ["neurodegenerative", "OBSERVATION_MODIFIER", 148, 165], ["diseases", "OBSERVATION", 166, 174], ["AAA", "ANATOMY", 408, 411], ["mammalian cells", "OBSERVATION", 471, 486]]], ["Other players described as part of the ribosome-associated quality control pathway are the integral ribosomal protein Rack1 [16], the surveillance complex formed by Pelota\u2013HBS1\u2013ABCE1 [4], [17] and the ribosome quality control proteins 1 and 2/NEMF [13], [18], [19].", [["ribosome", "ANATOMY", 39, 47], ["ribosomal", "ANATOMY", 100, 109], ["ribosome", "CELLULAR_COMPONENT", 39, 47], ["ribosomal", "CELLULAR_COMPONENT", 100, 109], ["Rack1 [16]", "GENE_OR_GENE_PRODUCT", 118, 128], ["Pelota\u2013HBS1\u2013ABCE1 [4]", "GENE_OR_GENE_PRODUCT", 165, 186], ["integral ribosomal protein", "PROTEIN", 91, 117], ["Rack1 [16]", "PROTEIN", 118, 128], ["surveillance complex", "PROTEIN", 134, 154], ["Pelota\u2013HBS1", "PROTEIN", 165, 176], ["ABCE1", "PROTEIN", 177, 182], ["ribosome quality control proteins 1 and 2", "PROTEIN", 201, 242], ["NEMF", "PROTEIN", 243, 247], ["the integral ribosomal protein Rack1", "TEST", 87, 123], ["the surveillance complex", "TEST", 130, 154], ["Pelota\u2013HBS1", "TEST", 165, 176], ["ABCE1", "TEST", 177, 182], ["the ribosome quality control proteins", "TEST", 197, 234], ["NEMF", "TEST", 243, 247]]], ["Beyond the poly-Lys sequence translated from poly(A) tails, diverse peptide sequences have been described to cause ribosomal stalling [2], [20].", [["ribosomal", "ANATOMY", 115, 124], ["poly-Lys", "CHEMICAL", 11, 19], ["poly(A", "CHEMICAL", 45, 51], ["poly-Lys", "CHEMICAL", 11, 19], ["poly(A)", "CHEMICAL", 45, 52], ["poly(A) tails", "GENE_OR_GENE_PRODUCT", 45, 58], ["ribosomal", "CELLULAR_COMPONENT", 115, 124], ["poly-Lys sequence", "PROTEIN", 11, 28], ["poly(A) tails", "PROTEIN", 45, 58], ["the poly-Lys sequence", "TREATMENT", 7, 28], ["poly(A) tails", "TREATMENT", 45, 58], ["diverse peptide sequences", "TREATMENT", 60, 85], ["ribosomal stalling", "PROBLEM", 115, 133]]], ["Some of them cause stalling at the STOP-codon and have been described in proteins of mammalian viruses, bacteria, fungi and plants [21], [22], [23], [24].IntroductionIn eukaryotic cells, the release from the ribosome of the terminated polypeptide occurs through recognition of the STOP-codon by the eukaryotic release factor (eRF) 1 and is mediated by eRF3 with recycling of the ribosomal subunits [25].", [["cells", "ANATOMY", 180, 185], ["ribosomal", "ANATOMY", 379, 388], ["mammalian viruses", "ORGANISM", 85, 102], ["[22]", "SIMPLE_CHEMICAL", 137, 141], ["cells", "CELL", 180, 185], ["ribosome", "CELLULAR_COMPONENT", 208, 216], ["STOP", "GENE_OR_GENE_PRODUCT", 281, 285], ["eukaryotic release factor (eRF) 1", "GENE_OR_GENE_PRODUCT", 299, 332], ["eRF3", "GENE_OR_GENE_PRODUCT", 352, 356], ["ribosomal", "CELLULAR_COMPONENT", 379, 388], ["STOP-codon", "DNA", 35, 45], ["eukaryotic cells", "CELL_TYPE", 169, 185], ["STOP-codon", "DNA", 281, 291], ["eukaryotic release factor (eRF) 1", "PROTEIN", 299, 332], ["eRF3", "PROTEIN", 352, 356], ["ribosomal subunits", "PROTEIN", 379, 397], ["stalling at the STOP-codon", "PROBLEM", 19, 45], ["mammalian viruses", "PROBLEM", 85, 102], ["bacteria", "PROBLEM", 104, 112], ["IntroductionIn eukaryotic cells", "TREATMENT", 154, 185], ["the terminated polypeptide", "TREATMENT", 220, 246], ["the STOP-codon", "TREATMENT", 277, 291], ["the ribosomal subunits", "TREATMENT", 375, 397], ["mammalian viruses", "OBSERVATION", 85, 102], ["eukaryotic cells", "OBSERVATION", 169, 185]]], ["Some strains of mammalian picornaviruses, however, encode for a peptide called 2A, which can trigger the release of the newly synthesized protein independently on the presence of a STOP-codon [26].", [["mammalian picornaviruses", "ORGANISM", 16, 40], ["2A", "GENE_OR_GENE_PRODUCT", 79, 81], ["STOP-codon", "DNA", 181, 191], ["Some strains of mammalian picornaviruses", "PROBLEM", 0, 40], ["a STOP-codon", "TREATMENT", 179, 191], ["mammalian picornaviruses", "OBSERVATION", 16, 40]]], ["This \u201cnon-conventional\u201d translation termination is the consequence of the 2A activity that mediates processing at its C-terminus altering ribosome activity to promote hydrolysis of the ester bond between the nascent peptide and the tRNA, rather than the formation of the peptide linkage with the aminoacyl-tRNA located on the downstream codon.", [["ester", "CHEMICAL", 185, 190], ["aminoacyl-tRNA", "CHEMICAL", 296, 310], ["C", "CHEMICAL", 118, 119], ["ester", "CHEMICAL", 185, 190], ["aminoacyl", "CHEMICAL", 296, 305], ["ribosome", "CELLULAR_COMPONENT", 138, 146], ["ester", "SIMPLE_CHEMICAL", 185, 190], ["C-terminus", "PROTEIN", 118, 128], ["aminoacyl-tRNA", "PROTEIN", 296, 310], ["downstream codon", "DNA", 326, 342], ["hydrolysis of the ester bond", "TREATMENT", 167, 195], ["the nascent peptide", "TREATMENT", 204, 223], ["the tRNA", "TREATMENT", 228, 236], ["the aminoacyl-tRNA", "TREATMENT", 292, 310], ["ribosome activity", "OBSERVATION", 138, 155], ["hydrolysis", "OBSERVATION_MODIFIER", 167, 177], ["tRNA", "ANATOMY_MODIFIER", 232, 236], ["downstream codon", "OBSERVATION", 326, 342]]], ["The result is a premature release of the upstream protein without ribosome dissociation.Introduction2A is a peptide 18 amino acids (aa) long that strictly requires for its activity the Asn-Pro-Gly sequence at its C-terminus and a Pro immediately downstream (Fig. 1a).", [["amino acids", "CHEMICAL", 119, 130], ["Asn-Pro-Gly", "CHEMICAL", 185, 196], ["amino acids", "CHEMICAL", 119, 130], ["Asn-Pro-Gly", "CHEMICAL", 185, 196], ["C", "CHEMICAL", 213, 214], ["Pro", "CHEMICAL", 230, 233], ["ribosome", "CELLULAR_COMPONENT", 66, 74], ["amino acids", "AMINO_ACID", 119, 130], ["upstream protein", "PROTEIN", 41, 57], ["Asn-Pro-Gly sequence", "PROTEIN", 185, 205], ["C-terminus", "PROTEIN", 213, 223], ["Pro immediately downstream", "PROTEIN", 230, 256], ["Fig. 1a", "PROTEIN", 258, 265], ["a premature release", "PROBLEM", 14, 33], ["ribosome dissociation", "PROBLEM", 66, 87], ["a peptide 18 amino acids (aa)", "TREATMENT", 106, 135], ["the Asn-Pro-Gly sequence", "TREATMENT", 181, 205], ["without", "UNCERTAINTY", 58, 65], ["ribosome dissociation", "OBSERVATION", 66, 87]]], ["As 2A allows co-translation of separate proteins encoded in a single open reading frame (ORF), it has been largely used for several biotechnological applications [27], [28], [29], [30].", [["[28], [29]", "SIMPLE_CHEMICAL", 168, 178], ["open reading frame", "DNA", 69, 87], ["ORF", "DNA", 89, 92], ["separate proteins", "PROBLEM", 31, 48]]], ["Mutation of the last Pro into a STOP-codon was reported to cause stalling of translation in in vitro systems (wheat germ and rabbit reticulocyte lysates) [31], [32], making it an interesting model to study ribosome stalling in living human cells.IntroductionHere we characterized how imposing conventional termination immediately after peptide 2A heavily impairs expression of the upstream protein in mammalian cells as a consequence of ribosome stalling at the Gly-STOP-codon boundary, and we report that two different human C-terminal peptides ending in Asn-Pro-Gly-STOP also induce stalling at the STOP-codon, resulting in proteasomal degradation of the terminated polypeptides.", [["germ", "ANATOMY", 116, 120], ["reticulocyte lysates", "ANATOMY", 132, 152], ["ribosome", "ANATOMY", 206, 214], ["cells", "ANATOMY", 240, 245], ["cells", "ANATOMY", 411, 416], ["ribosome", "ANATOMY", 437, 445], ["proteasomal", "ANATOMY", 626, 637], ["Gly", "CHEMICAL", 462, 465], ["C", "CHEMICAL", 526, 527], ["Gly", "CHEMICAL", 564, 567], ["wheat germ", "CELL", 110, 120], ["rabbit", "ORGANISM", 125, 131], ["reticulocyte lysates", "ORGANISM_SUBSTANCE", 132, 152], ["ribosome", "CELLULAR_COMPONENT", 206, 214], ["human", "ORGANISM", 234, 239], ["cells", "CELL", 240, 245], ["mammalian cells", "CELL", 401, 416], ["ribosome", "CELLULAR_COMPONENT", 437, 445], ["human", "ORGANISM", 520, 525], ["Asn-Pro-Gly-STOP", "GENE_OR_GENE_PRODUCT", 556, 572], ["STOP-codon", "DNA", 32, 42], ["living human cells", "CELL_TYPE", 227, 245], ["upstream protein", "PROTEIN", 381, 397], ["mammalian cells", "CELL_TYPE", 401, 416], ["Gly-STOP-codon boundary", "DNA", 462, 485], ["STOP-codon", "DNA", 601, 611], ["wheat", "SPECIES", 110, 115], ["rabbit", "SPECIES", 125, 131], ["human", "SPECIES", 234, 239], ["human", "SPECIES", 520, 525], ["wheat", "SPECIES", 110, 115], ["rabbit", "SPECIES", 125, 131], ["human", "SPECIES", 234, 239], ["human", "SPECIES", 520, 525], ["translation in in vitro systems", "PROBLEM", 77, 108], ["wheat germ", "TEST", 110, 120], ["rabbit reticulocyte lysates", "TEST", 125, 152], ["the upstream protein in mammalian cells", "PROBLEM", 377, 416], ["ribosome stalling", "PROBLEM", 437, 454], ["different human C-terminal peptides", "TREATMENT", 510, 545], ["stalling", "PROBLEM", 585, 593], ["proteasomal degradation of the terminated polypeptides", "PROBLEM", 626, 680], ["mammalian cells", "OBSERVATION", 401, 416], ["proteasomal degradation", "OBSERVATION", 626, 649]]], ["We found that the main endoplasmic reticulum (ER) chaperone binding immunoglobulin protein/glucose-regulated protein 78 kDa (BiP/GRP78) have an uncharacterized pivotal involvement in binding ribosome stalled secretory proteins and targeting them to the ER-associated degradation (ERAD) pathway.C-terminal 2A compromises the expression of upstream protein in human cells ::: ResultsWe designed a reporter secretory protein formed by an SV5-tagged single-chain variable fragment (scFv, pr1) fused to the foot and mouth disease virus (FMDV) peptide 2A at the C-terminus, followed by the UAG STOP-codon ().", [["endoplasmic reticulum", "ANATOMY", 23, 44], ["ER", "ANATOMY", 46, 48], ["ribosome", "ANATOMY", 191, 199], ["ER", "ANATOMY", 253, 255], ["cells", "ANATOMY", 364, 369], ["glucose", "CHEMICAL", 91, 98], ["glucose", "CHEMICAL", 91, 98], ["C", "CHEMICAL", 294, 295], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 23, 44], ["ER", "GENE_OR_GENE_PRODUCT", 46, 48], ["chaperone binding immunoglobulin protein", "GENE_OR_GENE_PRODUCT", 50, 90], ["glucose-regulated protein 78 kDa", "GENE_OR_GENE_PRODUCT", 91, 123], ["BiP", "GENE_OR_GENE_PRODUCT", 125, 128], ["GRP78", "GENE_OR_GENE_PRODUCT", 129, 134], ["ribosome", "CELLULAR_COMPONENT", 191, 199], ["ER", "GENE_OR_GENE_PRODUCT", 253, 255], ["ERAD", "GENE_OR_GENE_PRODUCT", 280, 284], ["C-terminal 2A", "GENE_OR_GENE_PRODUCT", 294, 307], ["human", "ORGANISM", 358, 363], ["cells", "CELL", 364, 369], ["pr1", "GENE_OR_GENE_PRODUCT", 484, 487], ["foot and mouth disease virus", "ORGANISM", 502, 530], ["endoplasmic reticulum (ER) chaperone binding immunoglobulin protein", "PROTEIN", 23, 90], ["glucose-regulated protein 78 kDa", "PROTEIN", 91, 123], ["BiP", "PROTEIN", 125, 128], ["GRP78", "PROTEIN", 129, 134], ["secretory proteins", "PROTEIN", 208, 226], ["ER", "PROTEIN", 253, 255], ["ERAD", "PROTEIN", 280, 284], ["C-terminal 2A", "PROTEIN", 294, 307], ["upstream protein", "PROTEIN", 338, 354], ["human cells", "CELL_TYPE", 358, 369], ["reporter secretory protein", "PROTEIN", 395, 421], ["SV5-tagged single-chain variable fragment", "PROTEIN", 435, 476], ["scFv", "PROTEIN", 478, 482], ["pr1", "PROTEIN", 484, 487], ["C-terminus", "PROTEIN", 556, 566], ["UAG STOP-codon", "DNA", 584, 598], ["human", "SPECIES", 358, 363], ["mouth disease virus", "SPECIES", 511, 530], ["FMDV", "SPECIES", 532, 536], ["human", "SPECIES", 358, 363], ["foot and mouth disease virus", "SPECIES", 502, 530], ["FMDV", "SPECIES", 532, 536], ["chaperone binding immunoglobulin protein", "TEST", 50, 90], ["glucose", "TEST", 91, 98], ["protein", "TEST", 109, 116], ["kDa", "TEST", 120, 123], ["BiP/GRP78", "TEST", 125, 134], ["an uncharacterized pivotal involvement", "PROBLEM", 141, 179], ["a reporter secretory protein", "TEST", 393, 421], ["an SV5", "TEST", 432, 438], ["tagged single-chain variable fragment (scFv", "TREATMENT", 439, 482], ["mouth disease virus", "PROBLEM", 511, 530], ["main", "OBSERVATION_MODIFIER", 18, 22], ["endoplasmic reticulum", "OBSERVATION", 23, 44], ["uncharacterized", "OBSERVATION_MODIFIER", 144, 159], ["pivotal involvement", "OBSERVATION", 160, 179], ["binding ribosome", "OBSERVATION", 183, 199], ["terminal 2A", "OBSERVATION_MODIFIER", 296, 307], ["foot", "ANATOMY", 502, 506], ["mouth", "ANATOMY", 511, 516]]], ["The FMDV-derived 23-aa-long peptide contains the 5 C-terminal residues of VP1 followed by the 18 aa of 2A, as it was shown to be more efficient in driving the independent expression of the upstream and downstream proteins [33].", [["C", "CHEMICAL", 51, 52], ["VP1", "GENE_OR_GENE_PRODUCT", 74, 77], ["5 C-terminal residues", "PROTEIN", 49, 70], ["VP1", "PROTEIN", 74, 77], ["2A", "PROTEIN", 103, 105], ["upstream and downstream proteins", "PROTEIN", 189, 221], ["FMDV", "SPECIES", 4, 8], ["FMDV", "SPECIES", 4, 8], ["The FMDV", "TEST", 0, 8], ["aa-long peptide", "TREATMENT", 20, 35], ["the 5 C-terminal residues of VP1", "TREATMENT", 45, 77]]], ["A second construct with a P-codon positioned between the 2A terminal G-codon and the STOP-codon was also obtained (Fig. 1b, left panel, construct 2A-P, while extremely low levels were obtained from construct 2A* (Fig. 1b, right panel).", [["P-codon", "DNA", 26, 33], ["2A terminal G-codon", "DNA", 57, 76], ["STOP-codon", "DNA", 85, 95], ["P", "DNA", 149, 150], ["A second construct", "PROBLEM", 0, 18], ["a P-codon", "TREATMENT", 24, 33], ["Fig", "TEST", 115, 118], ["left panel", "TEST", 124, 134], ["extremely low levels", "PROBLEM", 158, 178], ["right panel", "TEST", 222, 233], ["codon", "OBSERVATION", 71, 76], ["left", "ANATOMY_MODIFIER", 124, 128], ["right", "ANATOMY_MODIFIER", 222, 227]]], ["The product from construct 2A* was produced around 20 times less intracellularly, with this difference increasing to 100 times in the secreted material (Fig. 1c).C-terminal 2A compromises the expression of upstream protein in human cells ::: ResultsAs expected, we detected by mass spectrometry analysis the pr1 produced from construct 2A-P* terminated in NPG (approximately 50%) due to the non-conventional termination as well as in NPGP (Supplementary Table 1).", [["cells", "ANATOMY", 232, 237], ["C", "CHEMICAL", 162, 163], ["C-terminal 2A", "GENE_OR_GENE_PRODUCT", 162, 175], ["human", "ORGANISM", 226, 231], ["cells", "CELL", 232, 237], ["pr1", "GENE_OR_GENE_PRODUCT", 308, 311], ["NPG", "CANCER", 356, 359], ["C-terminal 2A", "PROTEIN", 162, 175], ["upstream protein", "PROTEIN", 206, 222], ["human cells", "CELL_TYPE", 226, 237], ["pr1", "DNA", 308, 311], ["P*", "DNA", 339, 341], ["NPGP", "PROTEIN", 434, 438], ["human", "SPECIES", 226, 231], ["human", "SPECIES", 226, 231], ["upstream protein in human cells", "TEST", 206, 237], ["mass spectrometry analysis", "TEST", 277, 303]]], ["The translation termination of construct 2A* was instead only conventional, STOP-codon mediated, as it did not encode the terminal P-codon.C-terminal 2A compromises the expression of upstream protein in human cells ::: ResultsThe inhibitory effect of 2A* was also observed with an engineered version of the type I membrane glycoprotein reporter MHC-I\u03b1 (Fig. 1d), indicating that expression impairment was not dependent on the reporter protein used.C-terminal 2A compromises the expression of upstream protein in human cells ::: ResultsSince these two initial reporters were translated from membrane-bound ribosomes, we then tested whether 2A* had the same effect also on cytosolic proteins translated by free ribosomes.", [["cells", "ANATOMY", 209, 214], ["cells", "ANATOMY", 518, 523], ["membrane", "ANATOMY", 590, 598], ["ribosomes", "ANATOMY", 605, 614], ["cytosolic", "ANATOMY", 671, 680], ["C", "CHEMICAL", 139, 140], ["C", "CHEMICAL", 448, 449], ["C-terminal 2A", "GENE_OR_GENE_PRODUCT", 139, 152], ["human", "ORGANISM", 203, 208], ["cells", "CELL", 209, 214], ["type I membrane glycoprotein reporter MHC-I\u03b1", "GENE_OR_GENE_PRODUCT", 307, 351], ["C-terminal 2A", "GENE_OR_GENE_PRODUCT", 448, 461], ["human", "ORGANISM", 512, 517], ["cells", "CELL", 518, 523], ["membrane", "CELLULAR_COMPONENT", 590, 598], ["ribosomes", "CELLULAR_COMPONENT", 605, 614], ["ribosomes", "CELLULAR_COMPONENT", 709, 718], ["STOP-codon", "DNA", 76, 86], ["terminal P-codon", "DNA", 122, 138], ["C-terminal 2A", "PROTEIN", 139, 152], ["upstream protein", "PROTEIN", 183, 199], ["human cells", "CELL_TYPE", 203, 214], ["type I membrane glycoprotein", "PROTEIN", 307, 335], ["MHC", "PROTEIN", 345, 348], ["I\u03b1", "PROTEIN", 349, 351], ["Fig. 1d", "PROTEIN", 353, 360], ["reporter protein", "PROTEIN", 426, 442], ["C-terminal 2A", "PROTEIN", 448, 461], ["upstream protein", "PROTEIN", 492, 508], ["human cells", "CELL_TYPE", 512, 523], ["cytosolic proteins", "PROTEIN", 671, 689], ["human", "SPECIES", 203, 208], ["human", "SPECIES", 512, 517], ["human", "SPECIES", 203, 208], ["human", "SPECIES", 512, 517], ["expression impairment", "PROBLEM", 379, 400], ["cytosolic proteins", "TREATMENT", 671, 689], ["terminal 2A", "OBSERVATION_MODIFIER", 141, 152], ["terminal 2A", "OBSERVATION_MODIFIER", 450, 461]]], ["Two cytosolic reporters were used, the same scFv lacking the ER-targeting leader peptide and EGFP.", [["cytosolic", "ANATOMY", 4, 13], ["scFv", "GENE_OR_GENE_PRODUCT", 44, 48], ["ER", "GENE_OR_GENE_PRODUCT", 61, 63], ["EGFP", "GENE_OR_GENE_PRODUCT", 93, 97], ["scFv", "PROTEIN", 44, 48], ["ER", "PROTEIN", 61, 63], ["EGFP", "PROTEIN", 93, 97], ["Two cytosolic reporters", "TEST", 0, 23]]], ["Expression of both proteins from 2A* constructs (EGFP-2A* and cyt-scFv-2A and cyt-scFv-2A-P construct compared to 2A-P* one (Supplementary Fig. 1b), indicating that the observed effect was not the consequence of reduced mRNAs levels.", [["EGFP-2A", "GENE_OR_GENE_PRODUCT", 49, 56], ["cyt-scFv-2A", "GENE_OR_GENE_PRODUCT", 62, 73], ["2A* constructs", "DNA", 33, 47], ["EGFP", "DNA", 49, 53], ["P construct", "DNA", 90, 101], ["mRNAs", "RNA", 220, 225], ["EGFP", "TEST", 49, 53], ["cyt-scFv", "TEST", 62, 70], ["cyt-scFv", "TEST", 78, 86], ["reduced mRNAs levels", "PROBLEM", 212, 232]]], ["Moreover, in vitro translation from T7 polymerase-driven transcripts of construct cyt-scFv-2A* confirmed a reduction of almost 3.5-fold in protein expression with respect to the control, indicating a defect at the translational level (Supplementary Fig. 1c).C-terminal 2A compromises the expression of upstream protein in human cells ::: ResultsTaken together, these results confirm that imposing conventional termination after 2A strongly impairs translation in mammalian cells, regardless of the reporter protein used or the cellular localization, a context consistent with stalling of ribosomes at the STOP-codon.Ribosomes stalling at the termination codon of 2A in human cells ::: ResultsWe then decided to investigate the role of the STOP-codon at the 2A C-terminus.", [["cells", "ANATOMY", 328, 333], ["cells", "ANATOMY", 473, 478], ["cellular", "ANATOMY", 527, 535], ["ribosomes", "ANATOMY", 588, 597], ["cells", "ANATOMY", 675, 680], ["C", "CHEMICAL", 258, 259], ["T7 polymerase", "GENE_OR_GENE_PRODUCT", 36, 49], ["cyt-scFv-2A", "GENE_OR_GENE_PRODUCT", 82, 93], ["C-terminal 2A", "GENE_OR_GENE_PRODUCT", 258, 271], ["human", "ORGANISM", 322, 327], ["cells", "CELL", 328, 333], ["mammalian cells", "CELL", 463, 478], ["cellular", "CELL", 527, 535], ["ribosomes", "CELLULAR_COMPONENT", 588, 597], ["Ribosomes", "GENE_OR_GENE_PRODUCT", 616, 625], ["human", "ORGANISM", 669, 674], ["cells", "CELL", 675, 680], ["STOP", "GENE_OR_GENE_PRODUCT", 739, 743], ["T7 polymerase", "PROTEIN", 36, 49], ["cyt-scFv", "PROTEIN", 82, 90], ["C-terminal 2A", "PROTEIN", 258, 271], ["upstream protein", "PROTEIN", 302, 318], ["human cells", "CELL_TYPE", 322, 333], ["mammalian cells", "CELL_TYPE", 463, 478], ["reporter protein", "PROTEIN", 498, 514], ["STOP-codon", "DNA", 605, 615], ["human cells", "CELL_TYPE", 669, 680], ["STOP-codon", "DNA", 739, 749], ["2A C-terminus", "DNA", 757, 770], ["human", "SPECIES", 322, 327], ["human", "SPECIES", 669, 674], ["human", "SPECIES", 322, 327], ["human", "SPECIES", 669, 674], ["T7 polymerase", "TEST", 36, 49], ["almost 3.5-fold in protein expression", "TREATMENT", 120, 157], ["a defect", "PROBLEM", 198, 206], ["the reporter protein", "TEST", 494, 514], ["the cellular localization", "TEST", 523, 548], ["stalling of ribosomes", "PROBLEM", 576, 597], ["Ribosomes stalling", "PROBLEM", 616, 634], ["reduction", "OBSERVATION_MODIFIER", 107, 116], ["defect", "OBSERVATION", 200, 206], ["terminal 2A", "OBSERVATION_MODIFIER", 260, 271], ["mammalian cells", "OBSERVATION", 463, 478], ["consistent with", "UNCERTAINTY", 560, 575]]], ["When the 11-amino-acid-long peptide roTag was added immediately after the C-terminal Gly (scheme in Fig. 2a, left panel), the expression of the fusion pr1-2A-roTag was totally rescued.", [["11-amino-acid", "CHEMICAL", 9, 22], ["11-amino-acid", "CHEMICAL", 9, 22], ["Gly", "CHEMICAL", 85, 88], ["amino-acid", "SIMPLE_CHEMICAL", 12, 22], ["Tag", "GENE_OR_GENE_PRODUCT", 38, 41], ["pr1", "GENE_OR_GENE_PRODUCT", 151, 154], ["Tag", "GENE_OR_GENE_PRODUCT", 160, 163], ["Tag", "PROTEIN", 38, 41], ["pr1", "PROTEIN", 151, 154], ["2A-roTag", "PROTEIN", 155, 163], ["amino-acid-long peptide roTag", "TREATMENT", 12, 41], ["the C-terminal Gly (scheme in Fig", "TREATMENT", 70, 103], ["a, left panel", "TEST", 106, 119], ["the fusion pr1", "TREATMENT", 140, 154], ["2A-roTag", "TREATMENT", 155, 163], ["left", "ANATOMY_MODIFIER", 109, 113]]], ["Instead, when Pro was included after 2A (2A-P-roTag construct [32].Ribosomes stalling at the termination codon of 2A in human cells ::: ResultsIt has been described that during translation of a bicistronic mRNA, 2A causes a quick and transient stalling of the ribosome, necessary to allow release of the upstream protein and to resume translation from the downstream P-codon [26].", [["cells", "ANATOMY", 126, 131], ["ribosome", "ANATOMY", 260, 268], ["Pro", "CHEMICAL", 14, 17], ["Ribosomes", "GENE_OR_GENE_PRODUCT", 67, 76], ["human", "ORGANISM", 120, 125], ["cells", "CELL", 126, 131], ["ribosome", "CELLULAR_COMPONENT", 260, 268], ["human cells", "CELL_TYPE", 120, 131], ["bicistronic mRNA", "RNA", 194, 210], ["upstream protein", "PROTEIN", 304, 320], ["P", "DNA", 367, 368], ["human", "SPECIES", 120, 125], ["human", "SPECIES", 120, 125], ["P-roTag construct", "TREATMENT", 44, 61], ["Ribosomes stalling", "PROBLEM", 67, 85], ["a bicistronic mRNA", "TREATMENT", 192, 210], ["a quick and transient stalling of the ribosome", "PROBLEM", 222, 268], ["the upstream protein", "TREATMENT", 300, 320]]], ["The presence of the STOP-codon would result in an excessively prolonged stalling of ribosomes at the 2A/STOP-codon boundary.", [["ribosomes", "ANATOMY", 84, 93], ["STOP", "GENE_OR_GENE_PRODUCT", 20, 24], ["ribosomes", "CELLULAR_COMPONENT", 84, 93], ["STOP-codon", "DNA", 20, 30], ["2A/STOP-codon boundary", "DNA", 101, 123], ["the STOP-codon", "PROBLEM", 16, 30], ["an excessively prolonged stalling of ribosomes", "PROBLEM", 47, 93], ["excessively", "OBSERVATION_MODIFIER", 50, 61], ["prolonged", "OBSERVATION_MODIFIER", 62, 71], ["stalling", "OBSERVATION", 72, 80]]], ["To confirm this point, we obtained two bicistronic constructs (schematically shown in Fig. 2b, left panel) in which the upstream protein (pr1) was produced following 2A non-conventional termination (i.e., 2A followed by Pro), while the downstream protein (pr2, same as pr1 with an extra polypeptide tag) terminated in either 2A* (pr2-2A (pr2-2A-P was synthesized at a lower rate (around 15-fold lower) than the one from construct 2A-P peptide is independent of mRNA codon usage but dependent of 2A amino acidic sequence ::: ResultsThe translation impairment was not due to the nucleotide sequence of the STOP-codon used, as the same result was obtained when the UAG codon was changed to UAA or UGA (Fig. 3a).", [["translation impairment", "DISEASE", 535, 557], ["nucleotide", "CHEMICAL", 577, 587], ["amino", "CHEMICAL", 498, 503], ["nucleotide", "CHEMICAL", 577, 587], ["2b", "GENE_OR_GENE_PRODUCT", 91, 93], ["pr1", "GENE_OR_GENE_PRODUCT", 138, 141], ["pr2", "GENE_OR_GENE_PRODUCT", 256, 259], ["pr1", "GENE_OR_GENE_PRODUCT", 269, 272], ["pr2-2A", "GENE_OR_GENE_PRODUCT", 330, 336], ["pr2-2A", "GENE_OR_GENE_PRODUCT", 338, 344], ["amino acidic", "AMINO_ACID", 498, 510], ["bicistronic constructs", "DNA", 39, 61], ["upstream protein", "PROTEIN", 120, 136], ["pr1", "PROTEIN", 138, 141], ["downstream protein", "PROTEIN", 236, 254], ["pr2", "PROTEIN", 256, 259], ["pr1", "PROTEIN", 269, 272], ["extra polypeptide tag", "PROTEIN", 281, 302], ["pr2", "PROTEIN", 330, 333], ["pr2", "PROTEIN", 338, 341], ["2A", "PROTEIN", 342, 344], ["P", "PROTEIN", 345, 346], ["2A amino acidic sequence", "PROTEIN", 495, 519], ["STOP-codon", "DNA", 604, 614], ["UAG codon", "DNA", 662, 671], ["UAA", "DNA", 687, 690], ["UGA", "DNA", 694, 697], ["two bicistronic constructs", "TREATMENT", 35, 61], ["left panel", "TEST", 95, 105], ["2A non-conventional termination", "TREATMENT", 166, 197], ["the downstream protein", "TEST", 232, 254], ["an extra polypeptide tag", "TREATMENT", 278, 302], ["pr2", "TEST", 338, 341], ["a lower rate", "TEST", 366, 378], ["mRNA codon usage", "TREATMENT", 461, 477], ["The translation impairment", "PROBLEM", 531, 557], ["the UAG codon", "TREATMENT", 658, 671], ["UAA", "TREATMENT", 687, 690], ["UGA", "TEST", 694, 697], ["left", "ANATOMY_MODIFIER", 95, 99], ["mRNA codon", "OBSERVATION", 461, 471]]], ["Similar result was obtained with all four different G-codons (Fig. 3b).", [["G-codons", "DNA", 52, 60]]], ["The independence from the nucleotide sequence was further confirmed by mutating all the codons of the 2A peptide (M), which showed impaired expression comparable to the wild type and rescued expression upon inclusion of the P-codon (Fig. 3c).", [["nucleotide", "CHEMICAL", 26, 36], ["nucleotide", "CHEMICAL", 26, 36], ["P-codon", "DNA", 224, 231], ["the nucleotide sequence", "TEST", 22, 45], ["impaired expression", "PROBLEM", 131, 150], ["the P-codon (Fig. 3c", "TREATMENT", 220, 240], ["impaired expression", "OBSERVATION", 131, 150]]], ["Similar results were obtained with the Teschovirus-derived peptide 2A (three residues different from FMDV;Fig. 3d).", [["Teschovirus-derived peptide 2A", "GENE_OR_GENE_PRODUCT", 39, 69], ["FMDV", "SPECIES", 101, 105], ["FMDV", "SPECIES", 101, 105], ["the Teschovirus", "TEST", 35, 50]]], ["Furthermore, the addition of a STOP-codon just upstream of the 2A sequences (constructs , ) completely rescued pr1 expression (Fig. 3e), strongly supporting the hypothesis that the lack of pr1-2A* production was dependent on the translation of the 2A peptide and independent of the nucleotide sequence.Ribosome stalling of 2A* peptide is independent of mRNA codon usage but dependent of 2A amino acidic sequence ::: ResultsWe then investigated which was the minimal 2A length required for the expression inhibitory activity by producing several deletion mutants (Fig. 4a).", [["nucleotide", "CHEMICAL", 282, 292], ["nucleotide", "CHEMICAL", 282, 292], ["amino", "CHEMICAL", 390, 395], ["pr1", "GENE_OR_GENE_PRODUCT", 111, 114], ["pr1-2A", "GENE_OR_GENE_PRODUCT", 189, 195], ["Ribosome", "CELLULAR_COMPONENT", 302, 310], ["2A* peptide", "GENE_OR_GENE_PRODUCT", 323, 334], ["amino acidic", "AMINO_ACID", 390, 402], ["STOP-codon", "DNA", 31, 41], ["2A sequences", "DNA", 63, 75], ["pr1", "DNA", 111, 114], ["pr1", "PROTEIN", 189, 192], ["2A amino acidic sequence", "PROTEIN", 387, 411], ["a STOP-codon", "TREATMENT", 29, 41], ["the nucleotide sequence", "TEST", 278, 301], ["mRNA codon usage", "TREATMENT", 353, 369], ["the expression inhibitory activity", "TREATMENT", 489, 523]]], ["Deletion of 3 to 5 N-terminal amino acids (constructs \u0394N3, \u0394N4 and \u0394N5) retained strong inhibitory activity, while deletion mutants lacking 6 to 15 aa from the 2A N-terminus (constructs \u2206 N6, \u2206 N7 and \u2206 N15) completely abolished the effect (Fig. 4b).", [["amino acids", "CHEMICAL", 30, 41], ["N", "CHEMICAL", 19, 20], ["amino acids", "CHEMICAL", 30, 41], ["N", "CHEMICAL", 163, 164], ["amino acids", "AMINO_ACID", 30, 41], ["5 N-terminal amino acids", "DNA", 17, 41], ["\u0394N3", "PROTEIN", 54, 57], ["\u0394N4", "PROTEIN", 59, 62], ["\u0394N5", "PROTEIN", 67, 70], ["2A N-terminus", "PROTEIN", 160, 173], ["N15", "PROTEIN", 203, 206], ["Deletion", "TEST", 0, 8], ["terminal amino acids (constructs \u0394N3", "TREATMENT", 21, 57], ["deletion mutants lacking", "PROBLEM", 115, 139], ["terminus (constructs \u2206 N6", "TREATMENT", 165, 190], ["\u2206 N7", "TREATMENT", 192, 196], ["strong", "OBSERVATION_MODIFIER", 81, 87], ["inhibitory activity", "OBSERVATION", 88, 107]]], ["Thus, the minimal length that caused stalling of translation was mapped to the last 13 residues, represented by the sequence LLKLAGDVESNPG* (construct \u2206 N5).", [["LLKLAGDVESNPG*", "DNA", 125, 139], ["stalling of translation", "PROBLEM", 37, 60], ["minimal", "OBSERVATION_MODIFIER", 10, 17], ["length", "OBSERVATION_MODIFIER", 18, 24]]], ["Interestingly, the minimal length required for 2A peptide non-conventional termination in a bicistronic mRNA was mapped to a very similar length (12 residues) [32].Ribosome stalling of 2A* peptide is independent of mRNA codon usage but dependent of 2A amino acidic sequence ::: ResultsWe next mapped 2A C-terminal residues.", [["amino", "CHEMICAL", 252, 257], ["C", "CHEMICAL", 303, 304], ["Ribosome", "CELLULAR_COMPONENT", 164, 172], ["2A* peptide", "GENE_OR_GENE_PRODUCT", 185, 196], ["amino acidic", "AMINO_ACID", 252, 264], ["bicistronic mRNA", "RNA", 92, 108], ["2A amino acidic sequence", "PROTEIN", 249, 273], ["2A C-terminal residues", "PROTEIN", 300, 322], ["2A peptide non-conventional termination", "TREATMENT", 47, 86], ["a bicistronic mRNA", "TREATMENT", 90, 108], ["mRNA codon usage", "TREATMENT", 215, 231], ["minimal", "OBSERVATION_MODIFIER", 19, 26], ["length", "OBSERVATION_MODIFIER", 27, 33], ["terminal residues", "OBSERVATION", 305, 322]]], ["In contrast to the inhibitory effect observed with full-length 2A (ending in NPG produced only pr1-2A-roTag fusion, completely abrogating non-conventional termination represented by product pr1-2A (Fig. 4f).Ribosome stalling of 2A* peptide is independent of mRNA codon usage but dependent of 2A amino acidic sequence ::: ResultsThese data collectively indicated that the 2A last 12 aa and in particular the C-terminal Gly residue are absolutely required not only for the 2A non-conventional termination, but also for the translational stalling at the STOP-codon.Proteasome degradation of products of stalled ribosomes ::: ResultsIn addition to ribosome stalling, which directly affects translation, other mechanisms can concomitantly operate in vivo to further reduce the level of protein expression.Proteasome degradation of products of stalled ribosomes ::: ResultsKinetic studies performed in cells treated with cycloheximide revealed that the secretory reporter protein produced from construct 2A* was fast degraded and hence not secreted, whereas the product from 2A-P* was actively secreted (Fig. 5a).", [["ribosomes", "ANATOMY", 608, 617], ["ribosome", "ANATOMY", 644, 652], ["ribosomes", "ANATOMY", 846, 855], ["cells", "ANATOMY", 896, 901], ["pr1-2A-ro", "CHEMICAL", 95, 104], ["cycloheximide", "CHEMICAL", 915, 928], ["amino", "CHEMICAL", 295, 300], ["Gly", "CHEMICAL", 418, 421], ["cycloheximide", "CHEMICAL", 915, 928], ["pr1-2A", "GENE_OR_GENE_PRODUCT", 95, 101], ["Tag", "GENE_OR_GENE_PRODUCT", 104, 107], ["pr1-2A", "GENE_OR_GENE_PRODUCT", 190, 196], ["Ribosome", "CELLULAR_COMPONENT", 207, 215], ["2A* peptide", "GENE_OR_GENE_PRODUCT", 228, 239], ["amino acidic", "AMINO_ACID", 295, 307], ["Proteasome", "GENE_OR_GENE_PRODUCT", 562, 572], ["ribosomes", "CELLULAR_COMPONENT", 608, 617], ["ribosome", "CELLULAR_COMPONENT", 644, 652], ["Proteasome", "GENE_OR_GENE_PRODUCT", 800, 810], ["ribosomes", "CELLULAR_COMPONENT", 846, 855], ["cells", "CELL", 896, 901], ["cycloheximide", "SIMPLE_CHEMICAL", 915, 928], ["full-length 2A", "PROTEIN", 51, 65], ["pr1", "PROTEIN", 95, 98], ["2A", "PROTEIN", 99, 101], ["pr1", "PROTEIN", 190, 193], ["2A", "PROTEIN", 194, 196], ["Fig. 4f", "PROTEIN", 198, 205], ["2A amino acidic sequence", "PROTEIN", 292, 316], ["C-terminal Gly residue", "PROTEIN", 407, 429], ["STOP-codon", "DNA", 551, 561], ["secretory reporter protein", "PROTEIN", 947, 973], ["2A", "PROTEIN", 1069, 1071], ["Tag fusion", "TREATMENT", 104, 114], ["mRNA codon usage", "TREATMENT", 258, 274], ["the C-terminal Gly residue", "PROBLEM", 403, 429], ["the translational stalling", "PROBLEM", 517, 543], ["Proteasome degradation", "TREATMENT", 562, 584], ["ribosome stalling", "PROBLEM", 644, 661], ["Proteasome degradation", "TREATMENT", 800, 822], ["ResultsKinetic studies", "TEST", 860, 882], ["cycloheximide", "TREATMENT", 915, 928], ["the secretory reporter protein", "TEST", 943, 973], ["ribosome stalling", "OBSERVATION", 644, 661]]], ["To investigate the degradation pathway of these secretory proteins, cells were treated with the proteasome inhibitor MG132 or with the autophagy inhibitor chloroquine (CQ).", [["cells", "ANATOMY", 68, 73], ["MG132", "CHEMICAL", 117, 122], ["chloroquine", "CHEMICAL", 155, 166], ["CQ", "CHEMICAL", 168, 170], ["MG132", "CHEMICAL", 117, 122], ["chloroquine", "CHEMICAL", 155, 166], ["CQ", "CHEMICAL", 168, 170], ["cells", "CELL", 68, 73], ["MG132", "SIMPLE_CHEMICAL", 117, 122], ["chloroquine", "SIMPLE_CHEMICAL", 155, 166], ["CQ", "SIMPLE_CHEMICAL", 168, 170], ["secretory proteins", "PROTEIN", 48, 66], ["proteasome", "PROTEIN", 96, 106], ["these secretory proteins", "PROBLEM", 42, 66], ["the proteasome inhibitor MG132", "TREATMENT", 92, 122], ["the autophagy inhibitor chloroquine", "TREATMENT", 131, 166]]], ["Significant accumulation of material was observed after MG132, but not after CQ treatment (Fig. 5b), indicating that polypeptides released from the ER-bound stalled ribosomes were degraded by the proteasome.", [["ER", "ANATOMY", 148, 150], ["ribosomes", "ANATOMY", 165, 174], ["MG132", "CHEMICAL", 56, 61], ["CQ", "CHEMICAL", 77, 79], ["MG132", "CHEMICAL", 56, 61], ["CQ", "CHEMICAL", 77, 79], ["MG132", "SIMPLE_CHEMICAL", 56, 61], ["CQ", "SIMPLE_CHEMICAL", 77, 79], ["ER", "GENE_OR_GENE_PRODUCT", 148, 150], ["ribosomes", "CELLULAR_COMPONENT", 165, 174], ["ER", "PROTEIN", 148, 150], ["proteasome", "PROTEIN", 196, 206], ["Significant accumulation of material", "PROBLEM", 0, 36], ["MG132", "TREATMENT", 56, 61], ["CQ treatment", "TREATMENT", 77, 89], ["polypeptides", "PROBLEM", 117, 129], ["accumulation of material", "OBSERVATION", 12, 36]]], ["Cells transfected with HA-tagged ubiquitin and treated with the MG132 also showed significantly higher accumulation of poly-ubiquitinated pr1 expressed from 2A* compared to 2A-P* (Fig. 5c).", [["Cells", "ANATOMY", 0, 5], ["MG132", "CHEMICAL", 64, 69], ["MG132", "CHEMICAL", 64, 69], ["Cells", "CELL", 0, 5], ["HA-tagged ubiquitin", "GENE_OR_GENE_PRODUCT", 23, 42], ["MG132", "SIMPLE_CHEMICAL", 64, 69], ["pr1", "GENE_OR_GENE_PRODUCT", 138, 141], ["HA", "PROTEIN", 23, 25], ["ubiquitin", "PROTEIN", 33, 42], ["poly-ubiquitinated pr1", "PROTEIN", 119, 141], ["2A", "PROTEIN", 173, 175], ["HA", "PROBLEM", 23, 25], ["tagged ubiquitin", "TREATMENT", 26, 42], ["the MG132", "TREATMENT", 60, 69], ["significantly higher accumulation of poly", "PROBLEM", 82, 123]]], ["Furthermore, co-expression with the viral cytosolic deubiquitinylase-like protein OTU (derived from the Congo hemorrhagic fever virus) also caused strong pr1 accumulation from 2A* (Fig. 5d).", [["cytosolic", "ANATOMY", 42, 51], ["hemorrhagic fever", "DISEASE", 110, 127], ["Congo hemorrhagic fever virus", "ORGANISM", 104, 133], ["pr1", "GENE_OR_GENE_PRODUCT", 154, 157], ["viral cytosolic deubiquitinylase-like protein OTU", "PROTEIN", 36, 85], ["pr1", "PROTEIN", 154, 157], ["Congo hemorrhagic fever virus", "SPECIES", 104, 133], ["Congo hemorrhagic fever virus", "SPECIES", 104, 133], ["the viral cytosolic deubiquitinylase", "TEST", 32, 68], ["protein OTU", "PROBLEM", 74, 85], ["the Congo hemorrhagic fever virus", "PROBLEM", 100, 133], ["strong pr1 accumulation", "PROBLEM", 147, 170]]], ["OTU removes ubiquitin from cytosolic poly-ubiquitinylated proteins targeted to degradation, impairing their engagement by the proteasome and therefore causing accumulation [35], [36].", [["cytosolic", "ANATOMY", 27, 36], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 12, 21], ["ubiquitin", "PROTEIN", 12, 21], ["cytosolic poly-ubiquitinylated proteins", "PROTEIN", 27, 66], ["proteasome", "PROTEIN", 126, 136], ["cytosolic poly-ubiquitinylated proteins", "TREATMENT", 27, 66], ["cytosolic poly", "OBSERVATION", 27, 41]]], ["Similarly, co-expression with the dominant negative mammalian deubiquitinylase YOD1 (YOD1-C160S) [37] or the dominant negative mutant of the AAA p97 ATPase, which lacks ATPase activity (p97QQ, E305 and E578 mutated into Q) [38], blocked degradation of pr1 from construct 2A ribosome stalled protein reporter (Fig. 5f).Proteasome degradation of products of stalled ribosomes ::: ResultsFinally, we explored the involvement of the E3 ubiquitin ligases Listerin (Ltn), found to be associated with stalled ribosomes [11].", [["ribosomes", "ANATOMY", 364, 373], ["ribosomes", "ANATOMY", 502, 511], ["mammalian deubiquitinylase YOD1", "GENE_OR_GENE_PRODUCT", 52, 83], ["YOD1-C160S) [37]", "GENE_OR_GENE_PRODUCT", 85, 101], ["AAA p97", "GENE_OR_GENE_PRODUCT", 141, 148], ["ATPase", "GENE_OR_GENE_PRODUCT", 149, 155], ["ATPase", "GENE_OR_GENE_PRODUCT", 169, 175], ["pr1", "GENE_OR_GENE_PRODUCT", 252, 255], ["Proteasome", "GENE_OR_GENE_PRODUCT", 318, 328], ["ribosomes", "CELLULAR_COMPONENT", 364, 373], ["E3", "GENE_OR_GENE_PRODUCT", 429, 431], ["Listerin", "GENE_OR_GENE_PRODUCT", 450, 458], ["Ltn", "GENE_OR_GENE_PRODUCT", 460, 463], ["dominant negative mammalian deubiquitinylase YOD1", "PROTEIN", 34, 83], ["YOD1", "PROTEIN", 85, 89], ["C160S", "PROTEIN", 90, 95], ["dominant negative mutant", "PROTEIN", 109, 133], ["AAA p97 ATPase", "PROTEIN", 141, 155], ["ATPase", "PROTEIN", 169, 175], ["E305", "PROTEIN", 193, 197], ["E578", "PROTEIN", 202, 206], ["pr1", "PROTEIN", 252, 255], ["construct 2A ribosome stalled protein reporter", "DNA", 261, 307], ["E3 ubiquitin ligases", "PROTEIN", 429, 449], ["Listerin", "PROTEIN", 450, 458], ["Ltn", "PROTEIN", 460, 463], ["ATPase activity", "PROBLEM", 169, 184], ["Proteasome degradation", "TREATMENT", 318, 340], ["the E3 ubiquitin ligases Listerin", "TREATMENT", 425, 458], ["dominant", "OBSERVATION_MODIFIER", 34, 42], ["negative", "OBSERVATION", 43, 51], ["dominant", "OBSERVATION_MODIFIER", 109, 117], ["negative", "OBSERVATION", 118, 126], ["AAA", "OBSERVATION", 141, 144], ["activity", "OBSERVATION_MODIFIER", 176, 184]]], ["Silencing of Ltn partially rescued expression from 2A* constructs (Fig. 5g).Proteasome degradation of products of stalled ribosomes ::: ResultsActivation of the ubiquitin\u2013proteasome pathway was also observed when translational stalling occurred on free ribosomes: the cytosolic leader-less scFv protein from construct 2A* accumulated upon MG132 treatment, following co-expression with OTU or p97QQ and upon Ltn silencing (Supplementary Fig. 2).Proteasome degradation of products of stalled ribosomes ::: ResultsIn conclusion, the reduced protein levels produced from constructs 2A* were the consequence of two concomitant effects: (i) ribosome stalling, which strongly impairs the rate of synthesis, and (ii) engagement of the terminated protein into the proteasomal degradation pathway.", [["ribosomes", "ANATOMY", 122, 131], ["ribosomes", "ANATOMY", 253, 262], ["cytosolic", "ANATOMY", 268, 277], ["ribosomes", "ANATOMY", 490, 499], ["ribosome", "ANATOMY", 635, 643], ["proteasomal", "ANATOMY", 755, 766], ["MG132", "CHEMICAL", 339, 344], ["MG132", "CHEMICAL", 339, 344], ["Ltn", "GENE_OR_GENE_PRODUCT", 13, 16], ["Proteasome", "GENE_OR_GENE_PRODUCT", 76, 86], ["ribosomes", "CELLULAR_COMPONENT", 122, 131], ["ubiquitin\u2013proteasome", "GENE_OR_GENE_PRODUCT", 161, 181], ["ribosomes", "CELLULAR_COMPONENT", 253, 262], ["MG132", "SIMPLE_CHEMICAL", 339, 344], ["Ltn", "GENE_OR_GENE_PRODUCT", 407, 410], ["Proteasome", "GENE_OR_GENE_PRODUCT", 444, 454], ["ribosomes", "CELLULAR_COMPONENT", 490, 499], ["ribosome", "CELLULAR_COMPONENT", 635, 643], ["Ltn", "PROTEIN", 13, 16], ["2A* constructs", "DNA", 51, 65], ["cytosolic leader", "PROTEIN", 268, 284], ["scFv protein", "PROTEIN", 290, 302], ["p97QQ", "DNA", 392, 397], ["Ltn", "PROTEIN", 407, 410], ["terminated protein", "PROTEIN", 727, 745], ["Proteasome degradation", "TREATMENT", 76, 98], ["the ubiquitin\u2013proteasome pathway", "PROBLEM", 157, 189], ["translational stalling", "PROBLEM", 213, 235], ["the cytosolic leader", "PROBLEM", 264, 284], ["MG132 treatment", "TREATMENT", 339, 354], ["Proteasome degradation", "TREATMENT", 444, 466], ["the reduced protein levels", "PROBLEM", 526, 552], ["ribosome stalling", "PROBLEM", 635, 652], ["proteasomal degradation", "OBSERVATION", 755, 778]]], ["These results indicate that molecules translated from membrane-bound ribosomes stalled at the STOP-codon are targeted to the proteasome requiring components of both the ribosomal quality control system and the ERAD pathway.Stalling of membrane-bound ribosomes triggers ERAD ::: ResultsWe further investigated involvement of the ERAD pathway by looking at retro-translocation of polypeptides from the ER lumen to the cytosol using our previously described in vivo retro-translocation assay [39] based on the specific in vivo biotinylation of molecules localized on the cytosolic side.", [["membrane", "ANATOMY", 54, 62], ["ribosomes", "ANATOMY", 69, 78], ["ribosomal", "ANATOMY", 169, 178], ["membrane", "ANATOMY", 235, 243], ["ribosomes", "ANATOMY", 250, 259], ["ER lumen", "ANATOMY", 400, 408], ["cytosol", "ANATOMY", 416, 423], ["cytosolic", "ANATOMY", 568, 577], ["membrane", "CELLULAR_COMPONENT", 54, 62], ["ribosomes", "CELLULAR_COMPONENT", 69, 78], ["ribosomal", "CELLULAR_COMPONENT", 169, 178], ["ERAD", "GENE_OR_GENE_PRODUCT", 210, 214], ["membrane", "CELLULAR_COMPONENT", 235, 243], ["ribosomes", "CELLULAR_COMPONENT", 250, 259], ["ERAD", "GENE_OR_GENE_PRODUCT", 328, 332], ["ER", "GENE_OR_GENE_PRODUCT", 400, 402], ["lumen", "CELLULAR_COMPONENT", 403, 408], ["cytosol", "CELLULAR_COMPONENT", 416, 423], ["STOP-codon", "DNA", 94, 104], ["proteasome", "PROTEIN", 125, 135], ["ERAD", "PROTEIN", 210, 214], ["membrane-bound ribosomes", "PROTEIN", 235, 259], ["ERAD", "PROTEIN", 269, 273], ["ERAD", "PROTEIN", 328, 332], ["membrane-bound ribosomes", "PROBLEM", 54, 78], ["molecules", "OBSERVATION", 28, 37], ["lumen", "ANATOMY_MODIFIER", 403, 408]]], ["Detection and quantification of the biotinylated (retro-translocated) fraction was carried out in a Western blot-retardation assay in which denatured samples, incubated with streptavidin (StrAv) before electrophoresis, produce retardation of the biotinylated proteins.", [["samples", "ANATOMY", 150, 157], ["streptavidin", "SIMPLE_CHEMICAL", 174, 186], ["StrAv", "SIMPLE_CHEMICAL", 188, 193], ["StrAv", "PROTEIN", 188, 193], ["biotinylated proteins", "PROTEIN", 246, 267], ["Detection", "TEST", 0, 9], ["the biotinylated (retro-translocated) fraction", "TREATMENT", 32, 78], ["streptavidin (StrAv", "TREATMENT", 174, 193], ["electrophoresis", "TEST", 202, 217], ["retardation of the biotinylated proteins", "PROBLEM", 227, 267]]], ["As shown in Fig. 6a, most of the intracellular secretory reporter produced from 2A* was biotinylated.", [["intracellular", "ANATOMY", 33, 46], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 33, 46], ["intracellular secretory reporter", "DNA", 33, 65]]], ["As expected, the material accumulated from construct 2A* upon proteasome inhibition with MG132, or co-expression with p97QQ or OTU, was mostly biotinylated (Fig. 6b), consistent with active retro-translocation from the ER lumen.", [["ER lumen", "ANATOMY", 219, 227], ["MG132", "CHEMICAL", 89, 94], ["MG132", "CHEMICAL", 89, 94], ["MG132", "SIMPLE_CHEMICAL", 89, 94], ["ER", "GENE_OR_GENE_PRODUCT", 219, 221], ["proteasome", "PROTEIN", 62, 72], ["p97QQ", "PROTEIN", 118, 123], ["the material", "PROBLEM", 13, 25], ["proteasome inhibition", "TREATMENT", 62, 83], ["MG132", "TREATMENT", 89, 94], ["active retro-translocation from the ER lumen", "PROBLEM", 183, 227], ["consistent with", "UNCERTAINTY", 167, 182], ["active", "OBSERVATION_MODIFIER", 183, 189], ["retro-translocation", "OBSERVATION", 190, 209], ["lumen", "ANATOMY_MODIFIER", 222, 227]]], ["Upon co-expression with the dominant negative chaperone BiP/GRP78 (T37G), which binds to newly synthesized protein substrates but is unable to undergo the conformational change upon ATP binding required for protein release, a large accumulation of pr1-2A* was observed, similarly to other ERAD targeted BiP substrates [35], [40].", [["ATP", "CHEMICAL", 182, 185], ["ATP", "CHEMICAL", 182, 185], ["BiP", "GENE_OR_GENE_PRODUCT", 56, 59], ["GRP78", "GENE_OR_GENE_PRODUCT", 60, 65], ["T37G", "AMINO_ACID", 67, 71], ["ATP", "SIMPLE_CHEMICAL", 182, 185], ["pr1-2A", "GENE_OR_GENE_PRODUCT", 248, 254], ["BiP", "GENE_OR_GENE_PRODUCT", 303, 306], ["dominant negative chaperone", "PROTEIN", 28, 55], ["BiP", "PROTEIN", 56, 59], ["GRP78", "PROTEIN", 60, 65], ["T37G", "PROTEIN", 67, 71], ["protein substrates", "PROTEIN", 107, 125], ["pr1", "PROTEIN", 248, 251], ["ERAD targeted BiP substrates", "PROTEIN", 289, 317], ["newly synthesized protein substrates", "PROBLEM", 89, 125], ["ATP binding", "TREATMENT", 182, 193], ["protein release", "TREATMENT", 207, 222], ["large", "OBSERVATION_MODIFIER", 226, 231], ["accumulation", "OBSERVATION_MODIFIER", 232, 244]]], ["This material was most likely trapped inside the ER, due to its strong interaction with the BiP mutant, as it was not biotinylated by the cytosolic biotin ligase (Fig. 6c, lanes 3 and 4).Stalling of membrane-bound ribosomes triggers ERAD ::: ResultsConsistently, polypeptides with an N-glycosylation tag added to construct 2A* (N-2A was fully glycosylated also in the absence of the mutated chaperone (Fig. 6d).ERAD targeting of peptides from stalled ribosome is specific ::: ResultsWe then assessed that targeting to ERAD was restricted to the product of the stalled ribosome.", [["ER", "ANATOMY", 49, 51], ["cytosolic", "ANATOMY", 138, 147], ["membrane", "ANATOMY", 199, 207], ["ribosomes", "ANATOMY", 214, 223], ["ribosome", "ANATOMY", 451, 459], ["ribosome", "ANATOMY", 568, 576], ["biotin", "CHEMICAL", 148, 154], ["N", "CHEMICAL", 284, 285], ["ER", "GENE_OR_GENE_PRODUCT", 49, 51], ["BiP", "GENE_OR_GENE_PRODUCT", 92, 95], ["biotin", "SIMPLE_CHEMICAL", 148, 154], ["membrane", "CELLULAR_COMPONENT", 199, 207], ["ribosomes", "CELLULAR_COMPONENT", 214, 223], ["ERAD", "GENE_OR_GENE_PRODUCT", 233, 237], ["N-2A", "GENE_OR_GENE_PRODUCT", 328, 332], ["ERAD", "GENE_OR_GENE_PRODUCT", 518, 522], ["ribosome", "CELLULAR_COMPONENT", 568, 576], ["ER", "PROTEIN", 49, 51], ["BiP mutant", "PROTEIN", 92, 102], ["cytosolic biotin ligase", "PROTEIN", 138, 161], ["Fig. 6c, lanes 3 and 4", "PROTEIN", 163, 185], ["membrane-bound ribosomes", "PROTEIN", 199, 223], ["ERAD", "PROTEIN", 233, 237], ["N-glycosylation tag", "PROTEIN", 284, 303], ["N-2A", "PROTEIN", 328, 332], ["mutated chaperone", "PROTEIN", 383, 400], ["Fig. 6d", "PROTEIN", 402, 409], ["ERAD", "PROTEIN", 411, 415], ["ERAD", "PROTEIN", 518, 522], ["the BiP mutant", "PROBLEM", 88, 102], ["the cytosolic biotin ligase", "TEST", 134, 161], ["an N-glycosylation tag", "TREATMENT", 281, 303], ["fully glycosylated", "PROBLEM", 337, 355], ["most likely", "UNCERTAINTY", 18, 29], ["trapped", "OBSERVATION", 30, 37], ["biotin ligase", "OBSERVATION", 148, 161], ["stalled ribosome", "OBSERVATION", 560, 576]]], ["We used a 2A* construct (pr2-2A construct (pr1-2A-P was affected, while pr1 from 2A-P* was not.", [["pr2-2A", "GENE_OR_GENE_PRODUCT", 25, 31], ["2A* construct", "DNA", 10, 23], ["pr2-2A construct", "DNA", 25, 41], ["pr1", "DNA", 43, 46], ["P", "DNA", 50, 51], ["pr1", "DNA", 72, 75], ["P*", "DNA", 84, 86], ["a 2A* construct (pr2-2A construct", "TREATMENT", 8, 41]]], ["A similar result was obtained with an irrelevant control secretory protein (scFv-ctrl; roTag-tagged), which was also not affected when co-expressed with construct pr2-2A* (Fig. 7b).ERAD targeting of peptides from stalled ribosome is specific ::: ResultsThus, proteins translated from membrane-bound stalled ribosomes are exclusively targeted to ERAD, without affecting those same polypeptides originating from non-stalled ribosomes.The product of membrane-bound stalled ribosomes binds to BiP/GRP78 ::: ResultsWe then investigated the interactome of polypeptides produced from stalled ribosomes using the BioID2 technique, based on the expression of the Aquifex aeolicus bacterial biotin-ligase with the R40G mutation [42].", [["ribosome", "ANATOMY", 221, 229], ["membrane", "ANATOMY", 284, 292], ["ribosomes", "ANATOMY", 307, 316], ["ribosomes", "ANATOMY", 422, 431], ["membrane", "ANATOMY", 447, 455], ["ribosomes", "ANATOMY", 470, 479], ["ribosomes", "ANATOMY", 585, 594], ["biotin", "CHEMICAL", 681, 687], ["scFv-ctrl", "GENE_OR_GENE_PRODUCT", 76, 85], ["roTag", "GENE_OR_GENE_PRODUCT", 87, 92], ["pr2-2A", "GENE_OR_GENE_PRODUCT", 163, 169], ["membrane", "CELLULAR_COMPONENT", 284, 292], ["ribosomes", "CELLULAR_COMPONENT", 307, 316], ["ERAD", "GENE_OR_GENE_PRODUCT", 345, 349], ["ribosomes", "CELLULAR_COMPONENT", 422, 431], ["membrane", "CELLULAR_COMPONENT", 447, 455], ["ribosomes", "CELLULAR_COMPONENT", 470, 479], ["BiP", "GENE_OR_GENE_PRODUCT", 489, 492], ["GRP78", "GENE_OR_GENE_PRODUCT", 493, 498], ["ribosomes", "CELLULAR_COMPONENT", 585, 594], ["Aquifex aeolicus", "GENE_OR_GENE_PRODUCT", 654, 670], ["biotin-ligase", "GENE_OR_GENE_PRODUCT", 681, 694], ["secretory protein", "PROTEIN", 57, 74], ["scFv-ctrl", "PROTEIN", 76, 85], ["roTag", "PROTEIN", 87, 92], ["pr2", "PROTEIN", 163, 166], ["ERAD", "PROTEIN", 181, 185], ["ERAD", "PROTEIN", 345, 349], ["-stalled ribosomes", "RNA", 413, 431], ["membrane-bound stalled ribosomes", "PROTEIN", 447, 479], ["BiP", "PROTEIN", 489, 492], ["GRP78", "PROTEIN", 493, 498], ["Aquifex aeolicus bacterial biotin-ligase", "PROTEIN", 654, 694], ["R40G", "PROTEIN", 704, 708], ["Aquifex aeolicus", "SPECIES", 654, 670], ["Aquifex aeolicus", "SPECIES", 654, 670], ["the BioID2 technique", "TREATMENT", 601, 621], ["the Aquifex aeolicus bacterial biotin-ligase", "TREATMENT", 650, 694], ["membrane", "OBSERVATION_MODIFIER", 447, 455]]], ["This enzyme lacks substrate specificity and is therefore able to biotinylate in vivo the interacting proteins.", [["interacting proteins", "PROTEIN", 89, 109], ["This enzyme", "TEST", 0, 11]]], ["Constructs with 2A* or 2A-P* at the C-terminus of BioID2 (Fig. 8a) were then independently expressed and the biotinylated proteins were analyzed by Western blot.", [["BioID2", "GENE_OR_GENE_PRODUCT", 50, 56], ["P*", "DNA", 26, 28], ["C-terminus", "PROTEIN", 36, 46], ["BioID2", "PROTEIN", 50, 56], ["biotinylated proteins", "PROTEIN", 109, 130], ["the biotinylated proteins", "TEST", 105, 130]]], ["As shown in Fig. 8a and b, the BioID2 activity was detected by its self-biotinylation.", [["BioID2", "GENE_OR_GENE_PRODUCT", 31, 37], ["BioID2", "PROTEIN", 31, 37]]], ["One band of around 78 kDa was found strongly biotinylated in cells expressing BioID2-2A* but not BioID2-2A-P* (Fig. 8a).", [["cells", "ANATOMY", 61, 66], ["cells", "CELL", 61, 66], ["BioID2-2A", "GENE_OR_GENE_PRODUCT", 78, 87], ["BioID2", "PROTEIN", 78, 84], ["BioID2", "PROTEIN", 97, 103], ["2A", "PROTEIN", 104, 106], ["P*", "DNA", 107, 109], ["kDa", "TEST", 22, 25], ["BioID2", "TEST", 78, 84], ["BioID2", "TEST", 97, 103]]], ["We suspected that it represented BiP/GRP78, which was confirmed by pull-down with StrAv followed by detection with anti-BiP as well as by BiP immunoprecipitation followed by detection with StrAv-HRP from cells expressing BioID2-2A* (Fig. 8c).", [["cells", "ANATOMY", 204, 209], ["BiP", "GENE_OR_GENE_PRODUCT", 33, 36], ["GRP78", "GENE_OR_GENE_PRODUCT", 37, 42], ["StrAv", "SIMPLE_CHEMICAL", 82, 87], ["anti-BiP", "SIMPLE_CHEMICAL", 115, 123], ["BiP", "GENE_OR_GENE_PRODUCT", 138, 141], ["StrAv-HRP", "GENE_OR_GENE_PRODUCT", 189, 198], ["cells", "CELL", 204, 209], ["BioID2-2A", "GENE_OR_GENE_PRODUCT", 221, 230], ["BiP", "PROTEIN", 33, 36], ["GRP78", "PROTEIN", 37, 42], ["StrAv", "PROTEIN", 82, 87], ["anti-BiP", "PROTEIN", 115, 123], ["BiP", "PROTEIN", 138, 141], ["StrAv", "PROTEIN", 189, 194], ["HRP", "PROTEIN", 195, 198], ["BioID2", "PROTEIN", 221, 227], ["BiP/GRP78", "PROBLEM", 33, 42], ["StrAv", "TREATMENT", 82, 87], ["anti-BiP", "TREATMENT", 115, 123], ["BiP immunoprecipitation", "TEST", 138, 161], ["StrAv", "TEST", 189, 194]]], ["Mass spectrometry analysis was then performed on pulled-down biotinylated proteins, confirming detection of BiP only in extracts of cells expressing BioID2-2A.", [["extracts", "ANATOMY", 120, 128], ["cells", "ANATOMY", 132, 137], ["BiP", "GENE_OR_GENE_PRODUCT", 108, 111], ["extracts", "ORGANISM_SUBSTANCE", 120, 128], ["cells", "CELL", 132, 137], ["BioID2-2A", "GENE_OR_GENE_PRODUCT", 149, 158], ["biotinylated proteins", "PROTEIN", 61, 82], ["BiP", "PROTEIN", 108, 111], ["BioID2-2A", "PROTEIN", 149, 158], ["Mass spectrometry analysis", "TEST", 0, 26], ["BiP", "TREATMENT", 108, 111]]], ["Mass spectrometry of BioID2-2A* biotinylated proteins also detected the 23-kDa nascent polypeptide-associated complex \u03b1-subunit (NACA) and the 71-kDa cytosolic chaperone HSPA8.", [["cytosolic", "ANATOMY", 150, 159], ["BioID2-2A", "GENE_OR_GENE_PRODUCT", 21, 30], ["NACA", "GENE_OR_GENE_PRODUCT", 129, 133], ["HSPA8", "GENE_OR_GENE_PRODUCT", 170, 175], ["BioID2-2A* biotinylated proteins", "PROTEIN", 21, 53], ["23-kDa nascent polypeptide-associated complex \u03b1-subunit", "PROTEIN", 72, 127], ["NACA", "PROTEIN", 129, 133], ["71-kDa cytosolic chaperone", "PROTEIN", 143, 169], ["HSPA8", "PROTEIN", 170, 175], ["Mass spectrometry", "TEST", 0, 17], ["BioID2", "TEST", 21, 27], ["biotinylated proteins", "TEST", 32, 53], ["cytosolic chaperone HSPA8", "TREATMENT", 150, 175]]], ["A complete list of polypeptides found with both proteins is shown in Supplementary Table 2.Stalling by non-viral peptides encoded in the human genome ::: ResultsIdentification of other sequences capable of inducing stalling of the ribosome at the STOP-codon is challenging.", [["human", "ORGANISM", 137, 142], ["ribosome", "CELLULAR_COMPONENT", 231, 239], ["human genome", "DNA", 137, 149], ["STOP-codon", "DNA", 247, 257], ["human", "SPECIES", 137, 142], ["human", "SPECIES", 137, 142], ["polypeptides", "PROBLEM", 19, 31], ["other sequences", "TEST", 179, 194], ["the ribosome", "PROBLEM", 227, 239]]], ["As 2A-like peptides are highly conserved at the last three C-terminal amino acids (NPG), we then searched for human proteins that terminate with the same NPG* sequence in the ENSEMBL data bank.", [["amino acids", "CHEMICAL", 70, 81], ["C", "CHEMICAL", 59, 60], ["amino acids", "CHEMICAL", 70, 81], ["NPG", "CHEMICAL", 83, 86], ["2A", "GENE_OR_GENE_PRODUCT", 3, 5], ["amino acids", "AMINO_ACID", 70, 81], ["human", "ORGANISM", 110, 115], ["C-terminal amino acids", "PROTEIN", 59, 81], ["human proteins", "PROTEIN", 110, 124], ["NPG* sequence", "DNA", 154, 167], ["human", "SPECIES", 110, 115], ["human", "SPECIES", 110, 115], ["C-terminal amino acids", "TREATMENT", 59, 81], ["human proteins", "TREATMENT", 110, 124]]], ["Only five proteins were found [CD99 molecule-like protein 2 (CD99L2), prostate ovary testis-expressed protein family members I and E (POTEI and POTEE), TBCA and SPIRE2, where POTEE and POTEI share the same C-terminal amino acidic sequence].", [["prostate ovary testis", "ANATOMY", 70, 91], ["C", "CHEMICAL", 206, 207], ["amino", "CHEMICAL", 217, 222], ["CD99 molecule-like protein 2", "GENE_OR_GENE_PRODUCT", 31, 59], ["CD99L2", "GENE_OR_GENE_PRODUCT", 61, 67], ["prostate ovary testis-expressed protein family members I", "GENE_OR_GENE_PRODUCT", 70, 126], ["E", "GENE_OR_GENE_PRODUCT", 131, 132], ["POTEI", "GENE_OR_GENE_PRODUCT", 134, 139], ["POTEE", "GENE_OR_GENE_PRODUCT", 144, 149], ["TBCA", "GENE_OR_GENE_PRODUCT", 152, 156], ["SPIRE2", "GENE_OR_GENE_PRODUCT", 161, 167], ["POTEE", "GENE_OR_GENE_PRODUCT", 175, 180], ["POTEI", "GENE_OR_GENE_PRODUCT", 185, 190], ["CD99 molecule-like protein 2", "PROTEIN", 31, 59], ["CD99L2", "PROTEIN", 61, 67], ["prostate ovary testis-expressed protein family members", "PROTEIN", 70, 124], ["I", "PROTEIN", 125, 126], ["E", "PROTEIN", 131, 132], ["POTEI", "PROTEIN", 134, 139], ["POTEE", "PROTEIN", 144, 149], ["TBCA", "PROTEIN", 152, 156], ["SPIRE2", "PROTEIN", 161, 167], ["POTEE", "PROTEIN", 175, 180], ["POTEI", "PROTEIN", 185, 190], ["C-terminal amino acidic sequence", "PROTEIN", 206, 238], ["five proteins", "TEST", 5, 18], ["CD99 molecule", "TEST", 31, 44], ["protein", "TEST", 50, 57], ["prostate ovary testis", "PROBLEM", 70, 91], ["prostate ovary", "ANATOMY", 70, 84], ["testis", "ANATOMY", 85, 91]]], ["In most cases, they represent alternative spliced transcripts.", [["alternative spliced transcripts", "RNA", 30, 61]]], ["We tested the effect exerted on expression of the cytosolic reporter (cyt-scFv) by the four different C-terminal sequences in constructs with and without the addition of the P-codon before the STOP-codon (Fig. 9a).", [["cytosolic", "ANATOMY", 50, 59], ["C", "CHEMICAL", 102, 103], ["cyt-scFv", "GENE_OR_GENE_PRODUCT", 70, 78], ["cytosolic reporter", "DNA", 50, 68], ["cyt", "PROTEIN", 70, 73], ["scFv", "PROTEIN", 74, 78], ["C-terminal sequences", "DNA", 102, 122], ["P-codon", "DNA", 174, 181], ["STOP-codon", "DNA", 193, 203], ["the cytosolic reporter", "TEST", 46, 68], ["the P-codon", "TREATMENT", 170, 181]]], ["While the C-termini from TBCA and SPIRE2 did not display any effect on the reporter translation, those from CD99L2 and POTE caused a strong expression decrease compared to the reporter without the terminal sequences (Fig. 9b).", [["TBCA", "GENE_OR_GENE_PRODUCT", 25, 29], ["CD99L2", "GENE_OR_GENE_PRODUCT", 108, 114], ["POTE", "GENE_OR_GENE_PRODUCT", 119, 123], ["TBCA", "PROTEIN", 25, 29], ["SPIRE2", "PROTEIN", 34, 40], ["CD99L2", "PROTEIN", 108, 114], ["POTE", "PROTEIN", 119, 123], ["terminal sequences", "DNA", 197, 215], ["the C-termini from TBCA and SPIRE2", "TEST", 6, 40], ["a strong expression decrease", "PROBLEM", 131, 159], ["the terminal sequences", "TEST", 193, 215]]], ["Of note, expression of proteins terminating with these two sequences was partially rescued by the addition of the C-terminal Pro, similar to what observed with peptide 2A.", [["C-terminal Pro", "PROTEIN", 114, 128], ["the C-terminal Pro", "TREATMENT", 110, 128]]], ["However, and despite of this, non-conventional translation termination was not observed as shown with a construct elongated with the 11-aa roTag downstream of Pro (shown for POTE, Fig. 9c, left panel).Stalling by non-viral peptides encoded in the human genome ::: ResultsRecently, a short sequence capable of inducing ribosome stalling was described in an ORF located at the 3\u2032UTR of adenosylmethionine decarboxylase 1 (AMD1) mRNA [43].", [["ribosome", "ANATOMY", 318, 326], ["adenosylmethionine", "CHEMICAL", 384, 402], ["human", "ORGANISM", 247, 252], ["ribosome", "CELLULAR_COMPONENT", 318, 326], ["adenosylmethionine decarboxylase 1", "GENE_OR_GENE_PRODUCT", 384, 418], ["AMD1", "GENE_OR_GENE_PRODUCT", 420, 424], ["11-aa roTag downstream", "DNA", 133, 155], ["POTE", "PROTEIN", 174, 178], ["human genome", "DNA", 247, 259], ["ORF", "DNA", 356, 359], ["UTR", "DNA", 377, 380], ["adenosylmethionine decarboxylase 1 (AMD1) mRNA", "RNA", 384, 430], ["human", "SPECIES", 247, 252], ["human", "SPECIES", 247, 252], ["a construct elongated", "PROBLEM", 102, 123], ["left panel", "TEST", 189, 199], ["inducing ribosome stalling", "PROBLEM", 309, 335], ["UTR of adenosylmethionine decarboxylase", "TREATMENT", 377, 416], ["ribosome stalling", "OBSERVATION", 318, 335]]], ["This sequence does not terminate in NPG (Fig. 9a), but its 22-aa-long C terminus (C-TAIL) strongly affected expression of the reporter protein to a level comparable to that of 2A (Fig. 9b, right panel).", [["C", "CHEMICAL", 70, 71], ["C-TAIL", "GENE_OR_GENE_PRODUCT", 82, 88], ["C terminus", "PROTEIN", 70, 80], ["C", "PROTEIN", 82, 83], ["TAIL", "PROTEIN", 84, 88], ["reporter protein", "PROTEIN", 126, 142], ["the reporter protein", "TEST", 122, 142], ["right panel", "TEST", 189, 200], ["right", "ANATOMY_MODIFIER", 189, 194]]], ["In this case, however, addition of the terminal Pro just upstream of the STOP-codon did not rescue expression and did not promote non-conventional termination in a similar elongated construct, indicating a different stalling mechanism to the one operating with 2A* (Fig. 9b and c, right panels).Stalling by non-viral peptides encoded in the human genome ::: ResultsWe then observed that, as 2A.", [["STOP", "GENE_OR_GENE_PRODUCT", 73, 77], ["human", "ORGANISM", 341, 346], ["terminal Pro", "PROTEIN", 39, 51], ["STOP-codon", "DNA", 73, 83], ["human genome", "DNA", 341, 353], ["human", "SPECIES", 341, 346], ["human", "SPECIES", 341, 346], ["the terminal Pro", "PROBLEM", 35, 51], ["a different stalling mechanism", "PROBLEM", 204, 234], ["right", "ANATOMY_MODIFIER", 281, 286]]], ["Both products accumulated upon treatment with MG132 as well as upon co-expression with OTU and p97QQ (Fig. 9e).", [["MG132", "CHEMICAL", 46, 51], ["MG132", "CHEMICAL", 46, 51], ["MG132", "SIMPLE_CHEMICAL", 46, 51], ["p97QQ", "PROTEIN", 95, 100], ["treatment", "TREATMENT", 31, 40], ["MG132", "TREATMENT", 46, 51], ["accumulated", "OBSERVATION_MODIFIER", 14, 25]]], ["Collectively, these data suggest that ribosome stalling at the STOP-codon, produced by viral and non-viral C-terminal sequences, represents a way to control gene expression at the translational level.DiscussionHere we describe the occurrence of ribosome stalling at the STOP-codon in human cells caused by the picornavirus peptide 2A when the P-codon immediately downstream from the C-terminal Gly, required for its non-conventional termination activity, is replaced by a STOP-codon.", [["ribosome", "ANATOMY", 38, 46], ["ribosome", "ANATOMY", 245, 253], ["cells", "ANATOMY", 290, 295], ["C", "CHEMICAL", 107, 108], ["Gly", "CHEMICAL", 394, 397], ["ribosome", "CELLULAR_COMPONENT", 38, 46], ["STOP", "GENE_OR_GENE_PRODUCT", 63, 67], ["ribosome", "CELLULAR_COMPONENT", 245, 253], ["human", "ORGANISM", 284, 289], ["cells", "CELL", 290, 295], ["picornavirus peptide 2A", "GENE_OR_GENE_PRODUCT", 310, 333], ["Gly", "AMINO_ACID", 394, 397], ["STOP-codon", "DNA", 63, 73], ["viral and non-viral C-terminal sequences", "DNA", 87, 127], ["STOP-codon", "DNA", 270, 280], ["human cells", "CELL_TYPE", 284, 295], ["P-codon", "DNA", 343, 350], ["C-terminal Gly", "PROTEIN", 383, 397], ["STOP-codon", "DNA", 472, 482], ["human", "SPECIES", 284, 289], ["human", "SPECIES", 284, 289], ["these data", "TEST", 14, 24], ["ribosome stalling", "PROBLEM", 38, 55], ["viral and non-viral C-terminal sequences", "PROBLEM", 87, 127], ["ribosome stalling", "PROBLEM", 245, 262], ["codon in human cells", "TREATMENT", 275, 295], ["the picornavirus peptide 2A", "PROBLEM", 306, 333], ["the P-codon", "TREATMENT", 339, 350], ["ribosome stalling", "OBSERVATION", 38, 55]]], ["This 2A-STOP-mediated impairment of translation represents a strong model of ribosome stalling at the STOP-codon, caused by the 2A last 13 aa and, in particular, by the C-terminal NPG sequence.", [["ribosome", "ANATOMY", 77, 85], ["2A", "GENE_OR_GENE_PRODUCT", 5, 7], ["STOP", "GENE_OR_GENE_PRODUCT", 8, 12], ["ribosome", "CELLULAR_COMPONENT", 77, 85], ["STOP", "GENE_OR_GENE_PRODUCT", 102, 106], ["STOP", "DNA", 8, 12], ["STOP-codon", "DNA", 102, 112], ["C-terminal NPG sequence", "DNA", 169, 192], ["impairment of translation", "PROBLEM", 22, 47], ["ribosome stalling", "PROBLEM", 77, 94], ["the C-terminal NPG sequence", "TEST", 165, 192], ["ribosome stalling", "OBSERVATION", 77, 94]]], ["This indicates that stalling is the consequence of the peptide conformation inside the RET.", [["RET", "GENE_OR_GENE_PRODUCT", 87, 90], ["RET", "DNA", 87, 90], ["stalling", "OBSERVATION", 20, 28]]], ["2A has been described to form an amphipathic \u03b1-helix over most of its length, with a reverse turn at its C-terminus [44], [45].", [["C", "CHEMICAL", 105, 106], ["2A", "GENE_OR_GENE_PRODUCT", 0, 2], ["amphipathic \u03b1-helix", "PROTEIN", 33, 52], ["C-terminus", "PROTEIN", 105, 115], ["an amphipathic \u03b1-helix", "TREATMENT", 30, 52], ["amphipathic", "OBSERVATION", 33, 44]]], ["In its normal viral context, this structure has been suggested to cause a transient stalling that favors the non-conventional translation termination of the upstream-encoded protein, determined by the position of the 2A terminal G-codon in the ribosome P site and the P-codon in the ribosome A site [32], [33].", [["ribosome", "ANATOMY", 244, 252], ["upstream-encoded protein", "PROTEIN", 157, 181], ["2A terminal G-codon", "DNA", 217, 236], ["ribosome P site", "DNA", 244, 259], ["P-codon", "DNA", 268, 275], ["ribosome A site", "DNA", 283, 298], ["a transient stalling", "PROBLEM", 72, 92], ["the 2A terminal G-codon", "TREATMENT", 213, 236], ["normal viral context", "OBSERVATION", 7, 27], ["suggested to cause", "UNCERTAINTY", 53, 71], ["transient", "OBSERVATION_MODIFIER", 74, 83], ["stalling", "OBSERVATION", 84, 92], ["codon", "OBSERVATION", 231, 236]]], ["Transient ribosome stalling is thought to occur because of re-orientation of the peptidyl-tRNAGly within the RET that disfavors peptide bond formation with the prolyl-tRNAPro and promotes instead hydrolysis and release of the nascent chain [44], [45].DiscussionInstead, when a STOP-codon is found in the A site in place of an aminoacyl-tRNA, stalling becomes more relevant with a profound effect on the expression of the upstream protein, likely because the 2A structure within RET impaired the polypeptide release or the recruitment of release factors.DiscussionPrevious report showed that an in vitro translated polypeptide from a construct terminating in 2A* can be associated with the tRNA (peptidyl-tRNAGly) [32].", [["ribosome", "ANATOMY", 10, 18], ["prolyl-tRNAPro", "CHEMICAL", 160, 174], ["peptidyl", "CHEMICAL", 81, 89], ["prolyl", "CHEMICAL", 160, 166], ["aminoacyl", "CHEMICAL", 326, 335], ["ribosome", "CELLULAR_COMPONENT", 10, 18], ["peptidyl-tRNAGly", "SIMPLE_CHEMICAL", 81, 97], ["RET", "GENE_OR_GENE_PRODUCT", 109, 112], ["prolyl-tRNAPro", "SIMPLE_CHEMICAL", 160, 174], ["RET", "GENE_OR_GENE_PRODUCT", 478, 481], ["peptidyl-tRNAGly", "PROTEIN", 81, 97], ["RET", "DNA", 109, 112], ["STOP-codon", "DNA", 277, 287], ["A site", "DNA", 304, 310], ["upstream protein", "PROTEIN", 421, 437], ["2A structure", "PROTEIN", 458, 470], ["RET", "PROTEIN", 478, 481], ["release factors", "PROTEIN", 537, 552], ["Transient ribosome stalling", "PROBLEM", 0, 27], ["the peptidyl-tRNAGly", "PROBLEM", 77, 97], ["the prolyl-tRNAPro and promotes instead hydrolysis", "TREATMENT", 156, 206], ["a STOP-codon", "PROBLEM", 275, 287], ["an aminoacyl-tRNA", "TREATMENT", 323, 340], ["the upstream protein", "PROBLEM", 417, 437], ["the polypeptide release", "TREATMENT", 491, 514], ["an in vitro translated polypeptide", "PROBLEM", 591, 625], ["the tRNA (peptidyl-tRNAGly)", "TREATMENT", 685, 712], ["ribosome stalling", "OBSERVATION", 10, 27]]], ["However, in living yeast cells, the majority of ubiquitinated products from stalled ribosomes, recognized by the co-translational quality control pathway, was found already hydrolyzed from the tRNA, owing to the involvement of the yeast release factors Sup45\u2013Sup35 (mammalian eRF1\u20133 homologues) [46].", [["yeast cells", "ANATOMY", 19, 30], ["ribosomes", "ANATOMY", 84, 93], ["yeast cells", "CELL", 19, 30], ["ribosomes", "CELLULAR_COMPONENT", 84, 93], ["Sup45", "GENE_OR_GENE_PRODUCT", 253, 258], ["Sup35", "GENE_OR_GENE_PRODUCT", 259, 264], ["mammalian eRF1\u20133 homologues", "GENE_OR_GENE_PRODUCT", 266, 293], ["ubiquitinated products", "PROTEIN", 48, 70], ["yeast release factors", "PROTEIN", 231, 252], ["Sup45", "PROTEIN", 253, 258], ["Sup35", "PROTEIN", 259, 264], ["mammalian eRF1\u20133 homologues", "PROTEIN", 266, 293], ["yeast", "SPECIES", 19, 24], ["yeast", "SPECIES", 231, 236], ["yeast", "SPECIES", 19, 24], ["yeast", "SPECIES", 231, 236], ["ubiquitinated products", "TREATMENT", 48, 70], ["stalled ribosomes", "PROBLEM", 76, 93], ["the tRNA", "TREATMENT", 189, 197], ["the yeast release factors", "PROBLEM", 227, 252], ["ubiquitinated products", "OBSERVATION", 48, 70], ["stalled ribosomes", "OBSERVATION", 76, 93]]], ["In line with this observation, we also detected the residual amount of non-degraded stalled protein as a fully terminated polypeptide mostly hydrolyzed from the tRNA.DiscussionAs a result of the stalling at the STOP-codon, the ubiquitin\u2013proteasome degradation pathway becomes activated to discard the newly synthesized products.", [["tRNA", "CELLULAR_COMPONENT", 161, 165], ["non-degraded stalled protein", "PROTEIN", 71, 99], ["STOP-codon", "DNA", 211, 221], ["non-degraded stalled protein", "PROBLEM", 71, 99], ["a fully terminated polypeptide", "PROBLEM", 103, 133], ["the tRNA", "TREATMENT", 157, 165], ["the stalling", "PROBLEM", 191, 203], ["the ubiquitin\u2013proteasome degradation pathway", "TREATMENT", 223, 267], ["the newly synthesized products", "TREATMENT", 297, 327], ["residual", "OBSERVATION_MODIFIER", 52, 60], ["amount", "OBSERVATION_MODIFIER", 61, 67]]], ["We found that the total levels of the mRNA encoding peptide that cause stalling (constructs 2A stalled free ribosomes were degraded by the proteasome.", [["ribosomes", "ANATOMY", 108, 117], ["ribosomes", "CELLULAR_COMPONENT", 108, 117], ["mRNA", "RNA", 38, 42], ["proteasome", "PROTEIN", 139, 149], ["the mRNA encoding peptide", "TREATMENT", 34, 59], ["stalling (constructs 2A stalled free ribosomes", "PROBLEM", 71, 117]]], ["In yeast, the p97 homologous Cdc48 is also part of the ribosome-associated quality control, which recognizes stalled ribosomes in NSD and NGD [13], [14], [15].", [["ribosome", "ANATOMY", 55, 63], ["ribosomes", "ANATOMY", 117, 126], ["p97", "GENE_OR_GENE_PRODUCT", 14, 17], ["Cdc48", "GENE_OR_GENE_PRODUCT", 29, 34], ["ribosome", "CELLULAR_COMPONENT", 55, 63], ["ribosomes", "CELLULAR_COMPONENT", 117, 126], ["p97 homologous Cdc48", "PROTEIN", 14, 34], ["yeast", "SPECIES", 3, 8], ["yeast", "SPECIES", 3, 8]]], ["The dominant negative mutant of chaperone BiP/GRP78 was able to retain the protein within the ER lumen.", [["ER lumen", "ANATOMY", 94, 102], ["BiP", "GENE_OR_GENE_PRODUCT", 42, 45], ["GRP78", "GENE_OR_GENE_PRODUCT", 46, 51], ["ER", "GENE_OR_GENE_PRODUCT", 94, 96], ["dominant negative mutant", "PROTEIN", 4, 28], ["BiP", "PROTEIN", 42, 45], ["GRP78", "PROTEIN", 46, 51], ["chaperone BiP/GRP78", "TREATMENT", 32, 51], ["dominant", "OBSERVATION_MODIFIER", 4, 12], ["negative mutant", "OBSERVATION", 13, 28], ["lumen", "ANATOMY_MODIFIER", 97, 102]]], ["This was the first indication that BiP/GRP78 was involved in targeting to degradation polypeptides produced by stalled ER-bound ribosomes.", [["ER", "ANATOMY", 119, 121], ["ribosomes", "ANATOMY", 128, 137], ["BiP", "GENE_OR_GENE_PRODUCT", 35, 38], ["GRP78", "GENE_OR_GENE_PRODUCT", 39, 44], ["ER", "GENE_OR_GENE_PRODUCT", 119, 121], ["ribosomes", "CELLULAR_COMPONENT", 128, 137], ["BiP", "PROTEIN", 35, 38], ["GRP78", "PROTEIN", 39, 44], ["ER", "PROTEIN", 119, 121], ["BiP/GRP78", "PROBLEM", 35, 44], ["degradation polypeptides", "PROBLEM", 74, 98]]], ["Indeed, we identified BiP/GRP78 as one of the main proteins interacting with the product of the stalled BioID-2A degradation of proteins, such BiP/GRP78 and YOD1, of the ER-associated quality control pathway and enzymes, such as Listerin, belonging to the ribosomal quality control system, indicates that translational stalling at the ER membrane activates a poorly described cellular mechanism at the interface of diverse protein quality control surveillance systems.DiscussionThe general idea that ribosome stalling may represent a mechanism to control protein expression is being increasingly appreciated.", [["ribosomal", "ANATOMY", 256, 265], ["ER membrane", "ANATOMY", 335, 346], ["cellular", "ANATOMY", 376, 384], ["ribosome", "ANATOMY", 500, 508], ["Listerin", "CHEMICAL", 229, 237], ["BiP", "GENE_OR_GENE_PRODUCT", 22, 25], ["GRP78", "GENE_OR_GENE_PRODUCT", 26, 31], ["BioID-2A", "GENE_OR_GENE_PRODUCT", 104, 112], ["BiP", "GENE_OR_GENE_PRODUCT", 143, 146], ["GRP78", "GENE_OR_GENE_PRODUCT", 147, 152], ["YOD1", "GENE_OR_GENE_PRODUCT", 157, 161], ["ER", "GENE_OR_GENE_PRODUCT", 170, 172], ["Listerin", "GENE_OR_GENE_PRODUCT", 229, 237], ["ribosomal", "CELLULAR_COMPONENT", 256, 265], ["ER", "GENE_OR_GENE_PRODUCT", 335, 337], ["membrane", "CELLULAR_COMPONENT", 338, 346], ["cellular", "CELL", 376, 384], ["ribosome", "CELLULAR_COMPONENT", 500, 508], ["BiP", "PROTEIN", 22, 25], ["GRP78", "PROTEIN", 26, 31], ["BioID", "PROTEIN", 104, 109], ["BiP", "PROTEIN", 143, 146], ["GRP78", "PROTEIN", 147, 152], ["YOD1", "PROTEIN", 157, 161], ["ER", "PROTEIN", 170, 172], ["enzymes", "PROTEIN", 212, 219], ["Listerin", "PROTEIN", 229, 237], ["ER", "PROTEIN", 335, 337], ["BiP/GRP78", "TREATMENT", 22, 31], ["enzymes", "TEST", 212, 219], ["Listerin", "TREATMENT", 229, 237], ["translational stalling at the ER membrane", "PROBLEM", 305, 346], ["ribosome stalling", "PROBLEM", 500, 517], ["translational stalling", "OBSERVATION", 305, 327]]], ["There are examples of small coding sequences, some of them having a STOP-codon, like the so-called upstream ORFs (uORF), that can regulate translation initiation of a downstream ORF [2], [20], [59].", [["small coding sequences", "DNA", 22, 44], ["STOP-codon", "DNA", 68, 78], ["upstream ORFs", "DNA", 99, 112], ["uORF", "DNA", 114, 118], ["downstream ORF", "DNA", 167, 181], ["small coding sequences", "PROBLEM", 22, 44], ["a STOP-codon", "PROBLEM", 66, 78], ["small", "OBSERVATION_MODIFIER", 22, 27]]], ["In contrast, in our case, the stalling strongly affects expression of the upstream encoded protein.", [["upstream encoded protein", "PROTEIN", 74, 98]]], ["Recently, an independent ORF was found immediately downstream (in the 3\u2032UTR) of the ORF for protein AMD1 and shown to regulate translation of the upstream ORF by causing ribosomal stalling [43].", [["ribosomal", "ANATOMY", 170, 179], ["AMD1", "GENE_OR_GENE_PRODUCT", 100, 104], ["ribosomal", "CELLULAR_COMPONENT", 170, 179], ["ORF", "DNA", 25, 28], ["3\u2032UTR", "DNA", 70, 75], ["ORF", "DNA", 84, 87], ["AMD1", "PROTEIN", 100, 104], ["upstream ORF", "DNA", 146, 158], ["an independent ORF", "PROBLEM", 10, 28], ["protein AMD1", "TEST", 92, 104], ["ribosomal stalling", "PROBLEM", 170, 188], ["ribosomal stalling", "OBSERVATION", 170, 188]]], ["We found that this sequence, however, produces stalling independently of the STOP-codon.DiscussionC-terminal sequences may represent efficient translational regulatory motifs with strong effects on the level of expression of the upstream protein by enacting stalling at the STOP-codon.", [["STOP", "GENE_OR_GENE_PRODUCT", 77, 81], ["STOP-codon", "DNA", 77, 87], ["DiscussionC-terminal sequences", "DNA", 88, 118], ["translational regulatory motifs", "DNA", 143, 174], ["upstream protein", "PROTEIN", 229, 245], ["STOP-codon", "DNA", 274, 284], ["efficient translational regulatory motifs", "PROBLEM", 133, 174], ["the upstream protein", "PROBLEM", 225, 245]]], ["Our first attempt to find sequences only partially related to the viral 2A (terminating in NPG-like stalling events could regulate protein expression in mammalian cells.Constructs ::: Materials and MethodsAll new plasmids used are cloned into pcDNA3 vector (Life Technologies).", [["mammalian cells", "ANATOMY", 153, 168], ["plasmids", "ANATOMY", 213, 221], ["NPG", "GENE_OR_GENE_PRODUCT", 91, 94], ["mammalian cells", "CELL", 153, 168], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 243, 249], ["viral 2A", "PROTEIN", 66, 74], ["mammalian cells", "CELL_TYPE", 153, 168], ["plasmids", "DNA", 213, 221], ["pcDNA3 vector", "DNA", 243, 256], ["the viral 2A", "PROBLEM", 62, 74], ["stalling events", "PROBLEM", 100, 115], ["protein expression in mammalian cells", "PROBLEM", 131, 168], ["Methods", "TREATMENT", 198, 205], ["All new plasmids", "TREATMENT", 205, 221], ["viral", "OBSERVATION", 66, 71], ["protein expression", "OBSERVATION", 131, 149], ["mammalian cells", "OBSERVATION", 153, 168]]], ["The 2A-P, 2A(M) with mutated codons, T2A, CD99L2, POTE, TBCA, SPIRE2 and C-TAIL coding sequences were inserted by digestion with enzymes KpnI and EcoRI (NEB) in frame at the C-terminus of previously described scFv anti-coronavirus 6A.C3 mAb [60], using oligoes described in Supplementary Table 3.", [["C", "CHEMICAL", 174, 175], ["T2A", "GENE_OR_GENE_PRODUCT", 37, 40], ["CD99L2", "GENE_OR_GENE_PRODUCT", 42, 48], ["POTE", "GENE_OR_GENE_PRODUCT", 50, 54], ["TBCA", "GENE_OR_GENE_PRODUCT", 56, 60], ["SPIRE2", "GENE_OR_GENE_PRODUCT", 62, 68], ["C-TAIL", "GENE_OR_GENE_PRODUCT", 73, 79], ["KpnI", "GENE_OR_GENE_PRODUCT", 137, 141], ["EcoRI", "GENE_OR_GENE_PRODUCT", 146, 151], ["NEB", "GENE_OR_GENE_PRODUCT", 153, 156], ["2A-P, 2A(M)", "DNA", 4, 15], ["mutated codons", "DNA", 21, 35], ["T2A, CD99L2, POTE, TBCA, SPIRE2 and C-TAIL coding sequences", "DNA", 37, 96], ["enzymes KpnI", "DNA", 129, 141], ["EcoRI", "DNA", 146, 151], ["NEB", "PROTEIN", 153, 156], ["C-terminus", "PROTEIN", 174, 184], ["scFv anti-coronavirus 6A.C3 mAb", "PROTEIN", 209, 240], ["mutated codons", "PROBLEM", 21, 35], ["T2A", "TEST", 37, 40], ["CD99L2", "TEST", 42, 48], ["POTE", "TEST", 50, 54], ["TBCA", "TEST", 56, 60], ["SPIRE2", "TEST", 62, 68], ["enzymes KpnI", "TREATMENT", 129, 141], ["EcoRI (NEB)", "TREATMENT", 146, 157]]], ["When indicated, SV5-tag (GKPIPNPLLGLD), roTag (SISSSIFKNEG) [61], HA-tag (YPYDVPDYA) and N-glycosylation site (NGT) were engineered at the indicated positions by site-directed mutagenesis (QuikChange Site Directed Mutagenesis Kit; Stratagene).", [["SV5-tag", "GENE_OR_GENE_PRODUCT", 16, 23], ["HA-tag", "GENE_OR_GENE_PRODUCT", 66, 72], ["YPYDVPDYA", "GENE_OR_GENE_PRODUCT", 74, 83], ["SV5-tag", "DNA", 16, 23], ["GKPIPNPLLGLD", "PROTEIN", 25, 37], ["roTag", "DNA", 40, 45], ["HA-tag", "DNA", 66, 72], ["YPYDVPDYA", "PROTEIN", 74, 83], ["N-glycosylation site", "DNA", 89, 109], ["NGT", "PROTEIN", 111, 114], ["SV5", "TEST", 16, 19], ["GKPIPNPLLGLD", "TEST", 25, 37], ["HA-tag (YPYDVPDYA)", "PROBLEM", 66, 84], ["N-glycosylation site (NGT", "TREATMENT", 89, 114], ["directed mutagenesis", "TREATMENT", 167, 187], ["Stratagene", "TREATMENT", 231, 241]]], ["Plasmids encoding secretory proteins bear an immunoglobulin secretion leader peptide [62] at the N-terminus as previously described [61].", [["N", "CHEMICAL", 97, 98], ["secretory proteins", "GENE_OR_GENE_PRODUCT", 18, 36], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 45, 59], ["secretory proteins", "PROTEIN", 18, 36], ["immunoglobulin", "PROTEIN", 45, 59], ["N-terminus", "PROTEIN", 97, 107], ["Plasmids", "TREATMENT", 0, 8]]], ["MHC-I\u03b1 having C-terminal 2A* and 2A-P* sequence was derived from a previously described MHC-I\u03b1 plasmid [39].", [["C", "CHEMICAL", 14, 15], ["MHC-I\u03b1", "GENE_OR_GENE_PRODUCT", 0, 6], ["C-terminal 2A", "GENE_OR_GENE_PRODUCT", 14, 27], ["MHC-I\u03b1", "GENE_OR_GENE_PRODUCT", 88, 94], ["MHC", "PROTEIN", 0, 3], ["I\u03b1", "DNA", 4, 6], ["C-terminal 2A* and 2A-P* sequence", "DNA", 14, 47], ["MHC-I\u03b1 plasmid", "DNA", 88, 102], ["MHC", "TEST", 0, 3]]], ["The coding sequence of BioID2 was previously described [42].", [["BioID2", "GENE_OR_GENE_PRODUCT", 23, 29], ["BioID2", "DNA", 23, 29]]], ["Plasmids expressing cyt-BirA and BiP mutant T37G were previously described [35].", [["cyt-", "GENE_OR_GENE_PRODUCT", 20, 24], ["BirA", "GENE_OR_GENE_PRODUCT", 24, 28], ["BiP", "GENE_OR_GENE_PRODUCT", 33, 36], ["cyt-BirA", "PROTEIN", 20, 28], ["BiP", "PROTEIN", 33, 36], ["T37G", "PROTEIN", 44, 48], ["Plasmids", "TREATMENT", 0, 8]]], ["CCHFV-L OTU plasmid was kindly provided by Adolfo Garc\u00eda-Sastre, the N-terminal FLAG-tagged human YOD1-C160S plasmid by Christian Schlieker, and the His6-tagged rat p97QQ plasmids by Linda Hendershot.In vitro protein expression ::: Materials and MethodsProtein expression in vitro was performed using the TnT kit (TNT\u00ae Quick Coupled Transcription/Translation System) following the manufacture's instruction.Cell culture and transfection ::: Materials and MethodsHEK293T cells were cultured in Dulbecco's modified Eagle's medium (Life Technologies), supplemented with 10% fetal calf serum (Life Technologies).", [["Cell", "ANATOMY", 407, 411], ["MethodsHEK293T cells", "ANATOMY", 455, 475], ["fetal calf serum", "ANATOMY", 571, 587], ["FLAG", "GENE_OR_GENE_PRODUCT", 80, 84], ["human", "ORGANISM", 92, 97], ["YOD1", "GENE_OR_GENE_PRODUCT", 98, 102], ["His6", "GENE_OR_GENE_PRODUCT", 149, 153], ["rat", "ORGANISM", 161, 164], ["p97QQ", "GENE_OR_GENE_PRODUCT", 165, 170], ["Cell", "CELL", 407, 411], ["MethodsHEK293T cells", "CELL", 455, 475], ["calf", "ORGANISM", 577, 581], ["serum", "ORGANISM_SUBSTANCE", 582, 587], ["CCHFV-L OTU plasmid", "DNA", 0, 19], ["N-terminal FLAG", "PROTEIN", 69, 84], ["human YOD1-C160S plasmid", "DNA", 92, 116], ["Christian Schlieker", "DNA", 120, 139], ["His6", "PROTEIN", 149, 153], ["rat p97QQ plasmids", "DNA", 161, 179], ["TnT", "PROTEIN", 305, 308], ["MethodsHEK293T cells", "CELL_LINE", 455, 475], ["human", "SPECIES", 92, 97], ["rat", "SPECIES", 161, 164], ["calf", "SPECIES", 577, 581], ["human", "SPECIES", 92, 97], ["CCHFV", "PROBLEM", 0, 5], ["L OTU plasmid", "TREATMENT", 6, 19], ["the N-terminal FLAG", "TEST", 65, 84], ["the TnT kit", "TREATMENT", 301, 312], ["the manufacture's instruction", "TREATMENT", 377, 406], ["Cell culture", "TEST", 407, 419], ["MethodsHEK293T cells", "TEST", 455, 475], ["Dulbecco", "TEST", 493, 501], ["10% fetal calf serum (Life Technologies", "TREATMENT", 567, 606], ["protein expression", "OBSERVATION", 209, 227]]], ["Transfection of 293T was performed in 6-well or 12-well plates (about 5 \u00d7 105 or 2.5 \u00d7 105 cells) with the calcium phosphate technique.", [["293T", "ANATOMY", 16, 20], ["cells", "ANATOMY", 91, 96], ["calcium phosphate", "CHEMICAL", 107, 124], ["calcium phosphate", "CHEMICAL", 107, 124], ["293T", "CELL", 16, 20], ["cells", "CELL", 91, 96], ["calcium", "SIMPLE_CHEMICAL", 107, 114], ["293T", "CELL_LINE", 16, 20], ["Transfection", "TEST", 0, 12], ["the calcium phosphate technique", "TEST", 103, 134]]], ["Eighteen hours after transfection, medium was changed, and cells were further incubated for at least 7\u20138 h, before medium and cell harvesting.", [["cells", "ANATOMY", 59, 64], ["cell", "ANATOMY", 126, 130], ["cells", "CELL", 59, 64], ["cell", "CELL", 126, 130], ["transfection", "TREATMENT", 21, 33], ["cell harvesting", "TREATMENT", 126, 141], ["cell harvesting", "OBSERVATION", 126, 141]]], ["Where indicated, the proteasome inhibitor MG132 (Sigma) or CQ (Sigma) was added at a concentration of 20 and 50 \u03bcM, respectively, for 4 h.", [["MG132", "CHEMICAL", 42, 47], ["CQ", "CHEMICAL", 59, 61], ["MG132", "CHEMICAL", 42, 47], ["CQ", "CHEMICAL", 59, 61], ["MG132", "SIMPLE_CHEMICAL", 42, 47], ["Sigma", "SIMPLE_CHEMICAL", 49, 54], ["CQ", "SIMPLE_CHEMICAL", 59, 61], ["Sigma", "SIMPLE_CHEMICAL", 63, 68], ["the proteasome inhibitor MG132", "TREATMENT", 17, 47]]], ["The translation inhibitor cycloheximide (Sigma) was used for the indicated time at the concentration of 100 \u03bcg/ml.", [["cycloheximide", "CHEMICAL", 26, 39], ["cycloheximide", "CHEMICAL", 26, 39], ["cycloheximide", "SIMPLE_CHEMICAL", 26, 39], ["Sigma", "SIMPLE_CHEMICAL", 41, 46], ["The translation inhibitor cycloheximide (Sigma)", "TREATMENT", 0, 47]]], ["For biotinylation analysis, 0.15 mM of biotin (Sigma) was added to the media for at least 4 h.Cell culture and transfection ::: Materials and MethodsFor silencing experiments, HEK293T cells were grown in 12-well plates.", [["Cell", "ANATOMY", 94, 98], ["HEK293T cells", "ANATOMY", 176, 189], ["biotin", "CHEMICAL", 39, 45], ["biotin", "CHEMICAL", 39, 45], ["biotin", "SIMPLE_CHEMICAL", 39, 45], ["Sigma", "SIMPLE_CHEMICAL", 47, 52], ["Cell", "CELL", 94, 98], ["HEK293T cells", "CELL", 176, 189], ["HEK293T cells", "CELL_LINE", 176, 189], ["biotinylation analysis", "TEST", 4, 26], ["biotin (Sigma)", "TREATMENT", 39, 53], ["Cell culture", "TEST", 94, 106], ["Materials", "TREATMENT", 128, 137], ["Methods", "TREATMENT", 142, 149], ["silencing experiments", "TREATMENT", 153, 174], ["HEK293T cells", "PROBLEM", 176, 189]]], ["Irrelevant (UCGUCUUCUACAACGUCAA) and Ltn-specific (GCAGUGGUGUGAAGAAUUA) siRNA (Sigma) were transfected with Lipofectamine RNAiMAX reagent (Life Technologies) according to the manufacturer's instruction.", [["Ltn-specific (GCAGUGGUGUGAAGAAUUA) siRNA", "DNA", 37, 77], ["Lipofectamine RNAiMAX reagent", "TREATMENT", 108, 137]]], ["Forty-eight hours after siRNA transfection, medium was discarded, and cells were transfected with DNA plasmids by the standard calcium phosphate procedure and lysed 24 h post-transfection.Cell extract preparation, gel retardation assay and Western blotting ::: Materials and MethodsTransfected HEK293T cells were washed with phosphate-buffered saline and lysed with SDS-lysis buffer [100 mM Tris\u2013HCl (pH 6.8), 6% SDS, 30 mM NEM (Fluka), 1% protease inhibitors cocktail (Sigma)] and sonicated.", [["cells", "ANATOMY", 70, 75], ["plasmids", "ANATOMY", 102, 110], ["Cell", "ANATOMY", 188, 192], ["HEK293T cells", "ANATOMY", 294, 307], ["calcium phosphate", "CHEMICAL", 127, 144], ["phosphate", "CHEMICAL", 325, 334], ["Tris\u2013HCl", "CHEMICAL", 391, 399], ["NEM", "CHEMICAL", 424, 427], ["Fluka", "CHEMICAL", 429, 434], ["calcium phosphate", "CHEMICAL", 127, 144], ["phosphate", "CHEMICAL", 325, 334], ["Tris\u2013HCl", "CHEMICAL", 391, 399], ["NEM", "CHEMICAL", 424, 427], ["Fluka", "CHEMICAL", 429, 434], ["cells", "CELL", 70, 75], ["DNA", "CELLULAR_COMPONENT", 98, 101], ["calcium", "SIMPLE_CHEMICAL", 127, 134], ["Cell", "CELL", 188, 192], ["HEK293T cells", "CELL", 294, 307], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 325, 350], ["Tris\u2013HCl", "SIMPLE_CHEMICAL", 391, 399], ["NEM", "SIMPLE_CHEMICAL", 424, 427], ["Fluka", "SIMPLE_CHEMICAL", 429, 434], ["DNA plasmids", "DNA", 98, 110], ["HEK293T cells", "CELL_LINE", 294, 307], ["siRNA transfection", "TREATMENT", 24, 42], ["DNA plasmids", "TREATMENT", 98, 110], ["the standard calcium phosphate procedure", "TREATMENT", 114, 154], ["Cell extract preparation", "TREATMENT", 188, 212], ["gel retardation assay", "TEST", 214, 235], ["MethodsTransfected HEK293T cells", "TREATMENT", 275, 307], ["phosphate-buffered saline", "TREATMENT", 325, 350], ["SDS", "TREATMENT", 366, 369], ["lysis buffer", "TREATMENT", 370, 382], ["Tris\u2013HCl (pH", "TREATMENT", 391, 403], ["mM NEM (Fluka)", "TREATMENT", 421, 435], ["1% protease inhibitors cocktail", "TREATMENT", 437, 468]]], ["For SDS-PAGE, samples were boiled 10 min in SDS-gel loading buffer [25 mM Tris\u2013HCl (pH 6.8), 1% SDS, 10% glycerol, 175 mM \u03b2-mercaptoethanol] before gel loading.", [["samples", "ANATOMY", 14, 21], ["Tris\u2013HCl", "CHEMICAL", 74, 82], ["glycerol", "CHEMICAL", 105, 113], ["\u03b2-mercaptoethanol", "CHEMICAL", 122, 139], ["Tris\u2013HCl", "CHEMICAL", 74, 82], ["glycerol", "CHEMICAL", 105, 113], ["\u03b2-mercaptoethanol", "CHEMICAL", 122, 139], ["Tris\u2013HCl", "SIMPLE_CHEMICAL", 74, 82], ["glycerol", "SIMPLE_CHEMICAL", 105, 113], ["\u03b2-mercaptoethanol", "SIMPLE_CHEMICAL", 122, 139], ["gel loading buffer", "TREATMENT", 48, 66], ["Tris\u2013HCl", "TEST", 74, 82], ["pH", "TEST", 84, 86], ["glycerol", "TREATMENT", 105, 113], ["mercaptoethanol", "TREATMENT", 124, 139], ["gel loading", "TREATMENT", 148, 159]]], ["For Western blot-retardation assays, samples were incubated after boiling without or with 1 \u03bcg StrAv (Sigma) for 20 min at room temperature before loading as previously described [39].Cell extract preparation, gel retardation assay and Western blotting ::: Materials and MethodsGels were blotted onto PVDF membranes (Millipore), reacted with mouse anti-SV5 (Life Technologies) or mouse anti-roTag mAbs [61] followed by incubation with a HRP-labeled anti-mouse whole IgG antibody (KPL) and developed by ECL reaction.", [["samples", "ANATOMY", 37, 44], ["Cell", "ANATOMY", 184, 188], ["PVDF membranes", "ANATOMY", 301, 315], ["PVDF", "CHEMICAL", 301, 305], ["Cell", "CELL", 184, 188], ["membranes", "CELLULAR_COMPONENT", 306, 315], ["mouse", "ORGANISM", 342, 347], ["anti-SV5", "SIMPLE_CHEMICAL", 348, 356], ["mouse", "ORGANISM", 380, 385], ["Tag", "GENE_OR_GENE_PRODUCT", 393, 396], ["HRP", "SIMPLE_CHEMICAL", 437, 440], ["KPL", "SIMPLE_CHEMICAL", 480, 483], ["mouse anti-SV5", "PROTEIN", 342, 356], ["mouse anti-roTag mAbs", "PROTEIN", 380, 401], ["HRP-labeled anti-mouse whole IgG antibody", "PROTEIN", 437, 478], ["KPL", "PROTEIN", 480, 483], ["mouse", "SPECIES", 342, 347], ["mouse", "SPECIES", 380, 385], ["mouse", "SPECIES", 342, 347], ["mouse", "SPECIES", 380, 385], ["Western blot-retardation assays", "PROBLEM", 4, 35], ["Cell extract preparation", "TREATMENT", 184, 208], ["gel retardation assay", "TEST", 210, 231], ["MethodsGels", "TREATMENT", 271, 282], ["mouse anti-SV5 (Life Technologies", "TREATMENT", 342, 375], ["mouse anti-roTag mAbs", "TREATMENT", 380, 401], ["a HRP", "TEST", 435, 440], ["anti-mouse whole IgG antibody", "TEST", 449, 478], ["ECL reaction", "PROBLEM", 502, 514]]], ["Where indicated, blots were developed using mAb anti-BiP (BD Bioscience), rabbit anti-EGFP serum, StrAv-HRP (Sigma) and anti-HA-HRP (Sigma) and when required by the appropriate HRP-conjugated anti-mouse or anti-rabbit secondary antibody (Jackson).", [["serum", "ANATOMY", 91, 96], ["BiP", "GENE_OR_GENE_PRODUCT", 53, 56], ["BD", "GENE_OR_GENE_PRODUCT", 58, 60], ["rabbit", "ORGANISM", 74, 80], ["anti-EGFP", "GENE_OR_GENE_PRODUCT", 81, 90], ["serum", "ORGANISM_SUBSTANCE", 91, 96], ["StrAv-HRP", "GENE_OR_GENE_PRODUCT", 98, 107], ["Sigma", "GENE_OR_GENE_PRODUCT", 109, 114], ["anti-HA-HRP", "GENE_OR_GENE_PRODUCT", 120, 131], ["Sigma", "SIMPLE_CHEMICAL", 133, 138], ["HRP", "SIMPLE_CHEMICAL", 177, 180], ["mAb", "PROTEIN", 44, 47], ["BiP", "PROTEIN", 53, 56], ["BD Bioscience", "PROTEIN", 58, 71], ["rabbit anti-EGFP serum", "PROTEIN", 74, 96], ["StrAv", "PROTEIN", 98, 103], ["HRP", "PROTEIN", 104, 107], ["Sigma", "PROTEIN", 109, 114], ["anti-HA", "PROTEIN", 120, 127], ["HRP", "PROTEIN", 128, 131], ["Sigma", "PROTEIN", 133, 138], ["HRP", "PROTEIN", 177, 180], ["conjugated anti-mouse", "PROTEIN", 181, 202], ["anti-rabbit secondary antibody", "PROTEIN", 206, 236], ["Jackson", "PROTEIN", 238, 245], ["rabbit", "SPECIES", 74, 80], ["anti-mouse", "SPECIES", 192, 202], ["anti-rabbit", "SPECIES", 206, 217], ["rabbit", "SPECIES", 74, 80], ["anti-rabbit", "SPECIES", 206, 217], ["blots", "TEST", 17, 22], ["mAb anti-BiP (BD Bioscience", "TREATMENT", 44, 71], ["rabbit anti-EGFP serum", "TEST", 74, 96], ["StrAv", "TEST", 98, 103], ["anti-HA", "TEST", 120, 127]]], ["Where indicated, blots were developed with mouse anti-\u03b2-tubulin (Calbiochem) or HRP-labeled anti-actin (clone AC-15; Sigma-Aldrich) antibodies, which were used as loading control.Cell extract preparation, gel retardation assay and Western blotting ::: Materials and MethodsQuantification of bands was performed with the image processing software ImageJ v1.43 (National Institutes of Health) or using UVItec Alliance detection system.Mass spectrometry analysis ::: Materials and MethodsHEK293T cells were transfected with scFv-2A-P* encoding plasmid and lysed 24 h post-transfection in TNN buffer [Tris\u2013HCl 100 mM (pH 8), NaCl 250 mM, NP-40 0.5%], and scFv reporter was immunoprecipitated using mAb anti-SV5.", [["Cell", "ANATOMY", 179, 183], ["MethodsHEK293T cells", "ANATOMY", 478, 498], ["plasmid", "ANATOMY", 541, 548], ["Tris\u2013HCl", "CHEMICAL", 597, 605], ["NaCl", "CHEMICAL", 621, 625], ["NaCl", "CHEMICAL", 621, 625], ["mouse", "ORGANISM", 43, 48], ["anti-\u03b2-tubulin", "SIMPLE_CHEMICAL", 49, 63], ["Calbiochem", "SIMPLE_CHEMICAL", 65, 75], ["HRP", "SIMPLE_CHEMICAL", 80, 83], ["anti-actin", "GENE_OR_GENE_PRODUCT", 92, 102], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 117, 130], ["Cell", "CELL", 179, 183], ["MethodsHEK293T cells", "CELL", 478, 498], ["TNN", "SIMPLE_CHEMICAL", 585, 588], ["scFv", "GENE_OR_GENE_PRODUCT", 651, 655], ["SV5", "GENE_OR_GENE_PRODUCT", 703, 706], ["mouse anti-\u03b2-tubulin", "PROTEIN", 43, 63], ["HRP-labeled anti-actin", "PROTEIN", 80, 102], ["clone AC-15; Sigma-Aldrich) antibodies", "PROTEIN", 104, 142], ["MethodsHEK293T cells", "CELL_LINE", 478, 498], ["scFv-2A-P* encoding plasmid", "DNA", 521, 548], ["scFv reporter", "DNA", 651, 664], ["mAb", "PROTEIN", 694, 697], ["SV5", "PROTEIN", 703, 706], ["mouse", "SPECIES", 43, 48], ["mouse", "SPECIES", 43, 48], ["blots", "PROBLEM", 17, 22], ["mouse anti-\u03b2-tubulin (Calbiochem", "TREATMENT", 43, 75], ["HRP", "TEST", 80, 83], ["anti-actin (clone AC", "TREATMENT", 92, 112], ["Sigma-Aldrich) antibodies", "TREATMENT", 117, 142], ["loading control", "TREATMENT", 163, 178], ["Cell extract preparation", "TREATMENT", 179, 203], ["gel retardation assay", "TEST", 205, 226], ["MethodsQuantification of bands", "TREATMENT", 266, 296], ["Mass spectrometry analysis", "TEST", 433, 459], ["MethodsHEK293T cells", "TREATMENT", 478, 498], ["scFv", "TEST", 521, 525], ["encoding plasmid", "TREATMENT", 532, 548], ["transfection in TNN buffer", "TREATMENT", 569, 595], ["Tris\u2013HCl", "TEST", 597, 605], ["pH", "TEST", 614, 616], ["NaCl", "TEST", 621, 625], ["NP", "TEST", 634, 636], ["scFv reporter", "TEST", 651, 664], ["mAb anti-SV5", "TREATMENT", 694, 706]]], ["For BioID encoding plasmids, transfection was performed in the presence of biotin and lysed 24 h post-transfection in TNN buffer.", [["plasmids", "ANATOMY", 19, 27], ["biotin", "CHEMICAL", 75, 81], ["biotin", "CHEMICAL", 75, 81], ["BioID", "GENE_OR_GENE_PRODUCT", 4, 9], ["biotin", "SIMPLE_CHEMICAL", 75, 81], ["TNN", "SIMPLE_CHEMICAL", 118, 121], ["BioID encoding plasmids", "DNA", 4, 27], ["BioID encoding plasmids", "TREATMENT", 4, 27], ["transfection", "TREATMENT", 29, 41], ["biotin", "TREATMENT", 75, 81], ["-transfection in TNN buffer", "TREATMENT", 101, 128]]], ["Pull-down of biotinylated proteins was performed using StrAv Mag Sepharose\u2122 (GE Healthcare).", [["biotinylated proteins", "PROTEIN", 13, 34], ["biotinylated proteins", "TREATMENT", 13, 34], ["StrAv Mag Sepharose\u2122 (GE Healthcare", "TREATMENT", 55, 90]]], ["For mass spectrometry analysis, samples were digested with 200 ng trypsin diluted in 20 mM triethyl ammonium bicarbonate (pH 8.5) for 12 h at room temperature.", [["samples", "ANATOMY", 32, 39], ["triethyl ammonium bicarbonate", "CHEMICAL", 91, 120], ["triethyl ammonium bicarbonate", "CHEMICAL", 91, 120], ["trypsin", "GENE_OR_GENE_PRODUCT", 66, 73], ["triethyl ammonium bicarbonate", "SIMPLE_CHEMICAL", 91, 120], ["trypsin", "PROTEIN", 66, 73], ["mass spectrometry analysis", "TEST", 4, 30], ["samples", "TEST", 32, 39], ["200 ng trypsin", "TREATMENT", 59, 73], ["20 mM triethyl ammonium bicarbonate", "TREATMENT", 85, 120], ["pH", "TEST", 122, 124]]], ["The supernatants were harvested, and the beads were washed once with digestion buffer.", [["supernatants", "ANATOMY", 4, 16], ["beads", "ANATOMY", 41, 46], ["The supernatants", "TREATMENT", 0, 16], ["the beads", "TREATMENT", 37, 46], ["digestion buffer", "TREATMENT", 69, 85], ["harvested", "OBSERVATION", 22, 31]]], ["The washes and the supernatants were pooled and purified using STAGE tips.", [["supernatants", "ANATOMY", 19, 31], ["The washes", "TREATMENT", 0, 10], ["the supernatants", "TREATMENT", 15, 31], ["STAGE tips", "TREATMENT", 63, 73], ["washes", "OBSERVATION", 4, 10], ["tips", "OBSERVATION_MODIFIER", 69, 73]]], ["The purified digested samples were subjected to LC\u2013MS/MS analysis using a picofrit nano-bore columns.", [["samples", "ANATOMY", 22, 29], ["The purified digested samples", "PROBLEM", 0, 29], ["LC\u2013MS", "TEST", 48, 53], ["MS analysis", "TEST", 54, 65], ["a picofrit nano-bore columns", "TREATMENT", 72, 100]]], ["The sample was loaded in 0.1% formic acid, and the column was developed with a discontinuous gradient and sprayed directly into an Amazon ETD ion trap (Bruker Daltonics).", [["sample", "ANATOMY", 4, 10], ["formic acid", "CHEMICAL", 30, 41], ["formic acid", "CHEMICAL", 30, 41], ["formic acid", "SIMPLE_CHEMICAL", 30, 41], ["The sample", "TEST", 0, 10], ["a discontinuous gradient", "TREATMENT", 77, 101], ["an Amazon ETD ion trap (Bruker Daltonics", "TREATMENT", 128, 168], ["column", "ANATOMY", 51, 57]]], ["A cycle of one MS scan followed by five MS/MS scans was performed throughout the run.", [["one MS scan", "TEST", 11, 22], ["five MS/MS scans", "TEST", 35, 51]]], ["Data were extracted from the runs using Data Analysis (Bruker Daltonics) and analyzed using the X!tandem search engine.[35S]-Methionine labeling ::: Materials and MethodsHEK293T cells were starved for 30 min in methionine/cysteine-free medium supplemented with 10% dialyzed fetal calf serum and then labeled for 15 min with 200 \u03bcCi/ml of [35S]-methionine/cysteine (PerkinElmer).", [["MethodsHEK293T cells", "ANATOMY", 163, 183], ["fetal calf serum", "ANATOMY", 274, 290], ["[35S]-Methionine", "CHEMICAL", 119, 135], ["methionine", "CHEMICAL", 211, 221], ["cysteine", "CHEMICAL", 222, 230], ["[35S]-methionine", "CHEMICAL", 338, 354], ["cysteine", "CHEMICAL", 355, 363], ["[35S]-Methionine", "CHEMICAL", 119, 135], ["methionine", "CHEMICAL", 211, 221], ["cysteine", "CHEMICAL", 222, 230], ["[35S]-methionine", "CHEMICAL", 338, 354], ["cysteine", "CHEMICAL", 355, 363], ["[35S]-Methionine", "SIMPLE_CHEMICAL", 119, 135], ["MethodsHEK293T cells", "CELL", 163, 183], ["methionine/cysteine", "SIMPLE_CHEMICAL", 211, 230], ["fetal calf", "ORGANISM_SUBSTANCE", 274, 284], ["serum", "ORGANISM_SUBSTANCE", 285, 290], ["[35S]-methionine/cysteine", "SIMPLE_CHEMICAL", 338, 363], ["MethodsHEK293T cells", "CELL_LINE", 163, 183], ["calf", "SPECIES", 280, 284], ["Data Analysis", "TEST", 40, 53], ["Bruker Daltonics)", "TREATMENT", 55, 72], ["Materials and MethodsHEK293T cells", "TREATMENT", 149, 183], ["methionine/cysteine", "TREATMENT", 211, 230], ["10% dialyzed fetal calf serum", "TREATMENT", 261, 290], ["methionine/cysteine (PerkinElmer)", "TREATMENT", 344, 377], ["calf", "ANATOMY", 280, 284]]], ["Cells were lysed in 100 \u03bcl of SDS-lysis buffer, diluted with 400 \u03bcl of TNN and digested with DNaseI (Promega) for 1 h at 37 \u00b0C. SV5-tagged proteins were immunoprecipitated with anti-SV5 mAb and Protein A agarose (Repligen) and eluted by boiling in SDS-lysis buffer, and samples were resolved on a reducing SDS-PAGE.", [["Cells", "ANATOMY", 0, 5], ["samples", "ANATOMY", 270, 277], ["TNN", "CHEMICAL", 71, 74], ["SDS", "CHEMICAL", 30, 33], ["TNN", "CHEMICAL", 71, 74], ["SDS", "CHEMICAL", 306, 309], ["Cells", "CELL", 0, 5], ["TNN", "SIMPLE_CHEMICAL", 71, 74], ["DNaseI", "SIMPLE_CHEMICAL", 93, 99], ["SV5", "GENE_OR_GENE_PRODUCT", 128, 131], ["Protein A agarose", "SIMPLE_CHEMICAL", 194, 211], ["Repligen", "SIMPLE_CHEMICAL", 213, 221], ["DNaseI", "PROTEIN", 93, 99], ["SV5", "PROTEIN", 128, 131], ["tagged proteins", "PROTEIN", 132, 147], ["SV5 mAb", "PROTEIN", 182, 189], ["Cells", "TEST", 0, 5], ["SDS-lysis buffer", "TREATMENT", 30, 46], ["TNN", "TREATMENT", 71, 74], ["DNaseI (Promega)", "TREATMENT", 93, 109], ["SV5", "TEST", 128, 131], ["tagged proteins", "TEST", 132, 147], ["anti-SV5 mAb", "TREATMENT", 177, 189], ["Protein A agarose (Repligen", "TREATMENT", 194, 221], ["lysis buffer", "TREATMENT", 252, 264]]], ["Gels were fixed in 10% acetic acid and 10% methanol, incubated for 20 min in Amplify fluorographic enhancer (GE Healthcare), dried and exposed for autoradiography on Kodak BioMax XAR films.RNA isolation, RT-PCR and qRT-PCR ::: Materials and MethodsTotal RNA from HEK293T cells was isolated with RNeasy mini Kit (Qiagen) following the manufacturer's instructions.", [["HEK293T cells", "ANATOMY", 263, 276], ["acetic acid", "CHEMICAL", 23, 34], ["methanol", "CHEMICAL", 43, 51], ["acetic acid", "CHEMICAL", 23, 34], ["methanol", "CHEMICAL", 43, 51], ["Gels", "SIMPLE_CHEMICAL", 0, 4], ["acetic acid", "SIMPLE_CHEMICAL", 23, 34], ["methanol", "SIMPLE_CHEMICAL", 43, 51], ["HEK293T cells", "CELL", 263, 276], ["MethodsTotal RNA", "RNA", 241, 257], ["HEK293T cells", "CELL_LINE", 263, 276], ["10% acetic acid", "TREATMENT", 19, 34], ["10% methanol", "TREATMENT", 39, 51], ["autoradiography", "TEST", 147, 162], ["RNA isolation", "TEST", 189, 202], ["RT-PCR", "TEST", 204, 210], ["MethodsTotal RNA from HEK293T cells", "TREATMENT", 241, 276], ["RNeasy mini Kit", "TREATMENT", 295, 310], ["HEK293T cells", "OBSERVATION", 263, 276]]], ["DNA was removed by treatment with RNAse-free DNAse I (Fermentas Inc., Waltham, MA, USA).", [["DNA", "CELLULAR_COMPONENT", 0, 3], ["RNAse", "SIMPLE_CHEMICAL", 34, 39], ["RNAse", "PROTEIN", 34, 39], ["DNAse I", "PROTEIN", 45, 52], ["DNA", "PROBLEM", 0, 3], ["RNAse", "TREATMENT", 34, 39]]], ["Total RNA was then retro-transcribed to cDNA by Moloney murine leukaemia RT (M-MLV-RT, Invitrogen) in the presence of random hexamers (IDT). qRT-PCR was based on SYBR Green Master Mix technology (Applied Biosystems), and the levels of target gene expression were normalized to those of GAPDH and \u03b1-globin.", [["Moloney murine leukaemia RT", "ORGANISM", 48, 75], ["M-MLV", "ORGANISM", 77, 82], ["Invitrogen", "ORGANISM", 87, 97], ["GAPDH", "GENE_OR_GENE_PRODUCT", 286, 291], ["\u03b1-globin", "GENE_OR_GENE_PRODUCT", 296, 304], ["cDNA", "DNA", 40, 44], ["GAPDH", "PROTEIN", 286, 291], ["\u03b1-globin", "PROTEIN", 296, 304], ["murine", "SPECIES", 56, 62], ["Total RNA", "TREATMENT", 0, 9], ["PCR", "TEST", 145, 148], ["the levels", "TEST", 221, 231], ["GAPDH", "TEST", 286, 291]]], ["A list of primers used for qRT-PCR and RT-PCR are given in Supplementary Table 3.", [["primers", "TREATMENT", 10, 17], ["qRT", "TEST", 27, 30], ["PCR", "TEST", 31, 34], ["RT-PCR", "TREATMENT", 39, 45]]]], "PMC3654617": [["Historical BackgroundThe term \u201cisolation\u201d in infectious diseases refers to the possibility to separate infected (or suspected to be infected) people from other subjects not affected by the disease, a concept practiced in many ancient societies.1 Around seven hundred years ago, the strategy of \u201cquarantine\u201d was introduced, originating from the Italian quaranta giorni, meaning \u201cforty days\u201d: the 40-d isolation of ships prior to entering the harbor of Dubrovnik, as a measure to prevent the spread of plague.", [["infectious diseases", "DISEASE", 45, 64], ["plague", "DISEASE", 500, 506], ["people", "ORGANISM", 142, 148], ["people", "SPECIES", 142, 148], ["Italian quaranta giorni", "SPECIES", 344, 367], ["infectious diseases", "PROBLEM", 45, 64], ["the disease", "PROBLEM", 185, 196], ["Dubrovnik", "TREATMENT", 451, 460], ["plague", "PROBLEM", 500, 506], ["infectious", "OBSERVATION", 45, 55], ["disease", "OBSERVATION", 189, 196], ["plague", "OBSERVATION", 500, 506]]], ["Other infectious diseases (e.g., leprosy and cholera) lent themselves to the practice of quarantine.2 Although the concept was crystal-clear, implementation was never easy, even before the emergence of antibiotic resistance.", [["infectious diseases", "DISEASE", 6, 25], ["leprosy", "DISEASE", 33, 40], ["cholera", "DISEASE", 45, 52], ["Other infectious diseases", "PROBLEM", 0, 25], ["antibiotic resistance", "TREATMENT", 202, 223], ["infectious", "OBSERVATION", 6, 16], ["clear", "OBSERVATION", 135, 140]]], ["After an international sanitary convention was concluded in Paris in 1912, the strict quarantine doctrine for ships was abandoned, an approximation to the principles advocated by Great Britain due to economic considerations.2Historical BackgroundAlthough leprosy hospices were part of many cities in medieval Europe, isolation in healthcare facilities was practiced only inconsistently during the past centuries.", [["leprosy", "DISEASE", 255, 262], ["leprosy", "OBSERVATION", 255, 262]]], ["This changed completely in the 20th century with the recognition of bacterial and viral pathogens as vehicles of spread of infectious diseases.", [["infectious diseases", "DISEASE", 123, 142], ["bacterial and viral pathogens", "PROBLEM", 68, 97], ["infectious diseases", "PROBLEM", 123, 142], ["bacterial", "OBSERVATION_MODIFIER", 68, 77], ["viral pathogens", "OBSERVATION", 82, 97], ["infectious", "OBSERVATION", 123, 133]]], ["The emergence of Staphylococcus aureus as a hospital pathogen in the 1950s and 1960s prompted the development of infection control programs in US hospitals.", [["Staphylococcus aureus", "DISEASE", 17, 38], ["infection", "DISEASE", 113, 122], ["Staphylococcus aureus", "ORGANISM", 17, 38], ["Staphylococcus aureus", "SPECIES", 17, 38], ["Staphylococcus aureus", "SPECIES", 17, 38], ["Staphylococcus aureus", "PROBLEM", 17, 38], ["a hospital pathogen", "TEST", 42, 61], ["infection control programs", "TREATMENT", 113, 139], ["Staphylococcus aureus", "OBSERVATION", 17, 38], ["infection", "OBSERVATION", 113, 122]]], ["In 1968, the first edition of the American Hospital Association\u2019s manual presented a simple scheme of barrier precautions for patients with communicable diseases, listing the need for gloves, gowns, masks, and visitor screening.DefinitionsNowadays, the concept of \u201cpatient isolation\u201d has been much refined.", [["communicable diseases", "DISEASE", 140, 161], ["patients", "ORGANISM", 126, 134], ["patient", "ORGANISM", 265, 272], ["patients", "SPECIES", 126, 134], ["patient", "SPECIES", 265, 272], ["barrier precautions", "TREATMENT", 102, 121], ["communicable diseases", "PROBLEM", 140, 161], ["visitor screening", "TEST", 210, 227], ["\u201cpatient isolation", "TREATMENT", 264, 282]]], ["The Centers for Diseases Control and Prevention (CDC) and the Hospital Infection Control Practices Advisory Committee (HICPAC) updated in 2007 a previous guideline and developed a two-level system for isolation precautions:3 standard precautions (SP), which apply to all patients, and transmission-based precautions (contact, droplet and airborne), put in place for patients with suspected or proven colonization or infection with certain microorganisms at risk of spreading.", [["infection", "DISEASE", 416, 425], ["patients", "ORGANISM", 271, 279], ["patients", "ORGANISM", 366, 374], ["patients", "SPECIES", 271, 279], ["patients", "SPECIES", 366, 374], ["Diseases Control", "TREATMENT", 16, 32], ["isolation precautions", "TREATMENT", 201, 222], ["infection", "PROBLEM", 416, 425], ["certain microorganisms", "PROBLEM", 431, 453], ["colonization", "OBSERVATION", 400, 412], ["infection", "OBSERVATION", 416, 425], ["spreading", "OBSERVATION_MODIFIER", 465, 474]]], ["Neither SP nor droplet or airborne precautions among those transmission-based precautions will be reviewed in detail, but the definitions of SP and contact precautions (CP) are herein summarized.DefinitionsSP combine the major features of universal precautions [designed in 1987 to initially prevent HIV transmission and one year after, hepatitis B virus and other blood-borne pathogens transmission, to the healthcare workers (HCWs)] and body substance isolation (designed in 1987 to prevent pathogen transmission from moist body surfaces to the HCWs).4 SP apply to all patients, regardless of suspected or confirmed infection status, in any setting in which health care is delivered: they include the performance of hand hygiene according to pre-specified guidelines, use of personal protective equipment, respiratory hygiene/cough etiquette, safe injection practices, use of masks for catheter insertion and lumbar puncture procedures, safe handling of contaminated equipment, textiles and laundry and routine cleaning and disinfection of environmental surfaces.3 Avoiding the exposure to potentially infectious sources such as blood, wounds, mucous membranes and excretions is the primary goal of SP.DefinitionsTransmission-based precautions, and CP among those, apply only to some patients, are more restrictive and often require physical patient isolation.3 The application of such precautions requires that gowns and gloves should be worn when entering the patient\u2019s room and removed before leaving it.", [["blood", "ANATOMY", 365, 370], ["body", "ANATOMY", 439, 443], ["body", "ANATOMY", 526, 530], ["hand", "ANATOMY", 718, 722], ["respiratory", "ANATOMY", 808, 819], ["catheter", "ANATOMY", 888, 896], ["lumbar", "ANATOMY", 911, 917], ["blood", "ANATOMY", 1131, 1136], ["wounds", "ANATOMY", 1138, 1144], ["mucous membranes", "ANATOMY", 1146, 1162], ["HIV transmission", "DISEASE", 300, 316], ["hepatitis B", "DISEASE", 337, 348], ["infection", "DISEASE", 618, 627], ["hepatitis B virus", "ORGANISM", 337, 354], ["blood", "ORGANISM_SUBSTANCE", 365, 370], ["body", "ORGANISM_SUBDIVISION", 439, 443], ["body", "ORGANISM_SUBDIVISION", 526, 530], ["patients", "ORGANISM", 571, 579], ["hand", "ORGANISM_SUBDIVISION", 718, 722], ["blood", "ORGANISM_SUBSTANCE", 1131, 1136], ["wounds", "PATHOLOGICAL_FORMATION", 1138, 1144], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 1146, 1162], ["patients", "ORGANISM", 1286, 1294], ["patient", "ORGANISM", 1344, 1351], ["patient", "ORGANISM", 1464, 1471], ["SP", "PROTEIN", 555, 557], ["SP", "PROTEIN", 1201, 1203], ["HIV", "SPECIES", 300, 303], ["hepatitis B virus", "SPECIES", 337, 354], ["patients", "SPECIES", 571, 579], ["patients", "SPECIES", 1286, 1294], ["patient", "SPECIES", 1344, 1351], ["patient", "SPECIES", 1464, 1471], ["HIV", "SPECIES", 300, 303], ["hepatitis B virus", "SPECIES", 337, 354], ["airborne precautions", "TREATMENT", 26, 46], ["based precautions", "TREATMENT", 72, 89], ["SP", "PROBLEM", 141, 143], ["universal precautions", "TREATMENT", 239, 260], ["hepatitis B virus", "PROBLEM", 337, 354], ["body substance isolation", "TREATMENT", 439, 463], ["infection status", "PROBLEM", 618, 634], ["hand hygiene", "TREATMENT", 718, 730], ["personal protective equipment", "TREATMENT", 777, 806], ["respiratory hygiene", "TREATMENT", 808, 827], ["cough etiquette", "TREATMENT", 828, 843], ["safe injection practices", "TREATMENT", 845, 869], ["masks", "TREATMENT", 878, 883], ["catheter insertion", "TREATMENT", 888, 906], ["lumbar puncture procedures", "TREATMENT", 911, 937], ["contaminated equipment", "TREATMENT", 956, 978], ["textiles", "TREATMENT", 980, 988], ["laundry", "TREATMENT", 993, 1000], ["routine cleaning", "TREATMENT", 1005, 1021], ["disinfection of environmental surfaces", "TREATMENT", 1026, 1064], ["potentially infectious sources", "PROBLEM", 1092, 1122], ["blood", "PROBLEM", 1131, 1136], ["wounds", "PROBLEM", 1138, 1144], ["mucous membranes", "PROBLEM", 1146, 1162], ["SP", "PROBLEM", 1201, 1203], ["based precautions", "TREATMENT", 1228, 1245], ["CP", "PROBLEM", 1251, 1253], ["physical patient isolation", "TREATMENT", 1335, 1361], ["such precautions", "TREATMENT", 1383, 1399], ["gowns", "TREATMENT", 1414, 1419], ["gloves", "TREATMENT", 1424, 1430], ["infection", "OBSERVATION", 618, 627], ["lumbar", "ANATOMY", 911, 917], ["infectious", "OBSERVATION", 1104, 1114], ["wounds", "ANATOMY", 1138, 1144], ["mucous membranes", "ANATOMY", 1146, 1162]]], ["Dedicated equipment such as stethoscopes or blood pressure cuffs should remain in the isolation room and not be used for other patients.", [["blood", "ANATOMY", 44, 49], ["blood", "ORGANISM_SUBSTANCE", 44, 49], ["patients", "ORGANISM", 127, 135], ["patients", "SPECIES", 127, 135], ["Dedicated equipment", "TREATMENT", 0, 19], ["stethoscopes", "TREATMENT", 28, 40], ["blood pressure cuffs", "TREATMENT", 44, 64]]], ["If supported by the hospital and laboratory information systems, electronic alerts that notify admitting personnel of patients who were colonized/infected with a resistant pathogen on a previous admission can help expedite isolation of patients.5 CP may include single-room isolation, an entire isolation ward, or cohorting of a group of patients (with or without designated staff).", [["patients", "ORGANISM", 118, 126], ["patients", "ORGANISM", 236, 244], ["patients", "ORGANISM", 338, 346], ["patients", "SPECIES", 118, 126], ["patients", "SPECIES", 236, 244], ["patients", "SPECIES", 338, 346], ["a resistant pathogen", "PROBLEM", 160, 180], ["single-room isolation", "TREATMENT", 262, 283]]], ["CP are aimed at preventing transmission of epidemiologically important pathogens from a colonized or infected patient through direct (the patient) or indirect (surfaces or objects in the patient\u2019s environment) contact.", [["patient", "ORGANISM", 110, 117], ["patient", "ORGANISM", 138, 145], ["patient", "ORGANISM", 187, 194], ["patient", "SPECIES", 110, 117], ["patient", "SPECIES", 138, 145], ["patient", "SPECIES", 187, 194], ["CP", "PROBLEM", 0, 2]]], ["Contact isolation is mostly indicated for patients colonized or infected with multidrug-resistant microorganisms (MDRO) that have a high risk of exogenous cross-transmission, such as methicillin-resistant S. aureus (MRSA) or vancomycin-resistant enterococci (VRE).", [["methicillin", "CHEMICAL", 183, 194], ["S. aureus", "DISEASE", 205, 214], ["MRSA", "CHEMICAL", 216, 220], ["vancomycin", "CHEMICAL", 225, 235], ["VRE", "DISEASE", 259, 262], ["methicillin", "CHEMICAL", 183, 194], ["vancomycin", "CHEMICAL", 225, 235], ["patients", "ORGANISM", 42, 50], ["methicillin-resistant S. aureus", "ORGANISM", 183, 214], ["MRSA", "CANCER", 216, 220], ["vancomycin-resistant enterococci", "SIMPLE_CHEMICAL", 225, 257], ["patients", "SPECIES", 42, 50], ["S. aureus", "SPECIES", 205, 214], ["MRSA", "SPECIES", 216, 220], ["S. aureus", "SPECIES", 205, 214], ["MRSA", "SPECIES", 216, 220], ["Contact isolation", "TREATMENT", 0, 17], ["multidrug-resistant microorganisms", "PROBLEM", 78, 112], ["exogenous cross-transmission", "PROBLEM", 145, 173], ["methicillin-resistant S. aureus", "PROBLEM", 183, 214], ["MRSA", "PROBLEM", 216, 220], ["vancomycin", "PROBLEM", 225, 235], ["resistant enterococci", "PROBLEM", 236, 257], ["VRE", "PROBLEM", 259, 262], ["aureus", "OBSERVATION", 208, 214]]], ["These guidelines stipulate that patients colonized or infected with clinically important MDRO should be isolated during hospitalization, to prevent nosocomial MDRO transmission from carriers to other patients, hospital visitors and HCWs.3 Together with hand hygiene, appropriate CP measures are sought to be of the utmost importance to decrease the risk of MDRO transmission in various health care settings.DefinitionsSeveral interventions and strategies that have been documented in the literature as being successful in the prevention and control of MDRO transmission have been recently reviewed.6 Whereas it is unclear which bundles of interventions are effective, there is a clear suggestion that multiple simultaneous interventions can be effective in reducing MDRO infections.", [["hand", "ANATOMY", 253, 257], ["MDRO", "DISEASE", 159, 163], ["MDRO", "DISEASE", 357, 361], ["MDRO", "DISEASE", 552, 556], ["infections", "DISEASE", 771, 781], ["patients", "ORGANISM", 32, 40], ["MDRO", "CANCER", 89, 93], ["patients", "ORGANISM", 200, 208], ["hand", "ORGANISM_SUBDIVISION", 253, 257], ["MDRO", "SIMPLE_CHEMICAL", 357, 361], ["MDRO", "GENE_OR_GENE_PRODUCT", 552, 556], ["MDRO", "SIMPLE_CHEMICAL", 766, 770], ["patients", "SPECIES", 32, 40], ["patients", "SPECIES", 200, 208], ["appropriate CP measures", "TREATMENT", 267, 290], ["Several interventions", "TREATMENT", 418, 439], ["strategies", "TREATMENT", 444, 454], ["MDRO transmission", "TREATMENT", 552, 569], ["multiple simultaneous interventions", "TREATMENT", 701, 736], ["reducing MDRO infections", "PROBLEM", 757, 781], ["multiple", "OBSERVATION_MODIFIER", 701, 709]]], ["Among these, continued educational programs including feedback to HCWs are important tools to improve compliance with hand hygiene,7 SP and CP.8,9Methodological LimitationsAlthough isolation measures are based on the current understanding of the mechanisms of transmission of organisms, few data are available to demonstrate their efficacy.", [["hand", "ANATOMY", 118, 122], ["hand", "ORGANISM_SUBDIVISION", 118, 122], ["SP", "PROBLEM", 133, 135], ["CP", "PROBLEM", 140, 142], ["isolation measures", "TREATMENT", 181, 199], ["organisms", "PROBLEM", 276, 285]]], ["First, mathematical models of transmission have allowed predictions about the effectiveness of various interventions that would be difficult or impractical to study in large clinical trials.10-12 Because healthcare-associated infections are relatively uncommon events, any study designed to demonstrate efficacy requires samples sizes that are often prohibitively large.", [["infections", "DISEASE", 226, 236], ["various interventions", "TREATMENT", 95, 116], ["associated infections", "PROBLEM", 215, 236], ["any study", "TEST", 269, 278], ["samples sizes", "PROBLEM", 321, 334], ["infections", "OBSERVATION", 226, 236], ["sizes", "OBSERVATION_MODIFIER", 329, 334]]], ["Thus, studies evaluating the efficacy of isolation measures often lack the power to allow one to conclude confidently that there has been a lack of effect.", [["studies", "TEST", 6, 13], ["isolation measures", "TREATMENT", 41, 59]]], ["Second, many clinical studies were conducted during epidemics while the majority of hospitals confronting these pathogens now face endemic resistance; the epidemiology of MDRO and the effectiveness of control measures are different in these two situations.", [["MDRO", "DISEASE", 171, 175], ["MDRO", "CANCER", 171, 175], ["many clinical studies", "TEST", 8, 29], ["these pathogens", "PROBLEM", 106, 121], ["face endemic resistance", "PROBLEM", 126, 149], ["MDRO", "TREATMENT", 171, 175], ["control measures", "TREATMENT", 201, 217]]], ["Third, most studies implemented multiple interventions either simultaneously or sequentially, making it impossible to determine which were linked to the outcome.", [["multiple interventions", "TREATMENT", 32, 54]]], ["Which of the following components is critical for successful control may therefore not be obvious:Methodological Limitations\u2022 identifying an at-risk patient;Methodological Limitations\u2022 obtaining a specimen for culture or PCR;Methodological Limitations\u2022 testing the specimen for multi-resistance;Methodological Limitations\u2022 providing the nurse or physician with the result;Methodological Limitations\u2022 placing the patient in a private room or cohorting the patient with other carriers;Methodological Limitations\u2022 posting signs indicating that the patient is in isolation;Methodological Limitations\u2022 stocking the patient\u2019s room with isolation supplies;Methodological Limitations\u2022 requiring visitors and HCWs who care for the patient to wear gloves and gowns;Methodological Limitations\u2022 enforcing strict hand hygiene;Methodological Limitations\u2022 providing for adequate environmental hygiene, including waste removalMethodological LimitationsFourth, most of the information available comes from quasi-experimental studies that may have failed to take into account stochastic or secular changes, that did not adequately control for bias or confounding, or that may have had very short periods of follow-up.13 Fifth, in studies of infection control interventions that require the active participation of HCWs in a clinical setting, such as studies of the effect of contact isolation on acquisition of colonization by a MDRO, compliance monitoring was rarely performed.", [["hand", "ANATOMY", 800, 804], ["multi-resistance", "DISEASE", 278, 294], ["infection", "DISEASE", 1223, 1232], ["patient", "ORGANISM", 149, 156], ["patient", "ORGANISM", 412, 419], ["patient", "ORGANISM", 455, 462], ["patient", "ORGANISM", 545, 552], ["patient", "ORGANISM", 610, 617], ["patient", "ORGANISM", 722, 729], ["hand", "ORGANISM_SUBDIVISION", 800, 804], ["patient", "SPECIES", 149, 156], ["patient", "SPECIES", 412, 419], ["patient", "SPECIES", 455, 462], ["patient", "SPECIES", 545, 552], ["patient", "SPECIES", 610, 617], ["patient", "SPECIES", 722, 729], ["a specimen", "TEST", 195, 205], ["culture", "TEST", 210, 217], ["PCR", "TEST", 221, 224], ["posting signs", "TEST", 511, 524], ["isolation supplies", "TREATMENT", 630, 648], ["gloves", "TREATMENT", 738, 744], ["gowns", "TREATMENT", 749, 754], ["waste removal", "TREATMENT", 897, 910], ["quasi-experimental studies", "TEST", 989, 1015], ["stochastic or secular changes", "PROBLEM", 1058, 1087], ["infection control interventions", "TREATMENT", 1223, 1254], ["contact isolation", "TREATMENT", 1357, 1374], ["compliance monitoring", "TEST", 1417, 1438], ["infection", "OBSERVATION", 1223, 1232]]], ["Studies that did monitor compliance often found it to be poor, raising questions about the validity of the causal inferences made by the authors.", [["Studies", "TEST", 0, 7]]], ["Finally, the reason for the success of isolation measures is not known definitively.", [["isolation measures", "TREATMENT", 39, 57], ["isolation", "OBSERVATION", 39, 48], ["not known definitively", "UNCERTAINTY", 61, 83]]], ["The outcome could be related to improved hand hygiene and decreased transmission, a positive intended effect, or to fewer HCW contacts with colonized or infected patients, an unintended effect with potentially negative consequences.14-16Methodological LimitationsAnother limitation on the effectiveness of CP to stop cross-transmission of MDRO is due to epidemiological differences among MDRO themselves.", [["hand", "ANATOMY", 41, 45], ["MDRO", "DISEASE", 339, 343], ["hand", "ORGANISM_SUBDIVISION", 41, 45], ["patients", "ORGANISM", 162, 170], ["MDRO", "CANCER", 388, 392], ["patients", "SPECIES", 162, 170], ["decreased transmission", "PROBLEM", 58, 80], ["CP", "PROBLEM", 306, 308], ["MDRO", "PROBLEM", 339, 343]]], ["The location of the MDRO in the host [mainly anterior nares and skin for MRSA; gastrointestinal tract for VRE and multidrug-resistant Gram-negative bacteria (MDR GNB)], the amount of MDRO, their propensity to spread in the environment and their survival in the environment can help to explain the various effectiveness of SP and CP reported in the literature.17MRSA and VRE ::: The role of CP to control sporadic or epidemic MDRO transmission ::: Current ControversiesDuring the past 50 years, CP have been successfully advocated and implemented in settings with low prevalence or small-scale outbreaks of MRSA and VRE.13,30-34 Frequently, CP were linked with other control measures, including implementation of active surveillance cultures (ASC) or decolonization procedures.", [["anterior nares", "ANATOMY", 45, 59], ["skin", "ANATOMY", 64, 68], ["gastrointestinal tract", "ANATOMY", 79, 101], ["gastrointestinal tract", "DISEASE", 79, 101], ["VRE", "CHEMICAL", 106, 109], ["SP", "CHEMICAL", 322, 324], ["MDRO", "DISEASE", 425, 429], ["MRSA", "DISEASE", 606, 610], ["VRE", "DISEASE", 615, 618], ["MDRO", "GENE_OR_GENE_PRODUCT", 20, 24], ["anterior nares", "MULTI-TISSUE_STRUCTURE", 45, 59], ["skin", "ORGAN", 64, 68], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 79, 101], ["multidrug-resistant Gram-negative bacteria", "GENE_OR_GENE_PRODUCT", 114, 156], ["MDRO", "GENE_OR_GENE_PRODUCT", 183, 187], ["MDRO", "PROTEIN", 20, 24], ["MRSA", "SPECIES", 73, 77], ["MRSA", "SPECIES", 361, 365], ["MRSA", "SPECIES", 606, 610], ["MRSA", "SPECIES", 606, 610], ["MRSA", "PROBLEM", 73, 77], ["gastrointestinal tract", "TEST", 79, 101], ["VRE", "PROBLEM", 106, 109], ["multidrug-resistant Gram-negative bacteria (MDR GNB", "PROBLEM", 114, 165], ["MDRO", "PROBLEM", 183, 187], ["SP", "PROBLEM", 322, 324], ["CP", "PROBLEM", 329, 331], ["MRSA", "PROBLEM", 361, 365], ["VRE", "PROBLEM", 370, 373], ["CP", "PROBLEM", 390, 392], ["CP", "PROBLEM", 494, 496], ["low prevalence", "PROBLEM", 563, 577], ["MRSA", "PROBLEM", 606, 610], ["VRE", "PROBLEM", 615, 618], ["CP", "PROBLEM", 640, 642], ["other control measures", "TREATMENT", 660, 682], ["active surveillance cultures", "TEST", 712, 740], ["decolonization procedures", "TREATMENT", 750, 775], ["MDRO", "OBSERVATION", 20, 24], ["anterior", "ANATOMY_MODIFIER", 45, 53], ["nares", "ANATOMY", 54, 59], ["skin", "ANATOMY", 64, 68], ["MRSA", "OBSERVATION", 73, 77], ["gastrointestinal tract", "ANATOMY", 79, 101], ["negative bacteria", "OBSERVATION_MODIFIER", 139, 156], ["MDRO", "OBSERVATION", 183, 187], ["MRSA", "OBSERVATION", 361, 365], ["small", "OBSERVATION_MODIFIER", 581, 586], ["-scale", "OBSERVATION_MODIFIER", 586, 592], ["MRSA", "OBSERVATION", 606, 610], ["VRE", "OBSERVATION", 615, 618]]], ["For instance, the University of Geneva Hospitals in Switzerland evaluated several intensive infection control measures on a hospital outbreak of MRSA occurring between 1990 and 1993.32 These measures included patient screening, on-site surveillance, contact isolation, decolonization, a computerized alert system and hospital-wide promotion of hand hygiene, and had a substantial impact on both the reservoir of MRSA patients and the attack rate of MRSA bacteremia.32 Similarly, an active infection control intervention, which included the obtaining of surveillance cultures, education, communication and the isolation of infected patients reduced the transmission of VRE in health care facilities of the Siouxland region of Iowa, Nebraska and South Dakota between 1996 and 1999.31 Other prominent examples of the effect of CP on the successful control of MDRO clusters (mostly stopped at an early stage) are listed in Table 1.", [["hand", "ANATOMY", 344, 348], ["infection", "DISEASE", 92, 101], ["MRSA", "DISEASE", 145, 149], ["MRSA", "DISEASE", 412, 416], ["bacteremia", "DISEASE", 454, 464], ["infection", "DISEASE", 489, 498], ["VRE", "DISEASE", 668, 671], ["CP", "CHEMICAL", 824, 826], ["patient", "ORGANISM", 209, 216], ["hand", "ORGANISM_SUBDIVISION", 344, 348], ["patients", "ORGANISM", 417, 425], ["patients", "ORGANISM", 631, 639], ["MDRO", "GENE_OR_GENE_PRODUCT", 856, 860], ["MRSA", "SPECIES", 145, 149], ["patient", "SPECIES", 209, 216], ["MRSA", "SPECIES", 412, 416], ["patients", "SPECIES", 417, 425], ["MRSA", "SPECIES", 449, 453], ["patients", "SPECIES", 631, 639], ["MRSA", "SPECIES", 449, 453], ["several intensive infection control measures", "TREATMENT", 74, 118], ["MRSA", "PROBLEM", 145, 149], ["patient screening", "TEST", 209, 226], ["decolonization", "TREATMENT", 269, 283], ["hand hygiene", "TREATMENT", 344, 356], ["MRSA", "PROBLEM", 412, 416], ["MRSA bacteremia", "PROBLEM", 449, 464], ["an active infection control intervention", "TREATMENT", 479, 519], ["surveillance cultures", "TEST", 553, 574], ["education", "TREATMENT", 576, 585], ["VRE", "PROBLEM", 668, 671], ["CP", "PROBLEM", 824, 826], ["MDRO clusters", "PROBLEM", 856, 869], ["intensive", "OBSERVATION_MODIFIER", 82, 91], ["infection", "OBSERVATION", 92, 101], ["MRSA", "OBSERVATION", 145, 149], ["MRSA", "OBSERVATION", 412, 416], ["MRSA", "OBSERVATION_MODIFIER", 449, 453], ["bacteremia", "OBSERVATION", 454, 464], ["active", "OBSERVATION_MODIFIER", 482, 488], ["infection", "OBSERVATION", 489, 498], ["VRE", "OBSERVATION", 668, 671], ["prominent", "OBSERVATION_MODIFIER", 788, 797]]], ["As mentioned above, it remains difficult to ascertain the unique role of CP in the control of sporadic or epidemic MDRO transmission, because of the multimodal intervention character of these studies.", [["MDRO", "DISEASE", 115, 119], ["MDRO", "CANCER", 115, 119], ["CP", "PROBLEM", 73, 75], ["these studies", "TEST", 186, 199]]], ["Nevertheless, most experts would agree that they are an essential component of the \u201csearch-and-destroy\u201d strategy to prevent further spread of MRSA in a healthcare setting.35 This latter policy has been successfully applied in countries with low to very low prevalence of MRSA, notably the Netherlands.36 In a 5-year study, control of MRSA was accomplished by the use of active surveillance cultures for persons at risk (patients or HCWs), by the preemptive isolation of patients at risk, and by the strict isolation of known MRSA carriers and the eradication of MRSA carriage.", [["MRSA", "DISEASE", 142, 146], ["MRSA", "DISEASE", 271, 275], ["MRSA", "DISEASE", 334, 338], ["MRSA", "DISEASE", 525, 529], ["MRSA", "DISEASE", 562, 566], ["persons", "ORGANISM", 403, 410], ["patients", "ORGANISM", 420, 428], ["patients", "ORGANISM", 470, 478], ["MRSA", "ORGANISM", 525, 529], ["MRSA", "CANCER", 562, 566], ["MRSA", "SPECIES", 142, 146], ["MRSA", "SPECIES", 271, 275], ["MRSA", "SPECIES", 334, 338], ["persons", "SPECIES", 403, 410], ["patients", "SPECIES", 420, 428], ["patients", "SPECIES", 470, 478], ["MRSA", "SPECIES", 525, 529], ["MRSA", "SPECIES", 562, 566], ["MRSA", "SPECIES", 142, 146], ["MRSA", "SPECIES", 271, 275], ["MRSA", "SPECIES", 334, 338], ["MRSA", "SPECIES", 562, 566], ["strategy", "TREATMENT", 104, 112], ["MRSA", "PROBLEM", 142, 146], ["MRSA", "PROBLEM", 271, 275], ["MRSA", "PROBLEM", 334, 338], ["active surveillance cultures", "TEST", 370, 398], ["known MRSA carriers", "PROBLEM", 519, 538], ["MRSA carriage", "PROBLEM", 562, 575], ["MRSA", "OBSERVATION", 142, 146], ["MRSA", "OBSERVATION", 271, 275], ["MRSA", "OBSERVATION", 334, 338], ["MRSA", "OBSERVATION", 525, 529]]], ["For unexpected cases of MRSA colonization or infection, patients placed in strict isolation or contact isolation and HCWs were screened.", [["MRSA", "DISEASE", 24, 28], ["infection", "DISEASE", 45, 54], ["patients", "ORGANISM", 56, 64], ["MRSA", "SPECIES", 24, 28], ["patients", "SPECIES", 56, 64], ["MRSA", "SPECIES", 24, 28], ["MRSA colonization", "PROBLEM", 24, 41], ["infection", "PROBLEM", 45, 54], ["strict isolation", "TREATMENT", 75, 91], ["contact isolation", "TREATMENT", 95, 112], ["MRSA", "OBSERVATION_MODIFIER", 24, 28], ["colonization", "OBSERVATION", 29, 41], ["infection", "OBSERVATION", 45, 54]]], ["In a survey of 231 Dutch hospitals inquiring about MRSA control, those who had implemented an isolation cohort (i.e., index cases were isolated on hospital admission) had only 4/73 (5%) cases of secondary MRSA transmission.", [["MRSA", "DISEASE", 205, 209], ["MRSA", "SPECIES", 51, 55], ["MRSA", "SPECIES", 205, 209], ["MRSA", "SPECIES", 51, 55], ["MRSA", "SPECIES", 205, 209], ["MRSA control", "TREATMENT", 51, 63], ["secondary MRSA transmission", "PROBLEM", 195, 222], ["secondary", "OBSERVATION", 195, 204], ["MRSA transmission", "OBSERVATION", 205, 222]]], ["By contrast, the non-isolation cohort (i.e., high-risk patients not put into isolation on admission) had 19/95 (20%) cases of secondary MRSA transmission.37 Interestingly, the Netherlands achieved MRSA control despite generally rather low hand hygiene compliance.", [["hand", "ANATOMY", 239, 243], ["MRSA", "DISEASE", 136, 140], ["patients", "ORGANISM", 55, 63], ["hand", "ORGANISM_SUBDIVISION", 239, 243], ["patients", "SPECIES", 55, 63], ["MRSA", "SPECIES", 136, 140], ["MRSA", "SPECIES", 197, 201], ["MRSA", "SPECIES", 136, 140], ["secondary MRSA transmission", "PROBLEM", 126, 153], ["MRSA control", "TREATMENT", 197, 209], ["MRSA transmission", "OBSERVATION", 136, 153], ["MRSA", "OBSERVATION", 197, 201]]], ["In an observational survey in ICUs and surgical departments of five hospitals of varying size in the Netherlands, hand hygiene compliance of 65 nurses, attending physicians, medical residents and medical students was monitored, with an overall compliance of only 19%.38MDR GNB ::: The role of CP to control sporadic or epidemic MDRO transmission ::: Current ControversiesThe prime value of CP to control outbreaks of MDR GNB has also been demonstrated (Table 1).", [["hand", "ANATOMY", 114, 118], ["MDRO", "DISEASE", 328, 332], ["GNB", "DISEASE", 421, 424], ["hand", "ORGANISM_SUBDIVISION", 114, 118], ["MDR GNB", "CANCER", 417, 424], ["CP", "PROBLEM", 293, 295], ["CP", "PROBLEM", 390, 392], ["MDR GNB", "PROBLEM", 417, 424], ["varying", "OBSERVATION_MODIFIER", 81, 88], ["size", "OBSERVATION_MODIFIER", 89, 93], ["MDR GNB", "OBSERVATION", 417, 424]]], ["In the past, intensified CP measures controlled the outbreak of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae before these bacteria became endemic.39,40 Several studies have demonstrated that outbreaks of ESBL-producing Klebsiella pneumonia could be due to a same single strain or clone, depending on the microbiological technique used for identification, and these bacteria could spread into an ICU41 or several units of the same hospital.42 In one study,41 reinforced control measures (cohorting and dedicated staff in addition to CP and screening of patients at admission and weekly) allowed to end an outbreak of 32 cases of ESBL-producing K. pneumoniae colonization or infection.", [["ESBL", "CHEMICAL", 98, 102], ["ESBL", "CHEMICAL", 228, 232], ["Klebsiella pneumonia", "DISEASE", 243, 263], ["ESBL", "CHEMICAL", 652, 656], ["K. pneumoniae colonization", "DISEASE", 667, 693], ["infection", "DISEASE", 697, 706], ["extended-spectrum beta-lactamase", "GENE_OR_GENE_PRODUCT", 64, 96], ["Enterobacteriaceae", "ORGANISM", 114, 132], ["ESBL", "GENE_OR_GENE_PRODUCT", 228, 232], ["Klebsiella pneumonia", "ORGANISM", 243, 263], ["clone", "CELL", 304, 309], ["patients", "ORGANISM", 576, 584], ["K. pneumoniae", "ORGANISM", 667, 680], ["ESBL", "PROTEIN", 98, 102], ["patients", "SPECIES", 576, 584], ["K. pneumoniae", "SPECIES", 667, 680], ["K. pneumoniae", "SPECIES", 667, 680], ["intensified CP measures", "PROBLEM", 13, 36], ["ESBL", "TEST", 98, 102], ["Enterobacteriaceae", "PROBLEM", 114, 132], ["these bacteria", "PROBLEM", 140, 154], ["endemic", "PROBLEM", 162, 169], ["Several studies", "TEST", 176, 191], ["ESBL", "PROBLEM", 228, 232], ["Klebsiella pneumonia", "PROBLEM", 243, 263], ["a same single strain or clone", "PROBLEM", 280, 309], ["the microbiological technique", "TEST", 324, 353], ["these bacteria", "PROBLEM", 383, 397], ["one study", "TEST", 469, 478], ["CP", "PROBLEM", 556, 558], ["ESBL", "PROBLEM", 652, 656], ["K. pneumoniae colonization", "PROBLEM", 667, 693], ["infection", "PROBLEM", 697, 706], ["ESBL", "OBSERVATION", 228, 232], ["Klebsiella", "OBSERVATION_MODIFIER", 243, 253], ["pneumonia", "OBSERVATION", 254, 263], ["could be due to", "UNCERTAINTY", 264, 279], ["infection", "OBSERVATION", 697, 706]]], ["However, environmental screening had not been performed.", [["environmental screening", "TEST", 9, 32]]], ["Clearly, if the source is not identified and eliminated, infection control measures could be ineffective.", [["infection", "DISEASE", 57, 66], ["infection control measures", "TREATMENT", 57, 83], ["infection", "OBSERVATION", 57, 66]]], ["For readers seeking additional background information, they can refer to standard sources.43-46MDR GNB ::: The role of CP to control sporadic or epidemic MDRO transmission ::: Current ControversiesThe latest fatal outbreak of carbapenem-resistant K. pneumoniae at the US National Institute of Health Clinical Center47 underscores that infection control precautions were the only effective measure that eventually stopped the outbreak.", [["MDRO", "DISEASE", 154, 158], ["carbapenem", "CHEMICAL", 226, 236], ["infection", "DISEASE", 335, 344], ["carbapenem", "CHEMICAL", 226, 236], ["carbapenem", "SIMPLE_CHEMICAL", 226, 236], ["K. pneumoniae", "ORGANISM", 247, 260], ["K. pneumoniae", "SPECIES", 247, 260], ["K. pneumoniae", "SPECIES", 247, 260], ["CP", "PROBLEM", 119, 121], ["carbapenem", "PROBLEM", 226, 236], ["resistant K. pneumoniae", "PROBLEM", 237, 260], ["infection control precautions", "TREATMENT", 335, 364], ["fatal", "OBSERVATION_MODIFIER", 208, 213], ["infection", "OBSERVATION", 335, 344]]], ["This outbreak led to 18 affected patients and 6 deaths attributable to K. pneumonia.", [["deaths", "DISEASE", 48, 54], ["pneumonia", "DISEASE", 74, 83], ["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["K. pneumonia", "SPECIES", 71, 83], ["K. pneumonia", "PROBLEM", 71, 83], ["pneumonia", "OBSERVATION", 74, 83]]], ["Whole-genome-sequencing performed after the end of the outbreak revealed that infections control practitioners failed to appreciate that the most important transmitters of MDROs were asymptomatic carriers and not sick cases (infection control measures were, in fact, not intensified for the carriers) and they failed to identify an environmental source (improperly disinfected respiratory equipment) of the MDR K. pneumoniae.", [["infections", "DISEASE", 78, 88], ["MDROs", "DISEASE", 172, 177], ["infection", "DISEASE", 225, 234], ["MDROs", "GENE_OR_GENE_PRODUCT", 172, 177], ["MDR K. pneumoniae", "ORGANISM", 407, 424], ["K. pneumoniae", "SPECIES", 411, 424], ["K. pneumoniae", "SPECIES", 411, 424], ["infections control practitioners", "PROBLEM", 78, 110], ["asymptomatic carriers", "PROBLEM", 183, 204], ["infection control measures", "TREATMENT", 225, 251], ["pneumoniae", "PROBLEM", 414, 424], ["infections", "OBSERVATION", 78, 88], ["pneumoniae", "OBSERVATION", 414, 424]]], ["The outbreak was ultimately contained by implementing strict cohorting of colonized patients to minimize sharing of hospital equipment and of care providers between outbreaks patients and the other patient in the hospital and adequate screening of patients.MDR GNB ::: The role of CP to control sporadic or epidemic MDRO transmission ::: Current ControversiesFor carbapenem-resistant Enterobacteriaceae (CRE), in settings with low prevalence and localized outbreaks, the aim of infection control measures should be the complete eradication of CRE, according to an adaptation of the classic \u201csearch and destroy strategy,\u201d whereby patients considered to be at risk of CRE carriage are isolated upon hospital admission pending the outcome of admission screening.48 Reliable detection of the first CRE index case in a hospital is crucial in order to implement interventions in a timely fashion.", [["MDRO", "DISEASE", 316, 320], ["carbapenem", "CHEMICAL", 363, 373], ["infection", "DISEASE", 478, 487], ["carbapenem", "CHEMICAL", 363, 373], ["patients", "ORGANISM", 84, 92], ["patients", "ORGANISM", 175, 183], ["patient", "ORGANISM", 198, 205], ["patients", "ORGANISM", 248, 256], ["carbapenem-resistant Enterobacteriaceae", "SIMPLE_CHEMICAL", 363, 402], ["patients", "ORGANISM", 629, 637], ["CRE", "DNA", 543, 546], ["CRE", "DNA", 666, 669], ["patients", "SPECIES", 84, 92], ["patients", "SPECIES", 175, 183], ["patient", "SPECIES", 198, 205], ["patients", "SPECIES", 248, 256], ["patients", "SPECIES", 629, 637], ["CP", "PROBLEM", 281, 283], ["carbapenem", "PROBLEM", 363, 373], ["resistant Enterobacteriaceae (CRE", "PROBLEM", 374, 407], ["low prevalence", "PROBLEM", 427, 441], ["localized outbreaks", "PROBLEM", 446, 465], ["infection control measures", "TREATMENT", 478, 504], ["CRE", "TEST", 543, 546], ["CRE carriage", "PROBLEM", 666, 678], ["admission screening", "TEST", 739, 758], ["interventions", "TREATMENT", 856, 869], ["resistant", "OBSERVATION_MODIFIER", 374, 383], ["Enterobacteriaceae", "OBSERVATION", 384, 402], ["low prevalence", "OBSERVATION_MODIFIER", 427, 441], ["localized", "OBSERVATION_MODIFIER", 446, 455], ["outbreaks", "OBSERVATION", 456, 465], ["infection", "OBSERVATION", 478, 487]]], ["Isolation precautions should be implemented and strictly applied to already identify carriers, although in several settings simple contact isolation was not sufficient to stop local outbreaks, and cohorting of patients with dedicated staff was warranted.49MDR GNB ::: The role of CP to control sporadic or epidemic MDRO transmission ::: Current ControversiesInternational spread of Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae from Greece has occurred to at least 9 European countries since 2007 with further transmission documented in some case.50 For example, Germany experienced an outbreak of KPC-producing K. pneumoniae in 2008.", [["MDRO", "DISEASE", 315, 319], ["KPC", "CHEMICAL", 618, 621], ["patients", "ORGANISM", 210, 218], ["Klebsiella pneumoniae carbapenemase", "ORGANISM", 382, 417], ["KPC", "GENE_OR_GENE_PRODUCT", 419, 422], ["K. pneumoniae", "ORGANISM", 434, 447], ["K. pneumoniae", "ORGANISM", 632, 645], ["patients", "SPECIES", 210, 218], ["Klebsiella pneumoniae", "SPECIES", 382, 403], ["K. pneumoniae", "SPECIES", 434, 447], ["K. pneumoniae", "SPECIES", 632, 645], ["Klebsiella pneumoniae", "SPECIES", 382, 403], ["K. pneumoniae", "SPECIES", 434, 447], ["K. pneumoniae", "SPECIES", 632, 645], ["Isolation precautions", "TREATMENT", 0, 21], ["CP", "PROBLEM", 280, 282], ["Klebsiella pneumoniae carbapenemase", "PROBLEM", 382, 417], ["K. pneumoniae", "PROBLEM", 434, 447], ["KPC", "PROBLEM", 618, 621], ["K. pneumoniae", "PROBLEM", 632, 645], ["Klebsiella pneumoniae", "OBSERVATION", 382, 403]]], ["Despite the introduction of infection control measures, transmission occurred in 8 patients.", [["infection", "DISEASE", 28, 37], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["infection control measures", "TREATMENT", 28, 54], ["infection", "OBSERVATION", 28, 37]]], ["A common source for the outbreak could not be established and the increasing risk of transmission with increasing contact times suggests that transmission via the hands of HCWs was the most likely mechanism of spread.", [["the outbreak", "PROBLEM", 20, 32], ["HCWs", "PROBLEM", 172, 176], ["increasing", "OBSERVATION_MODIFIER", 66, 76], ["most likely", "UNCERTAINTY", 185, 196], ["spread", "OBSERVATION", 210, 216]]], ["The outbreak resolved after implementation of strict isolation of the cases for the whole period of hospitalization and two prevalence screenings to search for asymptomatic carriers.51MDR GNB ::: The role of CP to control sporadic or epidemic MDRO transmission ::: Current ControversiesThus, effective tactics to control the spread of CRE include (1) cohorting CRE-colonized and -infected patients, (2) assigning dedicated staff to cohort units, (3) performing active surveillance for CRE by rectal swabs or stool cultures and (4) intensifying hand hygiene and environmental cleaning.", [["rectal swabs", "ANATOMY", 492, 504], ["stool cultures", "ANATOMY", 508, 522], ["hand", "ANATOMY", 544, 548], ["MDRO", "DISEASE", 243, 247], ["patients", "ORGANISM", 389, 397], ["hand", "ORGANISM_SUBDIVISION", 544, 548], ["CRE", "DNA", 335, 338], ["CRE", "DNA", 361, 364], ["CRE", "DNA", 485, 488], ["patients", "SPECIES", 389, 397], ["asymptomatic carriers", "PROBLEM", 160, 181], ["CP", "PROBLEM", 208, 210], ["effective tactics", "TREATMENT", 292, 309], ["CRE", "PROBLEM", 335, 338], ["active surveillance", "TEST", 461, 480], ["CRE", "TEST", 485, 488], ["rectal swabs", "TEST", 492, 504], ["stool cultures", "TEST", 508, 522], ["intensifying hand hygiene", "TREATMENT", 531, 556], ["environmental cleaning", "TREATMENT", 561, 583], ["rectal", "ANATOMY", 492, 498]]], ["In order to be effective in a region with epidemic CRE, infection control guidelines should be uniform for all involved hospitals, and drawn up by a central public health authority invested with the statutory power to oversee and enforce their implementation.MRSA and VRE ::: The role of CP to control endemic MDRO transmission ::: Current ControversiesObservational studies have shown beneficial effects of isolation on acquisition of MDRO, especially for MRSA and VRE colonization and infection.58-61 Often, enhanced infection-control strategies were associated with increased compliance.62-64 However, the value of CP has been questioned by some studies.", [["infection", "DISEASE", 56, 65], ["MRSA", "DISEASE", 259, 263], ["MDRO", "DISEASE", 310, 314], ["MRSA", "CHEMICAL", 457, 461], ["VRE", "CHEMICAL", 466, 469], ["infection", "DISEASE", 487, 496], ["infection", "DISEASE", 519, 528], ["MDRO", "GENE_OR_GENE_PRODUCT", 436, 440], ["MRSA", "SPECIES", 259, 263], ["MRSA", "SPECIES", 457, 461], ["MRSA", "SPECIES", 259, 263], ["MRSA", "SPECIES", 457, 461], ["epidemic CRE", "TREATMENT", 42, 54], ["infection control guidelines", "TREATMENT", 56, 84], ["MRSA", "PROBLEM", 259, 263], ["VRE", "PROBLEM", 268, 271], ["CP", "PROBLEM", 288, 290], ["Current ControversiesObservational studies", "TEST", 332, 374], ["MDRO", "TREATMENT", 436, 440], ["MRSA", "PROBLEM", 457, 461], ["VRE colonization", "PROBLEM", 466, 482], ["infection", "PROBLEM", 487, 496], ["enhanced infection", "PROBLEM", 510, 528], ["CP", "PROBLEM", 618, 620], ["some studies", "TEST", 644, 656], ["VRE", "OBSERVATION", 268, 271], ["VRE", "OBSERVATION_MODIFIER", 466, 469], ["colonization", "OBSERVATION", 470, 482], ["infection", "OBSERVATION", 487, 496], ["infection", "OBSERVATION", 519, 528]]], ["Aboelela et al. conducted in 2006 a systematic review of literature pertaining to the use of barrier precautions/patient isolation and surveillance cultures to prevent the transmission of MDROs and attributed a quality score to these studies.", [["MDROs", "DISEASE", 188, 193], ["patient", "ORGANISM", 113, 120], ["patient", "SPECIES", 113, 120], ["barrier precautions", "TREATMENT", 93, 112], ["patient isolation", "TREATMENT", 113, 130], ["surveillance cultures", "TEST", 135, 156], ["MDROs", "PROBLEM", 188, 193], ["these studies", "TEST", 228, 241]]], ["Only 7 studies with highest quality scores (\u2265 90%) were selected, four studies59,65-67 were in favor of barrier precautions and surveillance culture and three studies64,68,69 did not report a difference (Table 3).70 This lack of difference may have been explained by a number of factors including low screening compliance, delays in notification of results, poor compliance with general infection control measures such as hand hygiene and understaffing.", [["hand", "ANATOMY", 422, 426], ["infection", "DISEASE", 387, 396], ["hand", "ORGANISM_SUBDIVISION", 422, 426], ["four studies", "TEST", 66, 78], ["barrier precautions", "TREATMENT", 104, 123], ["surveillance culture", "TEST", 128, 148], ["three studies", "TEST", 153, 166], ["general infection control measures", "TREATMENT", 379, 413], ["infection", "OBSERVATION", 387, 396]]], ["These factors emphasize the importance of institutional measures (such as architecture, staffing and education) required to support CP interventions.", [["institutional measures", "TREATMENT", 42, 64], ["CP interventions", "TREATMENT", 132, 148]]], ["As mentioned above, this isolation debate is also influenced by research demonstrating that isolation is associated with adverse effects in terms of patient satisfaction and level of care provided by HCWs.71MRSA and VRE ::: The role of CP to control endemic MDRO transmission ::: Current ControversiesUncertainty still remains about the effectiveness of ASC programs to better guide isolation of suspected or confirmed MDRO carriers.", [["MRSA", "DISEASE", 207, 211], ["MDRO", "DISEASE", 258, 262], ["patient", "ORGANISM", 149, 156], ["MDRO", "GENE_OR_GENE_PRODUCT", 419, 423], ["patient", "SPECIES", 149, 156], ["MRSA", "SPECIES", 207, 211], ["MRSA", "PROBLEM", 207, 211], ["VRE", "PROBLEM", 216, 219], ["CP", "PROBLEM", 236, 238], ["ASC programs", "TREATMENT", 354, 366], ["MRSA", "OBSERVATION", 207, 211], ["VRE", "OBSERVATION", 216, 219]]], ["Two important studies have produced conflicting results on the implementation of ASC and their effectiveness in MRSA control.", [["MRSA", "SPECIES", 112, 116], ["MRSA", "SPECIES", 112, 116], ["ASC", "TREATMENT", 81, 84], ["MRSA control", "TREATMENT", 112, 124], ["MRSA", "OBSERVATION", 112, 116]]], ["Harbarth et al.72 found no reduction in the incidence of nosocomial MRSA infections among surgical patients enrolled in a single, large institution crossover cohort trial, whereas Robicsek et al.73 found that the use of ASC reduced MRSA infections by nearly 70% in an observational cohort study performed in two affiliated hospitals.", [["MRSA infections", "DISEASE", 68, 83], ["MRSA infections", "DISEASE", 232, 247], ["patients", "ORGANISM", 99, 107], ["MRSA", "SPECIES", 68, 72], ["patients", "SPECIES", 99, 107], ["MRSA", "SPECIES", 232, 236], ["MRSA", "SPECIES", 68, 72], ["MRSA", "SPECIES", 232, 236], ["reduction", "PROBLEM", 27, 36], ["nosocomial MRSA infections", "PROBLEM", 57, 83], ["ASC reduced MRSA infections", "PROBLEM", 220, 247], ["an observational cohort study", "TEST", 265, 294], ["no", "UNCERTAINTY", 24, 26], ["reduction", "OBSERVATION_MODIFIER", 27, 36], ["nosocomial", "OBSERVATION_MODIFIER", 57, 67], ["MRSA", "OBSERVATION", 68, 72], ["reduced", "OBSERVATION_MODIFIER", 224, 231], ["MRSA", "OBSERVATION_MODIFIER", 232, 236], ["infections", "OBSERVATION", 237, 247]]], ["More recently, two important studies performed in the United States have highlighted not only the efforts in prevention of MDROs but also the difficulties in gaining sustained and reproducible results.74,75 Jain et al.74 evaluated the effectiveness of a quality improvement initiative in preventing the acquisition and spread of MRSA among nearly 2 million patient admissions; the study included data from 196 ICUs in the US.", [["MDROs", "DISEASE", 123, 128], ["MRSA", "DISEASE", 329, 333], ["patient", "ORGANISM", 357, 364], ["MRSA", "SPECIES", 329, 333], ["patient", "SPECIES", 357, 364], ["MRSA", "SPECIES", 329, 333], ["MDROs", "PROBLEM", 123, 128], ["the acquisition", "TEST", 299, 314], ["MRSA", "PROBLEM", 329, 333], ["the study", "TEST", 377, 386]]], ["During the intervention period, an important decrease in infections caused not only by MRSA but also by other pathogens was observed.", [["infections", "DISEASE", 57, 67], ["MRSA", "DISEASE", 87, 91], ["MRSA", "SPECIES", 87, 91], ["MRSA", "SPECIES", 87, 91], ["infections", "PROBLEM", 57, 67], ["MRSA", "PROBLEM", 87, 91], ["other pathogens", "PROBLEM", 104, 119], ["important", "OBSERVATION_MODIFIER", 35, 44], ["decrease", "OBSERVATION_MODIFIER", 45, 53], ["infections", "OBSERVATION", 57, 67], ["MRSA", "OBSERVATION", 87, 91]]], ["Huskins et al.75 evaluated more than 9,000 patients in 18 ICUs with a cluster-randomized intervention aimed at implementing barrier precautions, carrying out ASC, and feeding back adherence information to personnel; however, the final result of the intervention showed no effect on MRSA and VRE colonization or infection rates, despite the improvement in compliance with precautions and procedures.MDR GNB ::: The role of CP to control endemic MDRO transmission ::: Current ControversiesCurrently, the expansion of ESBL resistance into the community presents challenges for prospective identification of colonized patients upon admission and infection control.", [["VRE", "DISEASE", 291, 294], ["infection", "DISEASE", 311, 320], ["MDRO", "DISEASE", 444, 448], ["ESBL", "CHEMICAL", 515, 519], ["infection", "DISEASE", 642, 651], ["patients", "ORGANISM", 43, 51], ["patients", "ORGANISM", 614, 622], ["patients", "SPECIES", 43, 51], ["MRSA", "SPECIES", 282, 286], ["patients", "SPECIES", 614, 622], ["MRSA", "SPECIES", 282, 286], ["a cluster-randomized intervention", "TREATMENT", 68, 101], ["barrier precautions", "TREATMENT", 124, 143], ["ASC", "TREATMENT", 158, 161], ["the intervention", "TREATMENT", 245, 261], ["MRSA", "PROBLEM", 282, 286], ["VRE colonization", "PROBLEM", 291, 307], ["infection rates", "PROBLEM", 311, 326], ["precautions", "TREATMENT", 371, 382], ["procedures", "TREATMENT", 387, 397], ["CP", "PROBLEM", 422, 424], ["ESBL resistance", "PROBLEM", 515, 530], ["infection control", "TREATMENT", 642, 659], ["MRSA", "OBSERVATION", 282, 286], ["infection", "OBSERVATION", 311, 320], ["expansion", "OBSERVATION_MODIFIER", 502, 511], ["ESBL resistance", "OBSERVATION", 515, 530], ["infection", "OBSERVATION", 642, 651]]], ["A recent systematic review has examined the efficacy of infection control interventions for the control of ESBL-producing Enterobacteriaceae in hospitals in non-outbreak settings.", [["infection", "DISEASE", 56, 65], ["ESBL", "CHEMICAL", 107, 111], ["infection control interventions", "TREATMENT", 56, 87], ["ESBL", "PROBLEM", 107, 111], ["Enterobacteriaceae", "PROBLEM", 122, 140], ["infection", "OBSERVATION", 56, 65], ["Enterobacteriaceae", "OBSERVATION", 122, 140]]], ["Although four uncontrolled, retrospective studies were included, no well-designed prospective study capable of informing infection control practice was identified.76 Although several studies in ICUs have supported the hypothesis that patient-to-patient transmission does not play an important role in ESBL-producing Enterobacteriaceae acquisition,77,78 a recent study has highlighted the importance of patient-to-patient transmission in the acquisition of ESBL- producing E. coli during hospitalization in rehabilitation centers and the varying dissemination potential of different clones.79 As CP have not been implemented in their institution, authors believe that infection control practices should be adapted and implemented in these rehabilitation centers.", [["infection", "DISEASE", 121, 130], ["ESBL", "CHEMICAL", 456, 460], ["infection", "DISEASE", 667, 676], ["patient", "ORGANISM", 234, 241], ["patient", "ORGANISM", 245, 252], ["patient", "ORGANISM", 402, 409], ["patient", "ORGANISM", 413, 420], ["ESBL", "ORGANISM", 456, 460], ["E. coli", "ORGANISM", 472, 479], ["clones", "CELL", 582, 588], ["patient", "SPECIES", 234, 241], ["patient", "SPECIES", 245, 252], ["patient", "SPECIES", 402, 409], ["patient", "SPECIES", 413, 420], ["E. coli", "SPECIES", 472, 479], ["E. coli", "SPECIES", 472, 479], ["retrospective studies", "TEST", 28, 49], ["prospective study", "TEST", 82, 99], ["infection control practice", "TREATMENT", 121, 147], ["several studies", "TEST", 175, 190], ["ESBL", "TEST", 301, 305], ["Enterobacteriaceae acquisition", "TEST", 316, 346], ["a recent study", "TEST", 353, 367], ["ESBL", "PROBLEM", 456, 460], ["E. coli", "PROBLEM", 472, 479], ["rehabilitation centers", "TREATMENT", 506, 528], ["different clones", "PROBLEM", 572, 588], ["infection control practices", "TREATMENT", 667, 694], ["E. coli", "OBSERVATION_MODIFIER", 472, 479], ["varying", "OBSERVATION_MODIFIER", 537, 544], ["different clones", "OBSERVATION", 572, 588], ["infection", "OBSERVATION", 667, 676]]], ["There is an urgent need for research in this area and future infection control studies should differentiate species of ESBL-producing Enterobacteriaceae.MDR GNB ::: The role of CP to control endemic MDRO transmission ::: Current ControversiesA recent review about control of endemic CRE reported various successful attempts in endemic settings.80 Although some differences in approach did exist, the interventions implemented were largely based on the rationale of surveillance cultures, isolation and cohorting, CP and assignment of dedicated staff.", [["infection", "DISEASE", 61, 70], ["MDRO", "DISEASE", 199, 203], ["ESBL-producing Enterobacteriaceae", "ORGANISM", 119, 152], ["ESBL", "PROTEIN", 119, 123], ["CRE", "DNA", 283, 286], ["research in this area", "TREATMENT", 28, 49], ["future infection control studies", "PROBLEM", 54, 86], ["ESBL", "PROBLEM", 119, 123], ["Enterobacteriaceae", "PROBLEM", 134, 152], ["CP", "PROBLEM", 177, 179], ["endemic CRE", "PROBLEM", 275, 286], ["endemic settings", "TREATMENT", 327, 343], ["the interventions", "TREATMENT", 396, 413], ["surveillance cultures", "TEST", 465, 486], ["isolation", "TREATMENT", 488, 497], ["CP", "PROBLEM", 513, 515], ["infection", "OBSERVATION", 61, 70], ["Enterobacteriaceae", "OBSERVATION", 134, 152]]], ["Interpretation of the published data, however, suggests that application of a bundle of infection control measures may be required for maximum containment of CRE.", [["infection", "DISEASE", 88, 97], ["CRE", "DNA", 158, 161], ["the published data", "TEST", 18, 36], ["a bundle of infection control measures", "TREATMENT", 76, 114], ["CRE", "TEST", 158, 161], ["bundle", "OBSERVATION_MODIFIER", 78, 84], ["infection", "OBSERVATION", 88, 97]]], ["Therefore, a group of experts suggested a multifaceted approach with different components.48 At the local level, control measures should include (1) physical separation of carriers from non-carriers, (2) dedicated staff, (3) active surveillance of high-risk patients, (4) training and measures to keep staff and hospital administration informed and (5) ongoing CRE surveillance with prospective data collection and daily census of CRE carriers.", [["patients", "ORGANISM", 258, 266], ["CRE", "DNA", 361, 364], ["patients", "SPECIES", 258, 266], ["a multifaceted approach", "TREATMENT", 40, 63], ["control measures", "TREATMENT", 113, 129], ["ongoing CRE surveillance", "TEST", 353, 377], ["prospective data collection", "TEST", 383, 410], ["CRE carriers", "TREATMENT", 431, 443]]], ["Crucial to a successful CRE control program is a national task force coordinated and supported by a central public health authority with competence in hospital infection control.", [["infection", "DISEASE", 160, 169], ["CRE", "DNA", 24, 27], ["a successful CRE control program", "TREATMENT", 11, 43], ["infection control", "TREATMENT", 160, 177]]], ["The aims of this task force are multifaceted and include top priority action items as providing (1) isolation guidelines for carriers, (2) monthly progress reports about CRE control for concerned institutions and (3) evaluation of concerned hospitals and identification of problem areas.", [["CRE", "DNA", 170, 173], ["CRE control", "TREATMENT", 170, 181], ["evaluation", "TEST", 217, 227], ["problem areas", "PROBLEM", 273, 286]]], ["Controlled studies and more mathematical modeling of CRE transmission and prevention11,81 are needed to specify the most appropriate procedures for containment or even eradication of CRE.ConclusionsThe cornerstone of control measures attempting to prevent MDRO transmission is the uniform use of SP and hand hygiene, along with CP and appropriate environmental cleaning for specific pathogens and situations, especially for outbreaks.", [["hand", "ANATOMY", 303, 307], ["MDRO", "DISEASE", 256, 260], ["hand", "ORGANISM_SUBDIVISION", 303, 307], ["CRE", "DNA", 53, 56], ["CRE", "DNA", 183, 186], ["Controlled studies", "TEST", 0, 18], ["CRE transmission", "TREATMENT", 53, 69], ["CRE", "TEST", 183, 186], ["control measures", "TREATMENT", 217, 233], ["MDRO transmission", "TREATMENT", 256, 273], ["SP and hand hygiene", "TREATMENT", 296, 315], ["CP", "PROBLEM", 328, 330], ["appropriate environmental cleaning", "TREATMENT", 335, 369]]], ["When these practices are inadequate to control the spread of MDROs, a more intensive approach should be implemented.", [["MDROs", "DISEASE", 61, 66], ["a more intensive approach", "TREATMENT", 68, 93]]], ["The combination of a comprehensive infection control strategy and an effective antimicrobial stewardship program may be complementary and lead to the prevention of emergence and transmission of MDRO.", [["infection", "DISEASE", 35, 44], ["MDRO", "DISEASE", 194, 198], ["MDRO", "GENE_OR_GENE_PRODUCT", 194, 198], ["a comprehensive infection control strategy", "PROBLEM", 19, 61], ["an effective antimicrobial stewardship program", "TREATMENT", 66, 112], ["MDRO", "PROBLEM", 194, 198], ["infection", "OBSERVATION", 35, 44], ["MDRO", "OBSERVATION", 194, 198]]], ["This includes multimodal strategies, variably combined, such as hand hygiene promotion, barrier precautions and asymptomatic patient decolonization, prevention bundles, environmental decontamination and \u201chigh quality\u201d antimicrobial prescription.", [["hand", "ANATOMY", 64, 68], ["hand", "ORGANISM_SUBDIVISION", 64, 68], ["patient", "ORGANISM", 125, 132], ["patient", "SPECIES", 125, 132], ["multimodal strategies", "TREATMENT", 14, 35], ["hand hygiene promotion", "TREATMENT", 64, 86], ["barrier precautions", "TREATMENT", 88, 107], ["asymptomatic patient decolonization", "TREATMENT", 112, 147], ["prevention bundles", "TREATMENT", 149, 167], ["environmental decontamination", "TREATMENT", 169, 198], ["\u201chigh quality\u201d antimicrobial prescription", "TREATMENT", 203, 244]]], ["To be potentially effective, such programs must be strongly supported by the hospital administration.ConclusionsIn summary, contact precautions probably remain the most effective and essential method of preventing transmission of MDROs, especially at the early stage of dissemination.", [["MDROs", "DISEASE", 230, 235], ["contact precautions", "TREATMENT", 124, 143], ["transmission of MDROs", "PROBLEM", 214, 235], ["effective", "OBSERVATION", 18, 27], ["dissemination", "OBSERVATION", 270, 283]]], ["Therefore, isolation measures should be integral part of any MDRO control program, despite the fact that they are often not applied consistently and rigorously.", [["isolation measures", "TREATMENT", 11, 29], ["any MDRO control program", "TREATMENT", 57, 81]]]], "5bb362d1be223686ad4467e317cf5abb8383ab3e": [["MethodsWe prospectively studied the aetiology of febrile illness in 677 children aged 2-59 months with acute uncomplicated fever managed by IMCI (Integrated Management of Childhood Illness) guidelines in Zanzibar, using point-of-care tests, urine culture, blood-PCR, chest Xray (CXR) of IMCI-pneumonia classified patients, and multiple quantitative (q)PCR investigations of nasopharyngeal (NPH) (all patients) and rectal (GE) swabs (diarrhoea patients).", [["urine", "ANATOMY", 241, 246], ["blood", "ANATOMY", 256, 261], ["nasopharyngeal", "ANATOMY", 374, 388], ["rectal", "ANATOMY", 414, 420], ["swabs", "ANATOMY", 426, 431], ["febrile illness", "DISEASE", 49, 64], ["fever", "DISEASE", 123, 128], ["pneumonia", "DISEASE", 292, 301], ["diarrhoea", "DISEASE", 433, 442], ["children", "ORGANISM", 72, 80], ["urine", "ORGANISM_SUBSTANCE", 241, 246], ["blood", "ORGANISM_SUBSTANCE", 256, 261], ["patients", "ORGANISM", 313, 321], ["nasopharyngeal", "CANCER", 374, 388], ["patients", "ORGANISM", 400, 408], ["rectal", "ORGANISM_SUBDIVISION", 414, 420], ["patients", "ORGANISM", 443, 451], ["children", "SPECIES", 72, 80], ["patients", "SPECIES", 313, 321], ["patients", "SPECIES", 400, 408], ["patients", "SPECIES", 443, 451], ["febrile illness", "PROBLEM", 49, 64], ["acute uncomplicated fever", "PROBLEM", 103, 128], ["urine culture", "TEST", 241, 254], ["blood", "TEST", 256, 261], ["PCR", "TEST", 262, 265], ["chest Xray", "TEST", 267, 277], ["CXR", "TEST", 279, 282], ["IMCI", "PROBLEM", 287, 291], ["pneumonia", "PROBLEM", 292, 301], ["PCR investigations", "TEST", 352, 370], ["nasopharyngeal (NPH)", "TREATMENT", 374, 394], ["rectal (GE) swabs", "TREATMENT", 414, 431], ["diarrhoea", "PROBLEM", 433, 442], ["chest", "ANATOMY", 267, 272], ["pneumonia", "OBSERVATION", 292, 301], ["nasopharyngeal", "ANATOMY", 374, 388], ["rectal", "ANATOMY", 414, 420]]], ["For comparison, we also performed NPH and GE qPCR analyses in 167 healthy community controls.", [["NPH", "TREATMENT", 34, 37], ["GE qPCR analyses", "TEST", 42, 58]]], ["Final fever diagnoses were retrospectively established based on all clinical and laboratory data.", [["fever", "DISEASE", 6, 11], ["laboratory data", "TEST", 81, 96]]], ["The utility of IMCI for identifying infections presumed to require antibiotics was evaluated.FindingsNPH-qPCR and GE-qPCR detected 1 pathogen in 657/672 (98%) and 153/164 (93%) of patients and 158/166 (95%) and 144/165 (87%) of controls, respectively.", [["infections", "DISEASE", 36, 46], ["patients", "ORGANISM", 180, 188], ["patients", "SPECIES", 180, 188], ["IMCI", "TREATMENT", 15, 19], ["infections", "PROBLEM", 36, 46], ["antibiotics", "TREATMENT", 67, 78], ["FindingsNPH", "TEST", 93, 104], ["qPCR", "TEST", 105, 109], ["GE-qPCR", "TEST", 114, 121], ["pathogen", "TEST", 133, 141], ["infections", "OBSERVATION", 36, 46]]], ["Overall, 57% (387/677) had IMCI-pneumonia, but only 12% (42/342) had CXR-confirmed pneumonia.", [["pneumonia", "DISEASE", 32, 41], ["pneumonia", "DISEASE", 83, 92], ["Overall", "TEST", 0, 7], ["IMCI", "TEST", 27, 31], ["pneumonia", "PROBLEM", 32, 41], ["CXR", "TEST", 69, 72], ["pneumonia", "PROBLEM", 83, 92], ["pneumonia", "OBSERVATION", 32, 41], ["pneumonia", "OBSERVATION", 83, 92]]], ["Two patients were positive for Plasmodium falciparum.", [["Plasmodium falciparum", "DISEASE", 31, 52], ["patients", "ORGANISM", 4, 12], ["Plasmodium falciparum", "ORGANISM", 31, 52], ["patients", "SPECIES", 4, 12], ["Plasmodium falciparum", "SPECIES", 31, 52], ["Plasmodium falciparum", "SPECIES", 31, 52], ["Plasmodium falciparum", "PROBLEM", 31, 52], ["positive for", "UNCERTAINTY", 18, 30], ["Plasmodium falciparum", "OBSERVATION", 31, 52]]], ["Respiratory syncytial virus (24.5%), influenza A/B (22.3%), rhinovirus (10.5%) and group-A streptococci (6.4%), CXR-confirmed pneumonia (6.2%), Shigella (4.3%) were the most common viral and bacterial fever diagnoses, respectively.", [["Respiratory syncytial virus", "DISEASE", 0, 27], ["influenza A/B", "DISEASE", 37, 50], ["rhinovirus", "DISEASE", 60, 70], ["group-A streptococci", "DISEASE", 83, 103], ["pneumonia", "DISEASE", 126, 135], ["fever", "DISEASE", 201, 206], ["Respiratory syncytial virus", "ORGANISM", 0, 27], ["influenza A/B", "ORGANISM", 37, 50], ["rhinovirus", "ORGANISM", 60, 70], ["Respiratory syncytial virus", "SPECIES", 0, 27], ["group-A streptococci", "SPECIES", 83, 103], ["Respiratory syncytial virus", "SPECIES", 0, 27], ["influenza A/B", "SPECIES", 37, 50], ["Respiratory syncytial virus", "PROBLEM", 0, 27], ["influenza A/B", "TEST", 37, 50], ["rhinovirus", "TEST", 60, 70], ["group-A streptococci", "TEST", 83, 103], ["CXR", "TEST", 112, 115], ["pneumonia", "PROBLEM", 126, 135], ["Shigella", "PROBLEM", 144, 152], ["the most common viral and bacterial fever diagnoses", "PROBLEM", 165, 216], ["syncytial virus", "OBSERVATION", 12, 27], ["pneumonia", "OBSERVATION", 126, 135], ["bacterial", "OBSERVATION_MODIFIER", 191, 200], ["fever", "OBSERVATION", 201, 206]]], ["Blood-PCR conducted in a sub-group of patients (n = 83) without defined fever diagnosis was negative for rickettsiae, chikungunya, dengue, Rift Valley fever and West Nile viruses.", [["Blood", "ANATOMY", 0, 5], ["fever", "DISEASE", 72, 77], ["chikungunya", "DISEASE", 118, 129], ["dengue", "DISEASE", 131, 137], ["Rift Valley fever", "DISEASE", 139, 156], ["West Nile viruses", "DISEASE", 161, 178], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["patients", "ORGANISM", 38, 46], ["Rift Valley fever", "ORGANISM", 139, 156], ["West Nile viruses", "ORGANISM", 161, 178], ["patients", "SPECIES", 38, 46], ["Rift Valley fever", "SPECIES", 139, 156], ["West Nile viruses", "SPECIES", 161, 178], ["Blood-PCR", "TEST", 0, 9], ["defined fever diagnosis", "PROBLEM", 64, 87], ["rickettsiae", "PROBLEM", 105, 116], ["chikungunya", "PROBLEM", 118, 129], ["dengue", "PROBLEM", 131, 137], ["Rift Valley fever", "PROBLEM", 139, 156], ["West Nile viruses", "PROBLEM", 161, 178]]], ["Antibiotics were prescribed to 500 (74%) patients, but only 152 (22%) had an infection retrospectively considered to require antibiotics.", [["infection", "DISEASE", 77, 86], ["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["Antibiotics", "TREATMENT", 0, 11], ["an infection", "PROBLEM", 74, 86], ["antibiotics", "TREATMENT", 125, 136], ["infection", "OBSERVATION", 77, 86]]], ["However, two children died.", [["children", "ORGANISM", 13, 21], ["children", "SPECIES", 13, 21]]], ["Only 68 (11%) patients remained febrile on day 3 and three of them had verified fever on day 14.", [["febrile", "DISEASE", 32, 39], ["fever", "DISEASE", 80, 85], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["febrile", "PROBLEM", 32, 39], ["fever", "PROBLEM", 80, 85], ["febrile", "OBSERVATION", 32, 39], ["fever", "OBSERVATION", 80, 85]]], ["An additional 29 (4.5%) children had fever relapse on day 14.", [["fever", "DISEASE", 37, 42], ["children", "ORGANISM", 24, 32], ["children", "SPECIES", 24, 32], ["fever relapse", "PROBLEM", 37, 50]]], ["Regression analysis determined C-reactive Protein (CRP) as the only independent variable significantly associated with CXR-confirmed pneumonia.ConclusionsThis is the first study on uncomplicated febrile illness in African children that both applied a comprehensive laboratory panel and a healthy control group.", [["pneumonia", "DISEASE", 133, 142], ["febrile illness", "DISEASE", 195, 210], ["C-reactive Protein", "GENE_OR_GENE_PRODUCT", 31, 49], ["CRP", "GENE_OR_GENE_PRODUCT", 51, 54], ["children", "ORGANISM", 222, 230], ["C-reactive Protein", "PROTEIN", 31, 49], ["CRP", "PROTEIN", 51, 54], ["CXR", "PROTEIN", 119, 122], ["children", "SPECIES", 222, 230], ["Regression analysis", "TEST", 0, 19], ["C-reactive Protein", "TEST", 31, 49], ["CRP", "TEST", 51, 54], ["CXR", "TEST", 119, 122], ["pneumonia", "PROBLEM", 133, 142], ["the first study", "TEST", 162, 177], ["uncomplicated febrile illness", "PROBLEM", 181, 210], ["pneumonia", "OBSERVATION", 133, 142]]], ["A majority of patients had viral respiratory tract infection.", [["respiratory tract", "ANATOMY", 33, 50], ["viral respiratory tract infection", "DISEASE", 27, 60], ["patients", "ORGANISM", 14, 22], ["tract", "ORGANISM_SUBDIVISION", 45, 50], ["patients", "SPECIES", 14, 22], ["viral respiratory tract infection", "PROBLEM", 27, 60], ["viral", "OBSERVATION_MODIFIER", 27, 32], ["respiratory tract", "ANATOMY", 33, 50], ["infection", "OBSERVATION", 51, 60]]], ["Pathogens were frequently detected by qPCR also in asymptomatic children, demonstrating the importance of incorporating controls in fever aetiology studies.", [["fever", "DISEASE", 132, 137], ["children", "ORGANISM", 64, 72], ["children", "SPECIES", 64, 72], ["Pathogens", "PROBLEM", 0, 9], ["fever aetiology studies", "TEST", 132, 155]]], ["The precision of IMCI for identifying infections requiring antibiotics was low.BackgroundDespite substantial decline in global child mortality over the past two decades, over six million children die annually due to preventable or treatable illnesses approximately 50% of them in resource-limited settings in Africa [1] .BackgroundThe Integrated Management of Childhood Illness (IMCI) guidelines were developed to improve clinical management of children below five years of age by primary health care workers.", [["infections", "DISEASE", 38, 48], ["children", "ORGANISM", 187, 195], ["children", "ORGANISM", 445, 453], ["children", "SPECIES", 187, 195], ["children", "SPECIES", 445, 453], ["IMCI", "PROBLEM", 17, 21], ["infections", "PROBLEM", 38, 48], ["antibiotics", "TREATMENT", 59, 70], ["treatable illnesses", "PROBLEM", 231, 250], ["Childhood Illness", "PROBLEM", 360, 377], ["infections", "OBSERVATION", 38, 48], ["substantial", "OBSERVATION_MODIFIER", 97, 108], ["decline", "OBSERVATION_MODIFIER", 109, 116], ["global", "OBSERVATION_MODIFIER", 120, 126]]], ["It is comprised of simple algorithms based on symptoms and clinical signs that lead to a recommended treatment and/or management.", [["symptoms", "PROBLEM", 46, 54], ["clinical signs", "TEST", 59, 73], ["treatment", "TREATMENT", 101, 110], ["management", "TREATMENT", 118, 128]]], ["However, the scientific base behind IMCI was generated over 20 years ago [2] , and since then profound changes in the epidemiology of childhood febrile illness have occurred in many parts of Africa following e.g. the introduction of new vaccines, reduced malaria transmission, use of malaria rapid diagnostic tests (RDTs), and increasing antibiotic resistance [3] .BackgroundTherefore, it is necessary to re-evaluate the aetiology of acute uncomplicated childhood fever and also to assess whether IMCI remains a reliable tool for identification of children with infections presumed to benefit from antibiotic treatment [4] .BackgroundThe complexity of fever aetiology has been highlighted by the application of molecular assays for detection of multiple pathogens [5, 6] .", [["febrile illness", "DISEASE", 144, 159], ["malaria", "DISEASE", 255, 262], ["malaria", "DISEASE", 284, 291], ["fever", "DISEASE", 464, 469], ["infections", "DISEASE", 562, 572], ["fever", "DISEASE", 652, 657], ["children", "ORGANISM", 548, 556], ["children", "SPECIES", 548, 556], ["childhood febrile illness", "PROBLEM", 134, 159], ["new vaccines", "TREATMENT", 233, 245], ["reduced malaria transmission", "PROBLEM", 247, 275], ["malaria rapid diagnostic tests", "TEST", 284, 314], ["RDTs", "TEST", 316, 320], ["increasing antibiotic resistance", "TREATMENT", 327, 359], ["acute uncomplicated childhood fever", "PROBLEM", 434, 469], ["IMCI", "PROBLEM", 497, 501], ["infections", "PROBLEM", 562, 572], ["antibiotic treatment", "TREATMENT", 598, 618], ["fever aetiology", "PROBLEM", 652, 667], ["molecular assays", "TEST", 711, 727], ["multiple pathogens", "PROBLEM", 745, 763], ["antibiotic resistance", "OBSERVATION", 338, 359], ["acute", "OBSERVATION_MODIFIER", 434, 439], ["complexity", "OBSERVATION_MODIFIER", 638, 648], ["fever", "OBSERVATION", 652, 657], ["multiple", "OBSERVATION_MODIFIER", 745, 753], ["pathogens", "OBSERVATION", 754, 763]]], ["The frequent detection of nucleic acids from pathogens among both patients and asymptomatic children [7, 8] points at the need to include healthy controls in fever aetiology studies.", [["nucleic acids", "CHEMICAL", 26, 39], ["fever", "DISEASE", 158, 163], ["nucleic acids", "AMINO_ACID", 26, 39], ["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["children", "SPECIES", 92, 100], ["nucleic acids", "PROBLEM", 26, 39], ["pathogens", "PROBLEM", 45, 54], ["fever aetiology studies", "PROBLEM", 158, 181], ["nucleic acids", "OBSERVATION", 26, 39]]], ["However, comprehensive studies of this type, especially those from Africa are lacking.BackgroundWe therefore studied the aetiology and outcome of acute uncomplicated febrile illness in children 2-59 months seeking care at primary health care level in Zanzibar, a malaria pre-elimination setting of sub-Saharan Africa, using both point-of-care tests, urine cultures, confirmatory chest X-ray (CXR) investigation (in patients with IMCI-pneumonia classification), as well as multiplex quantitative (q)PCR investigations of nasopharyngeal (NPH) and rectal swabs from both patients and healthy controls.", [["urine cultures", "ANATOMY", 350, 364], ["nasopharyngeal", "ANATOMY", 520, 534], ["NPH", "ANATOMY", 536, 539], ["rectal swabs", "ANATOMY", 545, 557], ["febrile illness", "DISEASE", 166, 181], ["malaria", "DISEASE", 263, 270], ["pneumonia", "DISEASE", 434, 443], ["children", "ORGANISM", 185, 193], ["urine", "ORGANISM_SUBSTANCE", 350, 355], ["patients", "ORGANISM", 415, 423], ["nasopharyngeal", "CANCER", 520, 534], ["NPH", "MULTI-TISSUE_STRUCTURE", 536, 539], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 545, 557], ["patients", "ORGANISM", 568, 576], ["children", "SPECIES", 185, 193], ["patients", "SPECIES", 415, 423], ["patients", "SPECIES", 568, 576], ["comprehensive studies", "TEST", 9, 30], ["this type", "PROBLEM", 34, 43], ["acute uncomplicated febrile illness", "PROBLEM", 146, 181], ["urine cultures", "TEST", 350, 364], ["confirmatory chest X-ray", "TEST", 366, 390], ["CXR) investigation", "TEST", 392, 410], ["IMCI", "PROBLEM", 429, 433], ["pneumonia", "PROBLEM", 434, 443], ["PCR investigations", "TEST", 498, 516], ["nasopharyngeal (NPH)", "TREATMENT", 520, 540], ["rectal swabs", "TREATMENT", 545, 557], ["acute", "OBSERVATION_MODIFIER", 146, 151], ["uncomplicated", "OBSERVATION_MODIFIER", 152, 165], ["chest", "ANATOMY", 379, 384], ["pneumonia", "OBSERVATION", 434, 443], ["nasopharyngeal", "ANATOMY", 520, 534], ["rectal", "ANATOMY", 545, 551]]], ["We also assessed the utility of IMCI in identification of infections presumed to require antibiotics.Study design and study siteThis was a prospective descriptive health facility based study conducted in North A District, Zanzibar, Tanzania between April-July 2011 that followed children with acute uncomplicated febrile illness for 14 days.", [["infections", "DISEASE", 58, 68], ["febrile illness", "DISEASE", 313, 328], ["children", "ORGANISM", 279, 287], ["children", "SPECIES", 279, 287], ["IMCI", "PROBLEM", 32, 36], ["infections", "PROBLEM", 58, 68], ["antibiotics", "TREATMENT", 89, 100], ["Study design", "TEST", 101, 113], ["study site", "TEST", 118, 128], ["acute uncomplicated febrile illness", "PROBLEM", 293, 328], ["infections", "OBSERVATION", 58, 68]]], ["A healthy community control group was recruited for comparison during the same study time period.Study design and study siteZanzibar has a tropical climate with seasonal rainfalls biannually.", [["siteZanzibar", "CHEMICAL", 120, 132], ["rainfalls", "DISEASE", 170, 179], ["Study design", "TEST", 97, 109]]], ["Malaria positivity rate has declined dramatically over the past decade from approximately 40% to 1-2% in febrile patients after wide-scale deployment of malaria control interventions [9] .", [["Malaria", "DISEASE", 0, 7], ["febrile", "DISEASE", 105, 112], ["malaria", "DISEASE", 153, 160], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["Malaria positivity rate", "PROBLEM", 0, 23], ["wide-scale deployment of malaria control interventions", "TREATMENT", 128, 182], ["declined", "OBSERVATION_MODIFIER", 28, 36], ["dramatically", "OBSERVATION_MODIFIER", 37, 49], ["malaria", "OBSERVATION", 153, 160]]], ["It was selected as study site based on its central location in the district, 24-hour service, presence of a research laboratory, and radiology equipment.Study staffThe study staff included clinicians (clinical officers with prescription rights), qualified nurses and laboratory technicians.", [["central", "OBSERVATION_MODIFIER", 43, 50]]], ["The clinicians had been trained in IMCI management, in particular regarding integration of malaria RDT as previously described [10] and measurement of respiratory rate.Patient enrolmentChildren presenting at the study site were screened for eligibility.", [["respiratory", "ANATOMY", 151, 162], ["malaria", "DISEASE", 91, 98], ["Children", "ORGANISM", 185, 193], ["Patient", "SPECIES", 168, 175], ["Children", "SPECIES", 185, 193], ["IMCI management", "TREATMENT", 35, 50], ["malaria RDT", "PROBLEM", 91, 102], ["respiratory rate", "TEST", 151, 167], ["malaria", "OBSERVATION", 91, 98], ["respiratory rate", "OBSERVATION", 151, 167]]], ["Up to 15 patients were enrolled daily Monday-Saturday.", [["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17]]], ["Inclusion criteria were: age 2-59 months; acute uncomplicated fever defined as history of fever in the preceding 24 hours (information from caretaker) and/or verified fever (axillary temperature of 37.5\u00b0C by electronic thermometer); and written informed proxy consent from an accompanying caretaker.", [["axillary", "ANATOMY", 174, 182], ["fever", "DISEASE", 62, 67], ["fever", "DISEASE", 90, 95], ["fever", "DISEASE", 167, 172], ["acute uncomplicated fever", "PROBLEM", 42, 67], ["fever", "PROBLEM", 90, 95], ["fever", "PROBLEM", 167, 172], ["axillary temperature", "TEST", 174, 194], ["acute", "OBSERVATION_MODIFIER", 42, 47], ["uncomplicated", "OBSERVATION_MODIFIER", 48, 61], ["fever", "OBSERVATION", 62, 67], ["fever", "OBSERVATION", 90, 95], ["axillary", "ANATOMY", 174, 182]]], ["Exclusion criteria were: signs of severe disease (according to IMCI); previous study enrolment in the last 28 days; and reported inability to return for follow-up.", [["severe disease", "PROBLEM", 34, 48], ["previous study enrolment", "TEST", 70, 94], ["severe", "OBSERVATION_MODIFIER", 34, 40], ["disease", "OBSERVATION", 41, 48]]], ["Data were documented in a structured IMCI-based questionnaire.Patient investigations and clinical managementAfter enrolment, (defined as day 0) a study nurse performed a malaria RDT and a study clinician conducted IMCI assessment and prescribed treatment.", [["malaria", "DISEASE", 170, 177], ["Patient", "SPECIES", 62, 69], ["Patient investigations", "TEST", 62, 84], ["clinical management", "TREATMENT", 89, 108], ["a study", "TEST", 144, 151], ["a malaria RDT", "PROBLEM", 168, 181], ["a study", "TEST", 186, 193], ["IMCI assessment", "TEST", 214, 229], ["prescribed treatment", "TREATMENT", 234, 254]]], ["This was followed by pre-defined investigations including point-of-care tests, sampling for microbiology analyses, and CXR, some performed in all patients others in patients with certain clinical features identified through IMCI management (Figs 1 and 2) .", [["patients", "ORGANISM", 146, 154], ["patients", "ORGANISM", 165, 173], ["patients", "SPECIES", 146, 154], ["patients", "SPECIES", 165, 173], ["pre-defined investigations", "TEST", 21, 47], ["microbiology analyses", "TEST", 92, 113], ["CXR", "TEST", 119, 122], ["IMCI management", "TREATMENT", 224, 239]]], ["Participants with pre-defined abnormal laboratory results and/or signs of severe disease were discontinued and referred for further clinical management (Table 1) .", [["Participants", "SPECIES", 0, 12], ["pre-defined abnormal laboratory results", "PROBLEM", 18, 57], ["severe disease", "PROBLEM", 74, 88], ["further clinical management", "TREATMENT", 124, 151], ["severe", "OBSERVATION_MODIFIER", 74, 80], ["disease", "OBSERVATION", 81, 88]]], ["All study investigations are presented in Fig 1, Fig 2 and S1A-S1L Appendix.", [["All study investigations", "TEST", 0, 24], ["Fig", "TEST", 49, 52], ["S1L Appendix", "ANATOMY", 63, 75]]], ["Sampling, storage and performance of all diagnostics were done according to manufacturers' instructions and study specific standard operating procedures.", [["all diagnostics", "TEST", 37, 52]]], ["Some investigations were conducted on-site or in Mnazi Mmoja referral hospital.", [["Some investigations", "TEST", 0, 19]]], ["The remaining laboratory analyses were performed in Sweden and France after study completion.", [["The remaining laboratory analyses", "TEST", 0, 33], ["study completion", "TEST", 76, 92]]], ["CXRs were performed and interpreted according to World Health Organization (WHO) standards with quality control readings done in Sweden [11] .Patient follow-upPatients had a first scheduled follow-up on day four (+/-2 days) and a second on day 14 (+/-2 days) for evaluation of fever outcome (Fig 3) .", [["fever", "DISEASE", 277, 282], ["CXRs", "PROTEIN", 0, 4], ["Patient", "SPECIES", 142, 149], ["CXRs", "TEST", 0, 4], ["evaluation", "TEST", 263, 273], ["fever outcome", "PROBLEM", 277, 290]]], ["Caretakers were instructed to return with their children in case any signs of severe disease occurred.", [["children", "ORGANISM", 48, 56], ["children", "SPECIES", 48, 56], ["severe disease", "PROBLEM", 78, 92], ["severe", "OBSERVATION_MODIFIER", 78, 84], ["disease", "OBSERVATION", 85, 92]]], ["On every follow-up visit a study clinician performed clinical reassessment including axillary temperature.", [["axillary", "ANATOMY", 85, 93], ["clinical reassessment", "TEST", 53, 74], ["axillary temperature", "TEST", 85, 105], ["axillary", "ANATOMY", 85, 93]]], ["Any patient with symptoms/signs of severe disease, predefined abnormal laboratory values or withdrawal of consent during the 14-day follow-up was discontinued from the study (Fig 3) .Healthy controlsHealthy controls (hereafter referred to as \"controls\"), defined as children aged 2-59 months with no history of diarrhoea, cough, running nose or fever (by history and/or electronic axillary temperature <37.5\u00b0C) in the preceding ten days were recruited during the same study time period.", [["diarrhoea", "DISEASE", 311, 320], ["cough", "DISEASE", 322, 327], ["fever", "DISEASE", 345, 350], ["patient", "ORGANISM", 4, 11], ["children", "ORGANISM", 266, 274], ["nose", "ORGANISM_SUBDIVISION", 337, 341], ["patient", "SPECIES", 4, 11], ["children", "SPECIES", 266, 274], ["symptoms", "PROBLEM", 17, 25], ["severe disease", "PROBLEM", 35, 49], ["predefined abnormal laboratory values", "PROBLEM", 51, 88], ["the study", "TEST", 164, 173], ["diarrhoea", "PROBLEM", 311, 320], ["cough", "PROBLEM", 322, 327], ["running nose", "PROBLEM", 329, 341], ["fever", "PROBLEM", 345, 350], ["electronic axillary temperature", "TEST", 370, 401], ["severe", "OBSERVATION_MODIFIER", 35, 41], ["disease", "OBSERVATION", 42, 49], ["fever", "OBSERVATION", 345, 350], ["axillary", "ANATOMY", 381, 389]]], ["Each study week, one of these eight villages was visited and asymptomatic children were identified through house-to-house screening.", [["children", "ORGANISM", 74, 82], ["children", "SPECIES", 74, 82], ["Each study", "TEST", 0, 10]]], ["Patient completed all follow-ups and did not fulfil any of the above-mentioned outcomes.", [["Patient", "SPECIES", 0, 7]]], ["No resolution of fever Verified fever on follow-up 1 and 2 a Patients not meeting these criteria but with a CRP of >150 mg/L, WBC >2510^9/L were followed up the next day.", [["fever", "DISEASE", 17, 22], ["fever", "DISEASE", 32, 37], ["Patients", "ORGANISM", 61, 69], ["CRP", "GENE_OR_GENE_PRODUCT", 108, 111], ["CRP", "PROTEIN", 108, 111], ["Patients", "SPECIES", 61, 69], ["fever", "PROBLEM", 17, 22], ["fever", "PROBLEM", 32, 37], ["a CRP", "TEST", 106, 111], ["WBC", "TEST", 126, 129], ["resolution", "OBSERVATION_MODIFIER", 3, 13], ["fever", "OBSERVATION", 17, 22]]], ["ARI, Acute respiratory tract infection Eligible children, maximum two per household, provided NPH and rectal swabs for qPCRanalyses (Fig 2) .Assessment of final diagnosesCriteria for the respective final diagnoses were defined by two study investigators (paediatricians) based on all available clinical and radiology/laboratory data from day 0 (Tables 1 and 2 , Fig 1) including the multiple regression analysis of qPCR results described further in S1J Appendix.", [["rectal swabs", "ANATOMY", 102, 114], ["ARI", "DISEASE", 0, 3], ["Acute respiratory tract infection", "DISEASE", 5, 38], ["children", "ORGANISM", 48, 56], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 102, 114], ["children", "SPECIES", 48, 56], ["ARI", "PROBLEM", 0, 3], ["Acute respiratory tract infection", "PROBLEM", 5, 38], ["NPH", "TREATMENT", 94, 97], ["rectal swabs", "TREATMENT", 102, 114], ["the multiple regression analysis", "TEST", 379, 411], ["qPCR", "TEST", 415, 419], ["Acute", "OBSERVATION_MODIFIER", 5, 10], ["respiratory tract", "ANATOMY", 11, 28], ["rectal", "ANATOMY", 102, 108], ["Appendix", "ANATOMY", 453, 461]]], ["Subsequently these criteria were applied on each patient.", [["patient", "ORGANISM", 49, 56], ["patient", "SPECIES", 49, 56], ["these criteria", "TEST", 13, 27]]], ["The diagnoses were categorized into three groups: 1) more probable causes of fever, 2) less probable causes of fever, and 3) \"no verified aetiology\".", [["fever", "DISEASE", 77, 82], ["fever", "DISEASE", 111, 116], ["fever", "PROBLEM", 77, 82], ["fever", "PROBLEM", 111, 116], ["fever", "OBSERVATION", 77, 82], ["fever", "OBSERVATION", 111, 116]]], ["If a more probable diagnosis was identified, all less probable diagnoses were ignored for that patient, but within one group each patient could receive more than one diagnosis.Assessment of infections requiring antibioticsStudy definitions are outlined in Table 1 .", [["infections", "DISEASE", 190, 200], ["patient", "ORGANISM", 95, 102], ["patient", "ORGANISM", 130, 137], ["patient", "SPECIES", 95, 102], ["patient", "SPECIES", 130, 137], ["infections", "PROBLEM", 190, 200], ["antibiotics", "TREATMENT", 211, 222], ["Study definitions", "TEST", 222, 239], ["infections", "OBSERVATION", 190, 200]]], ["Infections requiring antibiotics were defined retrospectively as those final diagnoses presumed to benefit from antibiotics based on WHO recommendations [12] .", [["Infections", "DISEASE", 0, 10], ["Infections", "PROBLEM", 0, 10], ["antibiotics", "TREATMENT", 21, 32], ["antibiotics", "TREATMENT", 112, 123]]], ["The association between these infections and both actually prescribed antibiotics and IMCI indication for antibiotics was assessed.Sample size calculation, study endpoints, data management and statistical analysisThis was an exploratory study, which precluded a sample size calculation.", [["infections", "DISEASE", 30, 40], ["these infections", "PROBLEM", 24, 40], ["antibiotics", "TREATMENT", 70, 81], ["IMCI indication", "TREATMENT", 86, 101], ["antibiotics", "TREATMENT", 106, 117], ["Sample size calculation", "TEST", 131, 154], ["study endpoints", "TEST", 156, 171], ["statistical analysis", "TEST", 193, 213], ["an exploratory study", "TEST", 222, 242], ["a sample size calculation", "TEST", 260, 285], ["infections", "OBSERVATION", 30, 40], ["size", "OBSERVATION_MODIFIER", 138, 142]]], ["However, we estimated that a sample of 650 patients would be sufficient to obtain a representative classification of fever causes according to IMCI, and that at least 150 controls would be required to make comparisons of microbiological findings obtained by PCR analysis of nasopharyngeal and rectal specimens.", [["nasopharyngeal", "ANATOMY", 274, 288], ["rectal specimens", "ANATOMY", 293, 309], ["fever", "DISEASE", 117, 122], ["patients", "ORGANISM", 43, 51], ["nasopharyngeal", "CANCER", 274, 288], ["rectal specimens", "CANCER", 293, 309], ["patients", "SPECIES", 43, 51], ["fever", "PROBLEM", 117, 122], ["IMCI", "TEST", 143, 147], ["microbiological findings", "TEST", 221, 245], ["PCR analysis", "TEST", 258, 270], ["nasopharyngeal and rectal specimens", "TEST", 274, 309], ["nasopharyngeal", "ANATOMY", 274, 288], ["rectal", "ANATOMY", 293, 299]]], ["Data were double entered in CSPro, validated and exported to STATA1 12 where all statistical analyses were performed.", [["STATA1 12", "DNA", 61, 70], ["all statistical analyses", "TEST", 77, 101]]], ["Frequencies, proportions and odds ratios (ORs) were calculated with 95% confidence intervals (CI).", [["CI", "TEST", 94, 96]]], ["P-values <0.05 were considered statistically significant.", [["P-values", "TEST", 0, 8]]], ["Fisher's exact test and exact binomial test was used for binary data and proportions, two-sample t-test for comparisons of means, and Mann-Whitney-U test for median comparisons.", [["Fisher's exact test", "TEST", 0, 19], ["exact binomial test", "TEST", 24, 43], ["binary data", "TEST", 57, 68], ["sample t-test", "TEST", 90, 103], ["Mann-Whitney-U test", "TEST", 134, 153], ["median comparisons", "TEST", 158, 176]]], ["In a univariate and multivariate logistic regression we assessed the association between CXR-confirmed pneumonia and the continuous and binary variables outlined in Table 3 .", [["pneumonia", "DISEASE", 103, 112], ["CXR", "PROTEIN", 89, 92], ["CXR", "TEST", 89, 92], ["pneumonia", "PROBLEM", 103, 112], ["the continuous and binary variables", "PROBLEM", 117, 152], ["pneumonia", "OBSERVATION", 103, 112]]], ["WBC (>20x 10^9/L) and CRP cut-off values (<20 and >80 mg/L), were chosen to concur with published literature [13] .Ethical considerationsThe study was conducted in accordance with the Declaration of Helsinki and approved by the Zanzibar Medical Research Ethics Committee (ID: ZAMREC/0001/April/010) and Regional Research Ethics Committees in Stockholm (ID:2009/387-31/2), and Gothenburg (ID:266-10), Sweden.", [["WBC", "ANATOMY", 0, 3], ["CRP", "GENE_OR_GENE_PRODUCT", 22, 25], ["CRP", "PROTEIN", 22, 25], ["WBC", "TEST", 0, 3], ["CRP cut", "TEST", 22, 29], ["The study", "TEST", 137, 146]]], ["A written informed proxy consent from an accompanying caretaker was obtained and subsequently recorded on a consent form for all patients as well as healthy controls recruited in the study.", [["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137], ["the study", "TEST", 179, 188]]], ["An assistant medical officer ensured that laboratory results requiring medical intervention (Table 2 ) and/or referral were managed accordingly.", [["medical intervention", "TREATMENT", 71, 91]]], ["Clinical management, treatments and referrals were provided free of charge to all study participants.", [["participants", "SPECIES", 88, 100], ["Clinical management", "TREATMENT", 0, 19], ["treatments", "TREATMENT", 21, 31]]], ["No participant received any financial incentive, except for travel expenses for patients.", [["patients", "ORGANISM", 80, 88], ["participant", "SPECIES", 3, 14], ["patients", "SPECIES", 80, 88]]], ["Study registration on clinicaltrials. org (NCT01094431) was done before data acquisition.Participant characteristics, IMCI classifications and fever outcomeBaseline characteristics of the 677 patients and 167 controls are presented in Table 4 .", [["fever", "DISEASE", 143, 148], ["patients", "ORGANISM", 192, 200], ["patients", "SPECIES", 192, 200], ["Study registration", "TEST", 0, 18], ["clinicaltrials", "TEST", 22, 36], ["data acquisition", "TEST", 72, 88], ["IMCI classifications", "TEST", 118, 138], ["fever outcomeBaseline characteristics", "PROBLEM", 143, 180]]], ["Fortytwo percent (286/677) of patients had verified fever at enrolment.", [["fever", "DISEASE", 52, 57], ["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["fever", "PROBLEM", 52, 57], ["fever", "OBSERVATION", 52, 57]]], ["All patients were classified according to IMCI (Fig 4) .", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["More than one IMCI classification was assigned to 166 (25%) patients.", [["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68]]], ["Of 642 (96%) patients who completed both of the follow-up visits (Fig 3) , 68 (11%) remained febrile on the first follow-up visit, and 3 of them had verified fever on day 14.", [["febrile", "DISEASE", 93, 100], ["fever", "DISEASE", 158, 163], ["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["febrile", "PROBLEM", 93, 100], ["fever", "PROBLEM", 158, 163], ["fever", "OBSERVATION", 158, 163]]], ["An additional 29 (4.5%) children had verified fever relapse on the second follow-up visit.Detection of pathogensA total of 22257 analyses were conducted for detection of 36 pathogens.", [["fever", "DISEASE", 46, 51], ["children", "ORGANISM", 24, 32], ["children", "SPECIES", 24, 32], ["fever relapse", "PROBLEM", 46, 59], ["36 pathogens", "PROBLEM", 170, 182]]], ["Crude qPCR detection rates of nasopharyngeal pathogens in patients and healthy controls as well as a comparison of Ct values between the groups are presented in Fig 5A, 5B , 5C and S2 Table.", [["nasopharyngeal", "ANATOMY", 30, 44], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["Crude qPCR", "TEST", 0, 10], ["nasopharyngeal pathogens in patients and healthy controls", "PROBLEM", 30, 87], ["Ct values", "TEST", 115, 124], ["nasopharyngeal", "ANATOMY", 30, 44], ["pathogens", "OBSERVATION", 45, 54]]], ["NPH qPCR detected one or more pathogens in 657/672 (98%) patients (median 3 pathogens, range: 1-7) and in 158/166 (95%) controls (median 2 pathogens, range: 1-7).", [["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["NPH qPCR", "TEST", 0, 8], ["median 2 pathogens", "TEST", 130, 148]]], ["Significantly higher detection rates were found in patients than controls for enterovirus, influenza A, influenza B and RSV (OR from 1.8 to 15.6, P<0.01, S1 Appendix, S1 File, S2 Table) .", [["enterovirus", "DISEASE", 78, 89], ["influenza A", "DISEASE", 91, 102], ["influenza B", "DISEASE", 104, 115], ["RSV", "DISEASE", 120, 123], ["patients", "ORGANISM", 51, 59], ["enterovirus", "ORGANISM", 78, 89], ["influenza A", "ORGANISM", 91, 102], ["influenza B", "ORGANISM", 104, 115], ["RSV", "ORGANISM", 120, 123], ["patients", "SPECIES", 51, 59], ["RSV", "SPECIES", 120, 123], ["Significantly higher detection rates", "PROBLEM", 0, 36], ["enterovirus", "PROBLEM", 78, 89], ["influenza", "PROBLEM", 91, 100], ["influenza B", "TEST", 104, 115], ["RSV", "TEST", 120, 123], ["P", "TEST", 146, 147], ["Appendix", "ANATOMY", 157, 165]]], ["Multiple pathogens were detected in 591 (88%) patients and 137 (83%) controls. controls (median 2 pathogens; range 1-6) (Fig 5C) .", [["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["Multiple pathogens", "TEST", 0, 18], ["pathogens", "OBSERVATION", 9, 18]]], ["Multiple pathogens were detected by GE-qPCR in 49/164 (30%) patients and 60/165 (36%) controls.", [["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["Multiple pathogens", "PROBLEM", 0, 18], ["GE-qPCR", "TEST", 36, 43], ["pathogens", "OBSERVATION", 9, 18]]], ["Significantly higher detection rates in patients than controls were seen for Cryptosporidium, norovirus genogroup II, and rotavirus (P0.001).", [["Cryptosporidium, norovirus genogroup II", "DISEASE", 77, 116], ["patients", "ORGANISM", 40, 48], ["norovirus genogroup II", "ORGANISM", 94, 116], ["patients", "SPECIES", 40, 48], ["norovirus genogroup II", "SPECIES", 94, 116], ["rotavirus", "SPECIES", 122, 131], ["Significantly higher detection rates", "PROBLEM", 0, 36], ["Cryptosporidium", "PROBLEM", 77, 92], ["norovirus genogroup II", "PROBLEM", 94, 116], ["rotavirus", "PROBLEM", 122, 131]]], ["Shigella and ETEC-estA were also identified as causes of gastroenteritis by their significantly higher pathogen load in faeces from patients as compared with controls [7] .", [["faeces", "ANATOMY", 120, 126], ["gastroenteritis", "DISEASE", 57, 72], ["Shigella", "ORGANISM", 0, 8], ["ETEC-estA", "GENE_OR_GENE_PRODUCT", 13, 22], ["faeces", "ORGANISM_SUBDIVISION", 120, 126], ["patients", "ORGANISM", 132, 140], ["estA", "PROTEIN", 18, 22], ["patients", "SPECIES", 132, 140], ["Shigella", "PROBLEM", 0, 8], ["ETEC", "PROBLEM", 13, 17], ["gastroenteritis", "PROBLEM", 57, 72], ["their significantly higher pathogen load in faeces", "PROBLEM", 76, 126], ["gastroenteritis", "OBSERVATION", 57, 72]]], ["Fig 5A shows urine culture, point-of-care and blood test results, all performed exclusively in patients.", [["urine", "ANATOMY", 13, 18], ["blood", "ANATOMY", 46, 51], ["urine", "ORGANISM_SUBSTANCE", 13, 18], ["blood", "ORGANISM_SUBSTANCE", 46, 51], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["Fig 5A", "TEST", 0, 6], ["urine culture", "TEST", 13, 26], ["blood test", "TEST", 46, 56]]], ["Two patients had Plasmodium falciparum detected by RDT, microscopy and PCR.", [["Plasmodium falciparum", "DISEASE", 17, 38], ["patients", "ORGANISM", 4, 12], ["Plasmodium falciparum", "ORGANISM", 17, 38], ["patients", "SPECIES", 4, 12], ["Plasmodium falciparum", "SPECIES", 17, 38], ["Plasmodium falciparum", "SPECIES", 17, 38], ["Plasmodium falciparum", "PROBLEM", 17, 38], ["RDT", "TEST", 51, 54], ["microscopy", "TEST", 56, 66], ["PCR", "TEST", 71, 74], ["Plasmodium falciparum", "OBSERVATION", 17, 38]]], ["All 83 specimens subjected to PCR-analyses for additional blood pathogens (rickettsiosis, chikungunya, dengue, Rift Valley fever and West Nile viruses) were negative.", [["specimens", "ANATOMY", 7, 16], ["blood", "ANATOMY", 58, 63], ["blood pathogens", "DISEASE", 58, 73], ["rickettsiosis", "DISEASE", 75, 88], ["chikungunya", "DISEASE", 90, 101], ["dengue", "DISEASE", 103, 109], ["Rift Valley fever", "DISEASE", 111, 128], ["blood", "ORGANISM_SUBSTANCE", 58, 63], ["Rift Valley fever", "ORGANISM", 111, 128], ["West Nile viruses", "ORGANISM", 133, 150], ["Rift Valley fever", "SPECIES", 111, 128], ["Rift Valley fever and West Nile viruses", "SPECIES", 111, 150], ["All 83 specimens", "TEST", 0, 16], ["PCR", "TEST", 30, 33], ["analyses", "TEST", 34, 42], ["additional blood pathogens", "PROBLEM", 47, 73], ["rickettsiosis", "PROBLEM", 75, 88], ["chikungunya", "PROBLEM", 90, 101], ["dengue", "PROBLEM", 103, 109], ["Rift Valley fever", "PROBLEM", 111, 128], ["West Nile viruses", "PROBLEM", 133, 150]]], ["When all microbiology results (point-of-care, urine culture and PCRs) were pooled (Fig 5A,5B and 5C ) a median of three pathogens (range 0-10) were observed per patient.", [["urine", "ANATOMY", 46, 51], ["urine", "ORGANISM_SUBSTANCE", 46, 51], ["patient", "ORGANISM", 161, 168], ["patient", "SPECIES", 161, 168], ["urine culture", "TEST", 46, 59], ["PCRs", "TEST", 64, 68], ["Fig", "TEST", 83, 86], ["three pathogens", "PROBLEM", 114, 129]]], ["Eight (1.2%) patients had no detectable pathogen.CXR-confirmed pneumoniaOut of 387 patients with IMCI-pneumonia classification, 359 underwent CXR, which confirmed pneumonia in 12% (42/342) of patients with sufficient CXR quality.", [["pneumonia", "DISEASE", 102, 111], ["pneumonia", "DISEASE", 163, 172], ["patients", "ORGANISM", 13, 21], ["patients", "ORGANISM", 83, 91], ["patients", "ORGANISM", 192, 200], ["CXR", "PROTEIN", 49, 52], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 83, 91], ["patients", "SPECIES", 192, 200], ["detectable pathogen", "PROBLEM", 29, 48], ["CXR", "TEST", 49, 52], ["IMCI", "PROBLEM", 97, 101], ["pneumonia", "PROBLEM", 102, 111], ["CXR", "TEST", 142, 145], ["pneumonia", "PROBLEM", 163, 172], ["no", "UNCERTAINTY", 26, 28], ["detectable", "OBSERVATION_MODIFIER", 29, 39], ["pathogen", "OBSERVATION", 40, 48], ["pneumonia", "OBSERVATION", 102, 111], ["pneumonia", "OBSERVATION", 163, 172]]], ["Univariate and multivariate regression analysis determined CRP as the only independent variable significantly associated with CXR-confirmed pneumonia (Table 3) , with CRP-levels >80mg/l corresponding to an OR of 5.9 (CI: (2.4-14.", [["pneumonia", "DISEASE", 140, 149], ["CRP", "GENE_OR_GENE_PRODUCT", 59, 62], ["CRP", "GENE_OR_GENE_PRODUCT", 167, 170], ["CRP", "PROTEIN", 59, 62], ["CRP", "PROTEIN", 167, 170], ["multivariate regression analysis", "TEST", 15, 47], ["CRP", "TEST", 59, 62], ["CXR", "TEST", 126, 129], ["pneumonia", "PROBLEM", 140, 149], ["CRP", "TEST", 167, 170], ["levels", "TEST", 171, 177], ["CI", "TEST", 217, 219], ["pneumonia", "OBSERVATION", 140, 149]]], ["NPH-qPCR detected pneumococci in 37, RSV in 11, influenza A or B in 6, and enterovirus in 2 of the 42 patients with CXR-confirmed pneumonia.Final diagnosesA total of 579/677 (86%) patients were assigned a final diagnosis (Fig 6) , including 160 with multiple diagnoses, resulting in 769 diagnoses in total.", [["influenza A", "DISEASE", 48, 59], ["enterovirus", "DISEASE", 75, 86], ["pneumonia", "DISEASE", 130, 139], ["NPH", "SIMPLE_CHEMICAL", 0, 3], ["RSV", "ORGANISM", 37, 40], ["B", "CELL", 63, 64], ["enterovirus", "ORGANISM", 75, 86], ["patients", "ORGANISM", 102, 110], ["patients", "ORGANISM", 180, 188], ["patients", "SPECIES", 102, 110], ["patients", "SPECIES", 180, 188], ["RSV", "SPECIES", 37, 40], ["influenza A", "SPECIES", 48, 59], ["NPH", "TEST", 0, 3], ["qPCR", "TEST", 4, 8], ["pneumococci", "PROBLEM", 18, 29], ["RSV", "TEST", 37, 40], ["influenza A", "PROBLEM", 48, 59], ["enterovirus", "PROBLEM", 75, 86], ["CXR", "TEST", 116, 119], ["pneumonia", "PROBLEM", 130, 139], ["pneumonia", "OBSERVATION", 130, 139]]], ["The most common diagnoses were viral respiratory tract infection caused by RSV, influenza B, rhinovirus, enterovirus and influenza A, whereas the most common bacterial infections were Group A streptococci (GAS), CXR-confirmed pneumonia and Shigella gastroenteritis (Fig 6, Fig 7B and 7C ).Severe diseaseThe two deceased children, out of seven that developed signs of severe illness after enrolment (Fig 3) , were assigned influenza A and enterovirus as final diagnoses.", [["respiratory tract", "ANATOMY", 37, 54], ["viral respiratory tract infection", "DISEASE", 31, 64], ["influenza B", "DISEASE", 80, 91], ["rhinovirus, enterovirus and influenza A", "DISEASE", 93, 132], ["bacterial infections", "DISEASE", 158, 178], ["pneumonia", "DISEASE", 226, 235], ["Shigella gastroenteritis", "DISEASE", 240, 264], ["illness", "DISEASE", 374, 381], ["tract", "ORGANISM_SUBDIVISION", 49, 54], ["RSV", "ORGANISM", 75, 78], ["influenza B", "ORGANISM", 80, 91], ["rhinovirus", "ORGANISM", 93, 103], ["enterovirus", "ORGANISM", 105, 116], ["influenza A", "ORGANISM", 121, 132], ["children", "ORGANISM", 320, 328], ["enterovirus", "ORGANISM", 438, 449], ["RSV", "SPECIES", 75, 78], ["influenza B, rhinovirus", "SPECIES", 80, 103], ["Shigella gastroenteritis", "SPECIES", 240, 264], ["children", "SPECIES", 320, 328], ["RSV", "SPECIES", 75, 78], ["influenza A", "SPECIES", 121, 132], ["Shigella gastroenteritis", "SPECIES", 240, 264], ["influenza A", "SPECIES", 422, 433], ["viral respiratory tract infection", "PROBLEM", 31, 64], ["RSV", "PROBLEM", 75, 78], ["influenza B", "PROBLEM", 80, 91], ["rhinovirus", "PROBLEM", 93, 103], ["enterovirus", "PROBLEM", 105, 116], ["influenza A", "PROBLEM", 121, 132], ["the most common bacterial infections", "PROBLEM", 142, 178], ["Group A streptococci (GAS", "TEST", 184, 209], ["CXR", "TEST", 212, 215], ["pneumonia", "PROBLEM", 226, 235], ["Shigella gastroenteritis", "PROBLEM", 240, 264], ["Fig", "TEST", 266, 269], ["Fig 7B", "TEST", 273, 279], ["Severe disease", "PROBLEM", 289, 303], ["severe illness", "PROBLEM", 367, 381], ["enrolment (Fig", "TREATMENT", 388, 402], ["influenza A", "PROBLEM", 422, 433], ["enterovirus", "PROBLEM", 438, 449], ["respiratory tract", "ANATOMY", 37, 54], ["infection", "OBSERVATION", 55, 64], ["RSV", "OBSERVATION", 75, 78], ["pneumonia", "OBSERVATION", 226, 235], ["Shigella gastroenteritis", "OBSERVATION", 240, 264], ["disease", "OBSERVATION", 296, 303], ["severe", "OBSERVATION_MODIFIER", 367, 373], ["illness", "OBSERVATION", 374, 381]]], ["Both received antibiotics at enrolment.", [["antibiotics", "TREATMENT", 14, 25]]], ["The remaining five children had coronavirus and rhinovirus infection (n = 2), bocavirus, GAS infection and influenza A, respectively.", [["coronavirus and rhinovirus infection", "DISEASE", 32, 68], ["GAS infection", "DISEASE", 89, 102], ["influenza A", "DISEASE", 107, 118], ["children", "ORGANISM", 19, 27], ["coronavirus", "ORGANISM", 32, 43], ["rhinovirus", "ORGANISM", 48, 58], ["children", "SPECIES", 19, 27], ["coronavirus", "SPECIES", 32, 43], ["coronavirus", "PROBLEM", 32, 43], ["rhinovirus infection", "PROBLEM", 48, 68], ["bocavirus", "PROBLEM", 78, 87], ["GAS infection", "PROBLEM", 89, 102], ["influenza A", "PROBLEM", 107, 118], ["rhinovirus", "OBSERVATION", 48, 58], ["GAS infection", "OBSERVATION", 89, 102]]], ["There was neither any difference in early fever resolution (Table 1) among patients with (39/45; 87%) or without (504/595; 85%) a serious bacterial infection (CXR-confirmed pneumonia and/or urinary tract infection [14] , Table 1 ), nor among patients treated (392/474, 83%) or not treated (143/174, 82%) with antibiotics (p>0.05 for both).Antibiotic prescriptions and infections requiring antibioticsAt enrolment, 500 (74%) patients were prescribed antibiotics of whom 472 (93%) received beta lactams (Table 4 ).", [["urinary tract", "ANATOMY", 190, 203], ["fever", "DISEASE", 42, 47], ["bacterial infection", "DISEASE", 138, 157], ["pneumonia", "DISEASE", 173, 182], ["urinary tract infection", "DISEASE", 190, 213], ["infections", "DISEASE", 368, 378], ["beta lactams", "CHEMICAL", 488, 500], ["beta lactams", "CHEMICAL", 488, 500], ["patients", "ORGANISM", 75, 83], ["urinary tract", "ORGANISM_SUBDIVISION", 190, 203], ["patients", "ORGANISM", 242, 250], ["patients", "ORGANISM", 424, 432], ["beta lactams", "GENE_OR_GENE_PRODUCT", 488, 500], ["patients", "SPECIES", 75, 83], ["patients", "SPECIES", 242, 250], ["patients", "SPECIES", 424, 432], ["early fever resolution", "PROBLEM", 36, 58], ["a serious bacterial infection", "PROBLEM", 128, 157], ["CXR", "TEST", 159, 162], ["pneumonia", "PROBLEM", 173, 182], ["urinary tract infection", "PROBLEM", 190, 213], ["antibiotics", "TREATMENT", 309, 320], ["Antibiotic prescriptions", "TREATMENT", 339, 363], ["infections", "PROBLEM", 368, 378], ["antibiotics", "TREATMENT", 389, 400], ["antibiotics", "TREATMENT", 449, 460], ["beta lactams", "TREATMENT", 488, 500], ["early", "OBSERVATION_MODIFIER", 36, 41], ["fever", "OBSERVATION", 42, 47], ["bacterial", "OBSERVATION_MODIFIER", 138, 147], ["infection", "OBSERVATION", 148, 157], ["pneumonia", "OBSERVATION", 173, 182], ["urinary tract", "ANATOMY", 190, 203]]], ["Among the 152/677 (22%) patients with infections requiring antibiotics ( Fig 7A and 7B ) 129 (85%) received antibiotics, the most common being GAS-infection and CXRconfirmed pneumonia.", [["infections", "DISEASE", 38, 48], ["GAS-infection", "DISEASE", 143, 156], ["pneumonia", "DISEASE", 174, 183], ["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["infections", "PROBLEM", 38, 48], ["antibiotics", "TREATMENT", 59, 70], ["antibiotics", "TREATMENT", 108, 119], ["infection", "PROBLEM", 147, 156], ["CXRconfirmed pneumonia", "PROBLEM", 161, 183], ["infections", "OBSERVATION", 38, 48], ["infection", "OBSERVATION", 147, 156], ["pneumonia", "OBSERVATION", 174, 183]]], ["The remaining 23 that were not prescribed antibiotics recovered, although one had an episode of convulsions during follow-up.", [["convulsions", "DISEASE", 96, 107], ["antibiotics", "TREATMENT", 42, 53], ["convulsions", "PROBLEM", 96, 107], ["convulsions", "OBSERVATION", 96, 107]]], ["Among the 525 patients without infections requiring antibiotics (Fig 7A and 7C) , 294 (56%) had IMCI indication for antibiotics, a majority of them (271/294; 92%) due to IMCI-pneumonia.", [["infections", "DISEASE", 31, 41], ["pneumonia", "DISEASE", 175, 184], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["infections", "PROBLEM", 31, 41], ["antibiotics", "TREATMENT", 52, 63], ["antibiotics", "TREATMENT", 116, 127], ["IMCI", "PROBLEM", 170, 174], ["pneumonia", "PROBLEM", 175, 184], ["pneumonia", "OBSERVATION", 175, 184]]], ["Conversely, 45/152 patients (30%) with infections requiring antibiotics had no IMCI indication for antibiotics.", [["infections", "DISEASE", 39, 49], ["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["infections", "PROBLEM", 39, 49], ["antibiotics", "TREATMENT", 60, 71], ["antibiotics", "TREATMENT", 99, 110]]], ["Yet 24 of these 45 (53%) received treatment.DiscussionThis is, to our knowledge, the first aetiology study on non-severe fever in African children that both applies a comprehensive laboratory panel and includes a healthy control group.", [["fever", "DISEASE", 121, 126], ["children", "ORGANISM", 138, 146], ["children", "SPECIES", 138, 146], ["treatment", "TREATMENT", 34, 43], ["non-severe fever", "PROBLEM", 110, 126]]], ["Viral respiratory tract infections were identified as the most common fever cause.", [["respiratory tract", "ANATOMY", 6, 23], ["Viral respiratory tract infections", "DISEASE", 0, 34], ["fever", "DISEASE", 70, 75], ["Viral respiratory tract", "ORGANISM_SUBDIVISION", 0, 23], ["Viral respiratory tract infections", "PROBLEM", 0, 34], ["respiratory tract", "ANATOMY", 6, 23], ["infections", "OBSERVATION", 24, 34]]], ["A vast majority, 98%, of patients had at least one detectable pathogen.", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["vast", "OBSERVATION_MODIFIER", 2, 6], ["majority", "OBSERVATION_MODIFIER", 7, 15], ["detectable", "OBSERVATION_MODIFIER", 51, 61], ["pathogen", "OBSERVATION", 62, 70]]], ["However, some agents did not qualify as causal aetiologies (e.g. pneumococci by NPH-qPCR), and 15% of the patients could not be assigned a final diagnosis.", [["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["pneumococci", "PROBLEM", 65, 76], ["NPH", "TEST", 80, 83]]], ["The results, with multiple pathogens being detected in a large proportion of specimens from both patients and controls, underline the complexity of childhood infections.", [["specimens", "ANATOMY", 77, 86], ["infections", "DISEASE", 158, 168], ["specimens", "CANCER", 77, 86], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["multiple pathogens", "PROBLEM", 18, 36], ["childhood infections", "PROBLEM", 148, 168], ["multiple", "OBSERVATION_MODIFIER", 18, 26], ["pathogens", "OBSERVATION", 27, 36], ["large", "OBSERVATION_MODIFIER", 57, 62], ["childhood", "OBSERVATION_MODIFIER", 148, 157], ["infections", "OBSERVATION", 158, 168]]], ["Also, many pathogens were detected in similar frequencies in patients and controls, as previously observed [7, 8] , emphasizing the need to incorporate controls in studies on causes of fever.DiscussionBy comparing qPCR Ct-values (in addition to crude positivity rates) as proxy for pathogen load in patients and controls and applying multiple regression analysis to control for confounding factors, the identification of causative agents was likely improved in our study (S1 Appendix, S2 Table, Tables A and B in S1 File).", [["fever", "DISEASE", 185, 190], ["patients", "ORGANISM", 61, 69], ["patients", "ORGANISM", 299, 307], ["patients", "SPECIES", 61, 69], ["patients", "SPECIES", 299, 307], ["many pathogens", "PROBLEM", 6, 20], ["fever", "PROBLEM", 185, 190], ["qPCR Ct-values", "TEST", 214, 228], ["pathogen load", "PROBLEM", 282, 295], ["multiple regression analysis", "TEST", 334, 362], ["confounding factors", "PROBLEM", 378, 397], ["causative agents", "TREATMENT", 421, 437], ["our study", "TEST", 461, 470], ["many", "OBSERVATION_MODIFIER", 6, 10], ["pathogens", "OBSERVATION", 11, 20], ["fever", "OBSERVATION", 185, 190], ["Appendix", "ANATOMY", 475, 483]]], ["Similar approaches for aetiology identification have previously been used for gastrointestinal [7, 15] as well as nasopharyngeal pathogens [8, 16] .", [["gastrointestinal", "ANATOMY", 78, 94], ["nasopharyngeal", "ANATOMY", 114, 128], ["nasopharyngeal pathogens", "DISEASE", 114, 138], ["gastrointestinal", "ORGAN", 78, 94], ["nasopharyngeal", "ORGAN", 114, 128], ["aetiology identification", "TEST", 23, 47], ["nasopharyngeal pathogens", "PROBLEM", 114, 138], ["nasopharyngeal", "ANATOMY", 114, 128], ["pathogens", "OBSERVATION", 129, 138]]], ["Overall, the NPH-qPCR results cohered with previous studies of acute respiratory tract infections in African preschool children [17, 18] .", [["respiratory tract", "ANATOMY", 69, 86], ["respiratory tract infections", "DISEASE", 69, 97], ["respiratory tract", "ORGANISM_SUBDIVISION", 69, 86], ["children", "ORGANISM", 119, 127], ["children", "SPECIES", 119, 127], ["the NPH-qPCR", "TEST", 9, 21], ["acute respiratory tract infections", "PROBLEM", 63, 97], ["acute", "OBSERVATION_MODIFIER", 63, 68], ["respiratory tract", "ANATOMY", 69, 86]]], ["However, the observation in our study that enterovirus was a common fever cause is novel and calls for confirmatory studies that like this study distinguish between enterovirus and rhinovirus detection.DiscussionA strength of our study is that, based on all clinical and microbiology data, we retrospectively assigned individual final patient diagnoses, which allowed assessment of whether antibiotics were prescribed to those presumed to benefit from treatment.", [["enterovirus", "DISEASE", 43, 54], ["fever", "DISEASE", 68, 73], ["enterovirus and rhinovirus", "DISEASE", 165, 191], ["enterovirus", "ORGANISM", 43, 54], ["enterovirus", "ORGANISM", 165, 176], ["rhinovirus", "ORGANISM", 181, 191], ["patient", "ORGANISM", 335, 342], ["patient", "SPECIES", 335, 342], ["our study", "TEST", 28, 37], ["enterovirus", "PROBLEM", 43, 54], ["a common fever", "PROBLEM", 59, 73], ["confirmatory studies", "TEST", 103, 123], ["this study", "TEST", 134, 144], ["enterovirus", "PROBLEM", 165, 176], ["rhinovirus detection", "TEST", 181, 201], ["our study", "TEST", 226, 235], ["assessment", "TEST", 368, 378], ["antibiotics", "TREATMENT", 390, 401], ["treatment", "TREATMENT", 452, 461]]], ["IMCI management has previously been shown to reduce inappropriate antibiotic prescription in comparison with standard fever case management [19] and a majority of the antibiotic-requiring infections in our study were indeed treated with antibiotics.", [["fever", "DISEASE", 118, 123], ["infections", "DISEASE", 188, 198], ["IMCI management", "TREATMENT", 0, 15], ["inappropriate antibiotic prescription", "TREATMENT", 52, 89], ["standard fever case management", "TREATMENT", 109, 139], ["the antibiotic", "TREATMENT", 163, 177], ["infections", "PROBLEM", 188, 198], ["our study", "TEST", 202, 211], ["antibiotics", "TREATMENT", 237, 248]]], ["Still, IMCI management resulted in substantial over-prescription of antibiotics in comparison with the final fever diagnoses retrieved based on all available clinical and laboratory data and their corresponding antibiotic requirement.", [["fever", "DISEASE", 109, 114], ["IMCI management", "TREATMENT", 7, 22], ["antibiotics", "TREATMENT", 68, 79], ["laboratory data", "TEST", 171, 186], ["their corresponding antibiotic requirement", "TREATMENT", 191, 233], ["substantial", "OBSERVATION_MODIFIER", 35, 46]]], ["Thus, among the 57% patients fulfilling the IMCI-pneumonia classification, only 12% had CXR-confirmed pneumonia.", [["pneumonia", "DISEASE", 49, 58], ["pneumonia", "DISEASE", 102, 111], ["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["the IMCI", "TEST", 40, 48], ["pneumonia classification", "PROBLEM", 49, 73], ["CXR", "TEST", 88, 91], ["pneumonia", "PROBLEM", 102, 111], ["pneumonia", "OBSERVATION", 49, 58], ["pneumonia", "OBSERVATION", 102, 111]]], ["Similar results have been reported by others in both hospitalized children [20, 21] , and in non-severe IMCI-pneumonias [22] , indicating that IMCI-pneumonia classification, based on presence of cough and rapid breathing has a low precision to identify lower antibiotic requiring respiratory tract infections.", [["respiratory tract", "ANATOMY", 280, 297], ["pneumonias", "DISEASE", 109, 119], ["pneumonia", "DISEASE", 148, 157], ["cough", "DISEASE", 195, 200], ["respiratory tract infections", "DISEASE", 280, 308], ["children", "ORGANISM", 66, 74], ["tract", "ORGANISM_SUBDIVISION", 292, 297], ["children", "SPECIES", 66, 74], ["pneumonias", "PROBLEM", 109, 119], ["IMCI", "PROBLEM", 143, 147], ["pneumonia classification", "PROBLEM", 148, 172], ["cough", "PROBLEM", 195, 200], ["rapid breathing", "PROBLEM", 205, 220], ["lower antibiotic", "TREATMENT", 253, 269], ["respiratory tract infections", "PROBLEM", 280, 308], ["pneumonias", "OBSERVATION", 109, 119], ["pneumonia", "OBSERVATION", 148, 157], ["cough", "OBSERVATION", 195, 200], ["respiratory tract", "ANATOMY", 280, 297]]], ["IMCI-pneumonia classification was the largest contributor to presumed unnecessary antibiotic prescription in our study.", [["pneumonia", "DISEASE", 5, 14], ["IMCI", "PROBLEM", 0, 4], ["pneumonia", "PROBLEM", 5, 14], ["unnecessary antibiotic prescription", "TREATMENT", 70, 105], ["our study", "TEST", 109, 118], ["pneumonia", "OBSERVATION", 5, 14]]], ["In a multiple logistic regression analysis, CRP was the only positive predictor of CXR-confirmed pneumonia.", [["pneumonia", "DISEASE", 97, 106], ["CRP", "GENE_OR_GENE_PRODUCT", 44, 47], ["CRP", "PROTEIN", 44, 47], ["CXR", "PROTEIN", 83, 86], ["CRP", "TEST", 44, 47], ["CXR", "TEST", 83, 86], ["pneumonia", "PROBLEM", 97, 106], ["pneumonia", "OBSERVATION", 97, 106]]], ["However, approximately 50% with CXR-confirmed pneumonia in our study had CRP <80 mg/L and a viral pathogen detected by NPH-qPCR, suggesting that some of the CXR-confirmed pneumonias might only have been of viral origin [23] .", [["pneumonia", "DISEASE", 46, 55], ["pneumonias", "DISEASE", 171, 181], ["CRP", "GENE_OR_GENE_PRODUCT", 73, 76], ["CXR", "GENE_OR_GENE_PRODUCT", 157, 160], ["CXR", "PROTEIN", 32, 35], ["CRP", "PROTEIN", 73, 76], ["CXR", "PROTEIN", 157, 160], ["CXR", "TEST", 32, 35], ["pneumonia", "PROBLEM", 46, 55], ["our study", "TEST", 59, 68], ["CRP", "TEST", 73, 76], ["a viral pathogen", "PROBLEM", 90, 106], ["NPH", "TEST", 119, 122], ["the CXR", "TEST", 153, 160], ["pneumonias", "PROBLEM", 171, 181], ["pneumonia", "OBSERVATION", 46, 55], ["pneumonias", "OBSERVATION", 171, 181]]], ["The IMCI guidelines have remained quite similar since its introduction, with the exception of the recent integration of malaria RDT, which has been proven useful in Zanzibar [10] .", [["malaria", "DISEASE", 120, 127], ["The IMCI guidelines", "TEST", 0, 19], ["malaria RDT", "PROBLEM", 120, 131], ["malaria", "OBSERVATION", 120, 127]]], ["If IMCI in combination with CRP and/or other biomarkers could play a similar role by reliably confirming or excluding bacterial infections like pneumonia needs to be further studied [5] .", [["infections", "DISEASE", 128, 138], ["pneumonia", "DISEASE", 144, 153], ["CRP", "GENE_OR_GENE_PRODUCT", 28, 31], ["CRP", "PROTEIN", 28, 31], ["IMCI", "PROBLEM", 3, 7], ["CRP", "TEST", 28, 31], ["bacterial infections", "PROBLEM", 118, 138], ["pneumonia", "PROBLEM", 144, 153], ["pneumonia", "OBSERVATION", 144, 153]]], ["When planning such studies on infections requiring antibiotics, the following issues should be addressed: Should severely and/or nonseverely ill patients be included?", [["infections", "DISEASE", 30, 40], ["patients", "ORGANISM", 145, 153], ["patients", "SPECIES", 145, 153], ["infections", "PROBLEM", 30, 40], ["antibiotics", "TREATMENT", 51, 62]]], ["The likelihood of finding a single laboratory test/biomarker in the near future that could distinguish all infections presumed to require antibiotics from other infections is low.", [["infections", "DISEASE", 107, 117], ["infections", "DISEASE", 161, 171], ["a single laboratory test/biomarker", "TEST", 26, 60], ["all infections", "PROBLEM", 103, 117], ["antibiotics", "TREATMENT", 138, 149], ["other infections", "PROBLEM", 155, 171], ["infections", "OBSERVATION", 107, 117], ["infections", "OBSERVATION", 161, 171], ["low", "OBSERVATION_MODIFIER", 175, 178]]], ["For instance, Fig 7B shows that GAS-infections and Shigellosis were the main infections requiring antibiotics that the IMCI algorithm did not identify.", [["GAS-infections", "DISEASE", 32, 46], ["Shigellosis", "CHEMICAL", 51, 62], ["infections", "DISEASE", 77, 87], ["GAS", "ORGANISM", 32, 35], ["Shigellosis", "SIMPLE_CHEMICAL", 51, 62], ["Fig 7B", "TEST", 14, 20], ["GAS-infections", "PROBLEM", 32, 46], ["Shigellosis", "PROBLEM", 51, 62], ["the main infections", "PROBLEM", 68, 87], ["antibiotics", "TREATMENT", 98, 109], ["the IMCI algorithm", "TEST", 115, 133], ["infections", "OBSERVATION", 36, 46], ["Shigellosis", "OBSERVATION", 51, 62], ["main", "OBSERVATION_MODIFIER", 72, 76], ["infections", "OBSERVATION", 77, 87]]], ["Hence, the way forward would probably be a more complex step-wise approach combining clinical signs, multiple biomarkers and point of care detection of pathogens.DiscussionThe overall health outcome was satisfactory with relatively few children who developed severe disease during follow-up.", [["children", "ORGANISM", 236, 244], ["children", "SPECIES", 236, 244], ["clinical signs", "TEST", 85, 99], ["multiple biomarkers", "TEST", 101, 120], ["pathogens", "PROBLEM", 152, 161], ["severe disease", "PROBLEM", 259, 273], ["severe", "OBSERVATION_MODIFIER", 259, 265], ["disease", "OBSERVATION", 266, 273]]], ["Our results concur with previous studies of IMCI management of uncomplicated childhood fever on first referral level of Pakistan and Papua New Guinea, which also reported no difference in outcome between children treated or not treated with antibiotics [24, 25] .DiscussionSimilar distribution of fever causes as observed in our study with a predominance of viral infections and <10% serious bacterial infections (7.4% in our study) [14] have been reported in high-income countries [26] .", [["fever", "DISEASE", 87, 92], ["fever", "DISEASE", 297, 302], ["viral infections", "DISEASE", 358, 374], ["bacterial infections", "DISEASE", 392, 412], ["children", "ORGANISM", 204, 212], ["children", "SPECIES", 204, 212], ["previous studies", "TEST", 24, 40], ["IMCI management", "TREATMENT", 44, 59], ["uncomplicated childhood fever", "PROBLEM", 63, 92], ["antibiotics", "TREATMENT", 241, 252], ["fever", "PROBLEM", 297, 302], ["our study", "TEST", 325, 334], ["viral infections", "PROBLEM", 358, 374], ["<10% serious bacterial infections", "PROBLEM", 379, 412], ["our study", "TEST", 422, 431], ["fever", "OBSERVATION", 297, 302], ["viral", "OBSERVATION_MODIFIER", 358, 363], ["infections", "OBSERVATION", 364, 374], ["serious", "OBSERVATION_MODIFIER", 384, 391], ["bacterial", "OBSERVATION_MODIFIER", 392, 401], ["infections", "OBSERVATION", 402, 412]]], ["Due to differences in methodology and inclusion criteria it is difficult to compare our findings to previous studies of fever aetiologies in African children [27] [28] [29] [30] [31] .", [["fever", "DISEASE", 120, 125], ["children", "ORGANISM", 149, 157], ["[27] [28] [29] [30", "SIMPLE_CHEMICAL", 158, 176], ["children", "SPECIES", 149, 157], ["previous studies", "TEST", 100, 116], ["fever aetiologies", "PROBLEM", 120, 137]]], ["A recent study from Tanzania also applied a broad microbiology test panel, and reported viral infections as the most common fever causes [32] .", [["viral infections", "DISEASE", 88, 104], ["fever", "DISEASE", 124, 129], ["A recent study", "TEST", 0, 14], ["a broad microbiology test panel", "TEST", 42, 73], ["viral infections", "PROBLEM", 88, 104], ["viral infections", "OBSERVATION", 88, 104]]], ["However, there are some important methodological differences between D'Acremont et al and our study; they included older children and, importantly, did not include a control group of asymptomatic children.DiscussionOur study has several limitations.", [["children", "ORGANISM", 121, 129], ["children", "ORGANISM", 196, 204], ["children", "SPECIES", 121, 129], ["children", "SPECIES", 196, 204], ["our study", "TEST", 90, 99], ["DiscussionOur study", "TEST", 205, 224]]], ["Firstly, it was conducted during the time period, directly following the main rainy season in Zanzibar, when respiratory tract infections are known to be more frequent and some diarrheal infections like rotavirus are less frequent and might therefore not be representative for infections occurring during a whole year.", [["respiratory tract", "ANATOMY", 109, 126], ["respiratory tract infections", "DISEASE", 109, 137], ["infections", "DISEASE", 187, 197], ["rotavirus", "DISEASE", 203, 212], ["infections", "DISEASE", 277, 287], ["tract", "ORGANISM_SUBDIVISION", 121, 126], ["rotavirus", "ORGANISM", 203, 212], ["rotavirus", "SPECIES", 203, 212], ["Zanzibar", "TREATMENT", 94, 102], ["respiratory tract infections", "PROBLEM", 109, 137], ["some diarrheal infections", "PROBLEM", 172, 197], ["rotavirus", "PROBLEM", 203, 212], ["infections", "PROBLEM", 277, 287], ["respiratory tract", "ANATOMY", 109, 126], ["diarrheal", "OBSERVATION_MODIFIER", 177, 186], ["infections", "OBSERVATION", 187, 197], ["rotavirus", "OBSERVATION", 203, 212], ["infections", "OBSERVATION", 277, 287]]], ["Secondly, controls were only sampled for nasopharyngeal and rectal swabs, and the lack of controls for other tests might for example have resulted in over-estimation of GAS infections.", [["nasopharyngeal", "ANATOMY", 41, 55], ["rectal swabs", "ANATOMY", 60, 72], ["infections", "DISEASE", 173, 183], ["nasopharyngeal", "CANCER", 41, 55], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 60, 72], ["GAS", "ORGANISM", 169, 172], ["nasopharyngeal and rectal swabs", "TEST", 41, 72], ["other tests", "TEST", 103, 114], ["GAS infections", "PROBLEM", 169, 183], ["rectal", "ANATOMY", 60, 66], ["GAS infections", "OBSERVATION", 169, 183]]], ["Thirdly, we chose not to include blood cultures due to an assumed low yield of bacteraemias [33] .", [["blood cultures", "ANATOMY", 33, 47], ["bacteraemias", "DISEASE", 79, 91], ["blood", "ORGANISM_SUBSTANCE", 33, 38], ["blood cultures", "TEST", 33, 47], ["bacteraemias", "PROBLEM", 79, 91]]], ["This focus on acute uncomplicated fever precludes any conclusions regarding the frequency or outcome of severe infections.DiscussionIn conclusion, this study on aetiology, antibiotic treatment and outcome of non-severe febrile childhood illness in a malaria pre-elimination setting of Africa, the first using a comprehensive laboratory panel and including a healthy control group, shows the complexity of determining infectious aetiologies.", [["fever", "DISEASE", 34, 39], ["infections", "DISEASE", 111, 121], ["febrile childhood illness", "DISEASE", 219, 244], ["malaria", "DISEASE", 250, 257], ["acute uncomplicated fever", "PROBLEM", 14, 39], ["severe infections", "PROBLEM", 104, 121], ["this study", "TEST", 147, 157], ["antibiotic treatment", "TREATMENT", 172, 192], ["non-severe febrile childhood illness", "PROBLEM", 208, 244], ["a comprehensive laboratory panel", "TEST", 309, 341], ["acute", "OBSERVATION_MODIFIER", 14, 19], ["uncomplicated", "OBSERVATION_MODIFIER", 20, 33], ["fever", "OBSERVATION", 34, 39], ["severe", "OBSERVATION_MODIFIER", 104, 110], ["infections", "OBSERVATION", 111, 121], ["infectious", "OBSERVATION", 417, 427]]], ["The majority of fevers were caused by viral upper respiratory tract infections, similarly to children in high-income countries.", [["upper respiratory tract", "ANATOMY", 44, 67], ["fevers", "DISEASE", 16, 22], ["viral upper respiratory tract infections", "DISEASE", 38, 78], ["tract", "ORGANISM_SUBDIVISION", 62, 67], ["children", "ORGANISM", 93, 101], ["children", "SPECIES", 93, 101], ["fevers", "PROBLEM", 16, 22], ["viral upper respiratory tract infections", "PROBLEM", 38, 78], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["fevers", "OBSERVATION", 16, 22], ["viral", "OBSERVATION_MODIFIER", 38, 43], ["upper", "ANATOMY_MODIFIER", 44, 49], ["respiratory tract", "ANATOMY", 50, 67], ["infections", "OBSERVATION", 68, 78]]], ["A majority of asymptomatic children had potential pathogens detected by NPH-qPCR, often in a similar proportion as patients, underlining the need to include controls.", [["children", "ORGANISM", 27, 35], ["patients", "ORGANISM", 115, 123], ["children", "SPECIES", 27, 35], ["patients", "SPECIES", 115, 123], ["potential pathogens", "PROBLEM", 40, 59], ["NPH", "TEST", 72, 75]]], ["The precision of IMCI to identify infections presumed to require antibiotics was low.DiscussionSupporting Information S1 Strobe Checklist.", [["infections", "DISEASE", 34, 44], ["IMCI", "PROBLEM", 17, 21], ["infections", "PROBLEM", 34, 44], ["antibiotics", "TREATMENT", 65, 76], ["infections", "OBSERVATION", 34, 44]]], ["(DOCX) S1 Appendix.", [["S1 Appendix", "ANATOMY", 7, 18]]]], "PMC7380220": [["Moreover, there have also been fears that redenomination risk could emerge (see, for example, Basse, 2014 and Sibbertsen et al., 2014).", [["redenomination", "DISEASE", 42, 56]]], ["This is a special type of exchange rate risk that will be discussed in more detail later.The European sovereign debt crisis seems to have ended tendencies towards interest rate convergence in the common currency union \u2013 at least for a while.", [["exchange rate risk", "TREATMENT", 26, 44], ["The European sovereign debt crisis", "PROBLEM", 89, 123], ["debt crisis", "OBSERVATION", 112, 123]]], ["Obviously, the introduction of the Euro has eliminated exchange rate risk within the currency union.", [["the Euro", "TREATMENT", 31, 39]]]], "PMC7461169": [["INTRODUCTIONWhile many measures to mitigate the multifactorial impact of COVID\u201019 are being implemented, one critical component of this strategy is the widespread testing and identification of individuals currently or previously infected by severe acute respiratory syndrome coronavirus 2 (SARS\u2010CoV\u20102).", [["acute respiratory syndrome coronavirus", "DISEASE", 248, 286], ["individuals", "ORGANISM", 193, 204], ["severe acute respiratory syndrome coronavirus", "SPECIES", 241, 286], ["COVID\u2010", "TREATMENT", 73, 79], ["the widespread testing", "TEST", 148, 170], ["individuals", "PROBLEM", 193, 204], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 241, 286], ["severe", "OBSERVATION_MODIFIER", 241, 247], ["acute", "OBSERVATION_MODIFIER", 248, 253], ["respiratory syndrome", "OBSERVATION", 254, 274]]], ["The delivery of effective care and mitigation of infection depend on the performance of SARS\u2010CoV\u20102 diagnostic testing and the clinical interpretation of results.", [["infection", "DISEASE", 49, 58], ["SARS", "DISEASE", 88, 92], ["effective care", "TREATMENT", 16, 30], ["infection", "PROBLEM", 49, 58], ["diagnostic testing", "TEST", 99, 117], ["infection", "OBSERVATION", 49, 58]]], ["The lack of a full understanding of the natural history and immunopathogenesis of COVID\u201019 infection creates unique challenges in the implementation of diagnostic testing strategies.", [["COVID", "DISEASE", 82, 87], ["infection", "DISEASE", 91, 100], ["COVID\u201019 infection", "PROBLEM", 82, 100], ["diagnostic testing strategies", "TEST", 152, 181], ["infection", "OBSERVATION", 91, 100]]], ["SARS\u2010CoV\u20102 diagnostic assays have fixed technical performance metrics (eg, sensitivity and specificity).", [["SARS", "DISEASE", 0, 4], ["diagnostic assays", "TEST", 11, 28], ["specificity", "TEST", 91, 102]]], ["Clinical sensitivity depends on more than technical performance and is also a function of pre\u2010analytical variables and the disease state of the patient.", [["patient", "ORGANISM", 144, 151], ["patient", "SPECIES", 144, 151], ["Clinical sensitivity", "TEST", 0, 20], ["pre\u2010analytical variables", "PROBLEM", 90, 114], ["the disease state", "PROBLEM", 119, 136]]], ["Interpretation becomes challenging because the clinical sensitivity changes as the virus clears and the immune response emerges.INTRODUCTIONThe goal of this study is to examine the clinical sensitivity and provide insights into the interpretation of the two most common SARS\u2010CoV\u20102 diagnostic test modalities: polymerase chain reaction (PCR) and serology.", [["SARS", "DISEASE", 270, 274], ["CoV\u20102", "PROTEIN", 275, 280], ["the clinical sensitivity changes", "PROBLEM", 43, 75], ["the virus clears", "PROBLEM", 79, 95], ["this study", "TEST", 152, 162], ["diagnostic test modalities", "TEST", 281, 307], ["polymerase chain reaction", "PROBLEM", 309, 334], ["PCR", "TEST", 336, 339], ["serology", "TEST", 345, 353]]], ["Laboratory\u2010based diagnosis of active SARS\u2010CoV\u20102 infection relies on the direct detection of virus\u2010specific nucleic acids, most commonly obtained from the nasopharynx of infected patients.", [["nasopharynx", "ANATOMY", 154, 165], ["SARS", "DISEASE", 37, 41], ["infection", "DISEASE", 48, 57], ["nucleic acids", "CHEMICAL", 107, 120], ["nasopharynx", "ORGAN", 154, 165], ["patients", "ORGANISM", 178, 186], ["patients", "SPECIES", 178, 186], ["active SARS", "PROBLEM", 30, 41], ["CoV\u20102 infection", "PROBLEM", 42, 57], ["virus\u2010specific nucleic acids", "PROBLEM", 92, 120], ["active", "OBSERVATION_MODIFIER", 30, 36], ["SARS", "OBSERVATION", 37, 41], ["nasopharynx", "ANATOMY", 154, 165], ["infected", "OBSERVATION", 169, 177]]], ["Indirect markers of infection include the detection of SARS\u2010CoV\u20102 specific antibodies, generated as part of the human immune response to the virus.", [["infection", "DISEASE", 20, 29], ["SARS", "DISEASE", 55, 59], ["human", "ORGANISM", 112, 117], ["SARS\u2010CoV\u20102 specific antibodies", "PROTEIN", 55, 85], ["human", "SPECIES", 112, 117], ["SARS\u2010CoV", "SPECIES", 55, 63], ["human", "SPECIES", 112, 117], ["infection", "PROBLEM", 20, 29], ["the detection", "TEST", 38, 51], ["SARS", "PROBLEM", 55, 59], ["CoV\u20102 specific antibodies", "TEST", 60, 85], ["the virus", "PROBLEM", 137, 146], ["infection", "OBSERVATION", 20, 29]]], ["Serologic testing holds promise as a blood\u2010based diagnostic aid, as a marker of viral exposure, and potentially as an indicator of protective immunity.", [["Serologic testing", "TEST", 0, 17], ["viral exposure", "PROBLEM", 80, 94]]], ["Understanding the presence of these biomarker in relationship to one another over the natural course of infection is required to effectively utilize these available diagnostic tests in clinical practice.1,2,3", [["infection", "DISEASE", 104, 113], ["1,2,3", "CHEMICAL", 203, 208], ["infection", "PROBLEM", 104, 113], ["diagnostic tests", "TEST", 165, 181], ["infection", "OBSERVATION", 104, 113]]]], "PMC7461079": [["Obesity and respiratory functionThe increased vulnerability of patients with obesity might have been predicted, in view of the research into the 2009 influenza A H1N1 pandemic, which showed they had twice the mortality rate of people with normal weight,9and the mounting evidence that obesity increases the risk of respiratory diseases and respiratory tract infections, including obesity hypoventilation syndrome, asthma, pulmonary embolism, influenza and community acquired pneumonia.10,11,12,13", [["respiratory", "ANATOMY", 12, 23], ["respiratory", "ANATOMY", 315, 326], ["respiratory tract", "ANATOMY", 340, 357], ["pulmonary", "ANATOMY", 422, 431], ["Obesity", "DISEASE", 0, 7], ["obesity", "DISEASE", 77, 84], ["influenza A H1N1 pandemic", "DISEASE", 150, 175], ["obesity", "DISEASE", 285, 292], ["respiratory diseases", "DISEASE", 315, 335], ["respiratory tract infections", "DISEASE", 340, 368], ["obesity hypoventilation syndrome", "DISEASE", 380, 412], ["asthma", "DISEASE", 414, 420], ["pulmonary embolism", "DISEASE", 422, 440], ["influenza", "DISEASE", 442, 451], ["pneumonia", "DISEASE", 475, 484], ["10,11,12,13", "CHEMICAL", 485, 496], ["patients", "ORGANISM", 63, 71], ["influenza A H1N1", "ORGANISM", 150, 166], ["people", "ORGANISM", 227, 233], ["tract", "ORGANISM_SUBDIVISION", 352, 357], ["pulmonary", "ORGAN", 422, 431], ["patients", "SPECIES", 63, 71], ["influenza A H1N1 pandemic", "SPECIES", 150, 175], ["people", "SPECIES", 227, 233], ["Obesity", "PROBLEM", 0, 7], ["respiratory function", "PROBLEM", 12, 32], ["obesity", "PROBLEM", 77, 84], ["A H1N1 pandemic", "PROBLEM", 160, 175], ["obesity", "PROBLEM", 285, 292], ["respiratory diseases", "PROBLEM", 315, 335], ["respiratory tract infections", "PROBLEM", 340, 368], ["obesity hypoventilation syndrome", "PROBLEM", 380, 412], ["asthma", "PROBLEM", 414, 420], ["pulmonary embolism", "PROBLEM", 422, 440], ["influenza", "PROBLEM", 442, 451], ["community acquired pneumonia", "PROBLEM", 456, 484], ["respiratory function", "OBSERVATION", 12, 32], ["increased", "OBSERVATION_MODIFIER", 36, 45], ["vulnerability", "OBSERVATION_MODIFIER", 46, 59], ["obesity", "OBSERVATION", 77, 84], ["obesity", "OBSERVATION", 285, 292], ["respiratory diseases", "OBSERVATION", 315, 335], ["respiratory tract", "ANATOMY", 340, 357], ["obesity", "OBSERVATION_MODIFIER", 380, 387], ["hypoventilation syndrome", "OBSERVATION", 388, 412], ["asthma", "OBSERVATION", 414, 420], ["pulmonary", "ANATOMY", 422, 431], ["embolism", "OBSERVATION", 432, 440], ["influenza", "OBSERVATION", 442, 451], ["pneumonia", "OBSERVATION", 475, 484]]]]}